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 Cardiovascular disease is the leading cause of death in the world whose 
incidence has increased in the last 20 years (Lozano, Naghavi et al. 2012; Go, 
Mozaffarian et al. 2013), with over 2000 people dying of cardiovascular disease 
every day in the United States alone (Go, Mozaffarian et al. 2013). 
Cardiovascular disease is a heterogeneous complaint compromising a wide 
spectrum of conditions that includes, but is not limited to, valvular heart disease, 
coronary heart disease, cardiomyopathy, hypertension, cerebral vascular 
disease, and arrhythmia. Valvular heart disease comprises a significant 
proportion of cardiovascular disease in children and adults, affecting an 
estimated 2.5% of the population of the United States (Go, Mozaffarian et al. 
2013). In adults, disease may result from valvular injury as a result of infection 
(Connolly, Crary et al. 1997), pharmacological therapy (Mylonakis and 
Calderwood 2001), or tumorigenesis (Robiolio, Rigolin et al. 1995). Together, 
these factors result in over 100,000 Americans a year undergoing surgery to 
repair or replace heart valves (Roger, Go et al. 2012). As the population 
becomes older and as the risk factors associated with adult valvular disease 
become more prevalent, the incidence of valvular heart disease is expected to 
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rise and remain a major public health concern (Lozano, Naghavi et al. 2012; Go, 
Mozaffarian et al. 2013).  
 Coronary heart disease is a major source of mortality in the United States 
and is associated with 1 of every 6 deaths (Lloyd-Jones, Adams et al. 2010). 
Coronary heart disease arises from a failure of the coronary vessels to supply 
sufficient circulation to the cardiac muscle, resulting in ischemic injury referred to 
as myocardial infarction. While advances in therapeutic and reperfusion 
strategies have improved survival rates in patients with myocardial infarction 
(Parikh, Gona et al. 2009), survivors have increased the pool of patients at risk of 
developing heart failure (Lewis, Moye et al. 2003). The overwhelming incidence 
of coronary heart disease requires renewed efforts to understand this disease 
process and develop new therapeutic modalities that may increase the efficiency 
of repair and preclude later disease progression. 
 
Congenital Heart Disease and Cardiac Repair 
 Congenital Heart Disease (CHD), which includes defects in valvular and 
coronary vessel development, occurs in 1 out of 100 live births and is responsible 
for ten percent of infant deaths per year (Loffredo 2000; Barnett and 
Desgrosellier 2003; Hauser 2005). Ninety percent of children with CHD now live 
to adulthood due to the surgical and medical advances of the past half century 
(Khairy, Hosn et al. 2008). As a result, adults now represent the largest age 
group with CHD, but because they are a relatively new class of patient, treatment 
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approaches are as yet unclear (Doetschman T 2012). Also, it is now well 
recognized that there is a developmental basis to adult cardiovascular disease 
(Doetschman T 2012). Currently, it is thought that the homeostatic and repair 
functions present in adults may use many of the same mechanisms involved in 
the original development and remodeling of these tissues. Indeed, several lines 
of evidence support the importance of developmental processes in cardiac repair 
and cardiac response to injury (reviewed (von Gise and Pu 2012)). Evidence 
includes a demonstrated role of the epicardium in myocardial repair (Limana, 
Capogrossi et al. 2011; Vieira and Riley 2011) after injury in response to insults 
such as resection (Lepilina, Coon et al. 2006; Major and Poss 2007; Kikuchi, 
Gupta et al. 2011) or ischemia (Zhou, Honor et al. 2011). After coronary ligation 
in mice, the epicardium undergoes specific morphological alterations and begins 
to express angiogenic factors (Zhou, Honor et al. 2011). Coronary ligation 
stimulates re-expression of the embryonic epicardial markers Raldh2, Tbx18, & 
Wt1 (Zhou, Honor et al. 2011) as epicardial cells and epicardially derived cells 
(EPDCs) begin to divide and increase in number. These epicardial cells lose 
epithelial character (EC) (Zhou, Honor et al. 2011) and express markers of EMT 
(van Wijk, Gunst et al. 2012). EPDC’s were found to differentiate along 
myofibroblast/fibroblast and smooth muscle lineages, assumed perivascular 
locations, and potently stimulated blood vessel formation in angiogenesis assays 
(Zhou, Honor et al. 2011). Whether these EPDCs subsequently invade into the 
myocardium is still controversial. Two different studies using viral labeling 
reported cell invasion in response to injury suggesting that some cells may 
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invade into the myocardium (Limana, Zacheo et al. 2007; Gittenberger-de Groot, 
Winter et al. 2010). These investigators also reported the generation of additional 
cell types by the epicardium, most notably myocardium. There are conflicting 
studies that label epicardial cells in mice using Wt1creERT2 (Zhou, Honor et al. 
2011) or Wt1cre (van Wijk, Gunst et al. 2012) that either disagree and agree with 
the invasion and myocardial differentiation of EPDCs after injury respectively. 
Although some results vary, together these studies establish that in response to 
cardiac injury the activated epicardium re-expresses developmental markers, 
undergoes EMT, and secretes angiogenic factors. 
 
Epithelial-to-Mesechymal Transformation in Development 
 Epithelial-to-Mesenchymal Transformation (EMT) is an important process 
in development (Lim and Thiery 2012), and occurs during key steps in both 
valvular (DeLaughter, Saint-Jean et al. 2011) and coronary vessel development 
(von Gise and Pu 2012). EMT arises when an epithelial cell undergoes a 
morphological and phenotypic transition from an epithelial cell into a motile 
mesenchymal cell (Kalluri 2009). Mesenchymal cells may then undergo 
Mesenchymal-to-Epithelial Transformation (MET) to generate secondary 
epithelial cell populations during organogenesis. In this manner EMT is process 
that generates cell diversity during development. EMT is also important in adults, 
regulating cancer progression and metastasis, tissue regeneration, and fibrosis 
(reviewed (Kalluri and Weinberg 2009)). Despite the importance of EMT the 
signaling pathways regulating EMT are still incompletely understood. 
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 Specific morphological and molecular cellular processes must necessarily 
occur during EMT if an epithelial cell is to transitions into a mesenchymal cell 
(Zeisberg and Neilson 2009).   Briefly, the initial steps of EMT involve the loss of 
apical-basal polarity as tight-junctions and other adhesion complexes are 
disassembled (Enciso, Gratzinger et al. 2003; Ma, Lu et al. 2005).  This adhesion 
complexes, particularly E-cadherin, and loss of EC is thought to be mediated by 
transcription factors associated with EMT whose expression is normally seen in 
transitioning cells. These transcriptional repressors include Goosecoid, Lef1, 
Snai1, Slug, Twist1, Zeb1, and Zeb2 among others (Timmerman, Grego-Bessa 
et al. 2004; Niessen, Fu et al. 2008; Shelton and Yutzey 2008).  These changes 
result in a major reorganization of the cytoskeleton, which morphologically can be 
viewed as rounded epithelial cells becoming elongate and assuming a 
mesenchymal phenotype. The expression of mesenchymal markers, which may 
include Smooth Muscle α-Actin (SMαA), is indicative of this change in 
cytoskeleton organization (Nakajima, Mironov et al. 1997). Other mesenchymal 
or fibroblast markers can be upregulated during EMT, including Cnn1 and 
Fsp1(Zeisberg and Neilson 2009). Expression of a particular mesenchymal 
marker is dependent on the cells and the cellular context where EMT occurs. For 
example, cells undergoing EMT during a fibrotic event often express Fsp1 
whereas cells undergoing EMT during gastrulation do not initially express 
Fsp1(Strutz, Okada et al. 1995). A fundamental function of EMT is to make 
motile cells, and as such the migration or invasion of cells into a substrate after 
EMT is an important functional indicator that EMT has occurred. Together, loss of 
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EC, through a switching of adhesion complexes and cytoskeletal reorganization, 
and invasion into a substrate are key land marks in defining whether a cell has 
undergone EMT.  
 Understanding the upstream signaling events which promote these 
processes in EMT has provided fundamental insights into organogenesis, 
including valvulogenesis and coronary vessel development.   
 
EMT in Valvulogenesis 
 After the primitive heart tubes fuse in a cranial to caudal process, the heart 
undergoes looping, bringing the common atria superior to the common ventricle 
(DeRuiter, Poelmann et al. 1992). The tubular heart at this point is comprised of 
two concentric layers of epithelium: the outer myocardial layer and the inner 
endocardial layer (Figure 1A). In between these layers is an acellular, gel-like 
matrix, the cardiac jelly. At Hamburger-Hamilton (HH) stage 14 (Hamburger and 
Hamilton 1951) in the chick or E9.0 in the mouse the cardiac jelly in the regions 
of the atrioventricular (AV) canal and the distal outflow tract (OFT) expands to 
form the endocardial cushions. A pivotal step in valvulogenesis occurs when a 
subpopulation of endocardial cells overlaying the endocardial cushions undergo 
EMT (Figure 1B). The resulting mesenchymal cells populate the cardiac cushions 
and by multiple methods aid in the formation of the valves and septa of the adult 
heart (reviewed (Aikawa, Whittaker et al. 2006; Butcher and Markwald 2007)). 





Figure 1: Endocardial cell populations exhibit functional heterogeneity during 
tubular heart morphogenesis.  A,  At e8.5/HH13, the u-shaped tubular heart is 
comprised of an outer layer of Myocardium (Red) and an inner layer of Endocardium 
(blue) with a layer of cardiac jelly in between. It possesses a common outflow tract 
(OFT), ventricle (Ven), atria (Atr) and atrioventricular canal (AVC), the region between 
the atria and ventricle.  B, By e9.0/HH14- swellings of ECM restricted to the AVC and 
OFT form the endocardial cushions.  Endocardial cells in the AVC initiate EMT soon 
afterwards, while the OFT endocardium undergo EMT at a later stage.  By e10.5/HH16 
endocardial cells overlaying the cushions undergo EMT and invade cardiac jelly.  C,  
The ventricular endocardium does not undergo EMT at this time, rather it begins the 
complicated process of trabeculation around this time.  The atrial endocardium 






pathways regulating endocardial EMT, but the developmental context, the 
endocardial cushions, and the heterogeneity observed between the endocardium 
of the cushions endocardium and the non-transforming ventricular endocardium.    
   
Formation of the Endocardial Cushions 
 The endocardium displays functional heterogeneity during both the 
formation of the endocardial cushions and subsequent endocardial EMT.  The 
first sign of this endocardial cell heterogeneity is seen in the initial formation of 
the endocardial cushions. The expansion of the endocardial cushions is due to 
the myocardial secretion of a glycosaminoglycan rich matrix which includes 
hyaluronic acid, versican and collagen I (Manasek 1970; Manasek, Reid et al. 
1973). Injection of hyaluronanidase into the cushions of chick embryos to cause 
breakdown of hyaluronic acid caused cushion formation to fail (Baldwin and 
Solursh 1989). These data were confirmed in the mouse by the inactivation of 
hyaluronan synthase 2 (Has2), which is specific to the cushion forming regions in 
the heart, to eliminate hyaluronic acid synthesis. Targeting Has2 precludes 
endocardial cushion formation and subsequent valve development (Camenisch, 
Spicer et al. 2000). Similarly, disruption of Cspg2, which encodes the 
Extracellular Matrix (ECM) protein Versican, yields a similar phenotype wherein 
the endocardial cushions are absent from the tubular heart among other heart 
defects (Mjaatvedt, Yamamura et al. 1998). Thus, the ECM of the endocardial 
cushions is distinct from that of the adjacent ventricle and atria. 
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 The signals which induce cushion formation are incompletely described, 
but include Bmp, Wnt and Notch signaling pathways (Lyons, Pelton et al. 1990; 
Schubert, Mootoosamy et al. 2002; Timmerman, Grego-Bessa et al. 2004). 
Bmp2 is expressed in the AV and OFT myocardium prior to cushion expansion, 
starting at E8.5 (Sugi, Yamamura et al. 2004). Mouse embryos with myocardial 
specific deletion of Bmp2 lack AV cushions, have decreased Has2 expression 
corresponding with decreased ECM deposition, and possess AV myocardium 
patterning defects (Ma, Lu et al. 2005). Notch has also been shown to be 
required for endocardial cushion formation.  Mice with deletions of Notch1 or its 
associated transcription factor RBPJk lack cushions (Timmerman, Grego-Bessa 
et al. 2004).  Inhibition of canonical Wnt signaling by overexpression of the Wnt 
antagonist Dickkopf-1 in zebrafish or by endothelial β-catenin deletion in mice 
prevents cushion tissue formation, while expansion of Wnt signaling with β-
catenin in zebrafish or Wnt9A overexpression in chick expand the domain of the 
endocardial cushions (Hurlstone, Haramis et al. 2003; Liebner, Cattelino et al. 
2004; Person, Garriock et al. 2005). These data identify Wnt signaling as a 
regulator of endocardial cell heterogeneity. The ultimate inductive signal that 
specifies and induces cushion formation, and the identity of the associated 
endocardium, is unknown. 
   
Endocardial Cell Transformation 
 Immediately after cushion formation at HH14+/E9.5, factors secreted by 
the myocardium induce a subpopulation of endocardial cells overlying the cardiac 
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cushions to undergo EMT. The criteria for determining if an endocardial cell has 
undergone EMT are derived from the morphological and molecular events which 
occur if an epithelial cell in a sheet is to transition into a mesenchymal cell.   
Briefly, the apical-basal polarity of the endothelial cells is lost as tight-junctions 
and other adhesion complexes are disassembled.  VE-cadherin and PECAM-1, 
important in endothelial cell-cell adhesion, are downregulated during the initial 
steps of EMT and their loss is associated with the loss of the endothelial 
phenotype (Enciso, Gratzinger et al. 2003; Ma, Lu et al. 2005).  The 
downregulation of cadherins and other adhesion complexes is thought to be 
mediated by transcription factors associated with EMT whose expression is 
normally seen in transitioning cells. These transcriptional repressors include 
snai1, slug, twist1, and goosecoid among others (Timmerman, Grego-Bessa et 
al. 2004; Niessen, Fu et al. 2008; Shelton and Yutzey 2008).  Loss of tight 
junctions and cell-cell adhesion cause a major reorganization of the cytoskeleton, 
which morphologically can be viewed as endothelial cells losing their rounded, 
‘cobblestone’ appearance and becoming elongate. The expression of Smooth 
Muscle α-Actin (SMαA) is a hallmark of cushion EMT and indicative of this 
change in cytoskeleton organization (Nakajima, Mironov et al. 1997).  During this 
process the transformed cells in the endocardial cushions also lose markers of 
endocardial cushion identity such as Nfatc1 (de la Pompa, Timmerman et al. 
1998).  A fundamental function of EMT is to make motile cells, and as such 
migration and invasion into the basal substrate are critical steps made possible 
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by the transition from the stationary epithelial to the more motile mesenchymal 
phenotype. 
 
In Vitro Atrioventricular Cushion Assay 
 Atrioventricular cushion (AVC) transformation has been studied 
extensively in avian systems using an in vitro assay in which the AVC is excised 
and placed on a collagen gel (reviewed (Barnett and Desgrosellier 2003). In this 
assay, transformation can be divided into three steps based on cellular 
morphology. Endocardial cells separate from the epithelial sheet and elongate in 
a step termed activation. Next, elongate mesenchymal cells enter the matrix, a 
step termed invasion. Finally, cells migrate through the gel in the migration step. 
These three steps - activation, invasion, and migration - constitute EMT. As in the 
developing heart, EMT is tightly restricted such that endocardial cells in AVC 
explants undergo EMT whereas endocardial cells in the ventricle do not 
(Bernanke and Markwald 1982; Mjaatvedt, Lepera et al. 1987). Transforming 
cells alter their pattern of gene expression downregulating molecules such as the 
endothelial marker PECAM-1 and upregulating SMαA and procollagen type I 
(Brown, Boyer et al. 1996; Sugi, Yamamura et al. 2004). EMT can be quantitated 
by counting the number of cells in the gel. 
 This system has been used to demonstrate that the endocardium of the 
cushions is functionally different from the endocardium overlaying the ventricle 
(Mjaatvedt, Lepera et al. 1987).  In in vitro explants assays, the myocardium 
adjacent to the endocardial cushions is necessary for the endocardium to 
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undergo EMT (Bernanke and Markwald 1982).  Removal of this myocardium 
results in a lack of EMT, indicating that inductive signals from the myocardium 
adjacent to the cushions regulate endocardial EMT (Krug, Mjaatvedt et al. 1987). 
Ventricular myocardium incubated with cushion endocardium does not result in 
EMT which implies that the inductive signal is present only in myocardium 
associated with the cushions. In addition, incubating AV cushion myocardium 
with ventricular endocardium does not result in endocardial EMT, demonstrating 
that the endocardium of the cushions is functionally distinct from endocardium 
overlaying the ventricles. Thus, there is restriction of both the endothelial cell 
population that transforms and restriction of the myocardial cell population that 
signals EMT. While the penultimate mechanism underlying this functional 
heterogeneity in the endocardium is unknown, extensive investigation of this 
system has defined distinct gene expression profiles and signaling pathway 
activation in the cushion endocardium as compared to the rest of the 
endocardium.   
 The collagen gel assay has been used for several years to study the 
process of endocardial cell EMT and has led to the identification of several key 
molecules in EMT (Barnett 2003; Schroeder, Jackson et al. 2003; Butcher and 
Markwald 2007). A role for members of the TGFβ family were identified in this 
manner and have been shown to be key regulators of endocardial cell EMT 
(reviewed (Barnett and Desgrosellier 2003)). Three TGFβ ligands signal through 
three receptors: the TGFβ Type I (TGFβR1), Type II (TGFβR2), and Type III 
(TGFβR3) receptors. In the canonical signaling pathway (Shi and Massague 
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2003) ligand binding to TGFβR2 recruits TGFβR1, activin receptor like kinase 
(ALK) 5, to the complex. The constitutively active kinase of TGFβR2 
phosphorylates and activates the kinase domain of ALK5 which subsequently 
phosphorylates and activates downstream receptor associated (R-) Smads 2 and 
3 (Kretzschmar and Massague 1998). TGFβR3 or betaglycan has a short, highly 
conserved intracellular domain with no apparent signaling function (Lopez-
Casillas, Cheifetz et al. 1991; Wang, Lin et al. 1991; Cheifetz, Bellon et al. 1992). 
Endoglin is a TGFβ co-receptor that shares this highly conserved intracellular 
domain with TGFβR3 (Lopez-Casillas, Cheifetz et al. 1991).  Endoglin regulates 
endothelial cell migration and proliferation via interactions with ALK1 and ALK5 
(Goumans, Valdimarsdottir et al. 2002; Goumans, Valdimarsdottir et al. 2003; 
Lebrin, Goumans et al. 2004; Lee, Ray et al. 2008). Using the chick in vitro 
model of endothelial cell EMT, and a combination of ligand addition, neutralizing 
antisera (Potts and Runyan 1989), and antisense oligonucleotides (Potts, Dagle 
et al. 1991; Mercado-Pimentel, Hubbard et al. 2007), the ligands TGFβ1, TGFβ2, 
and TGFβ3 as well as TGFβR1 (ALK5), TGFβR2, Endoglin, and TGFβR3 have 
all been implicated in endocardial cell EMT (reviewed (Barnett 2003; Person, 
Klewer et al. 2005).  
 The coupling of experimental embryology with viral gene transfer 
increased the utility of the AVC transformation assay to test for the role of 
molecules using both gain and loss of function paradigms (Figure 2). This was 
first demonstrated by overexpressing TGFβR3 in nontransforming ventricular 
cells and inducing EMT with ligand addition (Brown, Boyer et al. 1999). This was 
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compared with antisera to target the receptor in the AVC to inhibit EMT, a result 
later confirmed by siRNA (Townsend 2011). Therefore, explants from specific 
regions of the heart tube can be used to determine if molecules are sufficient, 
required, or both for EMT. This ability to score for gain-of-function and loss-of-
function of candidate molecules provides a powerful system in which to assay for 
molecules that regulate EMT (Desgrosellier, Mundell et al. 2005; Kirkbride, 
Townsend et al. 2008; Townsend, Wrana et al. 2008). These studies catalyzed 
an examination of the role of signaling molecules in endocardial cell EMT and the 
development and characterization of an in vitro system in the mouse 
(Camenisch, Molin et al. 2002). Studies have shown that downstream signaling 
molecules such as ALK2, Par6, and Smurf1 are both required and sufficient for 
EMT whereas ALK5, a major downstream effector of TGFβ, is only required (Lai, 
Beason et al. 2000; Desgrosellier, Mundell et al. 2005; Townsend, Wrana et al. 
2008). The requirement for ALK5 activity, Par6, and Smurf1 for TGFβR3-
dependent endocardial cell EMT is consistent with the documented role of this 
pathway in the dissolution of tight junctions (Ozdamar, Bose et al. 2005). A 
modification of these experiments used overexpression of TGFβR3 in normally 
nontransforming ventricular endocardial cells to identify additional ligands for 
TGFβR3. These experiments demonstrate that BMP2 not only binds to but can 
signal via TGFβR3 (Kirkbride, Townsend et al. 2008; Kirkbride, Townsend et al. 
2008). Overexpression of TGFβR3 in normally nontransforming ventricular 
endocardial cells was also used to demonstrate that TGFβR3-dependent  
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Figure 2:  Viral gene transfer into the endocardium of the tubular heart.  
HH10-12 chicks are dissected into Whatman rings and injected with virus 
expressing either GFP or a gene of interest.  These embryos are incubated for 
24 hours on egg agar.  The atrioventricular canal (AVC) or ventricle (Ven) are 
excised, cut lengthwise, and explanted endocardial side down onto a collagen I 
gel.  After 48 hours incubation, the explants are fixed and the total number of 
GFP positive transformed cells (in green) in the gel are counted.  Loss of function 
can be scored as a reduction in the number of transformed cells in gels 
incubated with AVC explants.  Gain of function scored is scored as the increase 
in the total number of transformed GFP positive cells in gels incubated with Ven 










endocardial cell EMT stimulated by either TGFβ2 or BMP2 requires Smad4 and 
activation of the Par6/Smurf1/RhoA pathway (Townsend 2011). 
 These approaches, combined with genetic manipulation experiments in 
species such as mouse and zebrafish, have established roles for several factors, 
such as TGFβs, BMP, Notch, Wnt-β catenin, and VEGF, as well as extracellular 
matrix molecules, in regulating endocardial cell EMT (reviewed (Barnett 2003; 
Schroeder, Jackson et al. 2003; Person, Klewer et al. 2005; Combs and Yutzey 
2009) and Table 1).  In particular, studies on BMP and Notch signaling pathways 
further emphasized the importance of signaling interactions between the 
endocardium and myocardium during endocardial cell EMT.  In vivo, BMP2 is 
expressed specifically in the cushion myocardium and signals to the cushion 
endocardium to promote EMT (Lyons, Pelton et al. 1990; Sugi, Yamamura et al. 
2004; Ma, Lu et al. 2005).  BMP type I receptors ALK2 and ALK3, both of which 
bind BMP2, are required in the endocardium for transformation in the cushion to 
occur (Wang, Sridurongrit et al. 2005; Song, Fassler et al. 2007).  A constitutively 
active form of ALK2 is sufficient to drive endocardial cell EMT ectopically in 
ventricular explants in vitro (Desgrosellier, Mundell et al. 2005).  This myocardial 
induced BMP signaling drives the endocardial expression of genes important in 
the progression of EMT, such as Twist1, Msx1, and Msx2, which are expressed 
in endothelial cells as they transition into mesenchyme (Ma, Lu et al. 2005).  
Notch signaling in the developing cushions has been shown to interact with 
BMP2 signaling during tubular heart development.  Notch signaling is required for 
cushion EMT and linked to BMP2 signaling (Timmerman, Grego-Bessa et al. 
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2004).  Notch1 signaling activity is restricted to the endocardium overlaying the 
cushions and drives Snai1 expression (Luna-Zurita, Prados et al. 2010).  While 
Notch1 targeted mice have hypoplastic valves, recent work has demonstrated 
that mice expressing the active form of the Notch receptor throughout the 
endocardium have expanded regions of EMT marker expression in vivo, though 
BMP2 is required to drive full invasion of ventricular endocardium in vitro (Luna-
Zurita, Prados et al. 2010).  Interestingly, increased Notch signaling in the 
myocardium reduces BMP2 expression there, while Notch1 deletion in the 
endocardium expands BMP2 expression, suggesting that the endocardium also 
signals back to the myocardium during valvulogenesis.  Therefore, not only does 
the myocardium send inductive signals to the endocardium, intact endocardial 
signaling is required for proper myocardial restriction of BMP signaling.  A more 
robust appreciation of other signal pathways involved in endocardial to 
myocardial signaling interaction may yield important insights into regulation of 
endocardial cell EMT during valve development. 
 A recent example of a concerted approach using mouse and chick model 
systems to address the role of specific molecules in the endocardium is the 
identification of the roles of Eph3A and Eph1A in endocardial EMT and 
valvulogenesis (Frieden 2010).  Eph3A is abundantly expressed in the valve 
mesenchyme as early as e10.5. Targeted deletion of Eph3A resulted in 
hypoplastic cushions associated with decreased EMT and mesenchyme 
production (Stephen, Fawkes et al. 2007).  Eph1A was noted to be expressed in 
the endocardial cells adjacent to the mesenchyme suggesting that Eph1A  
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Table 1:  Selected genes with valve formation defects in vivo in mouse 
knockout models.   
Receptor 
Expression in 
Cushion KO Phenotype CHD 
Alk2 Endo (Desgrosellier, 
Mundell et al. 2005) 
Endo deletion causes hypoplastic valves 
(Wang, Sridurongrit et al. 2005) 
Primum type ASD, 
MVP (Smith, 
Joziasse et al. 
2009) 
Alk3 Endo/Mese/Myo (Dewulf, 
Verschueren et al. 1995) 
Endo deletion causes hypoplastic valves, 
Myo deletion causes interventricular septum, 
trabeculae and AV cushion defects (Song, 
Fassler et al. 2007) 
~ 
Alk5 Endo/Mese/Myo  Endo deletion results in hypoplastic valves 
(Sridurongrit, Larsson et al. 2008) 
~ 
Bmpr2 Endo/Mese/Myo Defective septation of conotruncus, atrial 
septal defect, membranous VSD, and 
thickened valve leaflets (Beppu, Malhotra et 
al. 2009) 
AVSD, ASD, PDA, 
PAPVR+PAH 
(Roberts, McElroy 
et al. 2004) 
Tgfr2 Endo/Mese/Myo DILV (Jiao, Langworthy et al. 2006) ~ 
Tgfr3 Endo (Brown, Boyer et al. 
1999) 
Enlarged Valves (ECM) (Unpublished) ~ 
Notch1 Endo (Loomes, Taichman 
et al. 2002; Timmerman, 
Grego-Bessa et al. 2004) 
No cushion formation (Timmerman, Grego-
Bessa et al. 2004) 
VSD, TOF, BAV, 
MVS (Timmerman, 
Grego-Bessa et al. 
2004; Garg, Muth et 
al. 2005; Mohamed, 
Aherrahrou et al. 
2006; McKellar, 
Tester et al. 2007) 
Ligands    
Bmp2 Myo (Lyons, Pelton et al. 
1990) 
Cushions do not swell, no EMT, AV Myo 
patterning defects (Ma, Lu et al. 2005) 
~ 
Tgf2 Endo/Mes/Myo (Dickson, 
Slager et al. 1993) 
Conotruncal cardiac malformations (Sanford, 
Ormsby et al. 1997) 
~ 
Hb-Egf  Endo(Jackson, Qiu et al. 
2003) 
Enlarged Valves (Iwamoto, Yamazaki et al. 
2003) 
~ 
Extracellular Matrix Associated Molecules  
Vscn Myo (Zanin, Bundy et al. 
1999) 
No cushion formation (Mjaatvedt, 
Yamamura et al. 1998) 
~ 
Postn Mese (Kruzynska-Frejtag, 
Machnicki et al. 2001) 
Remodeling defects, AV mesenchyme 
maturation defects (Norris, Moreno-
Rodriguez et al. 2008) 
~ 
Has2 Endo/Mese/Myo 
(Camenisch, Spicer et al. 
2000) 








Adapted from (DeLaughter et al. 2011) 
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functioned as a ligand to stimulate Eph3A (Stephen, Fawkes et al. 2007). 
Subsequent gene targeting of Eph1A yielded a less severe phenotype 
characterized by hyperplastic valve leaflets greater in cross sectional area than 
wildtype mice. Cushion explants studies in chick revealed that the addition of 
Eph1A-Fc to cushion explants or overexpression of Eph1A in endocardial cells 
decreased endocardial cell EMT in vitro consistent with the loss of Eph1A 
resulting in enhanced EMT resulting in hyperplasia. These data suggest a 
relationship between Eph3A and Eph1A that is more than just a unidirectional 
ligand-receptor interaction.  Overexpression of Eph3A was sufficient to induce 
endocardial cell EMT in normally nontransforming ventricular cells demonstrating 
that Eph3A is sufficient for EMT while Eph1A is a negative regulator of EMT. 
Since Eph receptors can signal in both a kinase-dependent and kinase-
independent manner the expression of a kinase dead mutant was used to reveal 
a requirement of Eph3A kinase activity for this gain of function. These 
complementary approaches reveal a more complex role of this signaling pathway 
in endocardial cell EMT and valvulogenesis. 
 
What Can In Vitro Results Tell Us About In Vivo Phenotypes? 
 Studies of the role of the TGFβ are perhaps the most conspicuous 
example of apparently disparate in vitro and in vivo results. Although the 
abrogation of the function of the TGFβ ligands, and later the Type I, Type II, and 
Type III TGFβ receptors, was shown to inhibit EMT in vitro, targeting TGFβ2, 
TGFβR2, and TGFβR3 in vivo revealed that EMT can occur in the more complex 
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extracellular matrix (ECM) and growth factor environment found in the native 
cushions. These studies are well exemplified by TGFβR2. This constitutively 
active, serine threonine kinase receptor is a component of all described TGFβ 
receptor complexes (reviewed (Barnett 2003)). Brown et al (Brown, Boyer et al. 
1996) first targeted this receptor in vitro and showed that it was required for EMT. 
Later studies by Jiao et al (Jiao, Langworthy et al. 2006) used Cre-lox technology 
to selectively delete TGFβR2 from endothelial/endocardial cells. Surprisingly, 
these cells did undergo EMT in vivo. However, when AV cushion explants were 
placed on collagen gels EMT failed to occur. This suggests that EMT on collagen 
does require TGFβ while EMT on the more complex matrix in vivo lacks this 
requirement. Loss of TGFβR2 does result in abnormal AV cushion remodeling 
and cardiac looping resulting in double inlet left ventricle (Jiao, Langworthy et al. 
2006). Ongoing studies of TGFβR3 yield similar results. In the chick, targeting 
TGFβR3 in vitro inhibits endocardial cell EMT while overexpression of TGFβR3 in 
nontransforming ventricular endocardial cells causes EMT (Brown, Boyer et al. 
1999). Targeted deletion of TGFβR3 in the mouse reveals that EMT does occur 
in the AV cushion and OFT but the resulting cushions are greatly enlarged 
(Compton, Potash et al. 2007) (unpublished). When AV cushion explants from 
TGFβR3 null mice are placed on collagen gels, EMT fails to occur (unpublished). 
Interestingly, this in vitro requirement and in vivo phenotype is nearly identical to 
that seen for TGFβ2, the ligand that requires TGFβR3 for high affinity binding.  
 These observations suggest two conclusions concerning the role of TGFβ 
in EMT. First, the serendipitous use of collagen as the matrix for in vitro studies 
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revealed that EMT on this substrate is exquisitely sensitive to alterations in TGFβ 
signaling. There is an obligate requirement for intact TGFβ signaling for 
endocardial cells to undergo EMT on collagen. Second, in vivo, the more 
complex ECM and growth factor environment can support EMT in the absence of 
TGFβ signaling as revealed by Jiao (Jiao, Langworthy et al. 2006) and our 
studies (Compton, Potash et al. 2007). However, in the case of the targeting of 
TGFβR2 and TGFβR3, although the cells can bypass a requirement for TGFβ 
signaling for EMT, the loss of TGFβ signaling via these receptors results in 
abnormal behavior of the endocardially-derived mesenchyme resulting in double 
inlet left ventricle in the case of TGFβR2 (Jiao, Langworthy et al. 2006) and 
Double outlet right ventricle and hyperplastic cushions in the case of TGFβR3 
(Compton, Potash et al. 2007) and TGFβ2 (Bartram, Molin et al. 2001). 
 This requirement for TGFβ signaling for EMT on collagen provides an 
extremely sensitive biological system for studying TGFβ signaling in endocardial 
cells and the role of the extracellular matrix in supporting EMT. First, since EMT 
on collagen requires TGFβ receptor activation, this system can be used to screen 
for downstream mediators of TGFβ signaling. This approach is proving especially 
useful in identifying the mechanisms by which TGFβR3 signals. In fact, 
endocardial cell EMT on collagen is the only known assay for TGFβR3 signaling. 
Second, since EMT on collagen is TGFβ dependent while EMT in vivo is not, this 
system provides the opportunity to identify the factors in vivo that allow 
endocardial cells to bypass the requirement for TGFβ. Assays using TGFβR3 null 
endocardial cells can be used as a screen whereby extracellular components or 
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growth factors can be added back to the matrix in a systematic way in order to 
identify those that stimulate EMT in the absence of intact TGFβ signaling. 
Therefore, although the in vitro collagen gel assay cannot accurately foretell the 
phenotype in vivo, it can uniquely provide essential insight into both the 
mechanisms of TGFβ signaling that regulate EMT and the in vivo environment 
that can support TGFβ-independent EMT. In the case of the identification of 
TGFβ signaling mechanisms that regulate EMT, specifically those downstream of 
TGFβR3 where little is known about the signaling pathway, this data will be 
essential in selecting molecules that function to control endocardial cell–derived 
mesenchyme during valve formation and in formulating therapeutic strategies to 
predictably alter the behavior of this mesenchyme. Therefore, although some 
significant differences are evident in the results obtained from this in vitro assay 
(Camenisch, Molin et al. 2002) when compared to genetic manipulations in vivo 
(for example, (Jiao, Langworthy et al. 2006)), the AVC transformation assay 
continues to provide useful insight concerning the molecules that regulate 
endocardial cell EMT, mesenchymal cell maturation, and valvulogenesis. 
 
Valvular Interstitial Cell Function (VIC) in Valve Remodeling 
 Finally, after endocardial cell EMT seeds the cardiac jelly of the 
endocardial cushions, the resultant mesenchyme cells express genes indicative 
of mesenchyme differentiation, which in VICs include the upregulation of 
downstream BMP targets Msx1, Msx2 and Sox9 (Chan-Thomas, Thompson et 
al. 1993; Akiyama, Chaboissier et al. 2004; Chen, Ishii et al. 2008). These 
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differentiating mesenchymal cells play multiple roles in the formation and 
maintenance of valve structure (reviewed (Aikawa, Whittaker et al. 2006; Butcher 
and Markwald 2007)).  One of the roles is the secretion and remodeling of ECM 
components.  Cardiac cushion interstitial cells secrete procollagen-I, hyaluronic 
acid, and periostin, which are all required for cushion morphogenesis 
(Camenisch, Spicer et al. 2000; Inai, Norris et al. 2008).  Some secreted ECM 
components, such as periostin and cadherin11, might also regulate the lineage 
commitment and differentiation of interstitial cells themselves (Butcher, Norris et 
al. 2007; Shelton and Yutzey 2008).  The mesenchyme initiates the remodeling 
process by secreting ECM components, such as procollagen I, as well as 
proteins that modify the matrix, such as Mmp2 (Shelton and Yutzey 2008).  
Specific cleavage of the ECM components in the cardiac jelly continue at this 
stage, including cleavage of Versican (Kern, Twal et al. 2006).    The interstitial 
cells remodel the cardiac jelly into the highly organized ECM observed in the 
mature valves whose complexity is still being appreciated(Angel, Nusinow et al.).  
Compared to the early steps in valvulogenesis, however, the hemodynamic and 
molecular mechanisms governing remodeling and the subsequent role of 
endocardium in these processes are relatively unknown (Person, Klewer et al. 
2005). 
 While the processes regulating EMT in the AVC and to a lesser extent, the 
OFT, have been extensively investigated as described above, our understanding 
of the mechanisms that regulate post EMT valve remodeling are quite limited. 
This is due, in part to the fact that unlike EMT, there is no in vitro bioassay for 
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endocardial function in the later stages of valvulogenesis.  In addition this period 
of development has been essentially inaccessible to experimental manipulation 
because gene perturbation studies in the mouse result in embryonic demise in 
the midgestation mouse embryo. However, based on studies of normal mouse 
and human embryos (Maron and Hutchins 1974; Hurle, Colvee et al. 1980; Hurle 
and Colvee 1983), investigators have demonstrated that following the termination 
of EMT in the OFT of the mouse at E12.5, the condensed mesenchymal 
protrusions subsequently “elongate” to provide the true cardiac valve leaflets. 
The elongation of primitive valves appears to be a result of restricted proliferation 
of endocardial cells overlying the mesenchymal projections on the vascular side 
of the valve and selective cell death under the expanding endocardial rim. The 
growth of the endocardial edge and evacuation of apoptotic cells underneath the 
proliferating endocardial rim sculpt the swollen mesenchymal primitive valves into 
a typical excavated shape and results in morphogenesis of the sinuses of 
valsalva.  
 Recently, two studies using histochemistry, immunohistochemistry, and 
electron microscopy described late gestational and postnatal valve develop in 
chicken and mouse (Hinton, Lincoln et al. 2006) with a remarkably similar 
progression of developmental events seen in human fetuses (Aikawa, Whittaker 
et al. 2006). These studies document progression of remodeling and 
compartmentalization of the valve leaflet from a disorganized matrix of 
proteoglycans with little detectable elastin, and small amounts of disorganized 
collagen and relative uniform distribution of vascular interstial cells (VICs), to a 
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highly stratified ECM into the 3 organized layers of fibrosa (arterial aspect 
primarily composed of collagens), spongiosa (central aspect, primarily 
glycosaminoglycans), and ventricularis (ventricular aspect with elastin fibers) with 
compartmentalization of VICs resulting in increased cell density in the fibrosa and 
ventricularis. Notably, this process is not only conserved across species but 
extends well after birth into postnatal life. Both investigators documented 
significantly higher VIC density, proliferation, and apoptosis in the fetus which 
gradually decreased into adult life This decrease in VIC turnover was 
accompanied by a greater than 50 fold increase in valve cusp area in the chicken 
suggesting a major component of valve growth is from the increased production 
of ECM.  
 Evaluation of human fetal and adult valve formation resulted in several 
important observations potentially relevant to this remodeling process (Aikawa, 
Whittaker et al. 2006). First, valvular endothelial cells express an activated 
phenotype throughout fetal development as evidenced by accentuated 
expression of ICAM-1, VCAM-1, MMP-1, MMP13 and MHC-B nonmuscle myosin 
which is not seen in normal adult endothelium. Second, there is heterogeneity 
and plasticity of the VIC population with the majority of fetal VICs displaying an 
activated phenotype with progression to quiescence in the adult. Thus, fetal VIC 
activation occurs throughout development analogous to the valve changes that 
occur in pathological conditions and after surgical substitution (Rabkin, Aikawa et 
al. 2001; Rabkin-Aikawa, Farber et al. 2004) suggesting that analogous 
molecular mechanisms likely direct both normal developmental and pathological 
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interstitial cell activation (Rabkin-Aikawa, Farber et al. 2004). A recent in vitro 
study suggests that semilunar VIC plasticity may be the hallmark of a resident 
subpopulation of valve progenitor cells that maintain the ability to differentiate 
into either endothelial or interstitial cells in the valve leaflet (Paruchuri, Yang et al. 
2006).  
 There are a few mouse mutants that escape early embryonic demise and 
are thus informative in unravelling the mechanisms of late gestational and early 
postnatal semilunar valve pathology and many of these mutants point to a central 
role for endocardial cell signaling.  Most of these mouse models display normal 
EMT but then evolve a hyperplastic valve phenotype that suggests aberrations in 
valve remodeling. One common feature of many of these defects is perturbations 
that either enhance or attenuate RAS-MAPK signaling (reviewed (Yutzey, Colbert 
et al. 2005; Gelb and Tartaglia 2006). Epstein et al showed that hyperplastc 
aortic valve defects in Nf1 mutant embryos previously attributed to defects in 
cardiac NCC, result from a primary defect in OFT and AVC endocardium (Gitler, 
Zhu et al. 2003). These defects were at least partially due to elevations in 
endocardial MAPK signaling secondary to the loss of Nf1 suppression of Ras-Erk 
signaling resulting in increased proliferation and decreased apoptosis (Lakkis 
and Epstein 1998). Consistent with this, patients with Nf1 mutations, develop 
pulmonary stenosis and hypertension but rarely defects in the AVC (Lin, Birch et 
al. 2000). NF1 loss of function is mimicked by gain of function mutations in the 
tyrosine phosphatase Shp2/PTPN11 which results in a context and dosage 
dependent increase in Ras-Erk activation, increased proliferation, and decreased 
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apoptosis resulting in semilunar valve and AV valve hyperplasia (Araki, Mohi et 
al. 2004; Gelb and Tartaglia 2006). Autosomal dominant gain of function 
mutations in Shp2 have been identified as causative for Noonan’s syndrome, the 
most common non-chromosomal syndrome with cardiac abnormalities 
characterized by pulmonary stenosis, hypertrophic cardiomyopathy, and 
occasionally AV valve defects  (Tartaglia, Mehler et al. 2001; Tartaglia, Kalidas et 
al. 2002). Most recently, hypomorphic mutations in SOS1 an essential RAS 
guanine nucleotide-exchange factor (Ras-Gef), result in enhanced RAS-ERK 
activation and can account for as high as 20% of the cases of Noonan’s 
syndrome not explained by Shp2 mutations (Roberts, Araki et al. 2007) 
(Tartaglia, Pennacchio et al. 2006). 
 Significant attention has been focused on the potential role of Notch1 
signaling in the development of the outflow tract in general and more recently in 
semilunar valve formation specifically (reviewed (MacGrogan, Nus et al.)).  In 
addition to a prominent role in regulating early events of EMT, as described 
above, the observation that Notch1 mutations were associated with formation of 
a bicuspid aortic valve and subsequent calcification of the aortic valve has 
stimulated significant interest in a role for Notch1 in latter valve remodeling.  
Garg, and colleagues (Garg, Muth et al. 2005) hypothesized that Notch1 
signaling played a role in repressing Runx2 through activation of the hairy-related 
family of transcription repressors (Hrt or Hey). A truncated mutation of Hrt2 was 
used to demonstrate a de-repression of calcium deposition in addition to early 
developmental defects that led to progressive aortic valve disease.  
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Subsequently, investigators have documented other forms of left ventricular 
outflow tract obstruction (LVOTO) such as coarction of the aorta (COA) and 
hypoplastic left heart syndrome (HLHS) have been linked to polymorphisms of 
the Notch1 alleles as well as mutations within the ectodomain and extracellular 
domain of the Notch1 sequence ((McBride, Riley et al. 2008).  However, the 
exact cell populations involved in these defects remains somewhat ambiguous.  
Del Monte et al. (Del Monte, Grego-Bessa et al. 2007) were able to detect 
expression of the Notch intracellular domain (NICD), suggesting active Notch 
signaling, throughout the endocardium adjacent to the myocardium during at 
E9.0 - E9.5.  Subsequently, NICD expression became localized to the 
endocardial cells of the AVC and OFT. This expression persisted to E14.5 in the 
endocardium of the semilunar valves and was undetected in the mesenchymal 
cells of the valve leaflets.  NICD was also detected in other endocardial 
populations such as the atrium and ventricles.  This suggested that endocardial 
specific Notch signaling was the primary sight for Notch activity in latter valve 
development.  However, recently Jain, and colleagues (Jain, Engleka et al.) 
demonstrated semilunar valve defects utilizing secondary heart field expression 
of the Notch signaling component mastermind-like (MAML).  These data raise the 
possibility that non-endothelial Notch signaling affects cardiac NCC functions 
required for valve remodeling.   
 Recent evidence implicate EGF signaling as an important regulator of later 
valve remodeling and suggests members of this family may play different roles in 
OFT and AVC valve morphogenesis. Loss or attenuation of EGFR/ErbB1 
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signaling results in preferential hypercellularity of semilunar but not AV valves 
(Sibilia, Wagner et al. 2003) and this hyperplastic semilunar valve phenotype is 
augmented when crossed to mice heterozygous for a null mutation in Shp2 
(Chen, Bronson et al. 2000).  Deletion of the EGF ligand, heparin binding (HB)-
EGF, results in increased endocardial cushion size and cell proliferation of both 
semilunar and AV valves (Iwamoto, Yamazaki et al. 2003; Jackson, Qiu et al. 
2003). These mice show prolonged Smad 1/5/8  phosphorylation and loss of 
phospolipase e (Tadano, Edamatsu et al. 2005), a downstream component of 
EGF and Ras signaling, and similar to mice with a null mutation in inhibitory 
Smad (Galvin, Donovan et al. 2000), have hyperplastic similunar valves. 
Interestingly, null mutations in other EGFR ligands (EGF, ampiregulin, TGF-α) 
have no effect on valve formation. Thus, while abundant evidence suggests that 
Shp2-enhances signaling through EGF receptors via Ras (Shen, Ouyang et al. 
2002) and leads to a transition from proliferation and expansion to remodeling 
and elongation of the valve leaflet, the exact mechanism of regulation is likely to 
be context dependent and receptor specific and may involve the intersection of 
multiple growth factor signaling pathways. 
 
Unique Functions for the Ventricular Endocardium. 
 While the characteristic ability of the AVC and OFT endocardium to 
undergo EMT has been appreciated for quite some time, the unique role of the 
ventricular endocardium was “serendipitously” elucidated by studies of the 
neuregulin growth factor.  Previous studies on neuregulin signaling had primarily 
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focused on its role in neural development as well as oncogenic transformation. 
The discovery that mice deficient for neuregulin develop a relatively normal early 
heart but fail to undergo ventricular trabeculation (Figure 1C) documented an 
essential role for this receptor and it’s ligands in cardiac development (Meyer and 
Birchmeier 1995; Kramer, Bucay et al. 1996). This epidermal growth factor-like 
molecule signals through a family of protein tyrosine kinases of the EGFR family, 
Erb2, Erb3, Erb4 (reviewed (Pentassuglia and Sawyer 2009)) that form 
heterodimers (ErbB2/ErbB3 or ErbB2/ErbB4) at the cell surface.  Interestingly, 
neuregulin is expressed by the endocardium of the heart and the ErbB2/ErbB4 
complex is expressed in a reciprocal pattern by the underlying myocardium. In 
contrast, the ErbB2/ErbB3 complex is expressed by the mesenchymal cells 
adjacent to the endocardium of the endocardial cushions in the atrioventricular 
canal and outflow tract.  Deletion of either ErbB2 (Shen, Ouyang et al. 2002) or 
ErbB4 (Gassmann, Casagranda et al. 1995) results in absent trabeculation of the 
embryonic ventricle, decreased myocyte proliferation, and embryonic lethality at 
E10.5, similar to that seen in the neuregulin knock-out mice. These data firmly 
establish the neuregulin signaling pathway between endocardium and 
myocardium as a very specific and essential step in ventricular morphogenesis. 
Likewise, targeted null mutations in the ErbB3 receptor (Erickson, O'Shea et al. 
1997; Riethmacher, Sonnenberg-Riethmacher et al. 1997) results in abnormal 
endocardial cushion development and defective valve formation resulting in 
congestive heart failure at E13.5. Thus, endocardial signaling via neuregulin is 
critical for several events intrinsic to myocardial development. Similarly, 
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endocardial expression of Brg1 results in the repressed expression of ADAMTS1, 
which is required for trabeculation of the ventricle (Stankunas, Hang et al. 2008).  
These studies confirm unique chamber specific roles for endocardial signaling in 
the developing heart (reviewed (Brutsaert, De Keulenaer et al. 1996; Sedmera, 
Pexieder et al. 2000; Smith and Bader 2007)). 
 
Summary of Valve Development 
 Overwhelming evidence from several lines of investigation supports the 
importance of endocardial EMT and the subsequently derived mesenchyme in 
valve development though the gene regulatory networks (GRN) underlying these 
processes is incompletely understood. Furthermore, there exists a remarkable 
degree of endocardial heterogeneity that allows endocardial cell populations in 
the AVC and OFT cushions and in the ventricle to participate in several distinct 
events during cardiac morphogenesis. The basis for the generation and 
maintenance of this diversity is only now being revealed. We exploited this 
endocardial heterogeneity in Chapter II as a powerful tool in delineating the 
signaling pathways that distinguish between the developmental processes 
distinct to these endocardial cell populations. This knowledge will contribute to a 
clearer understanding of cardiac morphogenesis, contribute to our understanding 
of the molecular basis of congenital heart defects, and may provide novel 





EMT in Coronary Vessel Development 
 The epicardium is a layer of epithelial cells that covers vertebrate hearts 
and plays a major role during coronary vessel development (Mikawa and Gourdie 
1996; Dettman, Denetclaw et al. 1998; Gittenberger-de Groot, Vrancken Peeters 
et al. 1998; Cai, Martin et al. 2008; Zhou, Ma et al. 2008). In response to signals 
from the myocardium, a subpopulation of epicardial cells undergo EMT and 
invades into the subepicardial space and myocardium. These EPDCs are 
important for coronary vessel development as disrupting epicardial formation or 
EMT leads to defects in the myocardium and coronary vessels (Kwee, Baldwin et 
al. 1995; Yang, Rayburn et al. 1995; Sengbusch, He et al. 2002; Mellgren, Smith 
et al. 2008; Smith, Baek et al. 2011). Thus, key insights into coronary vessel 
formation have been derived from studies elucidating the signals that promote 
epicardial EMT.   
 
Formation of the Epicardium 
 The epicardium arises from a transient structure composed of mesothelial 
cells called the proepicardium (Manasek 1969; Viragh and Challice 1981; 
Manner 1992; Wessels and Perez-Pomares 2004; Serluca 2008). The 
proepicardium originates from cells adjacent to the septum transversum and the 
sinus venosus and attaches to heart tube at E10.5 (Viragh and Challice 1981; 
Rodgers, Lalani et al. 2008). Attachment is dependent of epicardial-myocardial 
interactions and targeted deletion of genes in the mouse which disrupts this 
interaction, such as Vcam1 or Itga4, prevents formation of the epicardium and 
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results in absent coronary vessels as well as myocardial defects (Kwee, Baldwin 
et al. 1995; Yang, Rayburn et al. 1995; Sengbusch, He et al. 2002). Several 
signals from the myocardium regulate proepicardial attachment. BMP2 is has 
perhaps the best defined role in direct cells from the proepicardial organ to attach 
to and migrate over the heart tube (Kruithof, van Wijk et al. 2006; Christiaen, 
Stolfi et al. 2010; Ishii, Garriock et al. 2010), forming the epicardium. Epicardial 
cells express Wt1 and Tbx18 which are commonly used as markers of embryonic 
epicardium (Zhou, Honor et al. 2011). The epicardium covers the heart tube and 
becomes a continuous epithelial layer by E12.5 (Komiyama, Ito et al. 1987).  
 Between the epicardium and the myocardium a layer of ECM forms in the 
subepicardial space. The myocardium and proepicardium both contribute to the 
ECM contained in the subepicardial space (Tidball 1992; Kalman, Viragh et al. 
1995). The myocardium secretes laminin, fibronectin, and collagens I and III on 
the surface of the heart tube (Tidball 1992; Tidball 1992). HA, a major ECM 
component within the subepicardial space, is produced by the proepicardium and 
transferred in vesicles to the surface of the heart as the epicardium migrates over 
the heart tube (Kalman, Viragh et al. 1995). The exact makeup and source of the 
ECM contained in the subepicaridal space is unknown.  
 
The Fate of EPDCs 
 After epicardial cells begin to migrate over the heart at E10.5, a subset of 
these cells undergoes EMT and invades into the subepicardial space and 
myocardium. Cell lineage tracings done principally in avians suggests that these 
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EPDCs contribute to several cell lineages, including interstitial fibroblasts, 
perivascular fibroblasts, vascular smooth muscle cells (VSMCs), and coronary 
endothelial cells (Mikawa and Gourdie 1996; Dettman, Denetclaw et al. 1998; 
Gittenberger-de Groot, Vrancken Peeters et al. 1998; Manner 1999; Wilting, 
Buttler et al. 2007). Similar lineage tracing studies in the mouse using cre/loxP 
systems have supported the epicardial origin of a majority of the VSMCs 
associated with coronary vessel development when using cre alleles expressing 
primarily in the epicardium, WT1-cre (Wilm, Ipenberg et al. 2005), Tbx18-cre 
(Cai, Martin et al. 2008), or cGata5-cre(Merki, Zamora et al. 2005). The EPDC 
contribution to the fibroblast lineages has also been supported by these same 
studies and that the absence of EPDCs results in a lack of perivascular and 
interstitial fibroblasts (Smith, Baek et al. 2011).  
 The contribution of EPDCs to the coronary endothelial and myocardial cell 
lineages in mammals has been controversial (reviewed (von Gise and Pu 2012)). 
Initial lineage tracing studies in mice failed to support an EPDC contribution to 
coronary endothelial cells using Wt1-cre or Tbx18-cre (Cai, Martin et al. 2008; 
Zhou, Ma et al. 2008). A recent lineage tracing study using the Sema3d-cre and 
Screlaxis-cre cre alleles labeled populations of proepicardial cells largely distinct 
from those expressing WT1 and Tbx18, suggesting that, while morphologically 
homogenous, the proepicardium contains distinct genetic subpopulations (Katz, 
Singh et al. 2012). Sema3d-cre and Screlaxis-cre labeled the proepicardium, 
migrating epicardium cells, and a small fraction (>10%) of either myocardium or 
coronary endothelial cells (Katz, Singh et al. 2012). Further studies have also 
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identify other sources of coronary endothelial cells, including major contributions 
from the sinus venosus to the venous coronary endothelium (Red-Horse, Ueno et 
al. 2010) and from the ventricular endocardium to the arterial coronary 
endothelium (Wu, Zhang et al. 2012). These data indicate that there are several 
lineages that can give rise to coronary endothelial cells. A comprehensive, 
quantitative examination of the relative contributions of these specific sources 
may assist in clarifying the mechanisms by which the coronary endothelium 
arises.  
 The ability of mammalian proepicardial and epicardial cells to differentiate 
into cardiomyocytes in vitro has been suggested though these studies did not 
exclude the possible inclusion of non-epicardial cells in culture (Kruithof, van Wijk 
et al. 2006; del Monte, Casanova et al. 2007). In mice in vivo, lineage tracing 
studies using WT1-creERT2 (Wilm, Ipenberg et al. 2005) and Tbx18-cre (Cai, 
Martin et al. 2008) labeled a small fraction of myocardial cells in the ventricular 
septum cells during cardiogenesis (Cai, Martin et al. 2008; Zhou, Ma et al. 2008). 
The validity of these results has been placed in doubt (Christoffels, Grieskamp et 
al. 2009); particularly in the case of Tbx18-cre as Tbx18 expression is seen at 
low levels in non-epicardial cells in the heart, including a subpopulation of 
myocardial cells. Overall, these studies indicate the myocardium does not arise 
from EPDCs. Despite the controversies concerning the contribution of EPDCs to 





Formation of Coronary Vessels 
 The coronary vessel development is a complex process involving careful 
coordination between the epicardium, myocardium, coronary endothelial cells 
and EPDCs (Olivey, Compton et al. 2004; Lavine and Ornitz 2009). At E11.5, the 
epicardium begins to undergo EMT and seed the subepicardial space with 
epicardially derived mesenchyme. EPDCs also invade into the myocardium as 
well. At approximately the same time, coronary vessel formation begins through 
the process of vasculogenesis. Vasculogenesis is the process in which de novo 
vascular networks are formed. The coronary endothelial cells in the subepicardial 
space and myocardium coalesce to form interconnected vascular tubes at 
approximately E11.5. These primitive vessels consist of single layer of 
endothelium. The formation of a vascular plexus begins at the atrioventricular 
junction on the inferior surface of the heart and proceeds to cover most of the 
right and left ventricles by E13.5. The coronary vascular plexus consists of 
EphB4-expressing, venous-fated, subepicardial vessels and EphrinB2-
expressing, arterial-fated, intramyocardial vessels which can have 
interconnections (Swift and Weinstein 2009). The coronary vessels attach to the 
base of the aorta through the right and left coronary ostia which allows the 
establishment of the coronary circulation (Gonzalez-Iriarte, Carmona et al. 2003). 
VSMCs and perivascular fibroblasts are then recruited, forming coronary vessels 
consisting of an inner layer of endothelium, a middle layer of VSMCs, and an 
outer layer of fibroblasts. The association of VSMCs is required for the 
stabilization and maturation of the nascent vessels (Poelmann, Gittenberger-de 
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Groot et al. 1993; Reese, Mikawa et al. 2002). Between E14.5 and E16.5, the 
process by which new blood vessels arise from existing ones, or angiogenesis, 
functions to further remodel the coronary vessels to insure adequate blood flow 
to the entire myocardium. Disruption of the epicardium, EPDCs, or epicardial-
myocardial signaling inhibits the formation of mature coronary arteries and veins 
(Olivey and Svensson 2010).  
 
Signaling Pathways Regulating Epicardial EMT 
 Signficant progress has been made in understanding how epicardial cell 
EMT is regulated during development in the last decade. Several excellent 
reviews have recently chronicled the roles of Wnt, TGFβ, BMP, PDGF, FGF, and 
RA signaling pathways and the interactions between the epicardium and 
myocardium in epicardial EMT (Gittenberger-de Groot, Winter et al. 2010; Olivey 
and Svensson 2010; von Gise and Pu 2012). Here, we have elected to discuss 
TGFβ signaling in coronary vessel development to provide important details that 
are pertinent to the research presented in Chapter III. 
 
TGFβ Signaling in Coronary Vessel Development 
The expression of TGFβ ligands in the embryonic epicardium suggested a 
potential role for TGFβ signaling in coronary vessel development. TGFβ2 is 
expressed in the myocardium while all ligands are expressed in the epicardium at 
E11.5 (Molin, Bartram et al. 2003; Olivey, Mundell et al. 2006). While it was 
initially reported that TGFβ ligand incubation inhibited epicardial EMT (Morabito, 
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Dettman et al. 2001), further studies demonstrated that TGFβ1 and TGFβ2 
promote loss of epithelial character and smooth muscle differentiation in cultured 
proepicardial (Olivey, Mundell et al. 2006) and epicardial cells (Compton, Potash 
et al. 2006; Austin, Compton et al. 2008; Sanchez, Hill et al. 2011) in vitro, 
suggesting a potential role for TGFβ in epicardial EMT. TGFβ ligand knockout 
models do not have coronary vessel abnormalities (Shull, Ormsby et al. 1992; 
Kaartinen, Voncken et al. 1995; Sanford, Ormsby et al. 1997), suggesting the 
ability of multiple TGFβ ligands to engage and signal through the same TGFβ 
receptors allows for compensation of the loss of a single ligand in epicardial cells 
in vivo. Similar to the TGFβ ligands, ALK5 is required for epicardial EMT in vitro 
(Austin, Compton et al. 2008; Sridurongrit, Larsson et al. 2008). Disruption of 
ALK5 signaling in the epicardium using Alk5:Gata5c-cre mice revealed a role for 
TGFβ signaling in epicardial development in vivo. Targeted deletion of ALK5 in 
the epicardium in mice in vivo results in interrupted epicardial attachment to the 
myocardium, loss of expression of specific adhesion molecules, thinned 
myocardium, and a loss of coronary smooth muscle (Sridurongrit, Larsson et al. 
2008). Alk5:Gata5c-cre embryos survive until birth. This suggests that the 
coronary vessels were able to support cardiac function to some degree as mice 
completely lacking coronary vessels die at approximately E14.5-E16.5 (Yang, 
Rayburn et al. 1995; Moore, McInnes et al. 1999; Tevosian, Deconinck et al. 
2000).  
Deletion of Tgfbr3 in mice resulted in failed coronary vessel formation 
associated with embryonic demise at approximately E14.5. (Compton, Potash et 
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al. 2007). The striking aspect of this phenotype was the specific disruption of 
coronary vasculature. While vasculature outside of the heart observed using 
SM22α transgene labeling appeared grossly normal in Tgfbr3-/- embryos, there 
was reduced staining for the vascular endothelial marker PECAM1 in the 
coronary vasculature. Tgfbr3-/- embryos did form a primitive vascular plexus and 
ostia. We assume the reduced number of vessels was insufficient to supply the 
heart with blood, resulting in embryonic death. A thin compact zone myocardium, 
likely secondary to defects in the epicardium, was also observed in Tgfbr3-/- 
embryos. Compared to Tgfbr3-/- littermates, Tgfbr3-/- hearts featured a 
discontinuous epicardium overlying an expanded, hyperplastic supepicaridal 
space containing blood islands. Examination of Tgfbr3-/- hearts revealed a 
significant decrease of proliferation in the epicardium and epicardially-derived 
mesenchyme. Epicardial cell invasion into the myocardium was decreased in 
Tgfbr3-/- embryos, demonstrating a defect in some component of epicardial EMT 
(Sanchez, Hill et al. 2011). Overall, the unique phenotype of Tgfbr3-/- embryos, 
when compared to phenotypes of mice with targeted deletions in TGFβ1, TGFβ2, 
TGFβ3, or ALK5, demonstrated an important and non-redundant role for 
TGFβR3 in regulating epicardial cell behavior and coronary vessel development.  
 Further work was undertaken by our laboratory to elucidate the signaling 
mechanisms by which TGFβR3 regulates epicardial cell behavior in embryonic 
epicardial cells in vitro (Figure 3). Tgfbr3+/+ epicardial cells undergo loss of 
epithelial character and invasion into collagen gels in vitro in response to TGFβ1, 
TGFβ2, BMP2, ligands known to bind TGFβR3 (Lopez-Casillas, Cheifetz et al. 
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1991; Kirkbride, Townsend et al. 2008). While loss of epithelial character was still 
observed after loss of TGFβR3, Tgfbr3-/- cells had reduced invasion in response 
TGFβ1, TGFβ2, and BMP2 that was rescued with TGFβR3 (Sanchez, Hill et al. 
2011; Hill, Sanchez et al. 2012; Sanchez and Barnett 2012). TGFβ1 and TGFβ2 
also promoted smooth muscle differentiation in Tgfbr3+/+ and Tgfbr3-/- cells while 
BMP2 did not (Hill, Sanchez et al. 2012). Surprisingly, other ligands known to be 
important in epicardial EMT also required TGFβR3 to promote invasion in 
epicardial cells (FGF2 (Morabito, Dettman et al. 2001; Tomanek, Sandra et al. 
2001), High Molecular Weight (HMW)-HA (Craig, Austin et al. 2010; Craig, 
Parker et al. 2010)). One may hypothesize that this may be explained by binding 
of these molecules to TGFβR3, and indeed FGF2 has been reported to bind 
TGFβR3 (Andres, DeFalcis et al. 1992). Additionally, the ability FGF2 to promote 
repair in porcine VIC cultures required TGFβR3 (Han and Gotlieb 2011). 
TGFβR3 binding has not been reported for HMW-HA, though. Alternately, 
signaling directed by FGF2 and HMW-HA may require a common mediator 
downstream of TGFβR3 signaling. The decrease in invasion in Tgfbr3-/- epicardial 
cell invasion was not due to a general inability of these cells invade, as PDGF-
AA, PDGF-BB, VEGF, or EGF incubation induced similar levels of invasion in 
Tgfbr3+/+ and Tgfbr3-/- epicardial cells (Sanchez, Hill et al. 2011).  
 The TGFβR3-dependent invasion after incubation with TGFβ1, TGFβ2, 
BMP2, HMW-HA, or FGF2 in vitro was shown to require the cytoplasmic domain  
of TGFβR3, a domain not required for ligand presentation (Blobe, Schiemann et 




     
 







Vehicle BMP2 TGFβ1 TGFβ2
Tgfbr3+/+ Vehicle TGFβ1 TGFβ2 BMP2
Reads 49.1 x 106 48.8 x 106 39.9 x 106 24.3 x 106
Genes 15,103 14,806 14,977 14,888
Tgfbr3-/- Vehicle TGFβ1 TGFβ2 BMP2
Reads 30.6 x 106 42.9 x 106 42.3 x 106 31.5 x 106
Genes 13,966 13,957 14,047 14,088

























































                                                                                                                 
Figure 3: Comparison of Tgfbr3+/+ and Tgfbr3-/- epicardial cell proliferation, 
apoptosis, and invasion. Depiction of ligand-induced differentiation and invasion in 
Tgfbr3+/+ and Tgfbr3-/- immortalized epicardial cells in vitro. Red line- ZO1. Purple- 




to TGFβ1, TGFβ2, BMP2, HMW-HA, or FGF2 whereas constructs expressing a 
TGFβR3 mutant lacking the last 3 amino acids on the C-terminus fail to rescue 
invasion (Sanchez, Hill et al. 2011; Hill, Sanchez et al. 2012; Sanchez and 
Barnett 2012). The C-terminal amino acids of TGFβR3 constitute a class I PDZ 
binding domain that binds to the scaffolding protein GIPC which in turn stabilizes 
TGFβR3 on the plasma membrane to promote signaling. The importance of this 
interaction is supported by the observation that GIPC is not only required for 
invasion in Tgfbr3+/+ epicardial cells, but GIPC overexpression can promote 
invasion in the absence of additional ligand. GIPC regulation of epicardial 
invasion depends on TGFβR3 since Gipc expression in Tgfbr3-/- cells fails to 
rescue invasion and inhibition of Gipc expression blocks the ability of TGFβR3 to 
rescue invasion in Tgfbr3-/- cells (Sanchez, Hill et al. 2011). These data support 
the hypothesis that the interaction of TGβR3 and GIPC is required for epicardial 
cell invasion. 
Together, these in vitro data suggest a model where the ability of the 
epicardium to respond to FGF, HA, BMP, and TGFβ growth factors is 
compromised after the loss of TGFβR3, contributing to defects in epicardial cell 
behavior that may lead to failed coronary vessel development.  This ability of 
TGFβR3 to mediate epicardial cell behavior in response to an array of ligands 
may explain the severity of the in vivo phenotype of Tgfbr3-/- embryos when 
compared to other mouse models which disrupt TGFβ signaling in the 
epicardium. In particular, the in vitro results linking the defects observed in 
invasion of Tgfbr3-/- epicardial cells to the cytoplasmic domain of TGFβR3 which 
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is not required for ligand presentation suggests a unique, non-redundant role for 
TGFβR3 in regulating epicardial EMT. Intriguingly, these results are similar to 
those observed in endocardial cushions where the interaction of TGFβR3 with 
GIPC is required to promote TGFβ2 and BMP2 dependent invasion in vitro 
(Townsend, Robinson et al. 2011). This suggests studies examining the 
mechanisms by which TGFβR3 regulates invasion may yield insights applicable 
to both epicardial and endocardial EMT. Together, these results indicate that 
TGFβR3 may represent a common pathway accessed by several upstream 
regulators of cell invasion. 
Despite the increasing evidence for the unique role of TGFBR3 signaling 
in important development and disease processes, little is known about the 
signaling mechanisms downstream of TGFβR3. In Chapter III we undertake the 
first comprehensive analysis of the signaling pathways dependent on TGFβR3 
signaling by coupling the well described epicardial culture system with next 
generation sequencing.  
 
Summary 
 EMT is an important process not only in development where it is required 
for the formation of mature structures in the heart, but in homeostasis and 
response to injury in the adult hearts as well. A sustained interest in examining 
EMT during valve and coronary vessel development has yielded many insights 
into the biology of these systems. In particular, we have shown an important role 
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for TGFβR3 in endocardial and epicardial EMT. Still, the signaling pathways 
regulating endocardial and epicardial EMT are incompletely understood and the 
field often progresses at the pace of a single gene study at a time. Here, we took 
advantage of known biology of these systems and the power of next-generation 
sequencing to devise transcriptional profiling strategies which allowed us to 
identify and validate novel candidate genes and signaling pathways regulating 
endocardial and epicardial EMT. Further analysis of the gene lists and GRNs 
identified by these studies may yield important insights into signaling events 
regulating endocardial and epicardial cell biology, which is essential to the design 
of novel therapeutic approaches to alter cell behavior in heart disease, and 

















SPATIAL TRANSCRIPTIONAL PROFILE OF THE CHICK AND MOUSE 
ENDOCARDIAL CUSHIONS IDENTIFY NOVEL REGULATORS OF 
ENDOCARDIAL EMT IN VITRO 
 
Introduction 
 Valvular heart disease comprises a major portion of cardiovascular 
disease in children and adults. Congenital Heart Disease (CHD), which includes 
a spectrum of valvular defects, occurs in 1 out of 100 live births and is 
responsible for ten percent of infant deaths per year (Hoffman 1968; Loffredo 
2000). Ninety percent of children with CHD now live to adulthood due to the 
surgical and medical advances of the past half century  (Khairy, Hosn et al. 
2008). As a result, adults now represent the largest age group with CHD, but 
because they are a relatively new class of patient, treatment approaches are as 
yet unclear. Also, it is now well recognized that there is a developmental basis to 
adult cardiovascular and valve disease. It is reasonable to assume that the 
homeostatic and repair functions present in adults would use many of the same 
mechanisms involved in the original development and remodeling of these 
tissues (reviewed in (Doetschman T 2012)). Therefore, the careful examination of 
genes and signaling pathways governing early valve development is likely to 
provide novel insight into the mechanisms underlying valve disease and suggest 
potential new therapies. 
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 Valvular interstitial cells (VICs) are a common substrate of both congenital 
and adult valvular disease (Doetschman T 2012). These cells are derived 
primarily from specialized endothelium, located in the atrioventricular (AVC) and 
outflow tract (OFT) cushion regions of the developing heart tube, which 
undergoes EMT (Barnett and Desgrosellier 2003). VICs direct both the 
remodeling of the ECM during valvulogenesis in the embryo and the 
maintenance of the structure of the valve leaflets in the adult. Despite a 
continued interest in the process of endocardial EMT (reviewed (DeLaughter, 
Saint-Jean et al. 2011; Lencinas, Tavares et al. 2012; von Gise and Pu 2012)) 
our understanding remains incomplete and often progresses at the pace of a 
single gene study at a time. We directed our analysis to an unbiased approach 
identifying genes and pathways associated with endocardial EMT. Previous 
studies have used a variety of gene expression analysis approaches to identify 
cushion-enriched genes in the AVC (Rivera-Feliciano, Lee et al. 2006; Wirrig, 
Snarr et al. 2007; Chakraborty, Cheek et al. 2008; Vrljicak, Chang et al. 2010). 
Comparisons of normal and aberrant cushion development, a strategy predicated 
on the availability of models with known heart defects, yielded only genes 
associated with the perturbed signaling pathway (Rivera-Feliciano, Lee et al. 
2006). While this approach has utility, many of the genes and signaling pathways 
associated with normal cushion development have yet to be determined. A 
second approach identified genes temporally regulated in the AVC by comparing 
different stages of development (Chakraborty, Cheek et al. 2008; Vrljicak, Chang 
et al. 2010). This strategy identified pathways that change over time in the AVC 
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but pathways specific to endothelial EMT were not directly queried. Both of these 
approaches focused on the use of a single spatial region of the heart for 
analyses. 
 We recognized that the inherent regional specificity observed in the 
developing heart tube presents a unique opportunity for analysis of endocardial 
EMT. EMT occurs specifically in the endothelium of the AVC and OFT but not in 
the adjacent endothelium of the common ventricle (VEN). Thus, a spatial 
transcriptional profile of these three regions of the heart tube enables a direct 
comparison between regions that do and do not undergo EMT. Further, the 
generation of data from these regions allows for genes expressed in the 
nontransforming ventricle to be subtracted from those genes expressed in the 
AVC and OFT in order to enrich for genes associated with endothelial EMT. This 
approach expands on earlier studies which focused on the AVC by comparisons 
that allow background subtraction of extraneous, non-target cell populations 
present during EMT. For example, at E10.5 proepicardial cells attach to the AVC 
(Viragh and Challice 1981) and subsequently migrate over the myocardium 
coincident with a population of PAX-3-positive cardiac neural crest cells entering 
the OFT (Conway, Henderson et al. 1997) . The approach here, which identifies 
genes with enriched expression specific to both the AVC and OFT, excludes 
genes expressed by either of these non-target cell populations, which are 
contained in only a single cushion. Therefore, this focuses our analysis on 




 In this chapter I collaborated with Jamille Robinson who performed the 





 HH18 chick (n=200, yielding 8 µg of RNA) and E11.0 ICR (n=100; n=60; 
yielding 17 µg and 10 µg of RNA, respectively) mouse hearts were dissected into 
AVC, OFT, and VEN (Figure 4A-B) and the samples were pooled.  Standard 
phenol-chloroform extraction of RNA was performed. 
RNA-seq 
 RNAseq libraries were generated as described without normalizations or 
RNA/cDNA fragmentation (Christodoulou, Gorham et al. 2011). Libraries were 
sequenced as 50 bp paired end sequences on a single lane of the Illumina 
HiSeq2000 producing 7 million reads per chick sample and an average of 10 
million reads per mouse sample. HiSeq 2000 reads are aligned by TOPHAT 
(Trapnell, Pachter et al. 2009) (http://tophat.cbcb.umd.edu/) to produce bam files. 
Gene expression profiles were generated as described (Christodoulou, Gorham 
et al. 2011) using a Bayesian p-value (Audic and Claverie 1997). Reads were 
normalized to total mRNA (total aligned reads on gene-loci per million). Data files 
have been deposited in the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/) and can be accessed via series record 
GSE43194. Variability was assessed as described in Figure 5 and 6. 
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Figure 4: Spatial transcriptional profile of heart identifies cushion-enriched 
genes. A-B, AVC, OFT and VEN were dissected from equivalent stages of chick 
HH18 (A) and mouse E11.0 (B). C, RNA-seq analysis identified genes with 
significantly expressed (>10 reads) in each spatial region of the developing heart 
tube. D, Mapping genes with enriched expression (>2-fold) onto each spatial 
region identifies those genes with cushion-enriched expression (in red), 198 in 
the chick and 105 in the mouse. Scale bars - 100µM. 
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Figure 5: Variability in RNA-seq data sets. A, The expression of Hprt1 
(normalized reads) in each region of the heart tube (AVC, OFT, VEN) for HH18 
chick and E11.0 mice is depicted. The expression of Hprt1 is not expected to 
vary based on the region of the heart tube examined (AVC, OFT, VEN) or 
biological replicates (n=100, n=6). Little variability in Hprt1 expression is 
observed in chick and mice. B-D, The two pools (n=100, n=60) of mouse tissue 
were processed separately as biological replicates for RNA-seq analysis and the 
reads for each gene in each pool were plotted against each other in (B) AVC 
(R=0.85), (C) OFT (R=0.93), and (D) VEN (R=0.93). These data support the 
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Figure 6: Comparison of differential gene expression between E11.0 
biological replicates. Plots mapping the fold (log base 2) difference (either (A) 
>1.25-fold or (B) >2.00-fold) in expression between AVC/VEN, OFT/VEN or 
AVC/OFT in mouse biological replicates (X-axis: n=60, Y-axis: n=100) are 
shown. Genes that show agreement, defined as having >1.25 or >2.00-fold 
(p<0.001) increased or decreased expression in a specific comparison in both 
replicates, are mapped to quadrants I (upper right) or III (lower left) of a plot. 
Genes that show disagreement, defined as having>1.25 or >2.00-fold (p<0.001) 
increased expression in a tissue in one replicate and decreased in another (or vis 
versa), are mapped to quadrants II (upper left) or IV (lower right). There was a 
high degree of agreement using either a >1.25-fold (R>0.91) or a >2.00-fold 





 First-strand synthesis was done with SuperScript III kit (Invitrogen). SYBR 
Fas Green (Biorad) was used for qRT-PCR. Primer sequences are in Table 2. 
 
Table 2: Primers Used to Confirm Gene Knockdown 
Gene Forward Primer Reverse Primer 
FOXP2 5’(GTGCCACAGACAGATGCAACAACA)3’ 5’(TTTGACGAAGCTCATGCGGAGGAT)3’ 
MEIS2 5’(AAGGGAGCCTTATGGACCAAACCA)3’ 5’(AGCTTCAGCTTAAACACCCGACCT)3’ 
HAPLN1 5’(AGCACCCAGCTGTGGCTAATTACT)3’ 5’(TCTATGTGCAAATGTGCAAGGCCG)3’ 
ID1 5’(AGACAACAGGGCTCTCCTCAAACT)3’ 5’(ACTGCGAGACCCAAGTCAGCAATA)3’ 
TGFR3 5’(ACCAGAGTGGCGTGTTAAGAAGGT)3’ 5’(TGCACAGAAAGGACCCAAAGCAAC)3’ 
   
 
Collagen Gel Assay 
 Collagen gel assays (reviewed (Lencinas, Tavares et al. 2012)) with 
siRNA or small molecule addition were performed as described (Townsend, 
Wrana et al. 2008). AVC were excised from stage 16 chick embryos, transected, 
and explanted endocardial side down onto a collagen I gel and incubated at 37oC 
with siRNA constructs. Control for siRNA toxicity was a randomized GC matched 
construct that do not correspond to any sequence. The positive control was 
siRNA targeting Tgfbr3 (Townsend, Robinson et al. 2011). siRNA sequences are 
listed in Table 3.  EMT was quantified by counting the number cells with 








Table 3: siRNA Construct Sequences 
  













Table 4: Collagen Gel Assay Counting Data 
Experiment Condition N 






Cells +/- SEM 
Foxp2 
Control 30 8886 100 +/- 4 
TGFβR3 30 5349 60+/-3 
FOXP2-A 31 5078 55+/-3 
FOXP2-B 30 4785 53+/-2 
Meis2 Control 30 8572 100+/-6 
TGFβR3 29 4589 55+/-3 
MEIS2-A 30 3413 39+/-3 
MEIS2-B 30 3209 37+/-3 
HAPLN1 
Control 28 11592 100+/-7 
TGFβR3 30 6127 49+/-3 
HAPLN1-A 30 5500 44+/-3 
HAPLN1-B 29 4884 40+/-3 
ID1 Control 21 6867 100+/-9 
TGFβR3 30 5971 60+/-5 
ID1-A 30 5511 56+/-4 







In Situ Hybridization 
 Dioxygenin labeled probes were generated from cDNA derived from E13.5 
whole heart tubes using primers in Table 5. In situ hybridization was performed 





Defining a spatial transcriptional profile of the developing heart tube 
 Chick and mouse models were used for their relative strengths as model 
systems and the ability to use cross species comparison to identify key 
regulatory genes. Equivalent stages in the chick (HH18) and mouse (E11.0) were 
chosen when robust EMT occurs in both the OFT and AVC but not the VEN at 
this time (Camenisch, Molin et al. 2002). Spatial transcriptional profiles of chick 
and mouse heart tubes were generated as described in methods (Figure 4A-B).   
 The dynamic nature of gene expression profiles generated by RNA-seq 
identified approximately 8,000 genes expressed throughout either the chick or 
mouse heart tube. A smaller number of genes were also localized to specific 
regions such as the AVC, OFT, & VEN (Figure 4C). As a first step to enrich for 
 
Table 5: Primers Used to Generate ISH Probes 
   
Gene Forward Primer Reverse Primer 
Foxp2 5’(CGCGAGCCTCCGAGAAAGCG)3’ 5’(CATCATGGCCACCGACACGGG)3’ 
Meis2 5’(TGGCGGACAGGTTATGGACATTCA)3’ 5’(TGAAGAAGCCTTCGCTCTGTCTCT)3’ 
Hapln1 5’(TGGACCAGGACGACGCAGTGATT)3’ 5’(GCAGCGGTCATAGCCCAGAA)3’ 
Id1 5’(CCCCTCCGCCTGTTCTCAGGA)3’ 5’(TACCCACTGGACCGATCCGC)3’ 
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genes mediating EMT, we subtracted genes found in the VEN sample from the 
AVC & OFT samples. By identifying genes upregulated in both cushions in the 
comparison we eliminated the influence of the epicardial cells (AVC) and neural 
crest cells (OFT) which are found only in a single cushion sample and therefore 
not in the shared gene list we identified (Figure 7A; see Wt1 (AVC, VEN), Sox10 
(OFT), BMP10 (VEN)). 
 This approach yielded a robust list of genes upregulated in the cushions. 
We mapped genes enriched >2-fold in each spatial region (Figure 4D) Genes 
associated with distinct regions of the heart tube in chick and mouse cushions, 
including the T-box family members, had spatial expression patterns consistent 
with the literature (Figure 7B). We observe a few hundred genes enriched in the 
cushions, consistent with the hypothesis that the AVC and OFT should share 
common genes involved in endothelial EMT (Figure 4D). Comparisons of the 
AVC & VEN or OFT & VEN did not reveal as many enriched genes since they do 
not share EMT as a common process. Therefore, genes with a significant p-value 
(p<.001) and >2-fold higher expression in the cushions (AVC & OFT) compared 
to VEN are considered to be enriched in these compartments and were potential 
candidates for involvement in EMT.  
 Overall, 198 genes were identified in the chick (Appendix A) and 105 in 
the mouse (Appendix B) that were >2-fold higher expressed in the cushions. A 
literature search was used to further characterize these gene lists. In total, 15 of 
the 198 genes in chick and 18 of the 105 genes in mouse have a previously 
described role in EMT (Table 6).  Genes known to be expressed regionally in the  
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Figure 7: Spatial expression of select genes in the HH18 chick and E11.0 
mouse heart tube. For each gene, expression was normalized to the region with 
the highest read count A, Regional expressed patterns in the mouse heart are 
consistent with previous observations at E10.5-E11.5. Bmp10 (VEN), Isl1 (OFT), 
Hand1 (VEN), Hand2 (endocardium throughout heart tube), Tbx18 and Wt1 
(Epicardium attaching to AVC and migrating towards VEN), and Sox10 (neural 
crest in OFT and in OFT and AVC cushions). B, Expression of T-box genes in 
chick and mouse are consistent with previous reports (reviewed (Greulich, Rudat 
et al.)). n.d.- TBX1 has not been annotated in the chick genome and is not 
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Table 6: Genes >2-fold Enriched in Chick or Mouse Cushions Previously 







Chick Genes Mouse Genes 
BMP2 (Lyons, Pelton et al. 1990; Ma, Lu 
et al. 2005) 
Col2a1 (Li, Prockop et al. 1995) 
CXCR7 (Yu, Crawford et al. 2011) Eln (Krishnamurthy, Opoka et al. 
2012) 
FBN1 (Ng, Cheng et al. 2004) Epha3 (Stephen, Fawkes et al. 2007)  
HAS2 (Camenisch, Spicer et al. 2000) Erbb3 (Erickson, O'Shea et al. 1997; 
Camenisch, Schroeder et al. 2002) 
IGF2 (Hartnett, Glynn et al. 2010) Fzd1 (Yu, Smallwood et al. 2010) 
MSX2 (Chen, Ishii et al. 2008) Gpc1 (Niu, Bahl et al. 1998) 
SNAI2 (Niessen, Fu et al. 2008) Has2 (Camenisch, Spicer et al. 
2000) 
SOX9 (Akiyama, Chaboissier et al. 2004; 
Lincoln, Kist et al. 2007) 
Msx1 (Chen, Ishii et al. 2008) 
TBX2 (Shirai, Imanaka-Yoshida et al. 
2009; Singh, Hoogaars et al. 2012) 
Msx2 (Chen, Ishii et al. 2008) 
TBX20 (Stennard, Costa et al. 2005) Pitx2 (Kitamura, Miura et al. 1999) 
TGFB2 (Sanford, Ormsby et al. 1997) Postn (Norris, Moreno-Rodriguez et 
al. 2008) 
WNT4 (Alfieri, Cheek et al. 2010) Rarg (Mendelsohn, Lohnes et al. 
1994) 
WNT6 (Alfieri, Cheek et al. 2010) Smad6 (Galvin, Donovan et al. 2000) 
WT1 (Zhou, Ma et al. 2009) Snai1 (Timmerman, Grego-Bessa et 
al. 2004) 
ZFPM2 (Ackerman, Herron et al. 2005; 
Zhou, Ma et al. 2009) 
Sox9 (Akiyama, Chaboissier et al. 
2004; Lincoln, Kist et al. 2007) 
 Tbx2 (Shirai, Imanaka-Yoshida et al. 
2009; Singh, Hoogaars et al. 2012) 
 Tgfb2 (Sanford, Ormsby et al. 1997) 
 Twist1(Chen and Behringer 1995; 
Shelton and Yutzey 2008; Lee and 






myocardium (Bmp4 (Keyes, Logan et al. 2003), BMP2 (Keyes, Logan et al. 
2003)) were identified as having cushion enriched expression in chick and mouse 
as expected. Of note, 31 of 105 identified in the mouse were found to be 
expressed in the endothelium or mesenchyme derived from endothelium. Thus, 
the RNA-seq methodology was sensitive enough to detect changes in gene 
expression in the endothelium and mesenchyme when the majority of the sample 
is derived from the myocardium. Relaxation of the stringency of gene enrichment 
to a level of >1.25-fold (p<0.001) (Figure 8) revealed 574 genes enriched in the 
chick (Appendix A) and 250 enriched in the mouse (Appendix B). Of these, 54 
genes in the chick and 41 genes in the mouse were associated with abnormal 
heart development and function. Several genes known to play important roles in 
endocardial EMT were revealed in the >1.25-fold gene lists. Though there is an 
increased chance of including false positive genes by lowering the stringency, 
there may also be novel candidate genes in the 1.25 fold gene lists that would 
otherwise be missed with a 2 fold cutoff. In particular, small changes (<2-fold) in 
the expression levels of transcription factors may have a significant effect on cell 
behavior (Niwa, Miyazaki et al. 2000). 
 
Gene Ontology (GO) Analysis of Cushion-Enriched Genes 
 To gain a better understanding of the genes in the >2-fold cushion 
enriched gene lists we examined the associated predicted protein location, 
predicted protein function and biological processes (Figure 9). Enriched genes 




Figure 8: Spatial transcriptional profile of heart identifies cushion-enriched 
genes. A-B, AVC, OFT and VEN were dissected from equivalent stages of chick 
HH18 (A) and mouse E11.0 (B).  C, RNA-seq analysis identified genes with 
significantly expressed (>10 reads) in each spatial region of the developing heart 
tube. D, Mapping genes with enriched expression (>1.25-fold) onto each spatial 
region identifies those genes with cushion-enriched expression (in red), 547 in 
the chick and 225 in the mouse. 
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Figure 9: Gene ontology, predicted protein location, and protein function of 
>2-fold cushion-enriched genes. A, Predicted protein function of genes 
identified in the mouse and chick cushion-enriched gene lists generated using 
IPA software. Percent of total genes with defined function is depicted. Genes with 
unknown function in chick (89) and mouse (44) are not shown. B, Predicted 
protein location of genes identified in mouse and chick cushion using IPA 
software. C-D, Analysis of genes found >2-fold enriched in chick and mouse AVC 
and OFT using DAVID software. Selected significantly enriched biological 
processes (from DAVID BP-FAT) are depicted for chick and mouse (p<0.0001 for 
all terms). Significance was based on p-values generated by DAVID 
software(Dennis, Sherman et al. 2003). Biological processes highlighted in 
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Figure 10: Gene ontology, predicted protein location, and protein function 
of >1.25 cushion-enriched genes. A, Predicted protein function of genes 
identified in the mouse and chick cushion enriched gene lists generated using 
IPA software. Percent of total genes with defined function is depicted. Genes with 
unknown function in mouse (96) and chick (265) are not shown. B, Predicted 
protein location of genes identified in mouse and chick cushion using IPA 
software. The number of genes predicted to be located to each region is 
depicted. C-D, Analysis of genes found >1.25-fold enriched in chick (C) and 
mouse (D) AVC and OFT using DAVID software revealed an enrichment of 
genes associated with biological processes important in EMT. Significance was 
based on p-values generated by DAVID software using a modified EASE score. 
Biological processes highlighted in yellow are shared between chick and mouse. 
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proteins predicted to be transcriptional regulators (Figure 9A-B). To examine 
which biological processes were associated with the cushion-enriched gene lists 
in chick and mouse we performed functional annotation using Database for 
Annotation, Visualization, & Integrated Discovery (DAVID) software(Dennis, 
Sherman et al. 2003). Several biological processes were identified in chick 
(Appendix C) and mouse (Appendix D) genes lists. Consistent with the shared 
underlying morphological processes occurring in the cushions of each, we 
identified biological processes enriched in both chick and mouse associated with 
the process of EMT (Figure 9C-D). Biological processes related to bone 
development (skeletal system organization) were observed and are consistent 
with the prior observation that there is a high degree of conservation in signaling  
pathways which regulate bone and valve development (Chakraborty, Cheek et al. 
2008). GO analysis of the >1.25-fold gene lists yielded results similar to those 
obtained with the >2-fold gene lists (Figure 10). Thus, GO analysis of cushion-
enriched gene lists in chick and mouse identified shared processes expected for 
a population of endothelial cells undergoing EMT. 
 
Gene Regulatory Network (GRN) Analysis of Cushion-Enriched Genes 
 To gain a better understanding of how the genes enriched in the cushion 
interact with each other, GRN analysis was undertaken of the chick and mouse 
>2-fold differentially expressed gene lists using Ingenuity Pathway Analysis 
software (IPA) (www.ingenuity.com). Figure 11 depicts an example mouse gene 











Figure 11: Gene regulatory networks generated from cushion-enriched-
gene lists identifies known regulators of endocardial EMT. Gene regulatory 
networks were generated with IPA software using >2-fold cushion-enriched 
genes in chick and mouse. An example mouse network is depicted. Lines denote 
interactions between genes observed in the literature across all systems, with 
solid lines reflecting a direct interaction and doted lines denoting an indirect 
interaction. Gene names over shapes denote nodes. Green nodes have 
decreased expression and red have increased expression. Additional genes 
were annotated based on known interactions in the literature (Bmp). Hapln1 and 
Meis2 nodes were added to identify potential interactions of novel candidate 
genes in this network. Genes were marked that are known to regulate EMT in 




















development several genes in this network have been previously demonstrated 
to regulate EMT in vitro in mice (green circles) or in chick (blue circles). We 
observed several genes in the network that when targeted in mice resulted in 
phenotypes associated with abnormal cushion or valve development (red 
circles). This high number of genes known to be important in cushion or valve 
development provides confidence that this gene network reflects the biological 
processes occurring in the cushions. Our analysis confirms TGFβ as a signaling 
node in regulating endocardial EMT and valvulogenesis (reviewed (DeLaughter, 
Saint-Jean et al. 2011)). This network also identified NF-κB as a node and the 
role of NF-κB in endocardial EMT is undescribed. Thus, GRN analysis of the 
cushion-enriched gene lists in chick and mouse provided insight into the 
relationships between genes known to regulate endocardial EMT and identified 
candidate signaling pathways for functional analysis.  
 
Identification of Gene Candidates for Functional Analysis 
 We selected candidate genes for further analysis using our knowledge of 
the biology of the system to target genes involved in critical signaling pathways. 
Hapln1, Id1, Meis2, and Foxp2 comprised our slate of candidate genes which 
were selected from both the >2-fold (Hapln1 (chick) and Foxp2 (mouse)) and 
>1.25 fold (Id1 (mouse) and Meis2 (mouse)) cushion enriched gene lists. For 
each candidate, whole mount in situ hybridization in E11.0 mouse embryos 
confirmed the expression pattern predicted by RNA-seq analysis (Figure 12). 





Figure 12: Confirmation of cushion-enriched gene expression in E11.0 
hearts. A-D, Whole mount in situ hybridization with probes specific for (A) 
Hapln1, (B) Id1, (C) Foxp2, and (D) Meis2 in E11.0 embryos in whole hearts 
(top) and 10 µM cryosections (bottom) revealed enriched expression in the AVC 
(brackets) and OFT (outlines) compared to VEN. avc- atrioventricular canal, oft- 



















































proteins in the extra-cellular space to affect ECM organization (Morgelin, 
Paulsson et al. 1995; Matsumoto, Shionyu et al. 2003). The deletion of Hapln1 in 
mice results in hypoplastic valves (Wirrig, Snarr et al. 2007). Inhibitor of DNA 
binding 1, ID1, is a helix-loop-helix (HLH) protein that acts as a dominant 
negative antagonist of basic HLH transcription factors and can regulate both 
TGFβ and BMP signaling. MEIS2 has recently been reported to be required for 
cardiac looping in zebra fish but has no described function in valve development 
(Paige, Thomas et al. 2012). FOXP2 is a forkhead/winged-helix transcription 
factor that has been extensively studied in the context of neural development. It 
is required for birds to learn song and mutations in FOXP2 have been linked to 
human speech pathologies (Enard 2011). Although some candidates have been 
studied in valvulogenesis, none have a described role in endocardial EMT.  
 A functional analysis using siRNA to target candidate genes in the well-
defined chick AVC explant collagen gel assay in vitro was used to assess any 
role in endocardial EMT (reviewed (DeLaughter, Saint-Jean et al. 2011; 
Lencinas, Tavares et al. 2012)). Each of two independent siRNA constructs 
targeting candidates resulted in a decrease of endocardial EMT (Figure 13 A-E). 
qPCR analysis of explants confirmed both the expression and successful 
targeting of these genes in the chick AVC explants (Figure 14).  These results 
establish a role for each candidate in the regulation of endocardial EMT in vitro 
and confirm our analysis was successful in identifying genes that regulate 
endocardial EMT. The lack of effect of control siRNA on EMT and the reported 
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Figure 13: Candidate genes are required for endocardial EMT in vitro. A, 
Representative photomicrographs of AVC explants incubated with HAPLN1-
targeted siRNA. B-E, Candidate gene expression in HH16 chick embryos was 
knocked down with siRNA in an in vitro collagen gel assay. The mean number of 
cells in the collagen gel was determined and normalized to the number of cells in 
controls (100%). Con - GC-content matched, randomized siRNA constructs with 
no homology to any known chick gene, TGFβR3 - siRNA targeting a gene known 
to be required for EMT in vitro. a or b - independent  constructs targeting 
indicated gene. * - p<0.01. F, Transcriptional network depicting genes known to 
be downstream of NF-κB which had increased expression in the AVC and VEN. 
See legend in Figure 11.  G, NF-κB inhibition by two independent small molecule 
inhibitors (10 µM BMS 345541 and 2 µM SN50) resulted in a loss of function an 
in vitro collagen gel assay. SB431542, an ALK5 kinase inhibitor, was used as a 




















Figure 14: Quantification of siRNA Knockdown. Explants were incubated with 
siRNA constructs targeting TGFβR3 (positive control), HAPLN1, Foxp2, ID1, 
MEIS2 or a randomized GC-matched construct (negative control) for 48 hours on 
a collagen gel. To get sufficient RNA, 15 explants were used for each siRNA 
construct (positive control, negative control, a, b) and repeated in triplicate for 
each gene targeted (HAPLN1, FOXP2, ID1, MEIS2). The expression of these 
genes was then assayed by quantitative real time (RT)-PCR. Expression was 
normalized to GAPDH for each experiment. TGFβR3 siRNA incubation 
significantly reduced TGFβR3 mRNA expression level by 53%. HAPLN1 mRNA 
expression levels were significantly reduced by 55% and 63% by siRNA 
treatment with HAPLN1-A and HAPLN1-B respectively. FOXP2 mRNA 
expression levels were significantly reduced by 78% and 76% by siRNA 
treatment with FOXP2-A and FOXP2-B respectively. ID1 mRNA expression 
levels were significantly reduced by 53% and 57% by siRNA treatment with ID1-
A and ID1-B respectively. MEIS2 mRNA expression levels were significantly 
reduced by 67% and 51% by siRNA treatment with MEIS2-A and MEIS2-B 
respectively. All genes depicted in the graph were significantly reduced 















on EMT (Townsend, Wrana et al. 2008; Townsend, Robinson et al. 2011) 
supports the validity and specificity of these results.  
 
Selection and Validation of Signaling Pathway Identified by GRN Analysis 
 An advantage of GRN analysis lies in the ability to generate networks from 
a list of differentially expressed genes to predict the involvement of genes and 
signaling pathways where expression is unchanged. This approach can identify 
potential regulatory nodes that may escape notice if only gene expression is 
examined. One such example from our GRN analysis is the NF-κB pathway  
(Figure 11) where signaling  activity is regulated on the protein level (reviewed 
(Vallabhapurapu and Karin 2009)) making it unlikely to appear in a screen of 
gene expression. Indeed, NF-κB pathway signaling components were not found 
in our cushion-enriched gene lists yet our strategy of using GRN analysis allowed 
us to identify NF-κB as a potential regulator of endocardial EMT. Many upstream 
regulators of NF-κB were observed and more edges were associated with NF-κB 
than other nodes, such as Pka (Figure 11).  We also examined those genes 
regulated by NF-κB in the cushion-enriched gene list. Figure 13F depicts genes 
enriched in the AVC and OFT which are known to be directly or indirectly 
regulated by NF-κB signaling, including several genes known to be important in 
endocardial EMT (Has2, Msx2, Twist1). NF-κB signaling has long been 
associated with adult heart disease (reviewed (Gordon, Shaw et al. 2011)) and 
has recently been linked to FGF-2 mediated EMT in corneal endothelial cells 
(Lee and Kay 2012). However, the role of NF-κB signaling in endocardial EMT 
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has not been investigated. Together, these data and the known role of NF-κB in 
EMT in other systems led us to select NF-κB for further study. 
 To test for a role of NF-κB in endocardial EMT we took advantage of 
the availability of small molecule inhibitors of NF-κB signaling. We chose 2 
different inhibitors (10 µM BMS 345541 and 2 µM SN50) with differing 
mechanisms of action to block NF-κB function in the collagen gel assay. BMS 
345541 specifically inhibits the phosphorylation of IκB kinase by inhibition of IKK 
(Burke, Pattoli et al. 2003) which prevents IκB targeting for degradation and the 
subsequent release of NF-κB into the nucleus. SN50 is a synthetic peptide which 
blocks the nuclear import of the NF-κB complex itself (Lin, Yao et al. 1995). 
Some explants were also incubated with 2.5 µM SB431542, an ALK5 inhibitor 
previously characterized in this system (Townsend, Wrana et al. 2008), as a 
positive control for small molecule inhibition of EMT, or vehicle as a negative 
control. Incubation with BMS 345541 or SN50 resulted in a 31% or 79% 
reduction in the number of cells invading into the collagen gel compared to 
vehicle-incubated explants, respectively (Figure 13G). Together, these data 




Spatial transcriptional profile of the heart tube in chick and mice 
 In this study we used an unbiased approach to identify important 
regulators of cardiac valvular EMT. Previous studies have used a similar spatial 
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analysis in E10.5 mouse hearts in an effort to identify genes associated with 
endocardial EMT and valvulogenesis. Analysis of the AVC and VEN by 
microarray (Wirrig, Snarr et al. 2007) and, more recently, examination of micro-
dissected atria, AVC, OFT, and VEN by TAG-seq (Vrljicak, Cullum et al. 2012), 
generated lists of genes enriched in the regions of the heart tube undergoing 
EMT. This information was used to identify and target a single gene, Hapln1, in 
vivo in mice. However, our approach was unique in that it coupled the power of 
spatial analysis with a rapid in vitro bioassay to confirm a role for candidate 
genes and pathways in endocardial EMT. To that end we took advantage of the 
longstanding collagen gel chick AVC explant assay and expanded our spatial 
analysis to include equivalent stages of both mouse and chick heart tubes. The 
inclusion of the chick model allowed for cross species comparison and provided 
primary data obtained from the species upon which our in vitro assay is based.    
 The genes identified as enriched in these two models were subjected to 
GO and GRN analysis which revealed biological processes, signaling pathways 
and gene interactions known to be important in endocardial EMT. Among others, 
key components of TGFβ (TGFβ2 chick/mouse), BMP (Bmp2 mouse), retinoic 
acid (CYP26B1 chick/mouse), and WNT (WNT4 chick, Wnt9b mouse) signaling 
pathways were revealed. Several genes common to both lists were known to 
play a role in valve formation (Table 7). Thus, the cushion-enriched gene lists 
accurately reflect the biological processes associated with endocardial EMT and 







Table 7: Genes >2-fold Enriched in Both Chick and Mouse Cushions 
 
Chick Mouse 
Gene AVC/VEN OFT/VEN Gene AVC/VEN OFT/VEN 
Cyp26b1* 3.799 3.099 Cyp26b1* 2.568 2.918 
Doc2b* 49 49 Doc2b* 11.022 16.155 
Has2 3.455 4.082 Has2 4.178 6.579 
Matn4* 19.256 8.164 Matn4* 23.974 7.754 
Msx2 2.991 3.08 Msx2 6.29 6.368 
Rspo3* 20.746 19.477 Rspo3* 10.651 15.906 
Sox9 3.99 3.549 Sox9 5.433 5.954 
Tbx2 6.81 2.826 Tbx2 9.415 4.846 
Tgfb2 2.123 3.047 Tgfb2 2.054 3.568 
*Denotes genes previously not linked to endocardial EMT. 
Mean fold enrichment in the AVC or OFT is indicated. 
 
Validation of candidate genes as regulators of endocardial EMT in vitro 
 We identified and confirmed the involvement of novel genes and a novel 
pathway in endocardial EMT in vitro. HAPLN1 is expressed throughout the heart 
tube at E10.0 and becomes restricted to the endocardium and mesenchyme of 
the AVC and OFT by E11.0 (Figure 12A) (Wirrig, Snarr et al. 2007). Deletion of 
Hapln1 in mice resulted in hypoplastic valves similar to, but less severe than, the 
null phenotypes of HA and Versican, both of which HAPLN1 binds (Perkins, 
Nealis et al. 1989; Matsumoto, Shionyu et al. 2003; Wirrig, Snarr et al. 2007). 
The authors noted that it was unclear whether the lack of cellularization of the 
cushions in these animals was due to a defect in post-EMT cell proliferation or in 
endothelial EMT itself (Wirrig, Snarr et al. 2007). Our data suggests that the 
hypoplastic valves observed in Hapln1 null mice may be at least partially due to 
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aberrant endocardial EMT. Similarly, Id1 is expressed in the endothelium and 
cushion mesenchyme at E10.5/E11.0 (Figure 12B) (Jen, Manova et al. 1996; 
Fraidenraich, Stillwell et al. 2004). Deletion of both Id1 and Id3 leads to 
hypoplastic cushions associated with discontinuous endothelium in the context of 
disrupted heart development (Fraidenraich, Stillwell et al. 2004). Targeting of Id1 
in the endothelium of Id3 null mice yields a less severe phenotype that displays 
signs of aberrant cushion mesenchyme development associated with valvular 
and septal defects (Zhao, Beck et al. 2011). These studies point to a potential 
role for Id1 in VIC development, yet Id1 had not been shown to regulate 
endothelial EMT. Our results suggest that compromised endothelial EMT may 
contribute to the phenotypes seen in Id1 null mice.   
 Members of the FOXP family of transcription factors have been implicated 
in heart development including FOXP1 (Wang, Weidenfeld et al. 2004) and 
FOXP4 (Li, Zhou et al. 2004). At E11.0, Foxp2 is expressed abundantly in the 
endocardium and mesenchyme of the OFT and AVC when compared to the VEN 
as well as in the myocardium of the OFT (Figure 12C). Both FOXP2 and FOXP4 
have been shown to promote the delamination of neuroepithelial cells in the 
mouse (Rousso, Pearson et al. 2012) demonstrating a role for each in regulating 
EMT in vivo. Foxp4 was also enriched in our RNA-seq data sets and can form 
heterodimers with FOXP2 (Li, Weidenfeld et al. 2004). The presence of Foxp4 in 
the cushions suggests that FOXP4 may compensate for the loss of FOXP2, 
explaining the lack of a reported cushion or valve phenotype in Foxp2 null mice 
(French, Groszer et al. 2007).  
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 A second transcription factor, MEIS2, is expressed in the endocardium 
and mesenchyme of the AVC and OFT at E11.0 (Figure 12D). Recent studies in 
zebrafish identified a role for meis2 in cardiac looping (Paige, Thomas et al. 
2012), yet no data concerning the role of MEIS2 in chick or mouse heart 
development has been reported. MEIS2 induces proximal gene expression while 
BMP signaling inhibits MEIS2 expression to promote distal limb gene expression 
and support proper limb patterning (Capdevila, Tsukui et al. 1999). The well 
described role of BMP in regulating endocardial EMT (Ma, Lu et al. 2005) 
provides a potential role for MEIS2 as a modulator of this process and 
subsequent valve maturation.  
  
NF-κB signaling pathway in endocardial EMT 
 Although the expression of components of the NF-κB pathway were not 
enriched in the AVC or OFT, GRN analysis revealed that several genes 
regulated by NF-κB had enriched expression in the AVC and OFT. Perturbation 
of the NF-κB signaling pathway with small molecule inhibitors revealed a 
requirement for NF-κB signaling in endocardial EMT. As the role of NF-κB in 
driving EMT in cancer cells via regulation of Snai1/Slug/Twist is well described 
(reviewed (Min, Eddy et al. 2008)), the NF-κB pathway may represent a 
mechanism by which transcription factors that repress the epithelial phenotype in 
endocardial EMT are regulated. Mouse embryos lacking p50 survive to adulthood 
with no apparent developmental defects (Sha, Liou et al. 1995) while mice 
lacking p65 (Beg, Sha et al. 1995) die at E15.5 from liver degeneration by 
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apoptosis. No valvular phenotypes were reported. Our findings suggest a 
targeted re-examination of NF-κB signaling in valve development may reveal 
previously unappreciated defects. It is also possible that disruption of NF-κB 
signaling in VICs may result in adult valvular disease or altered response to 
injury.  
 It is clear that the in vitro bioassay does not always recapitulate in vivo 
phenotypes (reviewed (Lencinas, Tavares et al. 2012)). The more complex ECM 
and signaling environment present in vivo may allow endocardial cells to 
compensate in ways cells exposed to the simpler collagen gel system cannot. 
For example, targeting of Tgfbr2 in vivo does not inhibit endocardial EMT, but 
AVC explants from these mice fail undergo EMT in vitro (Azhar, Runyan et al. 
2009).  However, later stages of cushion development are abnormal in Tgfbr2 
conditionally null mice, suggesting that the mesenchyme resulting from EMT is 
abnormal. Therefore, this system provides a robust bioassay to identify potential 
targets for gene perturbation in vivo. 
  
Future Studies 
 Other candidate genes identified by our analysis were left untested, but 
represent interesting avenues for future work.  For example, ECM remodeling is 
fundamentally important in valve development. We identified several genes 
encoding ECM related proteins that were enriched in mouse cushions including 
collagens (Col2a1, Col6a3, Col9a1, Col9a3), hyaluronic acid (Has2, Cd44), and 
Eln. Knowledge of the ECM, which the mesenchymal cells and VICs must 
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interact with and remodel subsequent to EMT, may provide important clues on 
how to better design in vitro systems that promote VIC differentiation and 
maintenance. Future studies combining spatial and temporal transcriptional 












































TRANSCRIPTIONAL PROFILING OF CULTURED, EMBRYONIC EPICARDIAL 
CELLS IDENTIFIES NOVEL GENES AND SIGNALING PATHWAYS 
REGULATED BY TGFβR3 IN VITRO 
 
Introduction 
  The epicardium plays an important role in coronary vessel development 
(reviewed (Olivey, Compton et al. 2004; Olivey and Svensson 2010)). Formation 
of the epicardium occurs when a population of mesothelial cells, termed the 
proepicardium, attach to and migrate over the heart tube myocardium (Viragh 
and Challice 1981; Manner 1993). A subpopulation of the epithelial, epicardial 
cells subsequently invade into the subepicardial space with some cells 
proceeding to invade into the myocardium as well (reviewed (von Gise and Pu 
2012)). These EPDCs differentiate into distinct lineages (Poelmann, 
Gittenberger-de Groot et al. 1993; Gittenberger-de Groot, Vrancken Peeters et 
al. 1998; Lie-Venema, Eralp et al. 2008; Christoffels, Grieskamp et al. 2009; 
Grieskamp, Rudat et al. 2011), that include cardiac fibroblasts, pericytes, and 
vascular smooth muscle cells, and support the formation of coronary vessels. 
Several lines of evidence are now revealing the importance of these same 
developmental processes in cardiac repair and that the epicardium makes critical 
contributions to cardiac response to injury (reviewed (von Gise and Pu 2012)). 




TGFβR3 deletion in mice leads to failed coronary vessel development 
(Compton, Potash et al. 2007). Tgfbr3-/- hearts featured a discontinuous 
epicardium overlying an expanded subepicaridal space. Further studies revealed 
a significant decrease in proliferation and invasion of epicardium and epicardially-
derived mesenchyme (Sanchez, Hill et al. 2011). Overall, these studies 
demonstrated that TGFβR3 plays an important and non-redundant role in 
epicardial behavior and coronary vessel development in vivo.  
 TGFβR3 binds TGFβ1, TGFβ2 and TGFβ3 and is uniquely required to 
bind TGFβ2 with high affinity (Lopez-Casillas, Cheifetz et al. 1991; Lopez-
Casillas, Wrana et al. 1993). TGFβR3 is also capable of binding and signaling in 
response to BMP2 (Kirkbride, Townsend et al. 2008) and functions as a receptor 
for inhibin (Wiater, Harrison et al. 2006). TGFβR3 presents ligand to TGFβR2 to 
promote both Smad-dependent and -independent signaling (Derynck and Zhang 
2003). The highly conserved 43 amino acid intracellular domain of TGFβR3 is not 
required for ligand presentation (Blobe, Schiemann et al. 2001) but may regulate 
other signaling events. Phosphorylation of the cytoplasmic domain of TGFβR3 by 
TGFβR2 at Thr841 is required for β-arrestin2 binding, leading to internalization of 
TGFβR3 and down-regulation of TGFβ signaling. The 3 C-terminal amino acids 
of TGFβR3, STA, are a Class I PDZ binding domain that binds the scaffolding 
protein GIPC which in turn stabilizes TGFβR3 on the plasma membrane to 
promote signaling (Blobe, Liu et al. 2001).  
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Tgfbr3+/+ epicardial cells undergo loss of epithelial character and invasion 
into collagen gels in vitro in response to TGFβ1, TGFβ2, and BMP2, ligands 
known to bind TGFβR3 (Lopez-Casillas, Cheifetz et al. 1991; Kirkbride, 
Townsend et al. 2008). While loss of epithelial character was still observed after 
loss of TGFβR3, Tgfbr3-/- cells had reduced invasion in response TGFβ1, TGFβ2, 
and BMP2, a response that was rescued by the addition of TGFβR3 (Sanchez, 
Hill et al. 2011; Hill, Sanchez et al. 2012; Sanchez and Barnett 2012). TGFβ1 
and TGFβ2 promoted smooth muscle differentiation in Tgfbr3+/+ and Tgfbr3-/- 
cells while BMP2 did not (Hill, Sanchez et al. 2012). Surprisingly, other ligands 
known to be important in epicardial EMT also required TGFβR3 to promote 
invasion in epicardial cells (FGF2 (Morabito, Dettman et al. 2001; Tomanek, 
Sandra et al. 2001), High Molecular Weight HMW-HA (Craig, Austin et al. 2010; 
Craig, Parker et al. 2010)). Impaired invasion was not due to a general inability of 
these cells invade as PDGFAA, PDGFBB and VEGFC still induced invasion in 
Tgfbr3-/- epicardial cells (Sanchez, Hill et al. 2011). This ability of TGFβR3 to 
regulate epicardial cell behavior in response to an array of ligands may explain 
the severity of the in vivo phenotype of Tgfbr3-/- embryos when compared to the 
absence of a phenotype in mice lacking individual TGFβ ligands (Shull, Ormsby 
et al. 1992; Sanford, Ormsby et al. 1997; Sridurongrit, Larsson et al. 2008). 
Targeted deletion of ALK5 in the epicardium in mice in vivo results in interrupted 
epicardial attachment to the myocardium, loss of expression of specific adhesion 
molecules, thinned myocardium, and a loss of coronary smooth muscle 
(Sridurongrit, Larsson et al. 2008). These embryos survive until birth, suggesting 
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that, unlike in embryos lacking TGFβR3, the coronary vessels function to some 
degree as mice lacking coronary vessels die at approximately E14.5-E16.5 
(Yang, Rayburn et al. 1995; Moore, McInnes et al. 1999; Tevosian, Deconinck et 
al. 2000). These data suggest that TGFβR3 signaling regulates a common 
pathway accessed by several upstream regulators of cell invasion. 
TGFβR3-dependent invasion stimulated by TGFβ1, TGFβ2, BMP2, HMW-
HA, or FGF2 was shown to require the cytoplasmic domain of TGFβR3 in vitro 
(Sanchez, Hill et al. 2011). Overexpression of TGFβR3 rescued invasion in 
Tgfbr3-/- epicardial cells in vitro in response to TGFβ1, TGFβ2, BMP2, HMW-HA, 
or FGF2, whereas constructs expressing a TGFβR3 mutant lacking the 3 C-
terminal amino acids required for GIPC binding fail to rescue invasion (Sanchez, 
Hill et al. 2011; Hill, Sanchez et al. 2012; Sanchez and Barnett 2012). The 
importance of this interaction is supported by the observation that GIPC is not 
only required for invasion in Tgfbr3+/+ epicardial cells, but GIPC overexpression 
can promote invasion in the absence of additional ligand. GIPC regulation of 
epicardial invasion depends on TGFβR3 since GIPC expression in Tgfbr3-/- cells 
fails to rescue invasion and inhibition of GIPC expression impairs the ability of 
TGFβR3 to rescue invasion in Tgfbr3-/- cells (Sanchez, Hill et al. 2011). Similar 
results were observed in endocardial cushions where the interaction of TGFβR3 
with GIPC is required to promote TGFβ2 and BMP2 dependent invasion in vitro 





Figure 15: Tgfbr3-/- epicardial cells have dysregulated proliferation, 
apoptosis, and invasion. A, Summary of the phenotypes of Tgfbr3+/+ and 
Tgfbr3-/- epicardial cells in vitro. EC - epithelial character, SM Diff.- smooth 
muscle differentiation. B, RNA-seq analysis of Tgfbr3+/+ and Tgfbr3-/- epicardial 
cells incubated with ligand for 72 hours. Reads - the total number of mapped 
sequences for each of the 8 groups (in duplicate). Genes - the total number of 
















Vehicle BMP2 TGFβ1 TGFβ2
Tgfbr3+/+ Vehicle TGFβ1 TGFβ2 BMP2
Reads 49.1 x 106 48.8 x 106 39.9 x 106 24.3 x 106
Genes 15,103 14,806 14,977 14,888
Tgfbr3-/- Vehicle TGFβ1 TGFβ2 BMP2
Reads 30.6 x 106 42.9 x 106 42.3 x 106 31.5 x 106
Genes 13,966 13,957 14,047 14,088



























































of Tgfbr3-/- epicardial cells to the cytoplasmic domain of TGFβR3 which is not  
required for ligand presentation suggests a unique, non-redundant role for 
TGFβR3 in regulating epicardial and endocardial EMT.  
Here, we use a well defined in vitro system based on immortalized 
epicardial cells coupled with RNA-seq analysis to generate a transcriptional 
profile of Tgfbr3+/+ and Tgfbr3-/- cells incubated with ligands that stimulate 
TGFβR3-dependent invasion. The resulting transcriptional profiles has identified  
regulators of epicardial cell behavior downstream of TGFβR3 and provided the 
first description of genes downstream of TGFβR3. 
Experiments in this chapter were performed in collaboration with Cyndi 
Hill, who performed the NF-ĸB reporter and invasion assays in Figure 24, and 




Generation of cell lines 
 Tgfbr3+/−:Immorto mice were generated as described (Austin, Compton et 
al. 2008) and maintained on a C57BL/6 SV129 mixed background. 
Tgfbr3+/+:Immorto and Tgfbr3−/−:Immorto immortalized epicardial cell lines were 
generated from littermates as described (Austin, Compton et al. 2008) from 






 To maintain the immortalized state, cells were grown at 33°C in DMEM 
containing 10% fetal bovine serum, 100 U/ml penicillin/streptomycin, Insulin– 
Transferrin–Selenium (ITS: 1 μg/ml insulin, 5.5 × 10−4 μg/ml transferrin, 
0.677 μg/ml selenium), and 10 U/ml interferon γ (INFγ). For experiments, the T-
antigen was inactivated by culturing at 37°C in the absence of ITS or INFγ. Cells 
were seeded at 200,000 cells per well of a 6-well tissue culture plate and allowed 
to adhere overnight at 37˚C. The medium was replaced with medium containing 
either VEH, 250 pM TGFβ1, 250 pM TGFβ2, or 5 nM BMP2. After a 72 hour 
incubation period at 37˚C, total RNA was isolated via standard phenol-chloroform 
extraction (TRIzol Invitrogen). RNA was purified (Qiagen mini-prep kit) following 
the manufacturer’s protocol. Quantity and quality of RNA was determined by an 
Agilent Bioanalyzer. One well of a 6-well plate yielded 10-20 µg of RNA. 
 
RNA-seq 
 The generation of RNAseq libraries without normalizations or RNA/cDNA 
fragmentation were performed as described (Christodoulou, Gorham et al.). 
Libraries were sequenced as 50bp paired end sequences on a single lane of the 
Illumina HiSeq2000. TOPHAT (Trapnell, Pachter et al. 2009) 
(http://tophat.cbcb.umd.edu/) was used to align HiSeq 2000 reads to produce 
bam files. Reads were normalized to total mRNA (total aligned reads per gene-
loci per million). Gene expression profiles were generated as described 




Figure 16: Immortalized epicardial cells undergo loss of epithelial 
character. A, The epicardium undergoes EMT at E11.5-13.5. Subsequently, 
transforming epicardial cells invade the subepicardial space and myocardium 
towards forming coronary vessels. Blue- epicardium. Purple- endothelium. 
Yellow- smooth muscle cells. Red- myocardium. B, Immortalized epicardial cells 
were derived from E11.5 Tgfbr3+/+ and Tgfbr3-/- embryos which expressed a 
temperature-sensitive large T-antigen. C, Immunohistochemistry of Tgfbr3+/+ or 
Tgfbr3-/- immortalized epicardial cells after 72 hours incubation with TGFβ2 or 
vehicle. TGFβ2 increased expression of SM22α and form stress fibers in the 






















Figure 17: Variability of RNA-seq data sets. The reads for the two biological 
replicates (n=1, n=2) for each group (VEH, TGFβ1, TGFβ2, BMP2) in Tgfbr3+/+ 
(A-D) or Tgfbr3-/- (E-H) were plotted against each other. There was a high degree 
of agreement in Tgfbr3+/+ (A-D) (R>0.87) or Tgfbr3-/- (E-H) (R>0.89) datasets. 



































































































































































Figure 18: Comparison of differential gene expression between biological 
replicates. Plots mapping the fold (log base 2) difference >2-fold in expression 
between VEH and ligand incubated groups in Tgfbr3+/+ (A) or Tgfbr3-/- (B) in 
biological replicates (X-axis: n=1, Y-axis: n=2) shown. Genes that have 
agreement, defined as having >2-fold (p<0.001) increased or decreased 
expression in a specific comparison in both replicates, are mapped to quadrants I 
(upper right) or III (lower left) of a plot. Genes that show disagreement, defined 
as having >2-fold (p<0.001) increased expression in a tissue in one replicate and 
decreased in another (or vis versa), are mapped to quadrants II (upper left) or IV 
(lower right). There was a high degree of agreement in Tgfbr3+/+ (A) (R>0.85) or 
Tgfbr3-/- (B) (R>0.89) datasets across all comparisons. 
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(Audic and Claverie 1997). Variability between biological replicates was 
determined (Figure 17-18). 
 
 SEAP Reporter System 
 The pNF-ĸB-SEAP (Clonetech) reporter was used to determine NF-κB 
activity in cells as described (Craig, Parker et al. 2009; Craig, Parker et al. 2010).  
Briefly, cells were co-transfected with pNF-ĸB-SEAP and β-galactosidase 
expression vector (p-CMVβ) and after 24 hours incubated with ligand (250pM 
TGFβ1, 250 pM TGFβ2, or 5nM BMP2).  24 hours after ligand addition the 
supernatant was assayed for alkaline phosphatase. β-galactosidase activity was 
used to normalize alkaline phosphatase activity.  
 
Transwell Invasion Assay 




Transcriptional profiles of Tgfbr3+/+ and Tgfbr3-/- cells confirm epicardial cell 
identity and ligand response  
 We undertook a transcriptional profiling approach to examine the genes 
downstream of TGFβR3 in epicardial cells in vitro. This system was chosen since 
it provides defined phenotypic endpoints to contrast between genotypes and 
different ligand incubation groups (Figure 15A). Tgfbr3+/+ and Tgfbr3-/- epicardial 
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cells were incubated for 72 hours with VEH or ligands known to drive TGFβR3-
dependent invasion (TGFβ1, TGFβ2, BMP2) (Sanchez and Barnett 2012). After 
incubation RNA was harvested and analyzed by RNA-seq as described. More 
than 24 million reads were obtained for each group (VEH, TGFβ1, TGFβ2, 
BMP2) in each genotype (Figure 15B – Genes). Over 13,900 genes were 
significantly expressed (Reads >10) in each dataset (Figure 15B – Reads). Of 
these genes, we observed that markers of embryonic epicardial cells (Wt1 
(Moore, Schedl et al. 1998), Tbx18 (Kraus, Haenig et al. 2001), Sema3d (Katz, 
Singh et al. 2012), Scx (Katz, Singh et al. 2012)) were markedly expressed in all 
data sets (Figure 19A) but markers of endothelial (Cdh5 (Lampugnani, Resnati et 
al. 1992), Pecam1 (Newman, Berndt et al. 1990), Tie1 (Partanen, Armstrong et 
al. 1992)) or myocardial (Tnni2 (Saggin, Gorza et al. 1989; Wang, Reiter et al. 
2001), Tnni3 (Saggin, Ausoni et al. 1988; Wang, Reiter et al. 2001)) lineages 
were not (Figure 19C). The expression profile observed confirms the epicardial 
identity of these cells. 
 We have previously reported that TGFβ1 and TGFβ2 promote loss of 
epithelial character, invasion, and smooth muscle differentiation defined as the 
increased expression of the smooth muscle markers α-Sma, Sm22α, and Cnn1 
(reviewed (Rensen, Doevendans et al. 2007)) in Tgfbr3+/+ and Tgfbr3-/- epicardial 
cells (TGFβ2 depicted in Figure 16C). BMP2 promotes loss of epithelial character 
and invasion but not smooth muscle differentiation (Hill, Sanchez et al. 2012). 
RNA-seq data sets demonstrated that the level of expression of α-Sma, Sm22α, 




Figure 19: Tgfbr3+/+ and Tgfbr3-/- epicardial RNA-seq datasets confirm cell 
identity and differential ligand response. A, Cells express epicardial markers. 
Mean normalized reads between replicates and standard error are depicted. B, 
Smooth muscle markers are markedly induced with TGFβ1 and TGFβ2 
compared to BMP2 incubation. Fold is relative to VEH for each genotype. C, 
Endothelial or myocardial markers are not notably expressed. Mean normalized 
reads between replicates and standard error are depicted. D, Genes >2-fold 
differentially expressed after ligand treatment compared to vehicle are depicted. 
Fewer genes are induced by incubation with TGFβ1-2 treatment in Tgfbr3-/- 






















































































































+2 Fold -2 Fold
TGFβ1 / VEH 1197 911
TGFβ2 / VEH 1129 1063
BMP2 / VEH 17 11
TGFβ1 / VEH 744 809
TGFβ2 / VEH 736 836



















genotype (Figure 19B). BMP2 incubation resulted in a considerably lower 
induction of smooth muscle markers (Figure 2B). Hundreds of genes had >2-fold 
increased or decreased expression after TGFβ1 or TGFβ2 incubation (Figure 
2B). Far fewer genes were >2-fold differentially expressed after BMP2 incubation 
(Figure 19B) which is likely due to the inability of BMP2 to induce smooth muscle 
differentiation. Of note, fewer genes were induced with TGFβ1 or TGFβ2 
incubation in Tgfbr3-/- cells when compared to Tgfbr3+/+ cells, while the opposite 
was found with BMP2 incubation. This transcriptional profile of Tgfbr3+/+ and 
Tgfbr3-/- epicardial cells confirms both the epicardial identity and the known 
response of these cells to ligand. Therefore we used these data sets for further 
analysis towards delineating the downstream signaling pathways of TGFβR3 in 
the epicardium. 
 
Dysregulation of gene expression in epicardial cells lacking TGFβR3 
 To ascertain the genes differentially regulated after the loss of Tgfbr3, we 
compared the expression profiles of Tgfbr3+/+ and Tgfbr3-/- epicardial cells 
incubated with VEH, TGFβ1, TGFβ2, or BMP2. We observed hundreds of genes 
>2-fold (p<0.001) differentially regulated between genotypes in cells incubated 
with VEH (604), TGFβ1 (515), TGFβ2 (553), or BMP2 (632) (Figure 20A; 
Appendices E-H). The overlap between these >2-fold differentially expressed 
gene lists were plotted (Figure 20B) identifying 129 genes similarly dysregulated 
across all groups. This list of genes is defined as those that are differentially 




Figure 20: RNA-seq analysis identifies genes dysregulated in Tgfbr3-/- 
epicardial cells: A, (Left) The number of genes >2-fold (p<0.001) differentially 
expressed between Tgfbr3+/+ and Tgfbr3-/- epicardial cells for each group.  (Right) 
The number genes similarly dysregulated within selected groups are shown with 
genes found in each. B, The number of overlapping genes >2-fold differentially 
regulated (p<0.001) was determined and mapped. 129 genes were similarly 
dysregulated across all groups. C, (Top) Gene ontology analysis of these 129 
genes by DAVID revealed a significant (p<0.0001) enrichment of genes 
associated with specific biological processes. emb.- embryonic. (Bottom) A 
representative network generated by gene regulatory network analysis of the 129 
genes using Ingenuity Pathway Analysis software is depicted. Green- expressed 







































































better understanding of the biological processes these genes may be associated 
with, Gene Ontology (GO) analysis was undertaken using Database for 
Annotation, Visualization, & Integrated Discovery (DAVID) software (Dennis, 
Sherman et al. 2003). GO analysis identified enriched biological processes 
(p<0.0001) associated with cell adhesion and extracellular structure organization 
indicating a potential defect in cell interaction with the ECM, a vital component of 
cell invasion (Figure 20C – Top). In order to understand how these genes may 
interact, Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com) was 
used to perform Gene Regulatory Network (GRN) analysis. An example network 
is depicted (Figure 20C – Bottom) which revealed TGFβ and Notch signaling 
pathways (del Monte, Casanova et al. 2007), both known important regulators of 
epicardial cell behavior and subsequent coronary vessel development. We also 
identified signaling pathways previously unexamined in epicardial development. 
For example, NF-ĸB signaling emerged as a central node in this analysis 
providing a candidate for further evaluation.  
 To gain a more detailed understanding of the genes dysregulated after 
loss of TGFβR3, we examined genes with dysregulated expression in specific 
ligand incubation groups. When considering the overlap between genes in at 
least any two groups (VEH, TGFβ1, TGFβ2, or BMP2) that are similarly >2-fold 
differentially expressed between genotypes (Figure 20B), we observed that there 
are many more genes shared between TGFβ1-TGFβ2 (198) and VEH-BMP2 
(191) than any other comparison (for example; VEH-TGFβ1 (10), BMP2-TGFβ2 
(22)). This may reflect the fact that both TGFβ1 and TGFβ2 induce smooth 
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muscle differentiation. GO analysis of the 198 genes uniquely dysregulated in 
Tgfbr3-/- cells after TGFβ1 and TGFβ2 incubation identified vasculature 
development as the most enriched biological process (p<0.001) (Table 8). This 
analysis is consistent with altered vascular development in epicardial cells after 
loss of Tgfbr3. However, processes associated with vascular development were 
not found to be significantly enriched by GO analysis in the 191 genes uniquely 
>2-fold dysregulated between genotypes with VEH and BMP2 incubation or in 
the 221 genes uniquely dysregulated with BMP2 incubation (Table 8). 
 Although we have reported that TGFβ2 promotes loss of epithelial 
character and smooth muscle differentiation via ALK5 signaling and BMP2 
promotes only the loss of epithelial character via ALK3 signaling, both ligands 
require TGFβR3 to mediate invasion (Hill, Sanchez et al. 2012). To gain a better 
understanding of how TGFβ and BMP signaling are impacted by the loss of 
Tgfbr3, we examined genes >2-fold differentially expressed between Tgfbr3+/+ 
and Tgfbr3-/- epicardial cells incubated with TGFβ2 or BMP2. GO analysis 
identified that biological processes associated with blood vessel development 
and angiogenesis were enriched (p<0.0001) in TGFβ2 but not BMP2 gene lists 
(genes including Fgf2 and Vegfc) (Figure 21A). Thus, while TGFβ induces 
smooth muscle differentiation in Tgfbr3-/- cells, there remain defects in the 
signaling networks associated with formation of the vasculature. Biological 
processes enriched in both of these TGFβ2 and BMP2 gene lists include 
processes associated with cell adhesion, extracellular matrix (ECM) organization, 




Table 8: GO Analysis of Genes >2-fold Differentially Expressed Between Genotypes 
Unique to Specific Ligand Incubation Groups. 
GO Term p-value 
TGFβ1 + TGFβ2   
GO:0001944~vasculature development 3.71E-04 
GO:0000122~negative regulation of transcription from RNA polymerase II promoter 0.001014 
GO:0032963~collagen metabolic process 0.001046 
GO:0006357~regulation of transcription from RNA polymerase II promoter 0.001059 
GO:0001525~angiogenesis 0.001153 
VEH + BMP2   
GO:0022037~metencephalon development 0.017354 
GO:0050900~leukocyte migration 0.018991 
GO:0030902~hindbrain development 0.043128 
GO:0042127~regulation of cell proliferation 0.048931 
GO:0008284~positive regulation of cell proliferation 0.051412 
BMP2   
GO:0007242~intracellular signaling cascade 1.63E-04 
GO:0009069~serine family amino acid metabolic process 0.001428 
GO:0006534~cysteine metabolic process 0.002140 
GO:0007188~G-protein signaling, coupled to cAMP nucleotide second messenger 0.002451 
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Figure 21: Gene regulatory network analysis identifies NF-kB signaling as a 
central node. Genes >2-fold (p<0.001) differentially expressed between 
Tgfbr3+/+ and Tgfbr3-/- epicardial cells incubated with either TGFβ2 (A) or BMP2 
(B) were subjected to gene ontology analysis (using DAVID software, p<0.0001). 
(C-D) NF-ĸB signaling (orange circle) is a central node in representative 
networks generated by gene regulatory network analysis (using Ingenuity 
Pathway Analysis software).   Green- expressed higher inTgfbr3+/+ , Red- 
expressed higher in Tgfbr3-/- . (E) The distribution of the predicted protein 






















epicardial phenotype of Tgfbr3-/- embryos (Compton, Potash et al. 2007; 
Sanchez, Hill et al. 2011). 
 To reveal interactions, genes >2-fold differentially expressed between 
genotypes after TGFβ2 or BMP2 incubation were used to generated GRNs using 
IPA software. Example networks are depicted in Figure 21C-D. The TGFβ2 
network features predicted proteins known to be located in the ECM that regulate 
cell-ECM interactions. Several of these genes have lower levels of expression in 
Tgfbr3-/- cells compared to Tgfbr3+/+ cells (green nodes). Also present are several 
genes encoding cytoplasm and plasma membrane proteins that are expressed at 
higher levels in Tgfbr3-/- epicardial cells compared to Tgfbr3+/+ cells (red nodes). 
These genes are associated with epithelial sheet stability and adhesion, for 
example (Krt18, Krt8). The BMP2 network also features genes that are 
expressed at higher levels in Tgfbr3+/+ cells whose proteins are known to 
associate with the plasma membrane to regulate cell adhesion and cell migration 
(Lin7a (Monzani, Bazzotti et al. 2009), Amot (Troyanovsky, Levchenko et al. 
2001)). Nodes associated with ECM protein synthesis (Csgalnact1 (Sato, Gotoh 
et al. 2003)) or post translation modification of receptors that interact with ECM 
(Chst7 (Ruffell, Poon et al. 2011)) were also observed in the BMP2 network. 
These networks indicate a deficit in the ability of cells to interact with the ECM 
and a potential defect in cell motility. NF-ĸB was a central node in not only the 
TGFβ2 and BMP2 networks (Figure 21C-D – Orange circle), but also in GRNs 
derived from genes differentially expressed between genotypes with VEH or 




Figure 22: Gene regulatory network analysis identifies NF-ĸB signaling as a 
central node. Genes >2-fold (p<0.001) differentially expressed between 
Tgfbr3+/+ and Tgfbr3-/- epicardial cells incubated with either TGFβ1 (A) or VEH 
(B) were subjected (A) to gene ontology analysis (using DAVID software, 
p<0.0001). C-D, NF-ĸB signaling (orange circle) is a central node in 
representative networks generated by gene regulatory network analysis (using 
Ingenuity Pathway Analysis software).   Green- expressed higher inTgfbr3+/+ , 
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Figure 23: Genes downstream of NF-ĸB signaling dysregulated with loss of 
Tgfbr3 in epicardial cells in vitro. Genes identified as being >2-fold 
differentially regulated between Tgfbr3+/+ or Tgfbr3-/- epicardial cells incubated 
with (A) VEH, (B) BMP2, (C) TGFβ1, or (D) TGFβ2. Solid lines denote a direct 
interaction while dotted lines denote indirect interaction between proteins. Green- 














Figure 24: Tgfbr3-/- epicardial cells fail to activate the NF-ĸB signaling 
pathway. A, (TOP) Genes dysregulated in each group (>2-fold, p<0.001) were 
counted. (BOTTOM) Shared targets of NF-ĸB signaling dyregulated in all groups 
are shown. Red - expressed higher inTgfbr3+/+, Green - expressed higher in 
Tgfbr3-/-. B, Cells transfected with an NF-ĸB responsive SEAP reporter construct 
and incubated with VEH, TGFβ2, or BMP2 revealed the inability of Tgfbr3-/- cells 
to induce NF-ĸB signaling.  C, Incubation of Tgfbr3+/+ epicardial cells in a 
transwell invasion assay with an NF-ĸB inhibitor (SN50) significantly reduced 
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downstream of NF-κB signaling that were differentially regulated in each ligand 
incubation group (Figure 23A-D) when compared between genotypes. A table 
depicting the overlap between these genes is shown (Figure 24A – Top). GRN 
analysis indicates that NF-ĸB signaling may be dysregulated with loss of 
TGFβR3 in epicardial cells. The dysregulated NF-ĸB signaling in both TGFβ2 and 
BMP2 gene lists, where a common phenotype is loss of invasion, suggests that 
NF-ĸB signaling may regulate cell invasion in response to these ligands.  
 
NF-ĸB signaling is dysregulated in Tgfbr3-/- epicardial cells in vitro 
 To test the hypothesis that TGFβR3 promotes NF-ĸB signaling to regulate 
epicardial cell invasion we examined if NF-ĸB activity was induced by TGFβ2 or 
BMP2 ligand incubation in epicardial cells in vitro (Figure 24B). Immortalized 
epicardial cells incubated with TGFβ2 or BMP2 increased NF-ĸB activity 
compared to VEH in Tgfbr3+/+ epicardial cells as described (Craig, Parker et al. 
2010). TGFβ2 or BMP2 ligand incubation failed to induce NF-ĸB activity in 
Tgfbr3-/- cells (Figure 24B). To determine if NF-ĸB signaling was required for 
epicardial cell invasion in vitro, we performed a transwell invasion assay with 
TGFβ1, TGFβ2, and BMP2 in the presence or absence of the NF-κB inhibitor, 
SN50. SN50 (2 µm) significantly decreased TGFβ1-, TGFβ2-, or BMP2-induced 
invasion in Tgfbr3+/+ cells when compared to VEH (Figure 24C). Together these 
data demonstrate that NF-ĸB signaling is dysregulated in Tgfbr3-/- epicardial cells 
and that NF-ĸB is required for epicardial cell invasion in vitro. These data support 







Transcriptional profiling of epicardial cells 
 We developed a transcriptional profiling strategy using immortalized, 
embryonic epicardial cells in vitro to identify genes and signaling pathways 
downstream of TGFβR3 that regulate cell invasion. Previous studies have 
profiled gene expression in adult epicardial cells (Rosati, Grau et al. 2006; 
Bochmann, Sarathchandra et al. 2010), the proepicardium (Buermans, van Wijk 
et al. 2010), and primary epicardial cells (E12.5) (Smith, Baek et al. 2011) using 
microarrays, but a comprehensive transcriptional profiling of embryonic epicardial 
cells has been lacking. Additionally, our choice of this system allows for a first 
systematic examination of the genes and signaling pathways regulated by 
TGFβR3.  
 
Tgfbr3-/- epicardial cells have altered expression of ECM associated genes  
 GO and GRN analysis of genes whose expression was >2-fold 
dyregulated between Tgfbr3+/+ and Tgfbr3-/- cells for each ligand incubation group 
revealed biological processes associated with ECM production, ECM binding, 
cell adhesion, and invasion. The dysregulation of gene expression associated 
with these processes is consistent with the known defects identified after loss of 
Tgfbr3 in vivo and in vitro. Epicardial cell abnormalities in Tgfbr3-/- embryos 
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include expansion of the subepicardial space and a hyperplastic, irregular 
epicardium, both of which suggest defects in epicardial cell interactions with the 
ECM (Compton, Potash et al. 2007). Invasion of epicardial cells is also defective 
in vivo and in vitro in cells lacking TGFβR3 (Sanchez, Hill et al. 2011). Consistent 
with a defect in cell interaction with the ECM, we observe that epicardial cells in 
vitro fail to invade in response to high molecular weight HA (Sanchez, Hill et al. 
2011), a major ECM component of the subepicardial space (Kalman, Viragh et al. 
1995). CD44 is the cell surface receptor which binds HA and this interaction is 
important for epicardial invasion (Craig, Parker et al. 2010). Upregulated 
expression of the chondroitin sulfotransferase, Chst7, is associated with 
increased chondroitin sulfation of CD44 and decreased CD44-HA binding in 
multiple cell types (Ruffell and Johnson 2005; Tjew, Brown et al. 2005; Ruffell, 
Poon et al. 2011).  Chst7 had markedly increased expression (>4-fold) in Tgfbr3-/- 
cells when compared to Tgfbr3+/+ cells across all ligand incubation groups. These 
data suggest that the inability of Tgfbr3-/- cells to undergo invasion in respond to 
HA may result from increased chondroitin sulfation of CD44.   
 The myocardium and proepicardium both contribute to the ECM contained 
in the subepicardial space (Tidball 1992; Kalman, Viragh et al. 1995), yet the 
exact makeup and source is unknown. Tgfbr3-/- epicardial cells show 
dysregulated expression of genes encoding proteins found in the ECM, 
suggesting that epicardial contributions to the ECM are altered after loss of 
TGFβR3. Mgp, Eln, and Tnc have decreased expression in Tgfbr3-/- cells when 
compared to Tgfbr3+/+ cells, while Matn4 and Emilin1 have increased expression 
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irrespective of ligand. Alterations in the expression of specific genes were also 
found to be ligand-specific. Versican is an ECM component contained in the 
supepicardial space (Zanin, Bundy et al. 1999) that promotes cell invasion in 
some cancer cells (reviewed (Ricciardelli, Sakko et al. 2009)) and is required for 
endocardial cushion formation and subsequent EMT (Mjaatvedt, Yamamura et al. 
1998; Kern, Twal et al. 2006). Versican has >2-fold higher expression after ligand 
(TGFβ1, TGFβ2, BMP2) incubation when compared to VEH in Tgfbr3+/+ cells. 
Ligand induction of Versican expression is lost in Tgfbr3-/- cells, demonstrating 
that Versican expression is dependent on Tgfbr3-ligand interaction. Together, 
these data suggest the defects in coronary vessel development are due to both 
the altered response to, and expression of, ECM components by epicardial cells 
following the loss of Tgfbr3. 
 
TGFβ- and BMP-mediated gene expression programs are dysregulated in 
Tgfbr3-/- epicardial cells 
  Distinct differences were observed in dysregulated gene expression 
between epicardial cells incubated with BMP and TGFβ ligands after loss of 
TGFβR3. Analysis of the genes dysregulated between Tgfbr3+/+ and Tgfbr3-/- 
epicardial cells revealed potentially different mechanisms between BMP2 and 
TGFβ1 or TGFβ2 mediated-GRNs that may underlay a defect in cell invasion. 
BMP2 is important in the specification and maintenance of proepicardial cell 
identity (Schlueter, Manner et al. 2006), directed proepicardial cell migration 
(Ishii, Garriock et al. 2010), and epicardial cell loss of epithelial character and 
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invasion (Sanchez and Barnett 2012). GRNs generated from the genes 
dysregulated between genotypes after BMP2 incubation revealed a grouping of 
genes encoding PDZ domain-containing proteins that had decreased expression 
in Tgfbr3-/- epicardial cells when compared to Tgfbr3+/+ cells (Amot, Cadm1, 
Cnksr3, Lin7a, Mpp6). Several of these genes (Amot (Troyanovsky, Levchenko 
et al. 2001; Ernkvist, Luna Persson et al. 2009; Zheng, Vertuani et al. 2009), 
Cadm1 (Masuda, Maruyama et al. 2010), Cnksr3 (Attar, Salem et al. 2012), 
Lin7a (Perego, Vanoni et al. 2002; Monzani, Bazzotti et al. 2009)) have been 
previously reported to promote cell migration but a role in the epicardium has not 
been described. These observations are consistent with the known role in BMP2 
in directing epicardial migration and the decrease of invasion observed in  
Tgfbr3-/- epicardial cells. These data also provide an intriguing set of candidate 
genes as the PDZ domain of TGFβR3 and a protein that interacts with this 
domain, GIPC, are required for TGFβR3-mediated invasion in vitro (Sanchez, Hill 
et al. 2011). GRNs generated from the genes dysregulated between genotypes 
after TGFβ1 or TGFβ2 incubation had different features from the BMP2 network. 
A large grouping of genes whose expression was reduced after loss of TGFβR3 
was localized to the extracellular space in the TGFβ1 and TGFβ2 networks. 
These genes were involved in the production of ECM components (Eln), matrix 
degradation (Mmp3, Elastase), and ECM organization (Mfap2). A different 
grouping of genes expressed at higher levels after loss of TGFβR3 localized to 
the cytoplasm were associated with epithelial sheet stability and non-motile cells 
(Krt8, Krt18). The GRNs are consistent with a population of cells with 
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dysregulated ECM interaction and reduced motility. In addition, genes in 
signaling pathways associated with vascular development and angiogenesis 
were dysregulated between genotypes with TGFβ1 and TGFβ2 but not BMP2 
incubation. This finding is particularly interesting as factors secreted by the 
epicardium after injury to the heart are hypothesized to promote the formation of 
new vessels in the impacted area (Zhou, Honor et al. 2011). To support proper 
coronary vessel development signaling events must be tightly regulated in the 
epicardium in vivo. Our data demonstrates TGFβR3 is an important component 
of the regulatory machinery that integrates TGFβ and BMP signaling in epicardial 
cells. 
 
Loss of TGFβR3 disrupts NF-κB signaling in embryonic epicardium  
 TGFβR3 is required for invasion promoted by TGFβ1, TGFβ2 and BMP2, 
suggesting that a TGFβR3-dependent signaling mechanism that regulates 
invasion is shared between these ligands. Our data predicts NF-ĸB signaling is 
dysregulated in Tgfbr3-/- epicardial cells. GRN’s generated from genes >2-fold 
differentially expressed between Tgfbr3+/+ and Tgfbr3-/- epicardial cells across 
each ligand incubation group (VEH, TGFβ1, TGFβ2, BMP2) identified NF-ĸB 
signaling as a central node. In support of a role for NF-ĸB signaling, genes 
known to be regulated directly or indirectly downstream of NF-ĸB were also 
dysregulated. Incubation of epicardial cells with TGFβ2 or BMP2 increased NF-
ĸB activity in Tgfbr3+/+ but not in Tgfbr3-/- cells, demonstrating that TGFβR3 is 
required for NF-ĸB activity in epicardial cells. Several mechanisms may account 
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for the ability of TGFβR3 to regulate NF-ĸB signaling. Previous studies have 
found that TGFβR3 can suppress NF-ĸB signaling via interaction with β-arrestin2 
(You, How et al. 2009). IL-1β, an upstream regulator of NF-ĸB signaling, can 
suppress TGFβR3 signaling by binding to TRAF6 which subsequently sequesters 
TGFβR3 from TGFβR2 (Lim, Bae et al. 2012). Here, reduced NF-ĸB activity may 
result from a >2-fold reduction in the expression of an important upstream 
regulator of NF-ĸB signaling, Il-1r (reviewed (Verstrepen, Bekaert et al. 2008)), in 
Tgfbr3-/- cells when compared to Tgfbr3+/+ cells. Reduced NF-ĸB activity may also 
result from decreased expression in Tgfbr3-/- cells of Myosin Light Chain Kinase 
(Mylk), which has recently been shown to promote activation of NF-ĸB signaling 
(Tauseef, Knezevic et al. 2012). MYLK kinase activity is required for MyD88 and 
IRAK4 complex formation, which in turn is required to activate NF-ĸB 
downstream of lipopolysaccharide (Medvedev, Lentschat et al. 2002; Kawagoe, 
Sato et al. 2008), in lung endothelial cells (Tauseef, Knezevic et al. 2012). Given 
the known roles of Mylk in regulating smooth muscle behavior (Cole and Welsh 
2011), cell migration (Kamm and Stull 2001), and a link to coronary artery 
disease (Wang, Hauser et al. 2007), the elucidation of the regulatory interactions 
between MYLK, TGFβR3, and NF-ĸB in epicardial cells may provide key insights 
into coronary vessel development. 
 While TGFβR3 signaling has been previously reported to both inhibit 
(Criswell and Arteaga 2007; You, How et al. 2009) and promote (Criswell, 
Dumont et al. 2008) NF-ĸB signaling, a consistent fact in all of these studies is 
that a decrease in NF-ĸB activity was coincident with decreased invasion. We 
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showed that NF-ĸB activity was required for epicardial cell invasion. These data 
suggest that NF-ĸB is a shared signaling pathway downstream of ligand and that 
TGFβR3 interaction is required for cell invasion. Therefore, we propose that the 
disruption of TGFβR3 regulated NF-ĸB signaling is a mechanism responsible for 
the loss of invasion in epicardial cells and ultimately failed coronary vessel 
development in Tgfbr3-/- embryos.  
 
Summary 
 Together, our data confirms the epicardial identity and ligand responses of 
embryonic epicardial cells in vitro. GO and GRN analysis identified novel genes 
and signaling pathways dysregulated after the loss of TGFβR3, which led us to 
the identification and validation of NF-ĸB as a potential regulator of epicardial cell 
invasion. Finally, the genes and signaling pathways identified through our 
analysis yield the first comprehensive list of candidate genes whose expression 
is dependent on TGFβR3 signaling. Further analyses of these data will likely 
yield insights into epicardial cell biology and TGFβR3 signaling. Our findings 
have broad applicability to development and disease given the importance of 
EMT and TGFβR3 not only in cardiogenesis but in pathological processes such 









SUMMARY AND CONCLUSIONS 
 
Heart disease and EMT 
 Cardiovascular disease remains a leading cause of death in the world. 
The understanding the signaling mechanisms that can give rise to or modulate 
cardiovascular disease remains a key goal of scientists. Coronary and valvular 
heart disease both contribute a significant portion to the global disease burden 
represented by cardiovascular disease and it has become increasingly 
appreciated that signaling pathways that promotes these complaints share many 
similarities with the signaling processes regulating the development of coronary 
arteries and the valves. In development, distinct cell populations undergo tightly 
regulated EMT events that are critical in the development of both coronary 
arteries and valves. In the adult, EMT in the epicardium has been implicated in 
cardiac regeneration following injury, making epicardial behavior an attractive 
target for therapeutic intervention. The goal of generating a stable population of 
functioning VICs to seed next-generation, prosthetic valves requires an 
understanding of the signaling pathways that regulate EMT to give rise to VICs in 
development. Given the shared pathways regulating EMT in the endocardium 
and epicardium, a careful examination of the GRNs that promote EMT is critical 
to the future design of therapeutic strategies to modulate coronary and valvular 
heart disease. In addition, EMT in endocardial cells has been linked to fibrosis in 
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adult hearts and a dysregulation of cell invasion outside of the heart has long 
been linked to cancer progression which broadens the impact of this study. 
  
Transcriptional profiling using next-generation sequencing 
 Despite the importance of EMT, our knowledge often progresses at the 
pace of a single gene study at time. In an effort to overcome this single gene 
focus we examined the GRNs regulating endocardial and epicardial EMT using 
transcription profiling strategies. We used next-generation sequencing, in the 
form of RNA-seq analysis, to analyze global gene expression. The use of RNA-
seq analysis can allow us to identify transcripts with low levels of or changes in 
expression on a global level that would have otherwise been missed. 
Transcription factors, in particular, can dramatically alter cell behavior with small 
changes in expression (Niwa, Miyazaki et al. 2000). Though not leveraged in the 
presented studies, the generated RNA-seq datasets may also allow for an 
examination of alternate splicing and alternate 5’ start sites during EMT in 
cardiogenesis (Shapiro, Cheng et al. 2011). Despite the sensitivity of RNA-seq 
methodology, in order to generate useful datasets for analysis careful 
consideration must be given to account for technical and biological variability. In 
our studies in the epicardium and endocardium we the observed low levels of 
biological and technical variability. Overall, the use of RNA-seq analysis enabled 





Spatial transcriptional profiling of the developing heart tube 
 In Chapter II we present an unbiased strategy to identify genes important 
in endocardial EMT using a spatial transcriptional profile. Endocardial cells 
overlaying the cushions of the AVC and OFT undergo an EMT to yield VICs. 
RNA-seq analysis of gene expression between AVC, OFT, and VEN isolated 
from chick and mouse embryos at comparable stages of development (chick 
HH18; mouse E11.0) was performed. EMT occurs in the AVC and OFT cushions, 
but not VEN at this time. We exploited this well described heterogeneity of the 
developing heart tube to identify genes with enriched expression in the valve 
forming regions of the heart. We found 198 genes in the chick and 105 genes in 
the mouse were enriched 2-fold in the cushions. GRN generated from cushion-
enriched gene lists confirmed TGFβ as a nodal point and identified NF-κB as a 
potential node. To reveal previously unrecognized regulators of EMT four 
candidate genes, Hapln1, Id1, Foxp2, and Meis2, and a candidate pathway, NF-
κB, were selected.  In vivo spatial expression of each gene was confirmed by in 
situ hybridization and a functional role for each in endocardial EMT was 
determined by siRNA knockdown in a collagen gel assay. Our spatial-
transcriptional profiling strategy yielded gene lists which reflected the known 
biology of the system. Further analysis accurately identified and validated 
previously unrecognized novel candidate genes and the NF-κB pathway as 
regulators of endocardial cell EMT in vitro.  
 These data validate our approach and suggest further examination of the 
cushion-enriched gene lists in chick and mouse may yield useful insights into VIC 
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behavior. It is important to note that the cushion-enriched genes could potentially 
regulate other aspects of VIC behavior aside from EMT. For example, after VICs 
invade into the endocardial cushions, they secrete proteins that interacting with, 
bind, cleave, or constitute ECM components found in the cardiac jelly. The 
signaling pathways which regulate valve remodeling are poorly understood yet 
this process is important for proper valve maturation (Lockhart, Wirrig et al. 
2011). In the cushion-enriched gene lists in chick and mice we identified several 
genes that play a role in ECM remodeling or organization. Adamts15 was 
identified as enriched in both chick and mouse cushions and is an intriguing 
candidate for involvement in valve remodeling because it is known to cleave 
Versican (Cross, Chandrasekharan et al. 2005). Versican cleavage is an 
important feature of valve remodeling (Kern, Twal et al. 2006; Dupuis, McCulloch 
et al. 2011). Matn4 is also enriched in chick and mouse cushions and is 
associated with ECM organization during cartilage formation, a process involving 
many of the same signaling pathways as valve development.  
 Thus, further analysis of the cushion-enriched candidate genes may 
reveal novel regulators of VIC behavior. To expand on this idea, broadening the 
spatial transcriptional profile to include different time points in valve development, 
such as before EMT (E9.0) or during remodeling (E13.5), may identify genes 
important in different aspects of valve development. Comparing the spatial 
expression observed before EMT occurs in the heart tube (E9.0) to the profile 
observed during EMT (E11.0) could identify the GRNs which initiate endocardial 
EMT. Comparing the expression of ECM components when the cardiac jelly 
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initially forms (E9.0), during EMT (E11.0) and during remodeling may identify 
ECM components associated specifically with EMT initiation and remodeling. 
Also, a spatial-temporal profile comparing AVC and OFT development may 
identify the signaling pathways that serve to remodel these tissues into distinctly 
different structures. Our understanding of endocardial EMT during valve 
formation is still incomplete, but comprehensive studies using transcription 
profiling approaches coupled with efficient functional assays may allow us to 
more rapidly delineate the GRNs regulating this EMT process. 
 
Transcriptional profile of epicardial cells identifies genes downstream of TGFβR3 
 Signaling mediated by TGFβR3 plays important roles in heart 
development and cancer progression. However, the signaling mechanisms and 
genes specifically activated by TGFβR3 are not well described. Therefore, we 
undertook a transcriptional profiling approach to identify the genes downstream 
of TGFβR3 in a well characterized epicardial cell culture system. The epicardium 
plays an important role in coronary vessel formation and Tgfbr3-/- mice exhibit 
failed coronary vessel development associated with decreased epicardial cell 
invasion and proliferation. Immortalized Tgfbr3-/- epicardial cells display the same 
defects. Tgfbr3+/+ and Tgfbr3-/- cells incubated with VEH or ligands known to 
promote invasion via TGFβR3, TGFβ1, TGFβ2, or BMP2, for 72 hours and 
harvested for RNA-seq analysis. We selected for genes >2-fold differentially 
expressed between Tgfbr3+/+ and Tgfbr3-/- cells when incubated with VEH, 
TGFβ1, TGFβ2, or BMP2. GO analysis of the genes >2-fold differentially 
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expressed between Tgfbr3+/+ and Tgfbr3-/- cells identified dysregulated biological 
processes consistent with the defects observed in Tgfbr3-/- cells, including those 
associated with the ECM interaction. GO and GRN analysis identified distinct 
expression profiles between TGFβ1 or TGFβ2 and VEH or BMP2 incubated cells, 
consistent with the differential ligand response of epicardial cells to these ligands 
in vitro. Despite the differences observed between Tgfbr3+/+ and Tgfbr3-/- cells 
after TGFβ and BMP ligand addition, GRNs constructed from these gene lists 
identified NF-ĸB as a key nodal point for all ligands examined. Tgfbr3-/- cells 
exhibited decreased expression genes known to be activated by NF-ĸB signaling. 
NF-ĸB activity was stimulated in Tgfbr3+/+ epicardial cells after TGFβ2 or BMP2 
incubation, while Tgfbr3-/- cells failed to activate NF-ĸB in response to these 
ligands Tgfbr3+/+ epicardial cells incubated with an inhibitor of NF-ĸB signaling no 
longer invaded into a collagen gel in response to  TGFβ2 or BMP2.  These data 
suggest that NF-ĸB signaling is dysregulated in Tgfbr3-/- epicardial cells and that 
NF-ĸB signaling is required for epicardial cell invasion in vitro. Thus, our 
approach was successful in identifying signaling pathways important in epicardial 
cell behavior downstream of TGFβR3. Overall, the genes and signaling pathways 
identified through our analysis yield the first comprehensive list of candidate 
genes whose expression is dependent on TGFβR3 signaling.  
 To further elucidate the role of TGFβR3-dependent in regulating epicardial 
cell behavior the transcriptional profiling strategy used in chapter III can be 
expanded temporally. The epicardial cells harvested for RNA-seq analysis in 
chapter III were collected after 72 hours of incubation with ligand. We know, 
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however, that EMT occurs within the first 24 hours after ligand addition. Also, 
defects in invasion after the loss of TGFβR3 are observed after 24 hours in the 
transwell invasion assay. Consistent with these observations, it has previously 
been described that there are distinct phases of gene expression that occur 
within the first 24 hours after ligand addition that are important in regulating 
different aspects of EMT (Vetter, Le Bechec et al. 2009; Tran, Corsa et al. 2011). 
RNA-seq analysis of time points before 72 hours after ligand incubation would 
allow for the definition of a temporal map of gene expression dependent on 
TGFβR3. This would allow us to ask more precise questions about the nature of 
the dysregulated expression observed in Tgfbr3-/- cells. Do Tgfbr3-/- cells have 
different phases of gene expression compared to Tgfbr3+/+ cells? Are the distinct 
phases of Snai1-regulated (early) and Twist1-regulated (late) gene expression 
altered in Tgfbr3-/- cells? Is the temporal expression pattern of cells incubated 
with TGFβ1 or TGFβ2 different from that of BMP2? Does this change in Tgfbr3-/- 
cells? When does the dysregulation of NF-κB signaling regulated genes occur? 
We predict that the temporal expression pattern of genes regulating loss of 
epithelial character and smooth differentiation will not be altered between 
genotypes while the temporal expression pattern of genes regulating cell motility 
may be disrupted. Whether the expression of these genes is completely lost from 
an early time point or whether their expression is delayed is unknown.  
 
TGFβR3 signaling in epicardial and endocardial EMT 
 Despite considerable effort by our laboratory and others, many questions 
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remain regarding the role of TGFβR3 in epicardial and endocardial EMT. Our 
laboratory has shown that TGFβR3 plays a unique role in both valve and 
coronary vessel development. TGFβR3 is required for invasion for embryonic 
endocardial and epicardial cells in vitro. In vivo, absence of the TGFβR3 results 
in a dysregulated EMT process, leading to hyperplasia in the endocardial cushion 
and the subepicardial space. These mesenchymal cells display defects in 
remodeling the cushion and in the epicardium there is a decrease in the ability of 
EPDCs to invade the myocardium. Despite these similarities, the regulation of 
EMT by TGFβ signaling is not identical in all cell types. ALK5 is required in 
endocardial and epicardial EMT in vitro, but it is sufficient for EMT only in the 
epicardium (Desgrosellier, Mundell et al. 2005; Hill, Sanchez et al. 2012). In 
addition, the Par6c/Smurf1/RhoA pathway was shown to be required and 
sufficient for EMT in endocardial and epicardial cells in vitro, but this pathway 
required the presence of TGFβR3 only in the epicardium (Townsend, Wrana et 
al. 2008; Sanchez and Barnett 2012). These differences underscore the 
importance of delineating the mechanisms by which TGFβR3 signaling regulates 
the common process of EMT in both the endocardium and the epicardium to 
yield distinct mesenchymal cell populations. 
 A major advantage of developing transcriptional profiles of both 
endocardial and epicardial EMT is the ability to compare these data sets. As 
previously mentioned, there is significant overlap between the signaling 
mechanisms which regulate endocardial and epicardial EMT, including Wnt, 
Notch, TGFβ, and BMP signaling pathways. In Chapter I and Chapter II we 
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demonstrated the requirement for NF-ĸB signaling for epicardial and endocardial 
EMT in vitro. This ability of TGFβ2 and BMP2 to stimulate NF-ĸB signaling was 
shown to be TGFβR3 dependent in the epicardium. These data suggest that NF-
ĸB may be a common downstream mediator of TGFβR3 promoted invasion in the 
epicardium. This begs the question; do endocardial cells require TGFβR3 to 
stimulate NF-ĸB signaling as well? Is NF-ĸB activity required for TGFβ2 or BMP2 
induced invasion in the endocardium? Is NF-ĸB signaling sufficient to induce 
EMT in either the epicardium or endocardium? The ability of TGFβR3 to both 
inhibit (Criswell and Arteaga 2007; You, How et al. 2009) and promote (Criswell, 
Dumont et al. 2008) NF-ĸB signaling in different cancer cell lines suggests the 
nature of TGFβR3 and NF-ĸB signaling crosstalk may be cell specific. 
Understanding the mechanisms that underlie the ability of TGFβR3 signaling to 
modulate NF-ĸB signaling in specific cells will be crucial in addressing the ability 
of TGFβR3 to promote invasion in different therapeutic contexts. Additional 
comparisons between the endocardially- and epicardially-derived gene lists may 
identify other common regulators EMT. For example, we observed a significant 
dysregulation in the expression of genes associated with ECM proteins, 
degradation, and organization after loss of TGFβR3 in epicardial cells, which may 
also underlay the valve phenotype of Tgfbr3-/- embryos. The AVC explants 
culture system is particularly amenable to study the importance of cell-ECM 
interaction and could be used to investigate how the loss of TGFBR3 affects and 
is affected by the ECM. In an iterative process, we may be able to use the 
findings from one system in the other to take advantage of the unique strengths 
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of each, furthering our ability to understand the regulatory mechanism that 






























HH18 Chick Genes with >1.25-fold Higher Expression in AVC and OFT 
Compared to VEN 
 
Red= >2-fold Enriched in both AVC and OFT compared to VEN 
Orange= >1.25-fold Enriched in both AVC and OFT compared to VEN 
Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
FAM26E 49.00 2.06E-04 49.00 7.92E-04 
KCTD8 49.00 2.06E-04 49.00 7.92E-04 
ATOH8 28.72 6.87E-08 15.58 2.06E-04 
GAL3ST1 26.42 2.95E-07 25.96 2.58E-07 
MOXD1 25.53 2.79E-107 22.73 9.64E-97 
SOX9 21.49 8.83E-83 22.12 1.61E-88 
PENK 21.44 1.27E-15 10.73 2.39E-07 
BMP2 18.38 5.41E-37 3.46 4.39E-04 
PTX3 17.23 3.39E-45 19.47 4.15E-54 
CNTN2 14.93 3.79E-04 39.47 3.61E-11 
RSPO3 14.29 2.68E-113 5.22 6.64E-28 
MATN4 13.79 1.66E-09 6.23 6.26E-04 
CA10 13.02 6.55E-09 12.12 1.91E-08 
BCMO1 13.02 6.55E-09 8.31 1.79E-05 
SOX8 11.49 1.65E-05 19.73 3.86E-10 
TMEM132C 11.49 4.18E-25 6.89 3.83E-13 
APCDD1L 10.91 3.26E-05 14.02 5.27E-07 
AASS 10.80 3.11E-11 10.59 2.60E-11 
SLC6A15 10.34 6.39E-05 7.79 9.99E-04 
ADCYAP1R1 9.70 9.60E-17 6.12 2.56E-09 
KCNJ5 9.57 1.85E-16 3.46 4.39E-04 
CD3E 9.38 4.14E-11 20.25 5.19E-29 
TBX2 9.36 7.50E-34 6.08 6.34E-19 
FGF13 9.08 5.11E-34 9.25 4.07E-36 
PDE1C 8.94 1.09E-22 5.42 1.60E-11 
SLIT1 8.81 2.92E-10 11.77 3.48E-15 
PCDH15 8.62 4.69E-04 19.73 3.86E-10 
Angptl1 8.62 4.81E-07 17.14 2.61E-16 
ARSI 8.04 3.84E-09 4.50 2.15E-04 
RELN 7.67 9.90E-32 2.99 4.98E-07 
DMRT1 7.47 1.11E-10 6.23 1.23E-08 
GAD1 7.24 1.73E-12 5.09 7.44E-08 
SOD3 7.18 3.89E-10 11.04 2.77E-18 
TMEM132D 7.12 1.02E-06 6.44 4.40E-06 
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Appendix A: Continued 
   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
SMAD9 7.08 9.02E-08 4.33 3.61E-04 
DIXDC1 6.89 1.91E-06 6.23 7.80E-06 
CD9 6.80 1.60E-14 4.63 1.56E-08 
HAPLN1 6.80 1.11E-39 3.61 2.35E-14 
CSGALNACT1 6.77 2.26E-10 4.15 2.34E-05 
TCF21 6.35 9.80E-36 3.80 8.75E-16 
WNT4 6.15 1.89E-13 5.27 4.71E-11 
SCTR 6.13 4.74E-09 14.19 5.95E-28 
TWIST2 6.13 1.95E-06 7.96 2.63E-09 
GEM 5.97 2.22E-05 10.18 9.00E-11 
MSX2 5.92 4.90E-28 3.97 5.37E-15 
PRMT8 5.91 5.80E-07 3.86 5.53E-04 
SAMD11 5.90 1.75E-25 3.32 5.38E-10 
IL1RL2 5.74 2.57E-04 5.19 6.52E-04 
COL20A1 5.74 4.70E-09 4.99 1.27E-07 
METRNL 5.74 4.69E-29 2.86 1.06E-08 
DBC1 5.49 9.21E-08 3.46 4.39E-04 
WNT6 5.32 5.06E-25 6.88 1.02E-38 
ANGPTL4 5.27 2.41E-09 3.38 7.34E-05 
CHODL 5.17 7.51E-17 3.20 1.02E-07 
GREB1 5.16 1.16E-67 4.43 4.71E-54 
AKR1B10 5.14 8.51E-15 2.52 2.00E-04 
EMID2 5.11 5.63E-21 4.52 9.07E-18 
SOX6 5.03 3.18E-06 7.27 1.23E-10 
CNTN4 4.83 4.23E-04 4.78 3.76E-04 
CHN2 4.79 1.11E-31 6.83 3.76E-58 
APCDD1 4.74 1.51E-18 2.78 2.83E-07 
ZNF608 4.68 1.52E-24 2.42 4.72E-07 
NID1 4.65 6.09E-36 2.54 3.11E-11 
SLC8A3 4.60 4.29E-07 6.04 6.39E-11 
TGFB2 4.56 4.61E-51 4.34 1.52E-48 
RERG 4.45 3.02E-05 6.88 7.04E-10 
COL24A1 4.44 9.71E-09 2.98 1.15E-04 
PXDNL 4.33 1.91E-07 3.12 1.57E-04 
PCDH17 4.33 1.91E-07 2.96 3.77E-04 
GRID1 4.31 6.50E-07 4.33 3.49E-07 
MMP24 4.16 2.48E-08 3.44 2.78E-06 
SMOX 4.11 9.88E-46 5.32 8.18E-75 
KIAA1324L 4.08 9.58E-10 2.54 2.41E-04 
ABCG4 3.97 1.10E-05 10.01 1.02E-21 
EPHA4 3.95 2.64E-18 2.39 6.79E-07 
SCD 3.94 4.58E-15 3.18 1.78E-10 
DPP10 3.91 4.03E-07 4.09 6.61E-08 
MXRA8 3.91 3.75E-05 3.84 3.56E-05 
TMEM86A 3.88 2.62E-04 3.64 4.97E-04 
IDNK 3.82 5.47E-15 4.66 5.21E-22 
RASD1 3.79 6.32E-05 3.32 3.84E-04 
HAS2 3.75 1.52E-55 3.12 1.24E-39 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
TSHZ2 3.73 4.42E-04 3.64 4.97E-04 
NEDD9 3.73 6.28E-13 3.53 4.02E-12 
BMP5 3.69 5.96E-112 2.45 7.18E-46 
SMTNL2 3.65 8.95E-17 3.30 2.33E-14 
GFPT2 3.64 1.96E-80 3.00 9.05E-56 
SESN3 3.62 2.82E-10 2.65 6.30E-06 
VSTM5 3.60 3.11E-06 4.92 1.41E-10 
WT1 3.60 3.11E-06 3.19 3.07E-05 
PRELP 3.60 7.30E-09 4.79 7.50E-15 
ANXA2 3.58 6.37E-55 4.14 4.46E-76 
CXCR7 3.41 7.29E-43 2.92 4.37E-32 
CADM1 3.40 1.98E-66 3.95 1.04E-93 
SYNPO2 3.38 3.38E-06 8.19 5.69E-25 
CERS1 3.32 1.23E-39 2.77 8.90E-28 
CTNNAL1 3.31 4.91E-19 2.72 4.49E-13 
IFNGR1 3.30 1.39E-16 2.04 8.31E-06 
GRIN3A 3.29 3.48E-09 2.22 2.56E-04 
C1R 3.26 2.81E-09 2.74 7.53E-07 
SYK 3.23 8.77E-07 9.79 4.96E-39 
BNC2 3.22 7.80E-04 3.32 3.84E-04 
CBLN1 3.18 7.17E-09 5.95 7.97E-27 
MYO16 3.16 2.09E-32 2.27 2.41E-15 
KRT222 3.14 5.81E-05 4.22 2.44E-08 
GDF3 3.14 2.62E-35 2.74 3.66E-27 
CADPS 3.08 1.78E-06 3.07 1.21E-06 
GPM6B 3.06 4.84E-04 4.41 2.10E-07 
MSANTD3 3.06 1.81E-05 3.52 3.44E-07 
GULP1 3.03 9.12E-09 2.58 1.44E-06 
CD109 3.01 8.95E-08 2.54 9.53E-06 
COLQ 3.00 3.58E-08 6.16 3.49E-29 
PIK3IP1 3.00 1.78E-07 2.34 1.08E-04 
LARGE 2.99 2.23E-14 5.16 2.80E-41 
SNAI2 2.98 1.30E-12 2.56 2.15E-09 
CACNA1H 2.97 3.73E-10 3.09 2.08E-11 
RAI14 2.96 4.89E-24 3.63 3.69E-38 
DISP1 2.96 8.13E-25 2.32 1.78E-14 
BMF 2.94 4.52E-05 3.35 1.37E-06 
CRMP1 2.93 2.99E-34 2.00 2.92E-13 
SLITRK4 2.92 6.03E-04 3.52 1.61E-05 
CAMKK1 2.90 5.49E-06 4.65 3.55E-14 
MAP1B 2.83 3.10E-52 2.59 6.23E-44 
ROBO1 2.82 5.46E-51 2.53 8.58E-41 
RGS9 2.82 4.32E-05 3.17 1.63E-06 
VDAC1 2.80 3.66E-19 2.07 2.41E-09 
CSRP2 2.79 1.11E-23 9.73 4.33E-217 
PRKCD 2.78 4.10E-06 2.28 3.29E-04 
LRP4 2.73 3.82E-10 2.62 1.43E-09 
ADORA2A 2.72 1.52E-06 2.98 4.20E-08 
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Appendix A: Continued 
   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
FUT8 2.70 6.23E-16 2.05 2.30E-08 
CCDC149 2.70 3.15E-05 3.43 1.92E-08 
IGF2 2.70 9.68E-06 3.08 1.18E-07 
HMGCLL1 2.66 3.32E-11 2.67 1.11E-11 
LECT1 2.65 4.70E-144 3.48 1.47E-280 
CPE 2.65 5.68E-62 3.65 1.94E-132 
TBX20 2.65 9.84E-152 2.77 5.64E-178 
PLCB4 2.65 8.25E-09 2.17 8.68E-06 
COL22A1 2.64 5.25E-04 5.07 2.15E-12 
ARSJ 2.63 3.73E-05 2.38 2.37E-04 
FOXO3 2.62 2.14E-06 2.14 2.77E-04 
ATRNL1 2.62 1.22E-21 3.52 3.86E-43 
Nrg1 2.61 9.85E-08 2.23 1.19E-05 
SNCB 2.60 5.37E-06 3.29 8.41E-10 
COL11A1 2.60 5.37E-06 2.56 5.39E-06 
DOCK5 2.59 6.94E-11 4.76 3.70E-37 
HMBOX1 2.59 1.38E-25 2.40 7.07E-22 
ST6GAL1 2.53 2.93E-06 2.08 3.57E-04 
ASTN2 2.53 1.04E-07 5.29 5.94E-32 
ADCY2 2.50 8.24E-07 2.02 2.47E-04 
ST8SIA6 2.49 9.32E-04 4.33 3.83E-10 
HINT3 2.49 9.32E-04 2.83 6.93E-05 
CD59 2.49 6.55E-09 3.21 5.16E-16 
SH3D19 2.48 7.15E-04 2.51 4.31E-04 
ZNF518A 2.47 6.54E-06 2.11 2.58E-04 
MSH2 2.46 6.92E-21 4.17 1.39E-67 
RPS6KA6 2.43 7.51E-06 2.40 6.48E-06 
ABTB2 2.42 1.81E-14 2.76 1.20E-20 
NKD1 2.39 2.09E-07 2.40 1.05E-07 
AMY2A 2.38 1.81E-11 2.74 1.27E-16 
CITED4 2.37 8.06E-16 2.28 9.10E-15 
DOC2B 2.35 5.51E-04 2.98 1.60E-06 
GDPD1 2.35 7.47E-07 2.59 7.75E-09 
LAMA4 2.33 1.98E-20 2.69 1.38E-30 
LPIN1 2.33 3.10E-05 2.63 5.52E-07 
FBN1 2.31 4.49E-72 3.57 4.32E-212 
ATP13A3 2.30 2.47E-84 2.14 3.09E-71 
BDH2 2.30 2.04E-06 2.21 4.43E-06 
LDHA 2.29 7.53E-251 2.33 5.62E-273 
OPTN 2.27 2.15E-29 2.00 6.50E-21 
COL27A1 2.27 2.33E-05 2.98 6.37E-10 
CYP27A1 2.26 3.28E-12 3.23 5.58E-29 
BOK 2.26 1.36E-34 4.19 2.09E-146 
GLIPR2 2.25 6.32E-09 4.85 5.92E-45 
PNPLA8 2.24 7.03E-09 2.01 6.06E-07 
CYP26B1 2.21 2.51E-15 2.81 3.35E-29 
MMP16 2.20 3.51E-07 2.18 2.85E-07 
KATNAL1 2.19 1.78E-04 2.01 8.32E-04 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
IGFBP5 2.18 4.51E-06 3.34 6.29E-16 
ZFPM2 2.17 1.58E-12 2.03 7.89E-11 
PPARGC1A 2.17 2.51E-10 2.51 1.58E-15 
MYOZ1 2.17 1.51E-04 5.04 7.76E-24 
SLC35F1 2.16 1.96E-04 2.69 2.52E-07 
PDZRN4 2.15 8.77E-08 2.12 8.87E-08 
ME3 2.14 4.01E-07 3.45 1.43E-21 
MRVI1 2.11 7.97E-04 4.36 3.21E-16 
ADAMTSL3 2.10 3.98E-04 2.96 6.36E-09 
SCUBE1 2.09 1.12E-06 4.38 1.25E-33 
SORBS1 2.08 2.04E-45 2.10 6.62E-49 
TPCN1 2.08 6.03E-06 2.50 1.26E-09 
WFIKKN1 2.06 8.44E-06 4.10 2.15E-26 
PLA2R1 2.05 4.41E-07 2.51 2.88E-12 
TOX2 2.03 1.57E-11 2.95 8.98E-31 
FADS2 2.02 4.08E-13 2.06 2.31E-14 
PARP8 2.02 2.54E-04 2.13 4.55E-05 
GRAMD1C 2.01 1.73E-09 2.09 5.78E-11 
TOM1 2.00 2.68E-08 2.29 2.00E-12 
NKAIN4 2.00 3.49E-05 2.08 6.56E-06 
SFRP1 3.54 1.52E-39 1.75 7.51E-07 
ITGA4 3.48 2.65E-50 1.59 3.66E-06 
C7 3.35 1.77E-11 1.96 8.43E-04 
SULF2 3.05 8.43E-35 1.66 8.67E-07 
HCN4 2.96 1.82E-36 1.56 6.70E-06 
PTPN13 2.91 1.43E-15 1.93 5.92E-06 
ANKH 2.85 5.02E-27 1.96 1.28E-10 
BAMBI 2.73 1.82E-80 1.91 2.52E-30 
GPX3 2.65 4.81E-62 1.49 2.16E-09 
ADSSL1 2.65 2.04E-11 1.99 6.41E-06 
HDAC10 2.61 3.09E-08 1.87 7.46E-04 
TRIM2 2.58 2.36E-22 1.96 4.45E-11 
LMO4 2.47 4.37E-44 1.99 7.30E-25 
LMBR1 2.43 1.34E-22 1.40 9.28E-04 
CNOT6L 2.43 2.45E-09 1.78 2.65E-04 
BRWD3 2.41 2.65E-14 1.85 3.96E-07 
KCTD15 2.39 2.47E-09 1.68 9.06E-04 
PXDN 2.36 3.11E-92 1.87 2.10E-46 
MICAL2 2.30 9.47E-73 1.64 6.88E-24 
FAM135A 2.29 5.23E-16 1.99 3.59E-11 
TLK1 2.29 7.82E-14 1.54 3.43E-04 
SOX5 2.28 3.82E-07 1.90 1.03E-04 
ATG13 2.27 5.92E-14 1.80 2.14E-07 
CNOT6 2.27 4.75E-26 1.67 3.76E-10 
SLC12A2 2.25 1.20E-61 1.33 1.94E-07 
PIK3C2A 2.24 3.48E-25 1.99 9.15E-19 
ALDH18A1 2.23 5.87E-16 1.69 4.80E-07 
RHOU 2.19 1.47E-05 1.94 3.09E-04 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
ADCK3 2.19 2.29E-49 1.76 4.48E-25 
REV3L 2.18 1.18E-27 1.77 1.31E-14 
ITFG1 2.18 6.44E-12 1.61 6.87E-05 
MAPK11 2.16 6.81E-17 1.92 1.91E-12 
LOX 2.15 1.97E-06 1.84 2.17E-04 
NAA16 2.15 1.89E-14 1.44 6.59E-04 
DPY19L4 2.14 2.41E-07 1.69 6.23E-04 
RASSF7 2.13 6.65E-07 1.78 2.18E-04 
SDC2 2.12 3.48E-15 1.99 3.24E-13 
ZNF217 2.12 5.30E-19 1.64 1.96E-08 
STXBP3 2.12 1.33E-20 1.47 7.58E-06 
DKK3 2.09 5.44E-121 1.28 7.04E-13 
CEP170 2.09 1.80E-28 1.66 2.27E-13 
TRPS1 2.08 1.16E-07 1.76 6.06E-05 
CLSTN3 2.08 4.62E-08 1.75 3.96E-05 
ING3 2.07 3.75E-07 1.95 2.98E-06 
CERK 2.07 6.10E-10 1.64 5.04E-05 
PARP4 2.06 1.67E-05 1.90 1.25E-04 
AFF1 2.05 2.29E-09 1.66 4.04E-05 
VCAN 2.04 4.09E-148 1.47 9.17E-39 
RECK 2.04 9.71E-08 1.62 4.89E-04 
EPCAM 2.03 1.01E-06 1.70 3.13E-04 
PLCB1 2.03 1.78E-14 1.68 3.19E-08 
ASB2 2.03 8.82E-34 1.48 1.87E-10 
EPHA5 2.02 6.45E-06 1.94 1.58E-05 
EML1 2.02 6.41E-05 1.87 3.68E-04 
PAPSS1 2.01 3.38E-20 1.96 1.76E-19 
SLCO5A1 2.01 8.39E-09 1.64 6.48E-05 
UBL3 2.00 2.01E-16 1.43 6.40E-05 
LPHN3 1.98 1.05E-16 1.86 4.13E-14 
CREB3L2 1.98 3.02E-11 2.39 9.55E-20 
GPC1 1.98 6.81E-21 1.40 1.17E-05 
PLXNA2 1.97 1.45E-10 3.01 3.24E-32 
FBXO7 1.97 2.13E-17 1.39 1.02E-04 
PRKD1 1.97 2.78E-08 1.65 6.13E-05 
MAN2B2 1.97 6.14E-09 2.02 5.04E-10 
LRRC73 1.96 4.90E-04 2.15 3.27E-05 
LSP1 1.96 2.06E-39 1.46 1.72E-12 
RNF130 1.95 1.01E-07 2.22 1.77E-11 
TMEM8A 1.95 1.01E-07 1.79 3.01E-06 
ADAMTS7 1.94 5.01E-10 2.87 5.38E-29 
BCAS3 1.94 1.99E-08 1.82 3.35E-07 
HEG1 1.93 1.80E-12 2.14 1.48E-17 
NETO2 1.93 2.80E-04 2.50 3.52E-08 
SACS 1.93 1.64E-28 1.62 1.61E-15 
SEC24D 1.92 4.39E-07 2.31 3.66E-12 
WNT11 1.91 3.60E-13 1.85 3.00E-12 
AKT1 1.91 2.48E-21 1.40 3.36E-06 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
SEMA5B 1.90 4.13E-07 1.68 5.53E-05 
PMP22 1.90 1.52E-10 1.88 1.03E-10 
NPC1 1.90 3.47E-09 1.49 4.27E-04 
SMARCAD1 1.89 2.01E-09 1.57 3.77E-05 
PKNOX1 1.89 1.31E-06 1.57 8.17E-04 
RAB11FIP4 1.88 5.92E-07 1.62 1.90E-04 
BPGM 1.88 3.44E-17 1.37 5.84E-05 
SYNE2 1.87 3.23E-58 2.14 1.46E-95 
ITPR1 1.87 7.53E-10 1.75 2.85E-08 
ANKRD50 1.85 5.71E-18 1.91 6.47E-21 
OSBPL5 1.84 1.60E-18 1.86 6.67E-20 
FUT10 1.84 7.50E-04 1.93 1.87E-04 
ROR2 1.84 3.36E-06 1.91 4.23E-07 
EP400 1.84 4.97E-20 1.39 2.11E-06 
PHF16 1.84 9.75E-11 1.56 3.15E-06 
SH3BGRL 1.83 1.52E-42 2.18 2.55E-79 
INPP4B 1.83 7.01E-09 1.88 3.96E-10 
NIPBL 1.83 3.56E-34 1.30 5.67E-07 
IGF2R 1.82 4.71E-16 1.69 7.80E-13 
SIPA1L1 1.82 2.45E-14 1.49 8.66E-07 
SEMA6A 1.82 4.96E-06 1.78 7.76E-06 
TBC1D14 1.82 1.49E-08 1.67 1.05E-06 
TBC1D1 1.81 8.57E-12 1.55 7.60E-07 
ROR1 1.81 1.16E-23 1.57 5.12E-14 
FBN2 1.81 8.74E-188 2.08 4.63E-319 
SNTB1 1.81 4.21E-21 1.27 3.12E-04 
FNDC3B 1.81 4.51E-15 1.64 5.51E-11 
OSBPL8 1.80 4.10E-14 1.44 5.24E-06 
INPP5A 1.80 1.04E-10 1.37 9.97E-04 
DOPEY2 1.80 3.07E-09 1.85 8.14E-04 
YPEL5 1.79 1.07E-21 2.35 1.07E-52 
PAM 1.79 7.92E-07 1.49 9.13E-04 
P4HA1 1.79 3.24E-19 1.35 9.62E-06 
DSC2 1.79 9.15E-04 2.48 9.63E-09 
ZBED4 1.79 4.29E-15 1.41 7.82E-06 
XRN1 1.79 2.51E-17 1.27 9.12E-04 
DAGLB 1.78 6.75E-05 1.87 7.73E-06 
LNPEP 1.78 5.47E-08 1.50 2.18E-04 
ADAMTS15 1.78 1.85E-04 2.02 1.76E-06 
KIAA1551 1.78 1.98E-10 1.42 1.98E-04 
AHNAK2 1.78 6.13E-13 2.00 9.24E-20 
LRRN4 1.78 1.20E-09 1.45 1.32E-04 
PPM1L 1.77 4.81E-05 2.09 2.38E-08 
ICK 1.77 1.46E-05 1.58 5.76E-04 
THBS1 1.77 1.94E-08 2.03 1.69E-13 
PIK3R1 1.77 1.31E-04 2.02 6.61E-07 
UTRN 1.77 1.21E-28 2.08 1.04E-52 
TTC28 1.77 5.79E-17 1.87 1.28E-21 
129 
 
Appendix A: Continued 
   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
EXOC6B 1.77 5.37E-10 1.38 7.23E-04 
RB1CC1 1.76 9.88E-08 1.87 1.22E-09 
GATA5 1.76 1.11E-141 1.72 5.73E-137 
GATA4 1.76 5.50E-39 1.62 8.50E-29 
SLC16A10 1.76 1.58E-08 1.84 2.67E-10 
MYO1C 1.76 1.31E-08 1.38 8.03E-08 
DSG2 1.75 4.83E-14 2.10 1.07E-26 
MRC2 1.75 2.49E-14 2.15 2.60E-29 
HECW1 1.74 1.04E-09 2.91 1.31E-42 
FILIP1L 1.74 2.04E-16 1.95 1.93E-25 
TRANK1 1.74 2.77E-04 1.74 2.13E-04 
FAM171B 1.74 1.23E-05 1.71 1.73E-05 
App 1.74 1.69E-89 1.81 1.05E-109 
CCNT2 1.74 1.05E-04 1.83 1.09E-05 
RALGAPA1 1.73 1.22E-15 1.44 2.16E-07 
FGFR3 1.73 4.22E-11 1.68 2.35E-10 
KIF13B 1.73 9.03E-05 2.09 1.61E-08 
STAT1 1.73 1.51E-09 1.46 3.69E-05 
MEF2A 1.72 1.78E-55 1.42 1.49E-22 
SSFA2 1.72 6.90E-08 1.72 3.77E-08 
TP53INP1 1.72 5.19E-09 1.99 3.67E-15 
NCALD 1.72 6.63E-05 2.05 1.28E-08 
NBR1 1.72 1.32E-16 1.47 7.41E-09 
FAT1 1.72 2.61E-62 1.30 2.15E-14 
PI4KA 1.72 4.76E-18 1.26 4.14E-04 
CAPRIN2 1.71 2.78E-06 1.59 5.00E-05 
DPYSL3 1.71 2.13E-23 1.94 6.96E-39 
KIF5B 1.70 5.39E-35 1.36 1.08E-11 
CHGB 1.70 2.93E-05 2.03 2.13E-09 
SMAD6 1.70 1.49E-45 1.70 8.23E-48 
RHOB 1.69 1.29E-20 2.75 4.81E-95 
GNB5 1.69 1.71E-05 1.50 9.68E-04 
FBXO8 1.68 9.50E-04 1.80 1.01E-04 
IDH1 1.68 1.60E-15 1.40 5.48E-07 
SHROOM3 1.68 4.45E-19 1.70 7.61E-21 
DST 1.68 4.12E-10 1.38 1.34E-04 
HEPH 1.67 8.07E-04 3.40 2.09E-22 
ALDH7A1 1.67 4.57E-18 1.49 2.01E-11 
GALNT1 1.67 6.69E-30 1.28 1.06E-07 
TACC2 1.67 6.47E-26 1.33 1.18E-08 
KIAA0232 1.67 2.28E-12 1.38 1.53E-05 
GNS 1.66 2.72E-13 1.53 1.02E-09 
MCAM 1.66 4.78E-12 1.88 1.68E-19 
ATP11C 1.66 1.92E-15 1.52 7.58E-11 
VPS13B 1.66 6.33E-08 1.39 6.63E-04 
MYH11 1.66 5.41E-08 2.46 7.44E-28 
LPGAT1 1.66 5.11E-17 1.35 1.22E-06 
USP46 1.65 5.70E-09 1.49 4.03E-06 
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Appendix A: Continued 
   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
USP3 1.65 1.28E-12 1.34 4.94E-05 
MLLT4 1.64 2.31E-39 1.42 9.90E-20 
LIMD2 1.64 3.89E-10 2.07 1.86E-23 
ADC 1.64 2.29E-10 2.03 1.89E-22 
TYRO3 1.64 6.64E-11 1.58 9.07E-10 
NRIP1 1.64 1.47E-05 1.68 2.61E-06 
ITGB5 1.64 3.07E-10 1.59 1.40E-09 
FNIP2 1.64 2.07E-06 1.53 3.42E-05 
LIMA1 1.63 4.79E-09 1.74 4.96E-12 
ZFYVE20 1.63 1.13E-07 1.43 9.65E-05 
ID2 1.62 2.71E-26 1.84 6.56E-45 
SLC19A1 1.62 5.77E-33 1.25 1.12E-07 
C16orf62 1.62 1.95E-14 1.36 2.48E-06 
MSANTD4 1.62 9.82E-05 1.90 3.39E-08 
NCAPG2 1.62 2.81E-05 1.60 2.83E-05 
Synrg 1.62 1.08E-08 1.39 1.23E-04 
STAU1 1.61 1.04E-29 1.27 4.26E-08 
ARHGAP32 1.61 1.31E-07 1.51 4.01E-06 
MAPK8 1.61 2.94E-09 1.35 3.06E-04 
C6orf62 1.61 2.19E-09 1.49 4.82E-07 
TCP11L2 1.61 6.32E-04 1.71 5.53E-05 
TM9SF3 1.60 1.48E-28 1.49 9.81E-21 
ERC1 1.60 3.75E-05 1.82 3.25E-08 
PUM2 1.60 8.80E-19 1.32 4.42E-07 
TIMP3 1.60 1.59E-17 2.08 8.78E-48 
HIF1A 1.60 1.37E-26 1.25 9.79E-07 
SMAD3 1.59 1.19E-05 1.67 6.06E-07 
SCD5 1.59 2.28E-07 2.03 1.09E-17 
TTC9 1.59 2.51E-05 1.65 2.00E-06 
ABCA5 1.59 1.35E-06 1.57 1.25E-06 
TGFBR1 1.59 1.36E-11 1.37 4.18E-06 
SMARCD3 1.58 1.53E-05 1.47 2.50E-04 
TPD52 1.58 7.11E-27 1.69 1.04E-37 
SLC25A6 1.58 3.05E-280 1.32 8.61E-102 
KDM3A 1.58 2.98E-17 1.26 4.03E-05 
RCBTB2 1.58 2.53E-04 1.68 1.44E-05 
LRRC10 1.57 3.32E-07 1.60 4.26E-08 
TIAM1 1.57 2.79E-05 1.58 1.24E-05 
CRB2 1.57 2.09E-11 1.75 3.30E-18 
PPFIBP2 1.57 2.26E-06 1.44 1.25E-04 
RASA3 1.56 1.17E-06 1.46 3.46E-05 
ADAM9 1.56 1.82E-08 1.36 1.11E-04 
LTBP1 1.56 1.01E-37 1.71 2.40E-58 
SERINC1 1.56 1.26E-28 1.28 3.13E-09 
TOP2B 1.56 6.20E-37 1.28 5.58E-12 
RNF19A 1.56 1.96E-04 1.52 3.39E-04 
TTL 1.56 1.79E-12 1.31 2.87E-05 
CTNNA3 1.55 2.91E-25 1.54 1.18E-25 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
VAT1 1.55 5.36E-12 1.38 3.14E-07 
FZD1 1.54 2.73E-15 1.29 5.00E-06 
DCLK2 1.54 2.05E-05 1.85 1.16E-10 
FGD3 1.54 1.80E-05 1.48 8.59E-05 
DBX2 1.54 3.01E-05 2.23 1.84E-18 
PRKACB 1.53 5.14E-08 1.53 3.54E-08 
EFR3A 1.53 8.06E-10 1.37 6.39E-06 
MAP4K4 1.53 1.05E-26 1.74 1.68E-49 
CFC1/CFC1B 1.52 9.09E-07 1.42 3.72E-05 
GJC2 1.52 6.55E-05 2.10 3.16E-15 
EAF2 1.52 2.96E-04 1.69 1.71E-06 
UFSP2 1.52 2.11E-05 1.39 6.70E-04 
GLI3 1.52 1.52E-05 1.36 2.99E-08 
SPECC1 1.52 4.32E-07 1.61 1.50E-09 
RFTN2 1.51 5.99E-04 2.09 1.01E-11 
RAP1GDS1 1.51 2.50E-10 1.32 2.16E-05 
SASH1 1.51 3.94E-07 1.71 2.85E-12 
ROCK2 1.51 4.79E-13 1.43 2.69E-10 
FKBP15 1.50 3.79E-05 1.59 1.28E-06 
NNT 1.50 2.86E-22 1.28 6.24E-09 
ASAP1 1.50 2.73E-07 1.35 1.17E-04 
DNM1L 1.49 1.14E-23 1.25 2.80E-08 
PATZ1 1.49 7.81E-04 1.50 4.97E-04 
IGSF3 1.49 8.66E-08 2.55 1.85E-49 
MKL1 1.49 8.60E-06 1.51 2.11E-06 
PNPLA7 1.49 7.45E-08 1.49 2.61E-08 
SLC12A4 1.49 6.14E-13 1.26 4.32E-05 
GPI 1.48 1.09E-78 1.27 1.77E-29 
KIDINS220 1.48 1.39E-17 1.32 1.60E-09 
MYLK3 1.48 9.23E-16 1.40 5.15E-12 
CLSTN1 1.48 2.06E-13 1.35 2.48E-08 
KBTBD10 1.48 9.99E-05 1.68 4.31E-08 
TTYH3 1.48 3.96E-07 1.42 3.89E-06 
NOTCH2 1.48 8.67E-15 1.46 2.35E-14 
PLCD1 1.48 4.91E-21 1.88 2.37E-62 
NDST2 1.47 1.07E-06 1.44 2.56E-06 
UGDH 1.47 1.18E-09 1.45 3.13E-09 
FBXO34 1.47 1.12E-06 1.72 2.06E-13 
RCBTB1 1.46 4.98E-05 1.55 1.48E-06 
PROS1 1.46 2.07E-04 1.40 8.21E-04 
TBC1D9 1.46 1.10E-04 1.38 9.73E-04 
VASH1 1.46 6.36E-11 1.36 7.02E-08 
LRP12 1.46 8.95E-04 1.77 7.70E-08 
COL4A6 1.46 6.64E-39 1.94 8.72E-141 
LIFR 1.46 9.51E-13 1.66 2.68E-24 
COL5A1 1.46 4.57E-21 2.13 1.98E-101 
PTPN21 1.46 1.34E-04 1.50 2.27E-05 
RAVER2 1.45 6.17E-05 1.45 5.13E-05 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
ADCY5 1.45 1.10E-06 1.51 2.84E-08 
CD151 1.45 8.48E-21 1.34 2.43E-13 
RBFOX2 1.45 6.76E-19 1.30 4.84E-10 
HIVEP1 1.45 1.15E-08 1.42 4.19E-08 
PLXNA1 1.45 3.94E-19 1.38 1.77E-15 
RSU1 1.45 3.07E-14 1.27 1.14E-06 
TMTC3 1.45 5.63E-10 1.39 3.02E-08 
TBC1D16 1.45 3.68E-04 1.52 2.31E-05 
NCOA4 1.44 5.03E-24 1.33 6.33E-15 
PTGFRN 1.44 2.69E-05 1.71 4.16E-11 
UBE4B 1.44 2.33E-05 1.48 2.49E-06 
SNAP29 1.44 1.29E-07 1.34 1.76E-05 
COL4A5 1.43 4.30E-65 1.88 8.48E-234 
TES 1.43 1.56E-06 1.43 1.12E-06 
WAPAL 1.43 7.69E-11 1.26 3.93E-05 
KALRN 1.43 9.82E-06 1.42 8.78E-06 
EHMT1 1.43 9.65E-12 1.28 2.51E-06 
PLEKHA7 1.43 3.07E-16 1.28 1.49E-08 
UNC5B 1.42 2.59E-06 1.62 1.26E-11 
LRRN1 1.42 1.27E-07 1.31 6.49E-05 
ACTA1 1.42 1.34E-23 2.59 1.39E-226 
EGFL7 1.42 7.66E-05 1.38 2.32E-04 
SETX 1.42 5.78E-06 1.36 5.00E-05 
ALDH6A1 1.41 3.36E-06 1.28 7.10E-04 
MYOZ2 1.41 3.28E-05 3.24 4.06E-73 
PBX1 1.41 2.70E-07 1.38 9.58E-07 
RBMS1 1.41 8.91E-09 1.27 7.38E-05 
MEX3B 1.41 1.76E-04 2.07 1.68E-19 
HTATSF1 1.40 5.58E-06 1.33 1.02E-04 
LAMP1 1.40 1.23E-18 1.33 9.34E-14 
STAM 1.40 5.24E-04 1.44 1.08E-04 
FAS 1.40 2.58E-20 2.02 6.79E-04 
CDH5 1.40 1.74E-19 1.52 5.14E-32 
BNIP3L 1.40 5.94E-15 1.30 8.60E-10 
MLL5 1.40 5.98E-10 1.25 3.39E-05 
ARRDC1 1.40 3.46E-05 1.77 2.11E-14 
LDB3 1.40 2.05E-12 1.31 6.98E-09 
PPFIBP1 1.40 3.45E-14 1.28 3.65E-08 
SDK1 1.40 2.12E-08 1.50 1.55E-12 
BMPR2 1.40 2.34E-09 1.38 3.92E-09 
ARID1B 1.39 6.62E-09 1.36 3.97E-08 
KSR1 1.39 5.43E-04 1.53 2.97E-06 
CLTCL1 1.39 2.82E-19 1.31 7.89E-14 
CSRP3 1.39 1.03E-47 1.27 1.32E-25 
JAM3 1.39 1.18E-06 1.27 5.28E-04 
AMBRA1 1.39 9.51E-06 1.47 7.08E-08 
TMEM131 1.39 2.11E-11 1.27 7.15E-07 
PPM1E 1.38 5.87E-05 1.83 1.90E-16 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
LAMB2 1.38 9.26E-05 2.00 4.00E-21 
PTGR1 1.38 4.87E-04 1.37 4.99E-04 
EP300 1.38 5.39E-13 1.29 1.04E-08 
CPPED1 1.38 2.27E-06 1.30 9.82E-05 
ZFHX3 1.38 1.73E-06 1.43 4.24E-08 
MECOM 1.38 9.50E-05 1.97 1.11E-20 
MFGE8 1.37 3.57E-16 1.44 1.20E-22 
IWS1 1.37 2.24E-10 1.25 6.01E-06 
ACLY 1.37 4.08E-12 1.27 9.67E-08 
WFS1 1.37 1.54E-04 1.64 1.34E-10 
SNAP23 1.37 1.60E-06 1.53 4.68E-12 
SLC25A17 1.36 8.23E-04 1.38 3.11E-04 
CCDC88A 1.36 9.45E-07 1.34 1.88E-06 
FKBP9 1.35 3.95E-09 1.29 6.33E-07 
CPM 1.35 2.50E-04 1.53 5.00E-08 
TOM1L2 1.35 6.16E-04 1.63 2.21E-09 
ZMIZ1 1.35 1.29E-06 1.35 7.79E-07 
UBE2H 1.35 1.11E-07 1.29 5.75E-06 
IRS2 1.35 2.08E-05 1.65 7.67E-15 
CDC42BPB 1.35 2.10E-15 1.43 4.24E-23 
PDCD6IP 1.34 1.41E-11 1.27 4.08E-08 
LY6E 1.34 4.20E-17 1.81 1.86E-79 
TPRG1L 1.33 2.15E-05 1.84 9.10E-24 
DCHS1 1.33 7.41E-04 1.65 1.64E-10 
SMYD1 1.33 1.89E-26 1.49 4.86E-56 
SRP68 1.33 1.03E-07 1.26 9.24E-06 
CALD1 1.32 5.07E-06 1.27 7.98E-05 
OLFML2B 1.32 4.10E-04 2.46 6.96E-43 
RNF11 1.32 7.80E-08 1.52 1.18E-17 
B4GALNT4 1.32 9.36E-05 1.57 6.64E-12 
HIPK2 1.32 6.49E-12 1.58 7.13E-35 
FARP1 1.31 4.35E-07 1.52 1.38E-16 
SLC25A12 1.31 8.06E-05 1.32 4.37E-05 
AKAP13 1.31 2.62E-04 1.51 4.54E-09 
SEPSECS 1.31 1.68E-04 1.28 3.79E-04 
TMTC4 1.30 1.43E-04 1.39 1.12E-06 
PHF21A 1.30 1.92E-04 1.26 9.69E-04 
CACNA2D1 1.30 7.86E-05 1.41 7.76E-08 
PTPRA 1.30 2.79E-05 1.55 4.39E-14 
ANXA11 1.30 4.63E-04 1.45 1.25E-07 
CAND2 1.30 7.25E-04 1.42 1.86E-06 
LAMB1 1.30 3.87E-17 1.39 2.43E-28 
KIF26B 1.29 3.48E-09 1.33 1.95E-11 
NFIB 1.29 6.16E-04 1.30 3.36E-04 
SEC63 1.29 1.52E-11 1.38 1.54E-18 
COL18A1 1.29 1.11E-41 1.66 1.62E-186 
UNC5C 1.29 3.31E-04 1.78 9.97E-20 
PACSIN3 1.29 1.35E-04 1.37 9.64E-07 
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   Gene Name AVC/VEN (Fold) p-value OFT/VEN (Fold) p-value 
LBH 1.28 3.83E-20 1.95 7.04E-173 
TNRC6C 1.28 6.12E-05 1.27 6.53E-05 
MAP7D3 1.28 7.81E-04 1.36 1.51E-05 
CMTM7 1.28 4.24E-04 2.53 5.07E-59 
AHCYL1 1.28 3.13E-04 1.38 6.11E-07 
PLS3 1.28 3.79E-09 1.29 5.25E-10 
BMP7 1.27 5.74E-05 1.35 2.05E-07 
NFRKB 1.27 6.27E-17 1.48 2.49E-49 
PAPPA 1.27 6.10E-04 1.29 1.64E-04 
ALDH2 1.27 1.46E-08 1.29 3.59E-10 
DOCK7 1.26 3.40E-06 1.38 2.20E-11 























E11.0 MOUSE GENES WITH >1.25-FOLD HIGHER EXPRESSION IN AVC AND 
OFT COMPARED TO VEN 
 
Red= >2-fold Enriched in both AVC and OFT compared to VEN 
   Orange= >1.25-fold Enriched in both AVC and OFT compared to VEN 
  
 















MATN4 23.97 5.58E-27 7.75 1.30E-07 19.26 1.55E-10 8.16 4.11E-04 
CTHRC1 20.78 6.54E-109 34.98 6.97E-218 9.11 1.14E-50 14.90 4.01E-96 
WNT9B 19.14 1.94E-36 9.21 5.40E-16 34.90 5.00E-20 28.57 4.33E-16 
BAALC 17.91 1.09E-15 51.43 9.93E-55 8.02 4.68E-13 9.19 1.64E-15 
CA3 16.31 3.03E-198 17.56 1.11E-237 5.69 9.12E-30 8.02 2.15E-49 
PRRX1 14.58 9.00E-54 49.00 1.49E-04 5.55 2.96E-11 9.80 1.19E-24 
TWIST1 13.83 1.26E-211 13.17 1.39E-217 10.29 1.34E-159 6.59 2.72E-83 
COL9A3 13.25 4.41E-96 17.31 1.56E-147 5.99 2.47E-31 8.11 8.94E-49 
PAPSS2 13.22 6.77E-120 29.28 0.00E+00 7.66 4.27E-56 13.27 7.29E-118 
CHST3 12.75 1.38E-10 21.81 3.00E-21 6.15 4.35E-04 12.79 1.47E-09 
PDE1A 11.60 7.37E-26 14.18 2.41E-36 6.50 5.43E-12 5.39 3.85E-09 
DOC2B 11.02 5.01E-05 16.16 4.34E-08 49.00 1.61E-04 49.00 1.42E-04 
RSPO3 10.65 1.78E-48 15.91 5.07E-89 20.75 3.04E-37 19.48 1.95E-34 
COL9A1 10.34 2.72E-162 23.40 0.00E+00 5.93 6.86E-30 17.67 2.62E-131 
BMPER 9.80 6.80E-45 11.53 3.80E-61 11.74 8.00E-29 15.73 2.75E-41 
CLMP 9.73 2.04E-52 14.30 1.68E-95 5.81 1.70E-16 8.64 5.21E-29 
TBX2 9.42 2.66E-74 4.85 1.20E-29 6.81 5.25E-46 2.83 7.30E-10 
NDUFA4L2 9.19 3.42E-10 20.10 1.91E-28 3.71 2.02E-04 4.90 1.35E-06 
MEOX1 8.61 3.35E-28 63.38 0.00E+00 3.59 1.21E-07 26.41 5.69E-117 
PCDHAC2 8.61 1.14E-06 9.96 1.54E-08 6.95 1.01E-04 5.72 9.75E-04 
PI16 8.57 2.25E-25 12.68 1.08E-46 4.15 3.12E-07 10.07 1.49E-25 
FST 8.54 5.85E-08 12.28 2.22E-13 4.55 9.70E-05 4.35 1.89E-04 
KIAA1755 8.27 2.37E-06 6.46 4.61E-05 8.83 1.72E-04 9.39 8.70E-05 
TNC 7.89 3.45E-40 94.42 0.00E+00 2.73 1.95E-12 20.47 3.76E-277 
MSX1 7.88 2.18E-63 5.16 3.38E-36 5.36 7.30E-21 4.70 7.90E-17 
SCARA3 7.62 3.46E-18 11.99 1.97E-36 5.54 1.50E-09 8.00 7.10E-16 
IGFBP7 7.50 2.19E-38 23.41 1.41E-185 4.45 3.77E-22 12.20 6.22E-98 
ELN 7.36 1.42E-41 81.48 0.00E+00 2.98 2.48E-09 46.92 0.00E+00 
ADAMTS8 7.17 6.46E-31 7.95 2.37E-39 4.59 1.17E-09 4.84 1.88E-10 
POSTN 7.14 0.00E+00 12.97 0.00E+00 5.58 3.15E-178 7.25 5.18E-268 
ADAM23 7.12 1.73E-13 11.22 5.08E-27 6.65 5.06E-09 7.70 6.53E-11 
NT5E 6.97 6.20E-19 10.71 1.81E-37 2.26 6.07E-04 3.27 5.23E-08 




Appendix B: Continued 
  
 















DLG2 6.80 1.82E-15 24.56 1.67E-87 7.36 5.17E-09 17.15 1.44E-25 
EPHA3 6.79 1.12E-38 3.64 4.76E-15 9.92 3.44E-23 5.42 5.15E-10 
NGFR 6.61 8.48E-06 23.48 1.45E-28 6.10 4.70E-06 10.45 6.92E-12 
LUM 6.53 4.18E-18 6.97 8.10E-22 5.65 3.63E-25 4.37 1.49E-16 
ROBO2 6.44 9.97E-36 13.65 4.73E-112 4.10 2.00E-14 6.56 2.04E-30 
MSX2 6.29 1.88E-20 6.37 7.69E-23 2.99 7.72E-07 3.08 3.43E-07 
PITX2 6.03 4.14E-36 6.25 5.53E-42 3.59 3.04E-13 2.27 3.13E-05 
SNAI1 5.73 1.29E-46 3.65 2.12E-23 3.82 7.31E-33 2.58 2.19E-14 
PDGFRA 5.57 2.28E-270 7.23 0.00E+00 3.16 2.87E-60 3.22 2.41E-62 
SOX9 5.43 1.63E-205 5.95 6.62E-265 3.99 2.56E-102 3.55 8.29E-81 
COL2A1 5.38 0.00E+00 8.94 0.00E+00 3.46 6.59E-94 7.57 0.00E+00 
COL6A3 5.14 1.40E-25 3.49 2.75E-14 4.47 2.76E-13 2.92 3.00E-06 
PCSK6 5.12 2.35E-86 4.02 7.65E-62 4.21 7.83E-45 3.64 7.01E-34 
TMEM26 5.12 1.99E-05 14.62 1.44E-22 24.87 1.98E-07 46.54 5.00E-14 
CLSTN2 4.86 1.65E-10 8.62 1.80E-26 4.98 3.57E-08 4.16 3.09E-06 
AQP1 4.79 4.15E-89 2.99 4.88E-39 4.87 6.51E-41 5.33 2.24E-47 
FRZB 4.73 2.78E-21 11.43 1.17E-86 2.95 2.03E-07 6.73 2.48E-29 
NCAM1 4.73 3.13E-261 4.66 1.06E-282 3.19 8.40E-50 2.75 1.44E-35 
C1QB 4.72 4.36E-12 8.15 5.71E-30 3.37 1.63E-04 5.31 6.10E-09 
NFATC4 4.71 3.58E-49 6.66 7.95E-96 2.84 3.44E-14 4.84 4.92E-39 
CRABP1 4.67 8.07E-17 19.28 3.56E-134 2.48 9.31E-05 8.65 3.84E-37 
STMN4 4.62 1.06E-09 22.24 4.59E-88 6.55 9.51E-08 26.67 1.33E-42 
PPP1R14A 4.48 1.79E-12 4.71 7.35E-15 4.65 2.96E-04 5.39 3.90E-05 
PDLIM3 4.30 0 7.44 0 2.99 4.14E-128 7.15 0 
FAM167A 4.20 5.55E-10 5.54 5.46E-17 5.96 8.75E-08 7.93 2.40E-11 
HAS2 4.18 2.17E-38 6.58 3.17E-91 3.46 3.36E-18 4.08 1.09E-24 
RGMA 4.16 1.82E-19 5.77 4.71E-37 3.17 2.45E-07 3.85 2.76E-10 
RARG 4.15 2.11E-41 6.73 1.61E-103 2.91 8.38E-15 6.06 2.81E-55 
C12orf68 4.13 4.10E-06 4.76 3.35E-08 17.65 2.93E-05 31.84 1.62E-09 
LPPR3 4.06 1.48E-15 5.53 9.24E-29 4.30 2.58E-10 4.27 3.50E-10 
PRSS35 4.06 2.19E-22 3.27 2.14E-16 5.13 2.24E-14 3.58 5.75E-08 
ERBB3 4.04 6.10E-29 8.57 8.16E-108 3.76 1.51E-11 9.54 4.63E-48 
SERINC2 3.90 1.33E-05 11.13 9.64E-27 3.13 5.17E-04 9.88 5.54E-21 
HTRA1 3.79 9.83E-26 7.42 2.54E-87 4.43 1.97E-16 8.53 2.20E-44 
UNC5C 3.72 5.85E-47 3.46 2.97E-45 3.12 4.17E-26 2.09 7.03E-10 
COX4I2 3.58 8.02E-06 9.62 2.67E-27 4.41 7.71E-07 9.88 5.54E-21 
NFIX 3.58 8.26E-17 4.56 8.71E-29 2.44 6.42E-05 2.45 6.22E-05 
ZNF503 3.53 3.00E-15 3.88 4.48E-20 3.29 2.42E-14 2.18 7.23E-06 
ADAMTS15 3.53 4.70E-36 3.88 3.35E-48 3.03 6.45E-18 3.32 2.19E-21 
DPYSL4 3.34 3.15E-06 2.83 4.66E-05 6.95 1.01E-04 9.80 5.08E-07 
THBS1 3.30 5.24E-152 6.53 0.00E+00 3.05 1.69E-86 3.72 7.24E-131 
ADA 3.23 5.10E-09 2.73 4.36E-07 2.79 6.98E-05 2.59 2.91E-04 
FOXP2 3.17 1.56E-10 7.75 8.24E-52 5.69 8.37E-11 8.24 4.91E-18 
GATA3 3.08 2.46E-13 10.83 5.59E-115 2.54 1.73E-05 7.67 1.64E-35 
TPBG 3.03 4.71E-20 2.68 7.29E-17 2.23 1.14E-05 2.74 8.21E-09 
DNM1 2.96 1.68E-18 3.04 1.17E-21 2.39 2.28E-09 2.25 5.45E-08 
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CRISPLD1 2.91 1.05E-04 3.11 9.78E-06 2.52 9.52E-05 2.68 2.48E-05 
MFAP4 2.86 3.62E-44 3.87 9.14E-94 2.45 3.84E-27 3.85 1.17E-73 
FZD1 2.86 6.90E-67 6.05 7.79E-317 2.15 1.91E-21 3.65 2.04E-74 
WNT2 2.85 1.50E-06 3.12 1.64E-08 2.69 1.39E-04 2.88 3.57E-05 
EDIL3 2.82 5.10E-23 2.78 8.74E-25 2.82 9.53E-13 2.04 6.45E-06 
PRRT4 2.79 2.50E-08 3.55 1.08E-14 2.41 5.63E-06 3.11 4.38E-10 
PHLDA1 2.78 1.48E-21 2.46 7.76E-18 2.61 1.98E-11 3.27 2.54E-18 
EEF1A2 2.77 5.57E-93 2.26 1.01E-60 3.21 1.27E-53 3.10 1.57E-49 
BMP6 2.76 8.82E-09 2.37 6.40E-07 2.41 5.03E-04 3.09 1.98E-06 
ADAMTSL2 2.62 9.59E-13 2.51 8.93E-13 5.92 1.21E-08 9.19 1.64E-15 
GARNL3 2.61 3.78E-11 2.14 1.45E-07 2.23 9.75E-07 2.13 5.61E-06 
CYP26B1 2.57 2.06E-16 2.92 1.81E-24 3.80 8.94E-22 3.10 1.36E-14 
INHBA 2.55 6.40E-07 14.05 3.52E-119 3.30 4.89E-04 15.06 2.99E-32 
BOC 2.55 5.70E-12 3.01 2.71E-19 2.74 1.13E-07 3.27 9.31E-11 
STX1A 2.50 1.01E-11 4.04 2.11E-35 2.05 4.81E-04 2.98 5.49E-09 
ITGB5 2.44 1.64E-64 2.46 1.04E-73 2.50 1.48E-41 2.53 6.91E-43 
SERPINE1 2.30 2.40E-04 9.26 2.01E-50 2.69 5.55E-04 9.68 4.36E-28 
BCAT1 2.28 8.60E-07 3.13 4.86E-15 2.06 4.97E-05 2.07 4.21E-05 
HSD17B11 2.24 8.94E-26 2.39 1.44E-34 2.24 4.46E-14 2.47 4.33E-18 
GPC1 2.22 2.57E-92 2.07 8.49E-84 2.37 5.34E-52 2.22 4.54E-43 
PXDC1 2.21 4.10E-14 4.84 9.56E-85 2.07 3.79E-06 5.97 2.31E-49 
RNF130 2.18 1.75E-08 2.78 8.36E-17 2.72 5.47E-10 2.92 1.59E-11 
LRP3 2.16 7.89E-07 2.25 2.55E-08 3.24 1.92E-09 3.39 3.33E-10 
ENC1 2.14 1.29E-41 2.88 1.36E-102 2.15 8.00E-28 2.42 1.48E-38 
SMAD6 2.12 6.43E-42 2.55 1.72E-78 2.04 5.19E-30 2.97 3.44E-80 
TGFB2 2.05 7.51E-53 3.57 1.34E-239 2.12 1.05E-32 3.05 4.67E-82 
APCDD1 6.20 3.49E-06 2.25 3.76E-23 6.02 5.66E-05 1.75 5.39E-07 
SNAI2 4.59 3.88E-33 4.86 2.08E-40 1.72 6.82E-04 1.87 6.75E-05 
ENO2 3.52 1.86E-21 1.92 7.82E-06 2.03 4.51E-04 2.22 5.70E-05 
FGFR2 3.12 9.22E-30 2.55 6.30E-21 2.38 2.84E-11 1.88 5.78E-06 
ROBO1 3.07 8.57E-89 2.61 2.49E-67 2.49 9.70E-36 1.43 2.14E-05 
GPC6 2.95 7.68E-33 3.18 4.13E-43 1.76 1.04E-06 1.96 2.96E-09 
HAPLN1 2.75 2.50E-198 2.07 1.50E-100 2.14 2.71E-72 1.51 2.63E-19 
PKNOX2 2.73 1.58E-11 3.92 2.74E-26 1.86 1.33E-05 2.05 2.57E-07 
CDH6 2.73 1.58E-11 1.83 1.11E-04 8.83 2.15E-11 4.76 4.98E-05 
SERPINF1 2.72 3.40E-21 7.18 5.67E-141 1.89 5.95E-07 5.12 1.52E-60 
ITGA4 2.69 3.59E-30 4.07 6.75E-81 1.96 7.78E-11 1.67 2.17E-06 
PCDH18 2.60 3.10E-31 2.97 4.02E-48 2.35 3.98E-16 1.96 8.78E-10 
SEMA3C 2.59 4.01E-25 5.49 7.82E-125 1.71 3.63E-05 3.23 8.68E-26 
HMGCS2 2.51 8.97E-09 2.48 2.56E-09 2.24 6.96E-07 1.93 1.01E-04 
KCNE1 2.48 9.43E-35 2.25 9.71E-30 2.05 1.06E-12 1.55 5.46E-05 
SPINT2 2.47 1.84E-27 2.15 3.32E-21 1.80 9.90E-06 2.18 9.15E-10 
HIST2H3C 2.34 7.70E-05 2.45 8.36E-06 1.37 6.82E-42 3.12 2.93E-04 
COL9A2 2.31 1.18E-14 2.41 3.64E-18 1.81 1.01E-04 1.97 6.50E-06 
SSBP2 2.29 1.02E-10 2.20 1.01E-10 1.39 3.74E-04 1.39 3.72E-04 
IGF1 2.28 4.14E-17 3.00 5.57E-37 2.28 9.86E-12 1.71 3.82E-05 
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TNFRSF19 2.24 3.72E-23 2.08 9.43E-21 1.99 3.25E-10 4.08 4.52E-04 
UCHL1 2.24 7.87E-22 2.33 2.46E-27 1.60 5.64E-09 2.49 3.38E-36 
MFAP2 2.22 5.73E-83 2.44 9.91E-122 1.68 1.61E-30 1.56 2.16E-22 
ANTXR1 2.19 1.81E-12 5.11 7.26E-83 1.87 2.42E-06 2.93 1.46E-19 
BNIP3 2.17 6.07E-85 1.86 1.77E-57 1.46 5.80E-10 1.33 6.99E-06 
PRRX2 2.17 2.74E-34 2.41 4.94E-52 1.66 1.13E-08 2.30 2.97E-24 
LIMCH1 2.14 2.58E-34 2.19 1.13E-40 1.91 1.11E-14 1.58 2.51E-07 
GAS6 2.14 3.20E-23 2.00 5.95E-21 2.12 1.99E-10 2.50 5.97E-16 
ID1 2.08 1.08E-60 2.33 1.20E-95 1.75 5.71E-18 2.01 5.90E-29 
LMCD1 2.08 1.02E-14 1.71 8.53E-09 2.30 9.58E-09 2.53 5.60E-11 
UNC5B 2.04 9.39E-150 2.62 0.00E+00 1.77 6.43E-51 2.59 1.22E-165 
SYT11 2.01 1.89E-17 3.64 3.52E-84 1.54 1.94E-05 2.93 1.13E-35 
LGALS1 1.99 3.15E-170 3.60 0.00E+00 1.73 6.99E-67 4.76 0.00E+00 
RASL11B 1.99 1.22E-23 3.39 8.85E-104 1.74 5.69E-09 2.91 7.95E-37 
ID3 1.99 3.65E-69 2.06 9.37E-88 1.46 9.87E-19 1.74 7.44E-41 
SORCS2 1.97 3.98E-16 1.42 4.76E-05 1.89 1.12E-08 1.78 3.09E-07 
FBLN2 1.97 4.34E-76 3.66 0.00E+00 1.73 3.14E-32 2.87 1.17E-146 
TAGLN2 1.97 9.06E-178 2.63 0.00E+00 1.64 2.89E-54 3.09 0.00E+00 
SYNPO 1.97 1.59E-37 3.85 3.39E-226 1.73 1.03E-14 3.55 1.76E-99 
CLIP3 1.95 8.97E-20 3.13 1.47E-77 2.06 8.91E-23 2.73 6.68E-48 
LTBP4 1.92 2.03E-38 4.27 0.00E+00 1.58 4.55E-13 3.20 9.79E-107 
EFS 1.91 7.70E-09 2.03 1.29E-11 1.67 2.01E-04 2.36 1.21E-11 
VASH1 1.91 2.45E-27 2.78 1.47E-89 1.79 7.04E-15 2.40 5.29E-36 
CLU 1.91 2.99E-39 3.43 9.72E-210 1.97 6.86E-22 4.87 7.67E-173 
NKD1 1.88 2.86E-09 1.75 5.33E-08 2.44 9.04E-10 1.98 8.18E-06 
PDGFC 1.88 1.22E-04 5.69 3.63E-50 2.05 1.54E-04 4.69 1.51E-23 
SOX11 1.88 2.13E-39 1.94 4.55E-49 1.39 9.20E-05 1.45 6.04E-06 
BMF 1.87 5.48E-10 2.80 4.30E-33 2.01 6.84E-08 3.83 4.08E-34 
TSPAN7 1.87 3.73E-22 1.52 6.15E-11 1.39 2.05E-05 1.44 1.86E-06 
TGIF1 1.86 1.45E-10 2.09 6.70E-17 1.61 2.67E-05 1.90 3.42E-09 
LTBP1 1.85 2.36E-65 2.81 2.46E-251 2.05 1.28E-56 1.99 8.73E-51 
CHST11 1.85 7.72E-14 1.52 3.50E-07 2.54 1.33E-13 1.68 2.18E-04 
SMAD7 1.84 3.35E-21 2.31 5.42E-48 2.19 1.92E-15 2.53 3.56E-22 
ATP1B1 1.84 2.90E-156 1.36 9.69E-39 2.06 4.38E-105 1.38 2.66E-18 
LOXL2 1.82 1.53E-95 3.70 0.00E+00 1.43 3.09E-20 2.45 1.96E-152 
PTPRB 1.81 1.33E-14 3.62 1.46E-98 2.92 1.06E-21 4.37 1.16E-47 
BAMBI 1.81 3.31E-50 2.12 1.06E-96 1.52 1.29E-15 1.63 4.52E-21 
ADAMTS17 1.81 2.94E-05 1.72 5.76E-05 3.65 4.80E-09 2.49 1.91E-04 
LTBP3 1.80 2.42E-14 2.29 8.83E-34 1.77 2.42E-09 2.01 5.45E-14 
SERF1A 1.80 8.89E-15 1.82 2.53E-17 1.96 6.06E-11 1.99 2.40E-11 
KLHDC8B 1.80 5.15E-38 1.47 1.86E-17 1.40 2.61E-06 1.72 2.81E-15 
ATOH8 1.79 3.21E-10 1.46 4.21E-05 2.31 3.83E-13 1.59 2.69E-04 
MMP11 1.79 2.64E-06 1.65 2.51E-05 2.13 6.15E-07 2.70 4.19E-12 
IER3 1.78 2.01E-05 2.82 7.82E-20 1.91 4.76E-05 2.08 2.66E-06 
NLGN2 1.78 7.95E-15 2.50 4.59E-46 1.46 2.26E-05 1.57 3.29E-07 
LOC728392 1.77 2.01E-13 2.39 1.35E-37 1.79 4.19E-11 1.62 8.02E-08 
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SBK1 1.77 4.92E-20 2.12 4.37E-41 1.65 2.77E-11 2.11 4.79E-26 
FLRT3 1.76 1.29E-13 2.47 3.89E-43 1.42 2.96E-04 1.54 4.96E-06 
NNAT 1.76 7.82E-49 1.69 3.30E-47 1.63 1.14E-20 1.70 1.53E-24 
PCDH1 1.75 6.53E-06 3.23 8.42E-32 1.64 6.84E-05 2.91 5.91E-23 
COL1A1 1.75 1.27E-79 2.95 0.00E+00 1.32 8.51E-19 1.56 1.44E-49 
VCAN 1.75 4.89E-236 2.47 0.00E+00 2.24 2.32E-239 2.12 1.33E-201 
CRIP1 1.74 6.02E-40 1.95 3.78E-69 1.80 2.76E-21 2.57 4.48E-62 
FURIN 1.73 3.75E-84 1.60 1.35E-66 1.80 2.02E-50 1.57 9.52E-29 
GLI3 1.72 6.60E-13 3.39 2.35E-92 1.41 3.72E-04 1.67 4.47E-08 
CD248 1.72 3.49E-11 2.84 5.50E-54 2.07 2.89E-12 2.76 1.46E-25 
HIST2H2AB 1.70 1.21E-10 1.34 3.45E-04 1.62 2.32E-05 1.93 2.06E-09 
TGFBI 1.70 2.80E-26 5.98 0.00E+00 1.33 2.86E-06 4.97 6.60E-281 
RGS12 1.70 6.04E-19 1.40 1.68E-08 1.99 3.33E-20 1.76 2.82E-13 
GPR153 1.67 3.10E-10 1.54 2.90E-08 1.63 1.76E-05 2.12 1.60E-12 
LHFPL2 1.67 4.35E-10 1.85 4.84E-16 2.03 6.91E-13 2.10 3.52E-14 
DBI 1.66 7.09E-32 1.31 6.06E-10 1.69 1.57E-13 2.05 4.60E-26 
CACHD1 1.66 6.89E-08 3.80 8.09E-79 1.61 1.92E-05 2.00 4.48E-11 
GATA5 1.64 1.34E-22 1.54 1.93E-19 1.67 4.36E-18 1.30 3.83E-05 
MEIS2 1.64 5.94E-21 1.69 5.48E-27 1.58 9.62E-12 1.39 2.50E-06 
DCHS1 1.62 1.70E-10 1.69 8.51E-14 1.45 8.20E-06 1.46 7.86E-06 
PTMS 1.62 8.24E-109 1.62 1.47E-120 1.37 4.20E-19 1.45 5.33E-27 
SLC12A2 1.62 3.33E-13 3.46 1.76E-128 1.47 1.38E-04 2.31 3.08E-20 
TRIM32 1.62 6.61E-13 1.63 1.06E-14 1.43 7.21E-05 1.39 2.57E-04 
FGFRL1 1.61 1.73E-09 2.79 2.19E-56 1.75 5.70E-08 3.34 5.06E-42 
NREP 1.59 4.33E-44 1.68 2.20E-63 1.51 2.11E-17 1.46 3.20E-14 
PLEKHA6 1.58 3.13E-12 2.04 1.77E-34 1.78 1.00E-11 1.65 6.52E-09 
COL6A1 1.57 3.54E-14 1.51 5.53E-13 2.41 8.77E-26 1.69 1.04E-08 
PPP2R5B 1.53 4.40E-08 1.89 7.86E-20 1.48 3.31E-05 1.76 3.50E-10 
MAP1B 1.52 2.58E-06 2.24 3.62E-26 1.55 3.32E-26 1.45 4.32E-05 
RHOB 1.52 2.86E-30 1.83 9.59E-76 1.42 4.91E-14 1.83 8.11E-43 
CHSY1 1.52 8.21E-18 2.07 1.73E-66 2.13 5.01E-28 2.47 8.78E-42 
TEAD3 1.51 6.08E-06 1.55 2.71E-07 1.59 1.77E-05 1.52 1.12E-04 
APBB1 1.51 1.29E-14 1.59 7.41E-21 1.30 3.14E-04 1.68 7.44E-14 
ERF 1.50 1.08E-29 1.91 5.14E-94 1.42 3.82E-15 1.85 4.69E-49 
FOXP4 1.50 2.04E-14 1.87 8.55E-41 1.29 1.05E-05 1.32 1.20E-06 
ANGPTL2 1.49 6.14E-19 1.72 2.07E-40 2.20 2.10E-07 2.12 1.08E-06 
RCOR2 1.49 9.56E-08 1.53 1.08E-09 1.40 6.28E-04 1.84 3.31E-11 
SKIL 1.49 1.44E-08 2.26 3.80E-43 1.50 2.72E-05 1.64 1.59E-07 
DPYSL3 1.48 4.89E-49 1.66 1.52E-94 1.37 1.08E-14 1.44 1.07E-19 
H2afv 1.47 1.36E-11 1.54 6.55E-16 1.46 3.76E-06 1.51 5.64E-07 
CDC42EP4 1.47 3.55E-09 1.41 3.07E-08 1.56 3.29E-07 1.67 2.66E-09 
ADAM19 1.47 4.18E-17 2.36 1.57E-112 1.50 1.77E-11 2.26 1.97E-50 
DDAH2 1.46 3.35E-19 1.57 3.06E-30 1.29 1.24E-05 1.72 2.29E-23 
NDUFA1 1.46 1.65E-45 1.33 2.90E-28 1.33 1.09E-07 1.28 8.17E-06 
ITGB3 1.46 9.68E-04 2.65 1.63E-25 1.78 4.99E-05 1.90 5.31E-06 
DBN1 1.46 3.14E-24 1.45 7.17E-27 1.26 3.94E-06 1.57 7.98E-21 
140 
 
Appendix B: Continued 
  
 















P4HA1 1.45 8.39E-14 1.54 3.77E-21 1.30 5.00E-04 1.35 7.43E-05 
PRAF2 1.44 1.43E-10 2.00 7.07E-46 1.36 1.57E-05 1.47 4.21E-08 
IRF2BPL 1.43 2.25E-21 1.30 8.38E-13 1.43 1.62E-10 1.28 1.51E-05 
WNT11 1.43 9.47E-05 2.58 3.13E-37 1.51 1.95E-04 2.72 1.03E-25 
DACT3 1.43 2.36E-13 1.99 3.10E-60 1.32 5.93E-06 1.90 5.64E-30 
PPM1L 1.42 9.72E-05 1.42 6.16E-04 1.78 4.61E-05 1.97 1.06E-05 
PCBP4 1.41 3.71E-19 1.51 2.62E-32 1.34 1.58E-10 1.42 4.60E-15 
MPP2 1.41 3.60E-07 1.43 1.59E-08 1.69 8.21E-11 1.79 2.91E-13 
NES 1.40 1.24E-15 2.78 5.99E-207 1.41 4.86E-08 2.47 1.00E-59 
Cd24a 1.40 1.39E-12 1.75 2.22E-40 1.40 1.76E-08 1.66 1.03E-18 
LRFN4 1.39 5.43E-08 1.85 9.58E-31 1.45 2.02E-06 2.01 2.63E-22 
ASB4 1.38 1.51E-06 2.25 4.66E-47 1.51 8.10E-06 2.01 7.91E-16 
GPC3 1.38 1.36E-43 1.41 4.51E-56 1.28 4.78E-14 1.30 9.44E-16 
WNK4 1.38 1.71E-05 1.52 1.15E-09 1.73 5.41E-06 2.01 2.29E-09 
PLOD1 1.38 2.28E-10 1.53 4.39E-20 1.25 4.56E-04 1.57 2.34E-13 
PLOD2 1.37 1.41E-05 2.10 2.52E-34 1.41 2.30E-04 1.97 4.13E-15 
LPHN1 1.37 2.51E-08 1.82 2.50E-34 1.46 1.56E-09 1.52 2.58E-11 
CTSB 1.37 1.13E-37 1.33 1.19E-35 1.43 2.14E-25 1.60 6.08E-45 
SSSCA1 1.35 1.39E-13 1.62 5.69E-39 1.27 3.19E-05 1.79 1.02E-27 
MESDC1 1.35 2.83E-10 1.50 1.01E-20 1.34 5.34E-05 1.49 1.26E-08 
GATA4 1.35 1.33E-34 1.47 6.76E-66 1.45 1.99E-39 1.61 3.55E-66 
S100A10 1.34 3.43E-08 1.69 1.45E-28 1.29 7.25E-06 1.61 1.91E-18 
ZNF516 1.33 2.91E-11 1.42 1.45E-18 1.37 5.79E-07 1.25 5.89E-04 
CD44 1.33 4.90E-06 1.81 2.51E-27 1.43 2.40E-05 1.42 3.70E-05 
PDGFRB 1.33 2.61E-07 1.44 6.25E-13 1.47 3.62E-08 1.58 1.83E-11 
HNRNPA0 1.31 2.86E-35 1.32 4.46E-42 1.29 3.10E-09 1.42 1.16E-16 
H1FX 1.31 1.53E-04 1.47 1.93E-09 1.90 3.11E-14 1.92 1.23E-14 
LMNA 1.30 6.42E-09 1.92 2.25E-64 1.46 3.12E-08 2.62 9.94E-59 
TNS3 1.29 7.01E-06 1.67 5.45E-25 1.29 3.80E-04 1.35 2.89E-05 
CYR61 1.27 6.22E-05 1.97 2.72E-41 1.33 1.52E-05 1.54 5.38E-12 
HIST1H2AB 1.27 5.52E-20 1.44 2.96E-110 1.50 2.16E-51 1.98 7.74E-196 
NDRG2 1.27 1.26E-07 1.27 1.82E-08 1.27 6.01E-04 1.35 1.10E-05 













CHICK GO ANALYSIS OF HH18 CHICK GENES WITH >2-FOLD HIGHER 
EXPRESSION IN AVC AND OFT COMPARED TO VEN 
GO Term p-value Genes 
GO:0007507~heart development 2.90E-05 MSX2, BMP2, TBX2, SCUBE1, FBN1, 
TBX20, ZFPM2, SOX6, SOX9, NRG1, 
COL11A1, TGFB2 
GO:0007167~enzyme linked 
receptor protein signaling pathway 
1.19E-04 BMP2, SMAD9, FUT8, ADORA2A, 
CD3E, ADCYAP1R1, IGF2, TGFB2, 




1.43E-04 BMP2, ADORA2A, MAP1B, MYOZ1, 
SOX6, SOX9, SLIT1, TGFB2, CD9, 
EPHA4, SLITRK4, ROBO1, CNTN2, 
RELN, CNTN4 
GO:0009891~positive regulation of 
biosynthetic process 
2.68E-04 BMP2, SMAD9, ADORA2A, CD3E, 
TBX20, IGF2, FOXO3, SOX6, SOX9, 
ABCG4, PPARGC1A, CITED4, SOX8, 
WT1, TGFB2, TCF21, SORBS1, 
ZFPM2, PTX3, SYK 
GO:0007155~cell adhesion 2.93E-04 CTNNAL1, CADM1, COL22A1, 
NEDD9, PCDH15, NID1, PCDH17, 
SOX9, CD9, LAMA4, SORBS1, 
ROBO1, COL27A1, CNTN2, RELN, 
CNTN4, COL24A1, COL11A1, 
COL20A1, SYK 
GO:0022610~biological adhesion 2.99E-04 CTNNAL1, CADM1, COL22A1, 
NEDD9, PCDH15, NID1, PCDH17, 
SOX9, CD9, LAMA4, SORBS1, 
ROBO1, COL27A1, CNTN2, RELN, 
CNTN4, COL24A1, COL11A1, 
COL20A1, SYK 
GO:0000904~cell morphogenesis 
involved in differentiation 
4.11E-04 EPHA4, SLITRK4, BMP2, ROBO1, 
MAP1B, CNTN2, CNTN4, RELN, 
SOX9, SLIT1, TGFB2 
GO:0007517~muscle organ 
development 
6.01E-04 TBX2, CACNA1H, CHODL, ZFPM2, 
SOX6, NRG1, CSRP2, COL11A1, 
IGFBP5, TGFB2 
GO:0000902~cell morphogenesis 6.47E-04 BMP2, ADORA2A, MAP1B, SOX6, 
SOX9, SLIT1, TGFB2, EPHA4, 




9.03E-04 MSX2, BMP2, LECT1, FBN1, IGF2, 
SOX6, SOX9, COL11A1, BMP5, 





MOUSE GO ANALYSIS OF E11.0 MOUSE GENES WITH >2-FOLD HIGHER 
EXPRESSION IN AVC AND OFT COMPARED TO VEN 
GO Term p-value Genes 
GO:0001501~skeletal system 
development 
5.20E-07 PRRX1, POSTN, COL2A1, SOX9, 
FRZB, MSX2, COL9A1, INHBA, MSX1, 
PDGFRA, PAPSS2, TWIST1, BMP6 
GO:0007155~cell adhesion 9.26E-07 CLSTN2, ADAM23, TNC, IGFBP7, 
ITGB5, POSTN, COL2A1, EDIL3, SOX9, 
TPBG, PCDHAC2, NCAM1, COL9A1, 
COL6A3, ROBO2, MFAP4, THBS1, BOC 
GO:0022610~biological adhesion 9.45E-07 CLSTN2, ADAM23, TNC, IGFBP7, 
ITGB5, POSTN, COL2A1, EDIL3, SOX9, 
TPBG, PCDHAC2, NCAM1, COL9A1, 
COL6A3, ROBO2, MFAP4, THBS1, BOC 
GO:0042127~regulation of cell 
proliferation 
1.94E-05 RARG, TBX2, ERBB3, IGFBP7, PRRX1, 
SOX9, ADA, TGFB2, FOXP2, MSX2, 
WNT2, MSX1, ADAMTS8, SERPINE1, 
PDGFRA, NGFR, THBS1 
GO:0030510~regulation of BMP 
signaling pathway 
3.20E-05 RGMA, BMPER, HTRA1, SMAD6, 
PCSK6 
GO:0007507~heart development 5.07E-05 MSX2, MSX1, TBX2, ERBB3, PDLIM3, 
NFATC4, COL2A1, SOX9, TGFB2 
GO:0009968~negative regulation 
of signal transduction 
6.15E-05 BMPER, ERBB3, HTRA1, SMAD6, 
CYP26B1, NGFR, FRZB, THBS1, ADA 
GO:0009611~response to 
wounding 
8.84E-05 ERBB3, TNC, CHST3, EPHA3, TGFB2, 
C1QB, SERPINE1, PDGFRA, NFATC4, 
NGFR, THBS1, PAPSS2, BMP6 
GO:0051216~cartilage 
development 




1.23E-04 FST, NGFR, SOX9, SNAI1, TGFB2 
GO:0042303~molting cycle 1.36E-04 FST, NGFR, SOX9, SNAI1, TGFB2 
GO:0010648~negative regulation 
of cell communication 
1.37E-04 BMPER, ERBB3, HTRA1, SMAD6, 
CYP26B1, NGFR, FRZB, THBS1, ADA 
GO:0030509~BMP signaling 
pathway 
1.48E-04 MSX2, MSX1, SMAD6, FST, BMP6 
GO:0048545~response to steroid 
hormone stimulus 
1.74E-04 WNT2, C1QB, IGFBP7, GATA3, 
PDGFRA, AQP1, THBS1, TGFB2 
GO:0035113~embryonic 
appendage morphogenesis 




1.92E-04 MSX2, MSX1, RARG, CYP26B1, 
PRRX1, TWIST1 
GO:0051094~positive regulation 
of developmental process 
2.99E-04 INHBA, FST, ROBO2, NGFR, THBS1, 
BOC, ADA, BMP6, TGFB2 
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Appendix D: Continued 
GO:0007517~muscle organ 
development 
3.09E-04 MSX1, TBX2, ERBB3, TNC, COL6A3, 
ELN, FOXP2, TGFB2 
GO:0043066~negative regulation 
of apoptosis 
3.10E-04 MSX2, MSX1, ERBB3, EEF1A2, 




3.15E-04 INHBA, FST, NGFR, TGFB2 
GO:0043069~negative regulation 
of programmed cell death 
3.44E-04 MSX2, MSX1, ERBB3, EEF1A2, 




3.50E-04 RARG, ERBB3, SMAD6, EEF1A2, 
COL2A1, SOX9, ADA, TGFB2, MSX2, 
INHBA, MSX1, NGFR, THBS1, PCSK6, 
PHLDA1 
GO:0060548~negative regulation 
of cell death 
3.51E-04 MSX2, MSX1, ERBB3, EEF1A2, 
SMAD6, COL2A1, NGFR, PCSK6, 
THBS1, ADA 
GO:0043067~regulation of 
programmed cell death 
3.87E-04 RARG, ERBB3, SMAD6, EEF1A2, 
COL2A1, SOX9, ADA, TGFB2, MSX2, 
INHBA, MSX1, NGFR, THBS1, PCSK6, 
PHLDA1 
GO:0010941~regulation of cell 
death 
4.02E-04 RARG, ERBB3, SMAD6, EEF1A2, 
COL2A1, SOX9, ADA, TGFB2, MSX2, 
INHBA, MSX1, NGFR, THBS1, PCSK6, 
PHLDA1 
GO:0007178~transmembrane 
receptor protein serine/threonine 
kinase signaling pathway 








4.65E-04 FST, NGFR, SNAI1, TGFB2 
GO:0043062~extracellular 
structure organization 


















GENES >2-FOLD DYSREGULATED BETWEEN TGFBR3+/+ AND TGFBR3-/- 
























XIST 999.00 0.00E+00 4515.39 0.00E+00 
1700125H03Rik 999.00 7.82E-06 999.00 9.82E-05 
9030619P08Rik 999.00 2.69E-15 999.00 2.55E-24 
RIMS2 999.00 7.67E-47 999.00 3.65E-41 
Rprl2 999.00 1.17E-57 999.00 2.66E-06 
Rprl3 999.00 5.16E-132 999.00 1.06E-15 
TSIX 999.00 0.00E+00 999.00 0.00E+00 
ALX4 999.00 5.76E-64 142.05 5.65E-73 
Ly6a 999.00 4.68E-22 111.30 6.43E-29 
ITIH5 999.00 9.82E-07 14.65 7.40E-04 
Gm8378 999.00 2.77E-06 6.83 5.19E-04 
CTNND2 102.98 2.38E-48 26.85 1.64E-18 
ANGPTL4 84.10 7.52E-134 9.08 1.39E-22 
CPNE7 70.17 1.89E-32 999.00 3.98E-05 
FZD10 45.56 1.22E-20 27.83 3.77E-07 
PPP1R16B 43.01 1.22E-46 17.99 4.71E-26 
BAI1 35.69 4.14E-89 9.37 3.50E-16 
FGF10 35.54 6.95E-16 21.97 7.73E-15 
DSP 33.87 5.77E-84 23.43 1.00E-25 
PVRL4 32.08 9.93E-34 6.96 5.96E-09 
NFATC2 30.98 3.14E-26 4.94 1.24E-05 
FAM134B 29.16 6.89E-13 14.65 1.93E-09 
DSCAML1 28.86 1.11E-35 68.83 9.30E-18 
KCNK1 25.52 3.72E-06 17.57 1.41E-04 
TACSTD2 25.52 3.72E-06 7.81 1.18E-04 
BCAT1 23.97 7.10E-184 30.98 1.02E-217 
ANKRD1 23.87 0.00E+00 5.62 1.57E-126 
PPP2R2C 23.51 3.93E-46 6.10 6.11E-06 
LIMCH1 22.61 0.00E+00 7.22 7.21E-98 
SH2D4A 21.48 4.52E-169 5.83 1.29E-87 




























FLT1 17.92 1.27E-20 3.09 3.98E-05 
RYR3 17.73 3.89E-36 20.50 6.41E-18 
PLD5 17.42 3.33E-29 60.78 3.27E-30 
Pbp2 17.13 1.60E-16 7.69 3.23E-10 
CSGALNACT1 16.58 1.16E-214 17.78 2.86E-274 
IL6 15.49 1.30E-06 11.42 4.23E-11 
ST14 15.49 2.91E-165 7.32 3.53E-37 
KCNC3 15.37 8.61E-62 7.20 2.15E-13 
LMO7 15.37 2.24E-278 9.44 4.89E-262 
GRM8 15.04 1.30E-11 5.57 1.37E-04 
GALNTL4 14.65 6.12E-68 9.90 2.92E-41 
AASS 14.58 1.02E-08 3.05 9.66E-04 
GNA15 14.19 1.37E-34 3.99 7.38E-08 
HMHA1 14.08 3.17E-69 6.85 5.36E-30 
B4GALNT2 13.81 1.36E-76 18.89 3.92E-184 
RIPK4 13.77 6.16E-22 4.69 3.10E-06 
CASQ2 13.67 8.38E-06 999.00 1.62E-05 
CUBN 13.67 8.38E-06 4.88 1.89E-04 
RBM20 13.65 7.80E-89 7.85 1.15E-45 
NFATC1 13.47 3.47E-41 6.02 6.18E-15 
WNT3 13.46 3.76E-30 5.02 4.03E-09 
RNF152 13.37 6.48E-08 4.39 6.99E-04 
CTSC 13.12 4.36E-12 999.00 1.91E-18 
IRF6 12.99 2.73E-18 20.50 2.64E-05 
CGREF1 12.89 1.29E-57 5.49 7.18E-17 
CKMT1A/CKMT1B 12.76 5.17E-22 11.72 2.12E-09 
SYCE1 12.76 5.17E-22 6.65 7.28E-13 
NKX2-8 12.69 1.77E-58 8.37 1.06E-27 
PARM1 12.53 3.80E-127 8.46 3.93E-52 
LRRC3 12.10 1.69E-22 4.03 3.07E-04 
LHX5 11.85 5.28E-05 8.79 6.61E-04 
MAB21L2 11.85 1.75E-27 8.42 1.65E-11 
Xlr3c 11.43 6.14E-21 10.49 1.33E-44 
LTBP1 11.40 3.07E-145 5.36 3.93E-85 
PPL 11.32 2.14E-140 5.41 1.45E-52 
PTPRB 11.24 8.38E-12 4.88 1.89E-04 
SPOCK2 11.10 4.70E-59 12.27 1.72E-63 
P2RX7 11.08 2.95E-126 3.53 1.17E-28 
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Klra18 10.94 2.47E-06 20.99 4.14E-14 
5930403L14Rik 10.94 1.31E-04 12.45 4.32E-10 
BC067074 10.94 9.06E-15 7.81 3.85E-08 
ANK2 10.94 4.29E-13 3.73 8.68E-05 
ATG9B 10.78 9.69E-188 4.13 1.78E-46 
SP9 10.68 1.93E-46 5.27 2.21E-07 
MATN4 10.61 5.18E-73 3.05 6.61E-09 
Klra4 10.33 6.05E-06 20.50 9.56E-14 
PDK4 10.21 3.93E-24 3.45 6.75E-06 
HS3ST6 10.17 5.22E-30 8.54 4.10E-09 
SLC37A2 9.78 2.26E-55 2.49 5.03E-05 
SERPINE2 9.73 0.00E+00 5.49 3.55E-121 
ODZ4 9.46 5.92E-65 6.41 4.12E-32 
MMP15 9.39 1.85E-255 3.51 3.18E-44 
NDUFA4L2 9.23 4.13E-21 9.00 3.93E-11 
MS4A10 9.11 2.67E-46 15.93 8.98E-77 
RAB39B 9.11 1.67E-06 13.67 9.74E-09 
GAL3ST2 9.11 2.01E-10 6.56 1.65E-19 
NT5E 8.91 1.22E-12 10.67 3.11E-26 
ANXA8L2  8.91 1.01E-317 6.16 9.29E-175 
CA12 8.83 2.93E-72 5.76 5.98E-41 
REM1 8.63 3.00E-19 2.76 1.57E-16 
PEX5L 8.40 2.65E-59 5.40 4.14E-25 
Ces2f 8.39 1.39E-44 4.06 9.14E-18 
PCOLCE2 8.20 9.44E-06 6.07 1.12E-06 
COL18A1 7.99 0.00E+00 3.18 6.09E-176 
GRHL3 7.97 5.07E-58 5.47 1.43E-20 
NPR2 7.96 8.55E-186 7.43 1.06E-83 
FAM159B 7.75 2.21E-05 10.25 4.89E-08 
NALCN 7.75 2.21E-05 8.49 9.55E-08 
RASGRP3 7.66 4.76E-36 4.25 1.26E-17 
DAPK2 7.63 4.94E-28 4.09 5.01E-18 
CTHRC1 7.62 2.01E-50 12.23 7.56E-74 
VAX2 7.59 2.86E-07 5.57 1.37E-04 
ZNF750 7.38 3.39E-20 3.24 1.33E-04 
Fhod3 7.31 6.79E-114 2.98 6.02E-24 
TLR5 7.29 8.89E-09 8.91 6.84E-18 
COL15A1 7.29 5.15E-05 8.79 6.61E-04 
COLQ 7.29 1.04E-09 4.03 3.07E-04 
FAM65B 7.29 7.62E-08 3.45 4.31E-05 
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B230344G16Rik 7.29 6.06E-50 2.21 1.12E-06 
APOL2 7.20 1.75E-19 4.39 2.46E-04 
WISP1 7.18 1.92E-229 7.93 8.93E-312 
FAM26E 7.13 3.33E-11 2.50 1.15E-04 
NIPAL4 7.06 2.14E-29 3.00 1.83E-05 
NKX2-3 6.99 1.51E-06 3.11 1.73E-06 
Mei4 6.93 1.33E-05 5.95 3.37E-13 
Cbr2 6.93 1.33E-05 3.60 1.57E-04 
PERP 6.90 0.00E+00 4.85 1.83E-166 
MAP2 6.90 9.83E-52 6.14 4.09E-46 
WASF3 6.88 6.63E-20 5.49 1.02E-11 
TMEM117 6.79 1.70E-10 6.96 9.11E-13 
D730039F16Rik 6.75 1.99E-23 9.15 2.97E-24 
ESR1 6.68 3.43E-06 6.87 1.75E-13 
INHBA 6.59 3.74E-107 3.06 4.05E-30 
FAXC 6.56 3.91E-13 7.54 7.59E-23 
COL5A3 6.52 3.74E-32 3.10 2.77E-10 
PAK6 6.46 9.32E-35 3.31 6.28E-10 
C1orf106 6.38 2.32E-07 4.21 1.64E-04 
MMRN1 6.38 2.32E-07 2.93 5.42E-06 
CRABP2 6.28 7.02E-42 18.58 2.37E-129 
CYFIP2 6.24 4.23E-25 5.58 5.18E-12 
FGF21 6.23 1.27E-23 6.22 9.60E-34 
CORO2A 6.21 3.26E-48 3.01 1.46E-15 
ZDHHC2 6.20 6.79E-05 999.00 1.62E-05 
LIN28B 6.20 1.60E-08 9.41 8.57E-12 
SOGA2 6.18 3.68E-14 2.93 4.32E-04 
KLRG2 5.95 6.59E-49 5.49 1.15E-29 
Apol10a 5.94 3.12E-42 2.74 7.02E-20 
PIANP 5.93 1.37E-37 8.45 1.50E-93 
VNN1 5.93 2.55E-183 3.73 2.68E-96 
GDF15 5.91 1.09E-36 2.12 1.84E-05 
FGF18 5.86 1.16E-40 3.25 2.71E-18 
P2RX3 5.83 5.63E-91 9.56 6.17E-62 
ROBO3 5.82 1.13E-92 2.97 4.37E-39 
A730035I17Rik 5.81 1.18E-11 16.11 1.66E-10 
COL4A3 5.80 2.02E-08 2.70 3.40E-04 
KCNJ4 5.79 1.46E-40 3.61 5.06E-09 
IL17RE 5.77 1.32E-31 9.75 1.42E-74 
KIAA1467 5.77 2.37E-20 3.91 1.21E-08 
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ANKS1B 5.77 2.27E-66 4.49 5.58E-43 
STRA6 5.62 1.15E-08 4.52 7.70E-07 
STOX2 5.56 3.40E-46 3.55 1.06E-18 
ADRB2 5.54 1.38E-15 4.39 1.45E-06 
SNAI3 5.42 3.17E-21 3.85 1.84E-10 
PRDM6 5.34 3.56E-49 3.75 3.60E-40 
FRAS1 5.32 1.84E-123 4.87 8.57E-96 
VSTM5 5.30 2.03E-07 2.75 3.81E-05 
CTH 5.27 8.61E-36 3.58 1.29E-28 
CUX2 5.27 3.77E-11 2.81 2.31E-05 
AVIL 5.26 2.01E-15 2.79 1.84E-06 
NOTCH3 5.21 0.00E+00 2.20 2.01E-35 
SLC7A5 5.17 0.00E+00 3.09 9.36E-248 
ITGB4 5.17 2.52E-313 2.90 5.58E-108 
ELL3 5.16 1.13E-07 2.60 2.42E-04 
MOXD1 5.14 1.16E-24 3.29 2.71E-10 
CCND1 5.12 0.00E+00 2.97 0.00E+00 
PLCXD2 5.07 8.25E-70 2.09 7.88E-15 
PTPRVP 5.01 7.12E-196 3.33 3.99E-55 
KRT8 4.99 5.18E-39 4.15 1.97E-20 
FAM132B 4.99 1.06E-121 3.55 8.51E-54 
MAMDC2 4.93 1.33E-09 8.22 2.33E-23 
KRT18 4.93 9.40E-18 4.49 3.71E-08 
SLC7A3 4.91 1.08E-49 4.38 6.89E-54 
MREG 4.91 3.21E-55 2.47 1.19E-15 
GJB3 4.91 1.31E-07 2.78 1.33E-04 
KCNT1 4.86 7.33E-10 4.27 2.72E-06 
LOC100129924 4.86 1.36E-05 3.02 1.64E-04 
FGFBP3 4.84 1.59E-41 3.64 2.91E-19 
PID1 4.81 4.63E-37 4.84 1.52E-23 
MAP1B 4.79 1.09E-209 2.57 6.15E-55 
ST6GALNAC2 4.77 2.74E-07 5.75 1.93E-10 
SCUBE3 4.73 1.46E-35 2.58 7.08E-10 
ABCG1 4.71 1.42E-22 2.44 3.49E-05 
SPACA3 4.69 2.07E-04 7.69 1.02E-05 
SNRPN 4.66 2.85E-05 35.15 5.11E-09 
ST6GAL1 4.66 3.14E-09 2.56 1.64E-04 
TMEM125 4.58 2.63E-15 4.95 5.87E-24 
TNFRSF18 4.58 1.35E-101 2.24 1.50E-17 
SLC4A4 4.49 2.67E-322 4.04 0.00E+00 
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DGKA 4.48 9.00E-219 2.47 9.25E-55 
PLTP 4.48 0.00E+00 2.67 6.96E-155 
AIF1L 4.44 3.00E-150 2.00 8.60E-27 
EPB41L3 4.43 5.97E-18 7.18 2.84E-21 
PRDM8 4.42 3.99E-17 6.80 3.37E-14 
ICA1L 4.37 3.15E-05 3.84 5.68E-04 
SEC16B 4.34 4.97E-29 3.73 2.87E-24 
AMN 4.31 1.14E-09 4.66 1.12E-06 
PROS1 4.27 4.79E-44 3.29 1.57E-27 
Ces2e 4.25 0.00E+00 2.80 5.10E-187 
COL8A1 4.24 0.00E+00 2.14 0.00E+00 
Nppb 4.23 1.83E-10 3.95 3.90E-23 
SP6 4.20 3.16E-20 2.13 6.17E-05 
RFTN2 4.17 2.58E-06 2.56 5.81E-04 
MFAP5 4.15 1.07E-07 10.54 7.46E-19 
ABLIM1 4.14 3.41E-05 2.63 5.37E-106 
CHD5 4.12 2.21E-30 2.08 7.49E-07 
CD109 4.09 3.40E-118 2.98 1.05E-142 
FAM196A 4.07 1.43E-45 2.60 1.52E-12 
Abcb1b 4.05 1.40E-119 2.09 4.22E-37 
SSC5D 3.98 8.07E-28 2.45 5.89E-11 
SHANK2 3.96 8.53E-40 2.96 3.95E-17 
ITGA6 3.96 2.02E-54 3.08 3.87E-23 
LRP2 3.95 0.00E+00 2.10 2.47E-95 
SVOP 3.94 6.40E-55 3.40 8.98E-36 
PSAT1 3.90 0.00E+00 2.11 1.65E-85 
LTK 3.88 1.88E-08 3.20 8.72E-04 
PGF 3.87 9.37E-04 6.15 3.37E-05 
P2RY6 3.87 4.61E-21 2.74 1.60E-07 
LTB4R 3.82 1.47E-75 3.35 2.44E-53 
MAP7D2 3.79 3.78E-05 5.86 3.82E-04 
KLK10 3.79 3.78E-05 5.13 9.65E-05 
CD44 3.78 1.83E-138 2.03 7.48E-57 
C9orf116 3.76 2.25E-84 2.86 2.69E-68 
STON2 3.72 4.16E-37 3.48 1.27E-31 
ACPP 3.72 1.10E-08 2.69 9.35E-07 
Tnfrsf26 3.71 1.01E-34 5.88 4.61E-122 
IGSF9B 3.70 3.09E-192 2.01 8.59E-29 
HLA-DRB1 3.70 0.00E+00 2.65 1.58E-235 
ARHGAP24 3.68 5.77E-17 3.66 1.74E-10 
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SNURF 3.65 2.65E-04 11.23 5.29E-07 
COL11A1 3.65 1.30E-33 7.69 1.02E-05 
BGLAP 3.65 1.40E-04 3.91 1.72E-05 
KRT80 3.65 5.05E-04 3.84 5.68E-04 
FGF5 3.65 8.03E-11 3.80 3.31E-22 
5830418P13Rik 3.65 5.46E-22 3.66 1.03E-17 
CELF5 3.64 2.98E-108 4.06 1.67E-69 
EXTL1 3.61 5.14E-14 2.63 6.76E-07 
PPFIBP2 3.60 5.99E-13 3.52 9.77E-12 
PLEK2 3.60 5.75E-22 2.07 4.99E-07 
EPHA1 3.54 1.28E-110 2.45 2.30E-48 
COX6A2 3.53 3.42E-09 4.45 4.26E-23 
REEP2 3.53 1.19E-51 2.79 9.65E-29 
ANGPTL2 3.51 5.80E-48 2.20 3.84E-13 
CPE 3.50 9.66E-310 3.85 1.92E-189 
LRRK2 3.50 1.42E-07 2.84 2.99E-04 
SAMD12 3.49 4.93E-07 2.21 2.74E-05 
CNKSR2 3.46 9.80E-04 9.76 5.54E-06 
BFSP2 3.46 8.64E-11 4.74 7.14E-12 
NEURL 3.45 1.60E-10 2.45 3.94E-07 
F2R 3.44 2.75E-287 2.34 4.47E-149 
LTB4R2 3.37 1.06E-117 3.57 4.46E-87 
E430014L09Rik 3.37 3.00E-10 3.25 4.65E-10 
SLC2A3 3.35 1.15E-76 2.53 1.10E-60 
PRRG4 3.33 3.35E-33 2.73 1.01E-34 
1700003M07Rik 3.33 1.39E-11 2.42 1.67E-08 
ARHGAP8 3.31 3.08E-14 2.37 1.03E-10 
Fndc3c1 3.28 1.42E-04 3.53 3.82E-06 
PITPNC1 3.25 3.26E-33 3.00 6.21E-25 
SULF2 3.24 0.00E+00 2.07 0.00E+00 
CEND1 3.23 6.00E-06 5.37 7.83E-09 
UGT1A3 3.22 9.41E-112 3.13 1.84E-145 
PVRL1 3.22 6.91E-42 2.32 1.29E-16 
SYN2 3.22 7.47E-05 4.52 7.70E-07 
UGT1A4 3.21 1.00E-110 3.12 1.80E-144 
UGT1A1 3.21 9.94E-111 3.14 2.30E-146 
UGT1A9 3.20 3.26E-110 3.13 5.19E-145 
DPP6 3.20 3.60E-53 2.31 1.22E-18 
PCSK6 3.18 0.00E+00 2.22 2.86E-216 
FAM115C 3.18 1.46E-34 2.06 3.18E-18 
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HMCN2 3.18 6.57E-17 2.08 5.48E-06 
EVPL 3.15 1.65E-48 2.12 5.96E-12 
PRKAA2 3.14 1.88E-17 2.32 1.21E-09 
UGT1A6 3.13 3.27E-117 3.14 3.83E-179 
TEX15 3.10 4.71E-07 3.42 7.01E-07 
NETO1 3.08 1.24E-24 3.71 5.04E-36 
ENG 3.08 6.51E-30 2.39 2.20E-16 
WNT9A 3.07 6.66E-235 3.01 9.03E-193 
ADM2 3.07 2.29E-15 3.10 1.42E-28 
SH3YL1 3.07 6.67E-12 2.44 1.34E-06 
GPX3 3.07 1.70E-17 2.81 9.15E-08 
SLC17A9 3.05 6.51E-12 3.33 4.63E-13 
SYTL1 3.04 2.24E-57 2.66 3.42E-33 
BMPR1B 3.04 3.75E-05 5.77 1.33E-12 
Ugt1a7c 3.02 6.44E-127 3.53 5.98E-256 
STC2 3.01 1.80E-12 2.78 2.00E-14 
B230206H07Rik 3.00 7.29E-11 2.39 1.25E-04 
NHSL2 2.99 2.72E-21 2.20 1.64E-16 
DCLK3 2.98 7.08E-11 3.83 1.13E-11 
CYP1B1 2.98 4.39E-129 2.66 1.48E-190 
SLC9A9 2.95 4.21E-07 2.16 3.12E-04 
GRIA4 2.95 2.43E-78 2.11 3.19E-61 
SNTG1 2.93 3.51E-05 2.70 3.98E-07 
CDH26 2.92 4.16E-10 3.20 2.43E-11 
RPRM 2.90 1.49E-72 3.04 2.36E-58 
PDGFRL 2.89 3.38E-05 3.47 1.04E-08 
FYN 2.86 9.37E-29 2.02 7.42E-12 
NOG 2.85 2.08E-89 5.22 8.03E-160 
TRIB3 2.85 2.82E-87 4.50 0.00E+00 
CAMK4 2.83 8.61E-25 3.04 8.84E-26 
PCDH19 2.83 1.03E-56 2.64 1.29E-64 
GLCE 2.83 2.95E-42 2.79 3.37E-18 
Gm11149 2.80 9.44E-30 2.11 2.93E-10 
PMEPA1 2.79 5.74E-180 2.73 1.13E-140 
POU3F1 2.79 3.19E-19 2.57 3.81E-24 
BMP3 2.78 6.45E-65 3.56 7.44E-127 
BHLHA15 2.76 1.14E-06 3.04 8.07E-07 
CRISPLD2 2.75 5.89E-15 3.52 5.55E-22 
APOL6 2.73 3.94E-04 5.19 8.11E-08 
NRN1 2.73 5.42E-05 2.38 2.64E-08 
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MGLL 2.72 1.51E-144 2.65 8.27E-234 
NUPR1 2.72 7.62E-101 2.87 5.61E-179 
WNT11 2.70 8.49E-69 2.21 6.15E-41 
LRP4 2.69 3.73E-04 3.10 6.17E-05 
GPC4 2.69 7.87E-123 2.68 2.03E-33 
BST1 2.66 9.38E-05 2.90 2.89E-18 
FBLN5 2.66 0.00E+00 2.83 0.00E+00 
9530053A07Rik 2.66 2.81E-11 2.56 2.49E-09 
SERPINA3 2.63 3.34E-19 2.76 4.95E-14 
DUSP8 2.63 2.64E-22 2.13 3.84E-14 
THPO 2.62 1.71E-04 2.70 3.40E-04 
CDKL2 2.62 1.14E-09 2.98 3.96E-24 
MMP2 2.61 0.00E+00 2.53 0.00E+00 
LHFPL2 2.61 1.19E-22 2.01 1.34E-14 
SRPX 2.61 5.04E-88 3.51 1.29E-282 
FOXC2 2.59 4.98E-08 2.15 1.70E-06 
C15orf59 2.58 4.71E-14 2.12 2.83E-11 
ANO3 2.58 9.42E-33 3.85 3.64E-99 
ITGB5 2.57 2.01E-108 2.32 5.97E-72 
KIF21B 2.56 1.15E-08 2.38 2.45E-09 
MDM2 2.55 0.00E+00 2.13 0.00E+00 
GATSL3 2.54 4.63E-15 2.22 8.83E-11 
FAM129A 2.54 1.81E-104 2.61 9.73E-154 
ACOT2 2.54 1.01E-37 3.27 9.34E-147 
SLIT2 2.53 0.00E+00 2.16 8.30E-237 
CTSH 2.53 8.70E-11 2.73 1.83E-27 
MEIS3 2.52 1.80E-08 4.50 8.54E-21 
COL12A1 2.51 0.00E+00 2.58 3.50E-273 
Pmaip1 2.50 1.05E-91 2.22 2.38E-133 
VAT1L 2.50 1.18E-21 2.12 5.96E-12 
AXIN2 2.50 2.01E-32 2.58 7.07E-48 
TMOD2 2.49 1.53E-05 3.62 7.67E-11 
CCND2 2.49 0.00E+00 3.02 0.00E+00 
KIF26B 2.49 1.67E-30 2.74 5.03E-34 
SIGLEC10 2.48 1.56E-11 3.52 9.32E-23 
FAM212B 2.45 2.30E-93 2.36 6.85E-77 
NPAS3 2.43 2.00E-32 2.21 1.34E-35 
CNTN2 2.42 2.30E-28 2.15 3.68E-16 
LRRTM1 2.41 2.39E-10 4.20 9.46E-34 
COL4A6 2.39 0.00E+00 2.09 0.00E+00 
153 
 
























Peg12 2.39 1.90E-05 3.08 1.90E-13 
Trim12a 2.38 1.45E-25 2.00 2.53E-29 
FGF9 2.38 2.08E-06 3.20 8.97E-15 
ALDH1L2 2.38 1.38E-71 3.40 7.50E-238 
WNT2B 2.34 2.84E-14 3.27 9.45E-26 
GPC1 2.31 1.35E-11 2.85 1.52E-14 
GARS 2.31 0.00E+00 2.04 1.42E-268 
NELL2 2.29 1.82E-71 2.05 1.49E-38 
FBXW7 2.29 1.07E-35 2.03 9.63E-35 
LIF 2.28 4.78E-55 2.01 1.16E-35 
GPR126 2.27 4.94E-18 2.10 7.33E-19 
DHRS9 2.26 7.68E-16 2.60 5.58E-38 
GLDC 2.24 1.20E-14 2.45 7.94E-12 
SEMA3C 2.22 5.81E-107 2.59 0.00E+00 
SEMA3B 2.21 3.12E-17 2.08 1.62E-15 
Rasl2-9 2.21 3.84E-10 2.30 2.77E-09 
LRFN3 2.20 2.04E-05 2.48 1.76E-04 
PAPPA2 2.19 3.79E-23 3.62 1.46E-87 
FAM131B 2.19 4.13E-05 2.78 2.84E-06 
C11orf88 2.18 2.77E-06 2.09 1.38E-09 
TMEM37 2.17 4.74E-09 2.95 4.74E-30 
DLX2 2.16 2.94E-05 2.64 3.93E-13 
RUNX1T1 2.15 2.42E-09 3.58 2.76E-47 
SERPINF1 2.12 6.84E-32 3.61 2.62E-95 
C13orf33 2.12 4.11E-12 3.33 9.79E-76 
AKR1B1 2.12 1.41E-64 2.06 3.22E-63 
Gm6644 2.11 2.14E-64 2.06 3.22E-63 
MORN4 2.07 1.31E-04 2.87 1.83E-09 
TTC9 2.03 7.43E-13 3.01 9.98E-41 
IL15 2.02 5.31E-04 2.76 2.43E-11 
NCAM1 2.02 1.81E-156 2.24 3.66E-264 
Bmyc 2.02 1.06E-21 3.37 7.67E-67 
PLXDC2 2.01 2.28E-91 2.25 5.58E-193 
PDIA5 2.01 6.34E-46 2.42 4.68E-80 
ASIC1 -2.00 6.60E-22 -2.40 1.63E-21 
BC026600 -2.00 9.28E-17 -3.61 1.59E-19 
HSPB7 -2.01 2.54E-26 -3.58 2.32E-25 
ZNF845 -2.01 8.35E-05 -3.57 1.68E-04 
PCDHA1 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA3 -2.01 6.66E-05 -3.76 3.18E-07 
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PCDHA4 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA5 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA6 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA7 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA9 -2.01 6.66E-05 -3.76 3.18E-07 
Pcdha10 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHA12 -2.01 6.66E-05 -3.76 3.18E-07 
PCDHAC1 -2.01 6.66E-05 -3.76 3.18E-07 
FAM84B -2.02 4.80E-269 -3.06 7.34E-239 
BNIP3 -2.02 1.05E-11 -3.58 3.27E-09 
NOS1AP -2.03 3.09E-11 -2.64 2.88E-19 
RAB20 -2.03 2.25E-12 -2.32 3.26E-09 
2310015A10Rik -2.03 1.77E-08 -2.45 2.08E-08 
CABLES1 -2.03 1.42E-08 -2.77 1.36E-14 
PCDHA11 -2.03 5.24E-05 -3.76 3.18E-07 
PCDHA13 -2.03 5.24E-05 -3.76 3.18E-07 
RASSF4 -2.04 1.43E-17 -2.57 9.66E-13 
NKX6-2 -2.04 6.53E-08 -2.61 1.09E-09 
CAPN6 -2.05 8.91E-13 -3.54 3.16E-19 
ZFP36L2 -2.05 1.61E-131 -2.02 1.56E-71 
H3f3a/H3f3b -2.06 0.00E+00 -2.48 0.00E+00 
PM20D2 -2.06 1.33E-12 -4.32 3.95E-28 
GMPR -2.06 1.10E-108 -3.20 5.32E-128 
SLC43A3 -2.07 1.06E-168 -2.48 1.24E-164 
CD1D -2.08 3.89E-08 -4.01 3.31E-11 
FAM19A2 -2.08 2.85E-07 -7.46 6.43E-16 
ALCAM -2.09 0.00E+00 -3.42 0.00E+00 
ST3GAL1 -2.10 9.23E-273 -4.56 1.14E-109 
FAM110C -2.11 4.60E-165 -2.31 1.09E-149 
MGAT3 -2.11 3.41E-49 -2.62 7.36E-46 
MATN2 -2.14 6.97E-28 -2.29 8.37E-18 
1010001N08Rik -2.14 8.33E-80 -3.03 4.47E-84 
ROM1 -2.15 2.80E-09 -2.00 5.67E-06 
IFI27L2 -2.18 3.28E-22 -2.37 0.00E+00 
BDH1 -2.18 5.06E-09 -3.19 1.13E-14 
SMPDL3A -2.19 3.64E-07 -9.64 4.84E-16 
LAMC3 -2.19 2.29E-14 -2.74 2.06E-12 
ID2 -2.19 1.13E-271 -2.81 6.07E-168 
IGSF3 -2.20 3.18E-96 -2.10 1.27E-41 
9930014A18Rik -2.20 1.02E-156 -3.03 1.39E-135 
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GSTM5 -2.21 2.55E-100 -2.39 5.94E-74 
TMEM44 -2.22 2.80E-08 -2.63 1.65E-06 
VSTM4 -2.22 1.31E-05 -3.29 1.64E-06 
PDGFRA -2.23 6.44E-268 -2.50 6.67E-108 
HEXIM2 -2.24 2.04E-05 -4.72 2.92E-08 
IGFBP5 -2.24 5.80E-62 -5.32 3.21E-62 
CPQ -2.26 2.44E-39 -2.24 5.55E-23 
Mocs1 -2.26 1.85E-90 -3.28 5.84E-99 
IDUA -2.26 4.75E-13 -2.67 2.78E-11 
G630016G05Rik -2.27 4.11E-04 -3.16 9.98E-07 
SPSB1 -2.30 1.87E-112 -2.15 7.22E-57 
LGI4 -2.30 2.37E-11 -6.67 2.36E-17 
Gm16793 -2.30 1.79E-06 -2.17 1.37E-04 
ABCC10 -2.30 2.99E-35 -2.22 2.21E-25 
KCNA7 -2.31 1.39E-08 -5.63 2.92E-19 
MAOA -2.32 4.92E-228 -4.10 3.83E-265 
PELI3 -2.33 8.72E-06 -2.38 4.46E-06 
TLE2 -2.34 1.87E-18 -3.94 6.85E-27 
PRRX2 -2.34 4.28E-15 -2.97 3.06E-17 
GPSM3 -2.34 1.23E-20 -2.82 6.77E-14 
CYP39A1 -2.37 2.86E-14 -2.24 2.10E-07 
C1orf226 -2.40 5.85E-32 -2.78 1.84E-29 
TMEM176A -2.40 8.51E-149 -2.04 7.06E-60 
CACNA1A -2.42 1.69E-14 -4.70 3.57E-22 
PLS1 -2.43 9.08E-04 -4.50 2.25E-04 
FDXR -2.45 2.77E-54 -2.34 3.73E-33 
PTPN18 -2.45 2.77E-09 -2.77 5.25E-06 
ME3 -2.46 6.41E-31 -2.36 4.42E-21 
CNRIP1 -2.46 1.07E-24 -4.02 2.09E-26 
TMEM138 -2.47 3.70E-18 -2.24 3.78E-06 
NRGN -2.52 1.29E-07 -3.17 4.29E-04 
TBX20 -2.53 7.72E-197 -2.59 1.66E-126 
NDRG2 -2.54 2.80E-27 -2.47 4.99E-18 
MYLK -2.60 0.00E+00 -2.96 1.36E-190 
SLC16A2 -2.61 8.07E-08 -4.01 1.97E-06 
SAA2 -2.61 4.53E-102 -5.22 3.47E-117 
NOVA1 -2.62 3.97E-06 -2.59 5.23E-04 
CPXM1 -2.63 7.45E-241 -3.19 2.18E-189 
TGM2 -2.65 0.00E+00 -4.23 0.00E+00 
CLDN15 -2.65 1.00E-156 -4.64 5.82E-147 
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FMO5 -2.67 7.27E-17 -2.57 8.93E-09 
MERTK -2.69 1.75E-97 -2.01 3.91E-32 
FAM84A -2.74 0.00E+00 -5.59 0.00E+00 
LIN7A -2.74 8.45E-13 -2.49 4.61E-07 
HIST1H2AB -2.75 1.16E-125 -2.74 1.23E-144 
ARHGEF3 -2.75 9.28E-17 -2.74 5.26E-08 
FMO2 -2.75 1.24E-14 -21.76 4.51E-19 
CXCL14 -2.77 1.97E-08 -3.67 2.76E-08 
HDDC3 -2.79 2.18E-41 -4.33 2.18E-47 
GSTA3 -2.81 4.14E-89 -3.55 4.19E-58 
FAM40B -2.81 2.40E-09 -2.39 5.72E-04 
RHOBTB1 -2.85 2.12E-42 -5.01 2.66E-46 
HOXB4 -2.85 8.05E-11 -3.45 1.38E-10 
EMILIN1 -2.89 1.23E-82 -2.67 1.38E-61 
SLFN13 -2.90 2.39E-52 -3.07 2.40E-19 
SEPP1 -2.93 1.45E-108 -2.47 6.66E-30 
RTN1 -2.96 6.56E-157 -3.78 6.86E-144 
DAAM2 -2.98 5.28E-71 -2.27 1.47E-21 
A930033H14Rik -3.03 1.38E-07 -5.71 5.22E-06 
SLC2A13 -3.04 5.44E-11 -2.48 1.80E-06 
ALDH1A2 -3.07 6.03E-38 -3.05 2.11E-21 
FADS6 -3.08 3.36E-31 -3.33 1.86E-23 
CPLX2 -3.09 7.16E-77 -2.64 1.40E-29 
MDK -3.09 1.73E-36 -2.73 6.03E-26 
ACVR1B -3.13 3.70E-68 -3.05 1.59E-41 
TBC1D10C -3.17 6.10E-08 -4.31 2.27E-05 
TGM1 -3.18 1.82E-17 -5.95 3.69E-28 
TUBA4A -3.20 6.51E-105 -3.44 1.10E-68 
LBP -3.21 2.50E-04 -5.67 5.75E-04 
H19 -3.23 0.00E+00 -10.68 0.00E+00 
RASL11A -3.23 0.00E+00 -6.02 0.00E+00 
PLEKHA6 -3.28 3.74E-06 -2.92 1.72E-64 
GUCY1A3 -3.28 0.00E+00 -6.19 0.00E+00 
CADM1 -3.29 4.01E-169 -9.72 7.44E-246 
FXYD1 -3.29 2.92E-41 -8.71 1.30E-30 
DLK2 -3.31 6.93E-16 -2.14 6.46E-09 
GBX2 -3.33 6.91E-04 -4.66 2.64E-05 
TNNT1 -3.33 6.91E-04 -7.41 5.94E-04 
MGP -3.33 0.00E+00 -11.79 0.00E+00 
IGLON5 -3.34 1.49E-19 -4.58 1.39E-18 
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ADAM33 -3.37 2.30E-67 -2.69 8.01E-37 
TMEM178A -3.41 2.83E-40 -14.46 7.47E-52 
CISH -3.44 3.66E-37 -2.75 3.44E-19 
AVPR1A -3.54 3.58E-130 -5.81 7.52E-115 
LGALS2 -3.54 1.18E-61 -7.64 3.37E-42 
E130310I04Rik -3.55 2.67E-37 -2.74 8.52E-14 
PLEK -3.62 7.25E-19 -4.51 6.03E-13 
EHD3 -3.65 0.00E+00 -4.41 0.00E+00 
MT1H -3.65 0.00E+00 -3.14 2.85E-44 
SCARB2 -3.69 0.00E+00 -2.35 2.53E-192 
GATA2 -3.72 3.85E-41 -6.69 6.66E-51 
TGFBI -3.74 6.39E-75 -4.28 1.03E-27 
ITIH4 -3.79 3.45E-05 -8.50 1.31E-04 
LRP3 -3.86 5.14E-09 -2.85 2.74E-05 
APOE -3.86 0.00E+00 -4.95 0.00E+00 
NRXN2 -3.90 8.15E-32 -11.86 1.28E-37 
FAM189A2 -4.00 2.38E-18 -5.61 1.05E-09 
STBD1 -4.06 2.30E-111 -3.36 3.40E-59 
BMF -4.09 6.67E-70 -7.83 4.29E-53 
Dcaf12l1 -4.15 1.48E-07 -4.71 1.18E-09 
TPBGL -4.17 9.80E-31 -12.96 4.49E-42 
KIAA1324L -4.19 6.88E-60 -2.80 4.31E-24 
1010001B22Rik -4.21 2.06E-04 -13.72 2.35E-04 
NXPH1 -4.35 3.88E-12 -3.37 8.46E-18 
ELN -4.35 0.00E+00 -7.79 0.00E+00 
SLC16A5 -4.35 3.63E-33 -2.18 3.52E-07 
HCN4 -4.37 4.25E-23 -6.75 7.39E-14 
EEF1A2 -4.40 4.36E-131 -3.04 7.27E-30 
PGAM2 -4.43 1.31E-26 -4.81 8.66E-24 
NPL -4.48 1.83E-32 -3.11 1.22E-14 
PRPH -4.58 3.35E-210 -11.43 0.00E+00 
RBKS -4.59 3.70E-15 -3.06 8.19E-05 
PYCARD -4.66 9.27E-28 -3.66 9.51E-12 
DOCK10 -4.67 7.66E-17 -3.09 5.19E-08 
PADI3 -4.78 2.17E-09 -3.13 2.47E-04 
NAP1L3 -4.95 5.45E-07 -5.41 2.06E-07 
SYNPO2 -5.05 1.59E-37 -4.11 2.87E-19 
SOSTDC1 -5.07 1.65E-15 -19.75 9.94E-12 
TEK -5.14 3.81E-56 -3.99 4.03E-29 
PCDH17 -5.23 2.25E-161 -10.53 3.61E-229 
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Cyp2d22 -5.60 2.10E-37 -13.25 1.75E-46 
PRR15 -5.83 4.25E-221 -19.79 4.77E-182 
TGFBR3 -5.84 4.03E-318 -4.93 3.99E-133 
C10orf10 -5.93 2.40E-79 -14.68 1.02E-30 
Serpinb6b -5.95 2.20E-92 -12.10 4.50E-50 
FGF8 -6.08 2.25E-11 -31.28 4.14E-10 
2410017I17Rik -6.12 2.50E-64 -14.66 1.16E-140 
NPAS4 -6.24 1.27E-08 -10.15 1.30E-05 
CYP7B1 -6.32 1.82E-05 -12.62 5.25E-04 
PDE3A -6.37 9.28E-08 -11.34 4.78E-09 
TNC -6.44 0.00E+00 -4.39 0.00E+00 
SUSD2 -6.49 1.88E-61 -4.65 9.16E-20 
TMEM196 -6.58 5.20E-23 -7.86 1.66E-15 
WDR86 -6.66 1.39E-10 -7.79 5.28E-09 
ADAMTSL2 -6.73 3.26E-33 -25.97 3.22E-23 
HOXB3 -6.73 2.03E-34 -4.54 1.07E-15 
GALNT14 -6.83 9.92E-10 -13.72 7.61E-08 
ALDOC -7.20 0.00E+00 -19.03 0.00E+00 
CFI -7.26 6.40E-16 -8.23 2.29E-11 
H2-Q10 -7.40 0.00E+00 -2.26 1.12E-106 
SLC39A4 -7.60 4.75E-24 -10.15 1.68E-28 
STC1 -7.63 0.00E+00 -23.59 2.53E-106 
PNLDC1 -7.65 7.66E-23 -23.04 2.49E-20 
HOXB2 -7.72 3.10E-49 -22.03 1.23E-43 
FGL2 -7.89 8.18E-63 -11.93 4.24E-35 
AQP1 -8.05 4.16E-66 -14.86 2.00E-42 
ACSS3 -8.48 5.17E-33 -7.53 1.30E-17 
UCP2 -8.52 0.00E+00 -4.93 0.00E+00 
ACTN3 -8.78 8.75E-61 -5.98 1.25E-34 
2610507I01Rik -9.13 1.11E-21 -44.99 1.04E-14 
H2-M2 -9.31 2.88E-22 -4.80 5.25E-07 
GGT5 -9.95 3.68E-45 -2.96 1.24E-12 
LINGO1 -10.24 1.37E-215 -9.36 2.07E-102 
CCDC68 -10.93 7.41E-06 -7.68 4.08E-04 
1700008P20Rik -10.93 7.41E-06 -13.72 2.35E-04 
IL16 -11.10 4.40E-40 -2.81 2.06E-07 
9530082P21Rik -11.42 5.04E-29 -61.45 2.81E-20 
8030451A03Rik -12.29 8.83E-04 -4.48 9.56E-65 
BC023719 -12.36 2.81E-29 -4.39 1.17E-08 
AARD -13.66 3.41E-04 -16.46 3.10E-05 
159 
 
























CDH13 -13.96 8.66E-31 -4.85 4.37E-10 
HLX -14.65 6.16E-71 -75.53 2.46E-73 
DLX3 -15.36 4.95E-16 -5.67 5.75E-04 
GBP2 -15.66 5.87E-62 -25.57 2.56E-37 
SDK1 -17.75 1.89E-05 -6.31 1.09E-05 
PADI1 -19.12 7.11E-06 -7.13 3.17E-05 
PDE2A -19.39 6.07E-26 -2.74 9.81E-04 
VSTM2A -20.36 6.59E-59 -19.31 4.41E-27 
USH1G -23.90 3.20E-20 -11.11 1.94E-11 
HLA-B -23.97 0.00E+00 -12.78 0.00E+00 
SORBS2 -28.58 1.75E-157 -17.90 5.63E-39 
TMEM215 -29.64 5.27E-42 -15.03 3.38E-20 
PKD1L2 -30.73 1.57E-09 -13.72 2.35E-04 
ADAM23 -32.78 3.50E-10 -14.81 1.05E-04 



















GENES >2-FOLD DYSREGULATED BETWEEN TGFBR3+/+ AND TGFBR3-/- 
























Rprl2 999.00 4.83E-15 999.00 1.41E-29 
TSIX 999.00 0.00E+00 999.00 2.65E-73 
XIST 999.00 0.00E+00 999.00 0.00E+00 
Rprl3 999.00 9.59E-35 164.74 3.99E-45 
Ly6a 999.00 4.33E-14 36.75 7.69E-10 
TMEM117 999.00 1.65E-05 11.41 2.50E-05 
Klra4 999.00 3.07E-04 5.07 1.55E-17 
CTNND2 49.70 2.14E-168 27.03 6.68E-111 
RIMS2 49.40 3.59E-65 45.20 3.20E-34 
ALX4 34.52 6.97E-27 38.65 1.18E-19 
9030619P08Rik 31.28 9.71E-09 27.88 1.85E-07 
LCE1B 30.20 1.95E-08 41.82 3.28E-11 
Lce1f 28.58 8.96E-29 3.66 3.34E-04 
FGF10 26.61 3.24E-20 10.14 1.63E-06 
FRMPD1 17.62 8.94E-13 12.67 3.34E-13 
FAM134B 14.56 3.16E-07 3.55 2.48E-04 
KCNK1 13.58 2.37E-89 3.59 5.38E-20 
BCAT1 12.26 2.15E-152 7.29 8.76E-63 
EPB41L3 12.19 2.98E-25 8.11 4.37E-14 
Lce1h 11.94 6.67E-34 5.97 1.92E-12 
NECAB1 11.87 1.67E-10 999.00 1.81E-06 
MEIG1 11.87 6.37E-36 4.37 1.98E-05 
Xlr3c 11.66 8.82E-60 7.48 1.27E-12 
9330179D12Rik 11.43 0.00E+00 27.76 1.76E-70 
IL17RE 10.07 2.26E-12 7.60 2.97E-08 
TLL1 9.71 1.75E-06 5.39 6.77E-04 
Lce1g 9.27 1.50E-45 5.88 2.71E-18 
SYCE1 8.56 2.72E-23 8.76 5.06E-17 
BMPR1B 8.27 4.72E-18 6.62 9.64E-10 
TBX4 8.22 2.23E-12 30.41 3.88E-08 
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TMEM132C 7.55 2.33E-07 4.53 1.04E-04 
FAXC 7.38 1.16E-23 6.80 7.33E-20 
WNT7A 7.21 6.95E-23 5.15 1.25E-21 
LIMCH1 6.79 6.36E-302 6.19 8.48E-126 
NKX2-3 6.74 1.68E-09 16.47 6.77E-08 
TNFRSF19 6.74 2.50E-05 5.83 4.49E-05 
Apol10a 6.74 2.50E-05 3.23 5.22E-04 
PPP1R16B 6.49 2.81E-68 5.16 2.03E-28 
B4GALNT2 6.46 4.11E-133 4.98 6.49E-43 
NPR2 6.38 2.13E-274 6.09 9.62E-217 
PIANP 6.37 1.65E-39 8.62 3.20E-22 
HMHA1 6.34 6.80E-55 8.72 7.17E-48 
PTPRB 6.20 1.17E-185 4.76 3.62E-110 
SNRPN 6.11 3.34E-09 3.69 6.28E-05 
FAM89A 6.09 3.80E-16 4.85 8.86E-11 
IL6 5.96 3.59E-82 2.85 1.10E-17 
DSP 5.88 1.21E-177 4.41 5.46E-94 
KRT8 5.85 7.55E-34 2.84 1.73E-17 
WASF3 5.81 8.13E-12 6.52 1.07E-07 
SEMA3G 5.53 3.19E-13 2.45 2.94E-05 
PPL 5.52 6.10E-131 7.00 1.71E-145 
PRDM6 5.49 3.24E-79 4.19 6.87E-41 
ANKRD1 5.40 0.00E+00 4.42 0.00E+00 
C6orf132 5.39 5.02E-12 5.76 1.50E-09 
SNURF 5.29 3.35E-08 4.12 2.98E-06 
MANSC1 5.29 3.35E-08 3.96 2.55E-04 
Msx3 5.20 1.11E-08 5.45 3.92E-08 
BTBD11 5.16 1.36E-10 6.59 6.41E-06 
MAB21L2 5.14 1.74E-129 3.72 3.73E-49 
Masp1 5.13 6.97E-23 4.24 6.40E-14 
ANGPTL4 5.12 3.63E-262 5.78 1.67E-173 
CDKN1C 5.11 0.00E+00 2.78 9.41E-170 
RUNX1T1 5.10 3.59E-18 19.26 1.33E-21 
Snhg9 5.08 3.31E-66 3.19 2.22E-38 
SEMA7A 4.97 1.70E-12 3.33 7.52E-10 
DUOXA1 4.78 2.06E-09 4.22 7.77E-04 
FAM43B 4.75 2.93E-21 7.18 2.98E-17 
CTSC 4.74 1.07E-52 2.72 9.01E-13 
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FSTL3 4.56 1.70E-116 3.60 5.13E-51 
GAP43 4.51 2.11E-15 2.48 2.63E-04 
RPH3A 4.49 2.41E-04 6.34 8.00E-04 
SOX21 4.47 1.72E-08 10.56 7.97E-07 
CHST7 4.47 7.65E-05 8.87 4.36E-04 
COL4A3 4.43 7.27E-38 3.27 7.25E-16 
GALNT9 4.31 4.15E-05 8.87 4.36E-04 
RNF152 4.24 3.60E-22 2.23 7.09E-05 
CKMT1A/CKMT1B 4.24 1.16E-99 3.96 3.80E-43 
GATM 4.23 3.84E-195 2.55 4.20E-32 
GALNTL4 4.22 6.32E-41 2.63 2.07E-11 
C1orf115 4.21 5.95E-45 2.19 1.29E-07 
TLR5 4.20 5.29E-10 4.35 1.87E-04 
IL28RA 4.20 2.24E-05 7.60 6.80E-06 
BCL11B 4.18 6.99E-05 8.24 8.78E-04 
TNFRSF11B 4.18 3.65E-150 2.06 1.18E-22 
PARVB 4.16 2.19E-04 8.24 8.78E-04 
AASS 4.12 3.93E-06 6.59 6.41E-06 
NPR3 4.12 2.26E-25 3.14 3.37E-10 
PP2D1 4.10 1.21E-05 4.53 1.04E-04 
CSGALNACT1 4.01 2.18E-70 5.18 3.54E-45 
FGF5 3.98 1.80E-38 2.79 8.45E-12 
PCOLCE2 3.96 4.80E-26 3.49 6.61E-12 
ZDHHC2 3.92 7.26E-68 3.62 6.46E-48 
FZD10 3.77 1.10E-81 5.66 4.07E-95 
SLC4A4 3.77 7.61E-144 3.87 1.21E-94 
DKKL1 3.76 1.05E-58 2.21 2.62E-11 
PM20D1 3.75 9.41E-10 5.65 4.01E-20 
TUBA8 3.74 3.09E-12 3.08 1.33E-07 
ST8SIA2 3.73 5.11E-10 2.20 4.58E-04 
KRT18 3.73 2.82E-09 3.30 1.45E-12 
CXXC4 3.71 1.05E-16 2.05 4.23E-07 
2410124H12Rik 3.71 1.97E-18 2.46 2.77E-08 
AMN 3.71 4.45E-182 2.85 2.76E-51 
CPNE7 3.70 1.14E-53 5.09 2.92E-61 
TFRC 3.63 2.73E-39 3.55 1.54E-28 
TSPAN12 3.54 5.32E-24 2.00 9.58E-05 
C4orf32 3.51 1.60E-11 2.11 9.52E-05 
KCNS3 3.48 3.10E-08 3.34 3.04E-07 
PLD5 3.44 1.05E-56 2.66 1.55E-18 
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SOX13 3.43 7.47E-43 3.33 1.09E-33 
KIAA1467 3.42 3.86E-85 3.75 1.27E-53 
DUOX1 3.41 1.65E-14 3.25 3.74E-07 
RBM20 3.41 1.32E-31 4.30 5.94E-24 
HECW2 3.40 4.29E-17 4.37 1.17E-14 
BAI1 3.32 1.05E-162 3.18 5.41E-68 
CCL17 3.31 5.40E-21 2.49 2.71E-09 
ACSBG1 3.29 1.02E-37 3.42 1.86E-21 
POU4F3 3.29 3.71E-07 3.56 2.98E-06 
LTBP1 3.28 3.16E-222 2.55 6.00E-73 
GDF15 3.28 7.24E-27 2.02 9.74E-06 
Usp44 3.28 3.09E-08 4.35 1.87E-04 
Pde4d 3.28 1.66E-08 3.36 2.02E-08 
AGPAT9 3.27 7.55E-10 5.07 9.38E-10 
AMPD3 3.24 6.18E-04 16.47 1.86E-04 
PEX5L 3.24 4.87E-08 5.42 3.44E-18 
Fndc3c1 3.17 1.14E-05 5.23 2.23E-06 
MEIS3 3.16 1.41E-19 3.01 2.79E-14 
GJB3 3.10 3.35E-05 3.06 4.73E-05 
ST6GAL1 3.09 2.45E-37 3.32 6.04E-26 
Rasl2-9 3.08 3.06E-14 2.38 6.46E-09 
CMAHP 3.07 4.24E-06 4.28 8.11E-05 
DSCAML1 3.03 2.64E-51 3.00 2.67E-22 
FERMT1 2.99 1.93E-45 2.16 8.09E-15 
Gm3230 2.95 7.55E-08 3.80 3.63E-05 
KIF1A 2.92 2.01E-06 4.05 1.16E-11 
NDUFA4L2 2.91 6.34E-88 4.69 1.02E-59 
KRT80 2.90 4.03E-10 3.80 1.05E-15 
RASGEF1A 2.88 8.16E-11 2.88 2.71E-06 
CORO2A 2.88 7.33E-145 2.51 2.70E-85 
ITGA2 2.88 3.09E-06 5.91 2.40E-08 
POU3F3 2.88 7.38E-07 4.25 1.87E-07 
B4GALNT1 2.87 1.68E-22 2.13 9.35E-07 
DGKI 2.85 4.48E-04 7.29 1.34E-05 
MAP2 2.85 4.17E-40 2.06 9.90E-11 
GRM8 2.84 5.17E-43 2.02 3.14E-08 
TMEFF2 2.84 2.65E-63 2.51 2.96E-30 
FOXL1 2.80 3.71E-05 7.42 3.93E-09 
ALOX12 2.80 4.43E-08 5.28 4.47E-09 
DLX2 2.80 1.71E-06 4.58 7.40E-08 
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NFATC1 2.79 2.76E-63 3.59 1.52E-64 
EGFL8 2.78 4.10E-279 2.22 3.13E-42 
ETNK2 2.78 6.96E-18 3.38 4.66E-12 
SLC7A5 2.77 0.00E+00 2.48 9.95E-321 
MAP7 2.76 2.93E-10 2.84 2.41E-08 
NRIP3 2.75 5.65E-05 2.99 3.29E-04 
PKP1 2.74 8.99E-09 3.17 4.55E-07 
KCNC3 2.72 1.45E-144 3.42 1.18E-159 
CGREF1 2.72 2.78E-224 2.31 1.20E-85 
C10orf47 2.71 3.03E-08 2.57 4.50E-07 
PRKAA2 2.71 1.89E-97 2.01 1.18E-20 
D730039F16Rik 2.70 8.25E-58 2.34 4.25E-20 
PLCXD2 2.69 1.36E-85 3.52 1.75E-71 
OLFM2 2.68 5.14E-07 2.83 1.76E-08 
Serpina3h 2.66 2.71E-09 2.14 2.88E-04 
FAM159B 2.66 4.67E-88 3.16 1.31E-34 
BC106179 2.65 3.42E-07 3.57 1.08E-04 
SORCS2 2.63 1.29E-20 2.47 4.83E-23 
LHX5 2.62 4.47E-34 3.36 1.87E-20 
Tnfrsf26 2.61 4.03E-176 2.09 1.03E-32 
LOXL4 2.58 6.16E-07 2.68 8.12E-10 
LMO7 2.55 4.73E-20 3.17 2.26E-19 
CPE 2.50 6.62E-300 2.21 1.66E-224 
MAP3K13 2.50 8.08E-11 2.00 3.17E-05 
GLIS3 2.49 8.42E-34 2.00 6.94E-11 
TEX15 2.48 4.19E-35 2.28 1.06E-14 
C21orf7 2.48 8.90E-30 2.02 1.72E-05 
ADRA1B 2.47 1.81E-08 5.15 7.60E-20 
MATN4 2.47 1.20E-230 2.34 1.79E-99 
WSCD1 2.45 7.85E-05 3.88 3.44E-07 
RAB37 2.44 5.11E-09 3.80 2.62E-07 
VCAN 2.42 6.91E-95 2.20 4.48E-57 
Foxl2os 2.42 2.35E-07 4.48 1.48E-08 
IRF6 2.40 1.23E-15 2.81 2.95E-11 
DPF1 2.40 7.03E-09 4.97 2.02E-16 
NFATC2 2.39 2.45E-27 3.83 1.08E-30 
SH2D4A 2.39 2.45E-27 3.20 4.17E-17 
FOSB 2.38 1.59E-14 2.88 9.47E-21 
CNTFR 2.36 1.34E-04 2.04 2.68E-04 
IGF2BP3 2.35 1.20E-27 2.18 4.23E-10 
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NPAS1 2.33 3.04E-04 3.72 2.32E-06 
SDC3 2.33 1.17E-58 2.29 2.85E-43 
LPL 2.32 8.99E-57 3.05 4.07E-21 
C16orf74 2.32 9.33E-11 3.02 2.17E-11 
SLC22A15 2.31 1.86E-05 2.53 1.23E-04 
SLC7A3 2.29 8.74E-27 2.50 1.03E-22 
Rps19-ps3 2.28 2.74E-109 2.67 8.23E-138 
ARTN 2.25 2.54E-13 3.11 6.66E-09 
ARHGAP8 2.25 2.38E-07 2.32 1.94E-04 
KDM6A 2.25 5.82E-48 2.14 3.85E-21 
DES 2.25 1.54E-34 2.86 8.41E-43 
UBA6 2.25 3.05E-05 4.89 3.12E-05 
PRDM16 2.24 1.81E-09 3.34 2.25E-09 
REM1 2.23 9.58E-15 2.81 2.88E-12 
PPP2R2C 2.23 3.00E-55 2.77 4.83E-62 
ITGA6 2.22 1.61E-48 2.20 4.36E-18 
COX7A1 2.22 3.23E-18 3.32 1.86E-17 
RANGRF 2.21 3.44E-13 2.05 2.05E-08 
PTP4A1 2.20 1.85E-172 3.36 9.21E-07 
FOXL2 2.20 1.43E-10 3.26 3.08E-14 
CCDC73 2.20 4.62E-14 2.60 4.12E-04 
CD80 2.19 9.58E-17 4.65 1.09E-13 
PRSS56 2.19 1.06E-10 3.31 8.45E-11 
FAT2 2.19 1.50E-04 4.97 6.88E-09 
RNF11 2.19 9.48E-15 2.09 3.51E-07 
DUS2L 2.19 9.60E-05 2.25 5.55E-04 
TMEM37 2.18 1.26E-56 2.04 9.22E-17 
HCK 2.17 4.54E-08 2.38 4.65E-07 
CYCS 2.16 4.04E-35 2.10 4.76E-26 
BCAP29 2.16 4.09E-16 4.06 3.46E-21 
TBX15 2.16 2.67E-08 2.26 1.43E-05 
SP6 2.14 5.79E-64 3.09 3.36E-82 
ARHGAP22 2.14 1.86E-06 2.26 3.90E-08 
THBD 2.13 9.64E-28 2.74 2.07E-21 
FLT1 2.12 2.82E-19 2.79 2.72E-15 
BOK 2.12 1.85E-23 2.31 1.08E-19 
EREG 2.11 4.59E-36 2.12 2.49E-20 
TM4SF1 2.10 5.56E-15 2.82 9.80E-13 
MFAP3L 2.10 2.83E-11 2.71 1.35E-09 
HOXA5 2.10 2.14E-04 2.66 1.36E-04 
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Gm15645 2.09 1.35E-05 3.88 3.44E-07 
RAP1GAP2 2.08 2.75E-17 2.62 1.09E-22 
APOO 2.08 2.70E-12 2.39 2.11E-08 
FRMD4B 2.07 1.73E-18 2.43 4.05E-21 
4833438C02Rik 2.05 8.19E-52 2.80 2.54E-51 
CILP2 2.04 3.93E-18 2.98 1.28E-27 
4921504A21Rik 2.01 2.35E-08 2.78 6.87E-06 
IGFBP6 -2.01 9.16E-12 -3.33 8.60E-79 
CTSW -2.01 5.45E-19 -2.29 3.85E-54 
GPSM3 -2.01 2.72E-06 -2.06 9.79E-16 
LTBP4 -2.01 5.08E-84 -2.34 2.56E-194 
NUP210 -2.01 4.93E-12 -2.67 3.99E-27 
SERPING1 -2.02 3.17E-105 -3.50 0.00E+00 
SNX32 -2.02 2.22E-09 -2.18 3.83E-21 
MAF -2.03 1.63E-29 -2.27 6.93E-121 
SYNE2 -2.03 1.54E-234 -2.00 0.00E+00 
AHR -2.03 6.14E-96 -2.80 0.00E+00 
MGAT3 -2.03 6.42E-06 -2.92 4.16E-19 
ENTPD4 -2.03 5.60E-35 -3.02 4.99E-45 
GPR68 -2.03 3.45E-04 -3.08 9.44E-12 
BPHL -2.04 5.05E-04 -2.18 5.28E-11 
Gbp4 -2.04 3.22E-06 -2.40 2.27E-27 
1010001N08Rik -2.05 1.70E-06 -2.55 1.19E-38 
PHACTR2 -2.05 1.08E-09 -2.60 7.06E-33 
MMP19 -2.06 9.21E-09 -3.66 8.11E-75 
CCDC125 -2.06 7.85E-04 -2.34 3.27E-13 
PAQR8 -2.07 6.56E-07 -2.04 1.74E-20 
E130310I04Rik -2.07 5.65E-04 -3.25 1.26E-15 
RGL3 -2.07 4.77E-07 -2.19 3.00E-11 
PLEKHF1 -2.08 7.47E-17 -3.24 9.69E-78 
ADAM12 -2.08 7.13E-28 -3.04 4.64E-125 
BTBD6 -2.09 1.05E-06 -2.44 4.45E-11 
ADAMTS20 -2.09 2.93E-04 -2.21 2.04E-08 
SLIT3 -2.10 1.07E-76 -2.89 1.74E-197 
NKD2 -2.10 2.11E-04 -3.71 4.33E-16 
MYO10 -2.10 5.18E-81 -2.36 1.35E-220 
C1S -2.11 1.75E-111 -4.21 1.55E-288 
SNCAIP -2.11 4.32E-11 -2.02 9.43E-23 
GAS1 -2.11 2.19E-144 -2.96 0.00E+00 
TMEM176B -2.11 1.04E-90 -2.19 5.23E-198 
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CPXM1 -2.11 1.47E-42 -3.55 1.64E-269 
SMTNL2 -2.12 5.70E-14 -3.12 2.33E-33 
ELN -2.12 9.92E-27 -6.24 1.29E-290 
WBSCR17 -2.12 1.62E-07 -2.85 4.19E-19 
DCN -2.12 4.72E-55 -3.66 0.00E+00 
FOLR1 -2.14 1.06E-42 -2.25 1.44E-119 
CLU -2.15 3.47E-18 -4.05 7.35E-134 
BICD1 -2.15 3.43E-08 -2.23 2.30E-17 
EML6 -2.16 4.05E-06 -2.05 3.55E-08 
FUOM -2.17 1.69E-19 -2.01 2.30E-50 
GSTM5 -2.17 6.72E-29 -2.35 7.69E-74 
PODXL -2.17 7.29E-04 -2.75 5.55E-07 
RBM47 -2.17 7.29E-04 -3.92 1.69E-16 
OLFML3 -2.17 3.41E-14 -3.37 2.17E-61 
KLHL29 -2.18 5.82E-07 -2.57 3.26E-16 
NOS1AP -2.18 4.73E-05 -2.73 1.95E-08 
RAI14 -2.20 1.61E-138 -2.11 1.93E-275 
Sprr3 -2.21 6.30E-17 -3.72 4.61E-45 
NDRG1 -2.21 1.55E-78 -3.41 0.00E+00 
SEMA3D -2.23 1.06E-96 -2.26 6.35E-277 
Mir546 -2.24 1.38E-05 -4.93 1.56E-15 
BC039771 -2.24 2.91E-04 -2.73 2.47E-20 
PHOX2A -2.25 5.17E-06 -2.80 1.44E-25 
CCDC8 -2.25 2.09E-04 -4.33 4.77E-12 
COLEC12 -2.25 2.16E-57 -2.54 7.33E-134 
EZR -2.26 0.00E+00 -2.45 0.00E+00 
SFRP2 -2.26 3.39E-50 -3.41 7.01E-252 
IGFBP5 -2.26 5.54E-05 -4.64 1.05E-04 
ZBTB8B -2.29 8.88E-29 -2.88 1.72E-80 
CNKSR3 -2.29 2.97E-27 -3.34 6.04E-104 
GNAI1 -2.30 3.22E-11 -2.98 2.57E-30 
RAB6B -2.30 5.97E-10 -5.40 1.62E-51 
Speer4a -2.30 3.13E-04 -2.74 3.61E-06 
GPNMB -2.31 1.23E-22 -3.00 2.32E-72 
A730049H05Rik -2.31 8.48E-10 -2.19 1.25E-14 
MYLK -2.32 2.93E-37 -2.77 3.76E-144 
SRRM4 -2.33 1.84E-11 -3.67 1.59E-57 
FGF2 -2.33 1.71E-09 -6.00 2.09E-81 
SMAD9 -2.33 4.53E-04 -4.45 4.12E-20 
PPP1R9A -2.33 1.66E-04 -2.36 2.50E-07 
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HEG1 -2.33 1.23E-91 -2.69 3.47E-138 
ADAMTS14 -2.34 1.63E-05 -3.73 1.56E-18 
CCDC141 -2.35 2.83E-12 -3.16 1.65E-42 
CCDC19 -2.37 8.75E-05 -2.61 1.73E-08 
Neat1 -2.39 2.77E-10 -3.88 1.89E-46 
Sprr1a -2.40 1.25E-17 -2.14 1.38E-48 
AIG1 -2.40 2.38E-05 -2.95 2.70E-11 
SCARB2 -2.40 0.00E+00 -3.08 0.00E+00 
MTSS1 -2.40 2.67E-26 -3.42 1.67E-141 
H6PD -2.40 4.52E-80 -4.47 0.00E+00 
SELENBP1 -2.40 1.75E-04 -2.78 2.83E-04 
ME3 -2.40 4.11E-11 -2.91 6.01E-31 
MMP16 -2.41 3.00E-27 -2.18 4.06E-56 
C3 -2.42 4.51E-60 -3.73 5.47E-175 
DPEP1 -2.42 4.68E-06 -2.03 1.08E-05 
FAM180A -2.43 1.53E-42 -2.49 7.67E-197 
FOXP2 -2.44 3.43E-06 -3.21 9.73E-18 
HLA-DQB1 -2.45 4.47E-49 -4.05 2.11E-246 
NLRC3 -2.45 5.85E-26 -2.62 1.78E-82 
PCDH9 -2.45 9.40E-17 -3.27 1.00E-50 
FAM184A -2.46 5.85E-15 -2.59 2.01E-34 
KALRN -2.46 8.13E-81 -3.02 7.66E-173 
PEG3 -2.46 7.99E-54 -2.81 2.23E-108 
STAP2 -2.46 3.90E-09 -2.69 6.74E-20 
ZNF467 -2.47 3.48E-06 -3.43 6.20E-22 
CFH -2.47 6.15E-42 -2.70 6.41E-167 
E130102H24Rik -2.49 1.81E-04 -3.41 4.57E-20 
KCNT1 -2.49 1.61E-10 -2.31 9.01E-19 
Cfhr2/Cfhr3 -2.51 4.95E-04 -2.76 3.40E-08 
KANK4 -2.52 1.33E-06 -3.01 5.73E-13 
HOXB4 -2.57 4.60E-11 -3.97 1.32E-33 
SERPINA3 -2.57 1.27E-15 -5.22 2.96E-140 
EPS8 -2.58 5.49E-72 -2.94 4.52E-201 
SLC43A3 -2.58 1.36E-218 -2.64 0.00E+00 
LDOC1L -2.59 1.17E-14 -2.61 6.70E-25 
SEMA5A -2.61 2.66E-07 -3.73 1.17E-22 
ART3 -2.62 2.54E-05 -3.75 5.66E-18 
N4BP2L1 -2.63 5.28E-08 -2.24 3.07E-23 
CNRIP1 -2.63 9.50E-06 -2.82 1.08E-11 
Gm2895 -2.64 2.17E-14 -4.10 7.78E-114 
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ACVR1B -2.64 2.54E-16 -3.51 3.63E-57 
BACE2 -2.66 6.80E-05 -2.86 5.04E-11 
LPAR1 -2.67 1.86E-85 -2.10 6.97E-147 
IL1RL2 -2.68 9.94E-08 -6.72 6.04E-58 
FMOD -2.68 4.94E-182 -2.55 0.00E+00 
ITGA7 -2.69 4.67E-65 -3.28 5.05E-147 
MT1H -2.74 1.42E-18 -2.92 8.68E-121 
TNIK -2.74 8.12E-20 -2.35 2.68E-34 
NEU3 -2.75 1.21E-31 -3.01 2.24E-85 
NID2 -2.75 0.00E+00 -3.18 0.00E+00 
XDH -2.77 2.90E-81 -4.61 0.00E+00 
SLC39A4 -2.80 3.74E-15 -3.09 6.09E-35 
NPR1 -2.81 2.07E-43 -2.88 5.61E-91 
NXPH1 -2.81 3.76E-24 -2.80 8.39E-90 
TF -2.83 2.07E-73 -2.48 2.32E-132 
SLFN13 -2.85 8.10E-13 -5.49 2.64E-58 
TMEM221 -2.86 6.47E-05 -2.17 4.01E-06 
SPRR2G -2.87 2.36E-06 -4.59 1.39E-74 
FAM110C -2.88 4.87E-65 -2.58 1.61E-121 
ID2 -2.88 2.38E-33 -4.56 4.02E-292 
PRPH -2.91 1.74E-16 -7.27 1.25E-61 
RGS3 -2.92 1.93E-46 -3.44 1.85E-133 
PCDHB16 -2.94 1.19E-05 -3.49 5.27E-11 
AUTS2 -2.99 1.20E-30 -5.67 1.01E-155 
IGFBP4 -3.00 1.16E-83 -5.52 0.00E+00 
ALCAM -3.01 2.56E-225 -2.34 0.00E+00 
CISH -3.05 2.05E-27 -2.53 5.75E-42 
FIGF -3.05 1.36E-55 -2.74 1.62E-120 
THRB -3.05 2.06E-07 -3.60 3.49E-32 
MTUS2 -3.06 3.34E-16 -6.21 7.41E-105 
ATP1B1 -3.10 0.00E+00 -5.53 0.00E+00 
SEPP1 -3.11 1.53E-16 -10.42 8.84E-123 
IDUA -3.13 2.60E-10 -2.55 2.65E-16 
GJB4 -3.16 1.11E-04 -2.48 1.63E-05 
TCF21 -3.17 1.63E-151 -3.62 0.00E+00 
DPP4 -3.21 1.72E-63 -4.38 2.00E-172 
RIMS1 -3.21 1.01E-05 -2.13 3.53E-05 
Gm19557 -3.21 1.01E-05 -2.46 5.11E-06 
GAS7 -3.23 3.32E-08 -4.29 6.79E-19 
ECSCR -3.23 1.82E-26 -2.50 2.39E-35 
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TGFBR3 -3.27 2.12E-44 -4.99 1.98E-227 
RGS16 -3.28 1.60E-31 -3.80 6.84E-59 
RASL11A -3.31 2.96E-64 -3.14 2.09E-250 
KLHL30 -3.33 2.08E-51 -4.81 4.76E-175 
LRRN4 -3.34 1.61E-162 -7.63 0.00E+00 
5430435G22Rik -3.37 3.25E-06 -2.42 6.58E-09 
Nup62cl -3.38 1.30E-10 -3.26 7.28E-15 
ISLR -3.39 1.40E-04 -5.10 1.58E-09 
PCDH10 -3.40 1.54E-46 -4.10 1.19E-107 
SYNPO2 -3.41 7.64E-15 -3.87 2.76E-40 
BMF -3.42 2.77E-04 -6.18 1.87E-15 
AVPR1A -3.43 1.29E-41 -3.10 3.37E-84 
EMILIN1 -3.43 8.23E-57 -7.37 1.08E-186 
HMCN1 -3.44 4.81E-05 -3.32 3.88E-09 
MFAP2 -3.49 2.80E-31 -2.52 6.33E-40 
MSRB2 -3.52 3.13E-09 -2.59 7.31E-11 
ST3GAL1 -3.57 5.45E-21 -5.51 0.00E+00 
APOE -3.57 7.70E-131 -6.60 0.00E+00 
UCP2 -3.58 0.00E+00 -5.23 0.00E+00 
Gsta4 -3.63 2.51E-32 -2.27 1.96E-23 
SVEP1 -3.64 2.27E-55 -4.20 7.96E-136 
IL4R -3.73 4.15E-127 -4.41 1.24E-290 
BC023719 -3.74 2.12E-07 -6.12 1.82E-24 
CMYA5 -3.75 3.42E-06 -3.84 3.04E-10 
RAB27B -3.76 3.01E-13 -4.02 2.54E-38 
CPQ -3.76 1.82E-23 -2.79 1.17E-35 
SLC2A13 -3.79 1.93E-05 -2.82 4.32E-06 
GLI1 -3.84 9.51E-08 -2.86 5.05E-12 
SMOC2 -3.87 3.22E-31 -7.51 8.96E-99 
IVL -3.88 5.12E-60 -4.72 2.37E-171 
FADS6 -4.07 1.55E-07 -4.92 4.14E-16 
PGAM2 -4.08 5.29E-10 -3.58 4.31E-22 
Gm10389 -4.08 7.66E-27 -3.71 2.41E-49 
RORC -4.10 1.24E-08 -6.15 4.23E-32 
DAAM2 -4.15 4.42E-34 -5.47 1.66E-120 
PRR15 -4.21 3.72E-15 -7.87 4.42E-107 
PPP2R2B -4.24 1.51E-38 -5.11 7.14E-121 
H2-Q10 -4.28 3.72E-311 -9.19 0.00E+00 
A930024E05Rik -4.34 1.83E-04 -2.91 8.21E-08 
KIAA1244 -4.38 2.42E-07 -2.39 8.29E-05 
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ID3 -4.44 0.00E+00 -3.55 0.00E+00 
TNC -4.50 0.00E+00 -6.88 0.00E+00 
HLX -4.56 1.31E-06 -7.99 1.84E-19 
SFRP1 -4.56 7.48E-112 -6.44 4.51E-308 
CACNA1A -4.59 3.93E-21 -4.22 1.45E-40 
UNC5A -4.60 1.53E-08 -4.68 1.55E-12 
DOCK10 -4.60 7.73E-05 -16.50 7.24E-20 
MMP3 -4.62 7.98E-39 -10.92 0.00E+00 
OTUD7A -4.62 1.71E-05 -3.11 1.01E-05 
ANKRD65 -4.74 2.28E-04 -2.70 2.54E-09 
8030451A03Rik -4.76 5.25E-44 -12.98 8.75E-04 
STAC -4.77 7.64E-15 -3.60 2.81E-22 
GGT5 -4.83 6.52E-55 -5.86 6.24E-122 
TNNT2 -4.89 0.00E+00 -3.82 0.00E+00 
EHD3 -4.91 4.60E-203 -7.37 0.00E+00 
PDZD2 -4.93 9.88E-143 -30.60 7.14E-09 
OLR1 -4.96 5.89E-11 -3.33 3.99E-13 
ID1 -4.99 0.00E+00 -3.42 0.00E+00 
PLEK -5.07 2.93E-06 -4.17 6.58E-10 
HDDC3 -5.21 1.80E-33 -5.70 8.96E-77 
HOXB3 -5.24 3.13E-20 -6.00 1.13E-48 
AMDHD1 -5.38 5.79E-14 -9.35 2.96E-43 
SEMA6D -5.60 9.27E-10 -7.68 5.54E-25 
HAL -5.63 2.50E-46 -5.78 1.26E-122 
ATOH8 -5.63 1.65E-45 -8.59 9.15E-154 
IGLON5 -5.71 1.15E-19 -7.08 3.97E-43 
CNTNAP3 -5.72 2.78E-08 -2.09 7.46E-05 
Clca1/Clca2 -5.76 0.00E+00 -5.78 0.00E+00 
CFI -5.79 2.55E-09 -9.52 3.05E-28 
PRSS12 -5.85 8.58E-26 -5.03 1.63E-46 
PDE2A -5.88 1.61E-09 -6.54 2.80E-36 
LRTM2 -6.12 4.30E-05 -4.37 6.95E-05 
Gbp6 -6.12 4.30E-05 -4.85 1.80E-09 
TGFBI -6.23 2.17E-19 -30.21 5.45E-147 
CADM1 -6.28 2.15E-126 -6.29 0.00E+00 
Lipo1 -6.31 3.15E-04 -3.83 2.23E-07 
PDGFRA -6.47 1.93E-53 -15.73 0.00E+00 
SOD3 -6.51 5.28E-40 -4.83 1.67E-79 
Serpina3k -7.10 3.95E-06 -9.40 1.18E-13 
STEAP4 -7.22 4.17E-10 -35.65 2.42E-103 
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MEGF6 -7.25 4.85E-227 -10.21 0.00E+00 
C2orf40 -7.28 8.40E-13 -4.38 1.86E-31 
PNMAL2 -7.30 2.43E-06 -36.16 4.79E-20 
SAA2 -7.37 4.57E-05 -50.76 2.33E-56 
Cyp2d22 -7.38 1.31E-19 -9.55 6.97E-50 
SCG2 -7.50 8.98E-04 -5.56 1.25E-07 
mir-101 -7.50 8.98E-04 -7.11 1.08E-04 
SEZ6L -7.50 8.98E-04 -7.42 3.19E-06 
CCDC68 -7.65 4.30E-15 -5.42 1.23E-31 
Clca4 -7.74 4.30E-46 -5.22 8.73E-177 
HLA-B -7.76 1.30E-224 -20.49 0.00E+00 
SYT8 -7.89 5.46E-04 -3.64 5.00E-06 
PLAC8 -7.89 5.46E-04 -6.80 1.86E-04 
TEK -7.94 1.34E-24 -11.24 1.31E-57 
ITGBL1 -7.96 1.94E-33 -5.26 8.11E-41 
ANGPTL7 -8.08 6.36E-52 -22.50 0.00E+00 
SMPDL3A -8.21 7.04E-09 -4.00 4.64E-14 
S100A4 -8.38 0.00E+00 -3.29 0.00E+00 
SLC13A4 -8.42 6.32E-06 -3.48 6.99E-04 
2410137M14Rik -8.68 2.01E-04 -67.68 6.04E-20 
HOXB2 -9.13 3.13E-26 -5.68 4.84E-34 
WDR86 -9.47 7.27E-05 -5.72 3.11E-06 
SDK1 -9.67 6.18E-09 -5.47 5.12E-09 
GPR88 -10.00 3.04E-07 -12.61 1.27E-27 
STBD1 -10.05 7.61E-234 -10.25 0.00E+00 
TMEM215 -10.06 1.33E-17 -20.61 8.29E-65 
ADAMTSL2 -10.06 0.00E+00 -4.65 0.00E+00 
A630023A22Rik -10.10 1.69E-11 -3.35 2.63E-13 
KIAA1324L -10.44 1.30E-67 -14.70 1.19E-183 
PCDH17 -11.05 2.85E-98 -16.87 5.25E-298 
ADAM23 -11.44 5.52E-06 -4.97 1.62E-08 
2610507I01Rik -12.10 4.87E-09 -10.51 7.54E-20 
GUCY1A3 -12.17 1.02E-69 -26.14 9.06E-241 
PYCARD -12.31 1.23E-14 -7.53 1.58E-53 
REC8 -12.63 1.71E-09 -24.85 7.71E-32 
GBP2 -16.97 2.25E-17 -55.32 1.19E-46 
AIF1 -17.36 1.90E-09 -11.44 3.85E-08 
SLC16A2 -18.15 2.00E-05 -10.43 2.12E-09 
HSD11B1 -18.15 2.00E-05 -26.89 1.36E-14 
ZFHX4 -18.94 1.16E-05 -65.83 2.19E-19 
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INPP5D -20.04 5.18E-26 -12.13 3.43E-61 
PNLDC1 -21.50 8.57E-23 -11.40 2.13E-56 
CLDN15 -21.62 2.22E-28 -9.83 1.86E-85 
2410017I17Rik -22.10 2.35E-212 -6.69 2.77E-127 
Serpinb6b -26.30 2.58E-42 -40.24 7.39E-214 
























GENES >2-FOLD DYSREGULATED BETWEEN TGFBR3+/+ AND TGFBR3-/- 
























3300005D01Rik 2.05 2.96E-06 2.50 2.11E-06 
4833438C02Rik 2.13 2.24E-46 2.14 2.22E-35 
5730588L14Rik 2.07 6.11E-15 2.08 2.47E-07 
9330179D12Rik 71.64 0.00E+00 2.31 2.82E-20 
A330033J07Rik 3.39 2.70E-07 3.26 1.37E-04 
AASS 15.85 2.65E-12 18.00 1.21E-08 
ABCB11 5.15 1.37E-11 2.42 1.78E-04 
ACAN 84.79 4.14E-26 10.28 1.35E-06 
ACSBG1 2.85 2.06E-28 2.04 1.41E-10 
AGPAT9 2.85 5.77E-07 4.67 5.14E-07 
AKAP12 2.03 5.50E-155 2.03 2.62E-149 
ALOX12 3.11 4.54E-09 4.46 1.89E-08 
ALX4 86.38 1.31E-26 71.98 2.29E-19 
AMN 3.43 1.31E-121 2.23 1.56E-31 
ANGEL1 2.68 1.77E-09 2.38 1.20E-06 
ANGPTL4 7.55 5.20E-298 6.32 1.00E-142 
ANKRD1 4.34 0.00E+00 5.30 0.00E+00 
ANKRD33B 4.04 5.28E-06 10.28 1.35E-06 
Apol10a 13.63 1.59E-16 3.42 1.27E-21 
ARHGAP20 3.96 2.72E-06 4.04 7.70E-07 
ARHGAP22 2.70 4.51E-08 2.50 2.94E-06 
ARHGAP8 2.12 4.91E-05 3.59 3.18E-07 
ARTN 2.28 4.39E-11 2.47 1.30E-07 
ATP2A3 2.16 4.62E-04 2.39 9.75E-04 
B3GNT5 5.42 5.00E-06 4.79 2.82E-07 
B4GALNT1 2.16 1.68E-11 2.06 1.49E-07 
B4GALNT2 10.80 2.66E-155 5.91 9.36E-53 
BAI1 3.69 1.78E-135 3.67 3.49E-74 
BC067074 17.43 3.31E-05 8.36 7.94E-04 
BCAP29 2.25 5.60E-16 2.23 5.25E-12 
BCAT1 11.71 7.23E-136 5.91 1.43E-56 



























BTBD11 8.88 8.75E-10 10.71 6.59E-07 
C10orf47 5.90 7.08E-18 3.18 6.49E-11 
C1orf115 2.55 4.10E-13 3.21 1.29E-11 
C21orf7 2.75 1.23E-26 2.36 4.14E-08 
C6orf132 4.88 5.46E-10 4.67 5.14E-07 
CAMK2N1 2.34 5.93E-04 2.19 1.14E-04 
CCDC36 7.92 1.62E-05 28.28 1.54E-07 
CCDC153 3.32 1.29E-09 2.52 2.09E-04 
CCL17 4.50 3.54E-30 2.21 2.35E-08 
CCRN4L 2.27 3.89E-24 2.25 1.75E-20 
Cd24a 5.14 5.95E-24 3.72 1.08E-07 
CDKN1C 7.25 0.00E+00 3.25 7.14E-220 
CGNL1 2.03 3.26E-45 2.31 7.57E-38 
CGREF1 3.45 1.48E-270 2.79 3.64E-98 
CHD5 2.59 5.33E-38 2.51 1.60E-19 
CILP2 3.05 6.42E-35 3.72 3.49E-30 
CKMT1A/CKMT1B 4.40 2.57E-84 4.32 3.65E-37 
CMAHP 7.92 5.87E-10 3.86 3.83E-04 
CNTFR 2.02 2.81E-04 3.50 1.08E-08 
COL2A1 2.68 1.03E-17 2.52 1.08E-07 
COL4A3 7.06 1.51E-53 4.34 2.01E-26 
COL5A3 2.10 6.69E-28 2.45 1.77E-25 
COL7A1 2.80 5.73E-27 2.65 5.66E-22 
COL9A2 2.58 3.21E-06 3.03 1.04E-06 
CORO2A 3.96 4.14E-213 2.35 3.43E-68 
COX7A1 2.01 7.23E-14 2.28 5.33E-14 
CPE 4.37 0.00E+00 2.21 8.20E-181 
CPNE7 4.22 5.11E-57 5.88 3.52E-62 
CSF3 5.55 4.46E-07 5.36 3.20E-05 
CSGALNACT1 6.44 7.90E-97 4.29 1.77E-31 
CTNND2 121.88 5.51E-185 32.69 3.86E-107 
CTSC 3.30 6.83E-27 2.25 2.62E-11 
CYP46A1 2.74 1.19E-07 2.17 2.19E-04 
DENND5B 2.03 3.02E-15 2.58 7.07E-17 
DES 3.39 2.81E-57 2.87 1.01E-29 
DGKI 7.33 2.29E-06 5.78 3.15E-04 
DKKL1 3.75 1.29E-49 3.80 3.13E-25 
DLX2 5.28 1.68E-10 4.76 1.18E-06 
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DPF1 2.12 1.20E-05 2.47 2.32E-06 
DSCAML1 3.15 1.63E-39 3.00 1.59E-20 
DSP 8.03 7.27E-195 5.56 1.14E-109 
Dux (includes 
others) 20.60 3.71E-06 3.39 2.61E-04 
E230032D23Rik 3.43 2.63E-04 16.71 1.67E-04 
ENG 2.11 5.41E-29 3.28 1.19E-49 
EPB41L1 2.05 1.29E-22 2.06 1.30E-17 
EPB41L3 19.49 3.66E-25 11.39 1.13E-15 
EREG 2.01 8.65E-28 2.22 5.28E-25 
ETNK2 4.74 3.68E-29 2.88 1.53E-08 
EXOC3L2 2.34 3.31E-16 2.72 1.42E-12 
FAM123A 2.12 2.61E-10 2.14 1.50E-06 
FAM134B 6.08 4.88E-04 3.86 3.83E-04 
FAM159B 2.59 3.56E-70 3.11 3.57E-53 
FAM20A 3.22 1.82E-16 2.05 8.69E-05 
FAM43B 5.65 7.37E-22 4.39 3.64E-09 
FAM71F1 2.54 3.19E-06 2.44 8.96E-04 
FAM81A 3.17 4.00E-21 2.43 5.77E-08 
FAM89A 7.44 1.84E-18 2.97 1.40E-04 
FAT2 3.09 1.88E-06 10.03 6.64E-10 
FAXC 12.48 5.86E-34 8.21 1.51E-24 
FCHO1 2.18 1.34E-06 2.79 1.64E-07 
FERMT1 2.87 1.01E-33 2.57 2.44E-20 
FEV 5.07 8.92E-05 999.00 2.25E-04 
FGF5 4.47 8.13E-39 2.82 2.59E-14 
FGF10 54.68 1.16E-16 10.28 1.35E-06 
Fhod3 2.42 2.11E-39 2.40 3.69E-37 
FLT1 2.54 5.33E-22 2.93 9.16E-13 
FOSB 2.62 4.62E-15 2.18 1.33E-10 
FOXL2 4.03 4.65E-22 2.92 2.21E-11 
Foxl2os 3.96 8.13E-12 2.71 6.53E-06 
FRMD4B 2.55 6.22E-24 2.91 1.88E-22 
FRMPD1 14.66 1.20E-14 20.14 4.57E-14 
FSTL3 4.44 5.82E-92 4.90 7.65E-72 
FZD10 6.32 1.09E-128 4.54 2.25E-72 
GALNT9 8.72 3.62E-06 20.57 1.67E-05 
GALNTL4 5.35 1.81E-36 3.18 6.49E-11 
GAP43 4.43 7.11E-11 3.36 2.26E-08 
GATM 3.24 9.61E-111 2.86 7.13E-48 
GDF15 2.10 3.54E-09 2.94 1.48E-07 
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GLIS3 3.42 2.62E-46 2.49 7.71E-19 
Gm3230 2.41 5.89E-05 3.47 3.58E-04 
Gm11549 2.35 1.09E-04 3.05 8.54E-05 
GNAL 2.46 3.42E-47 2.69 1.35E-39 
GRID2 4.29 2.52E-10 3.16 1.71E-07 
GRM8 3.32 1.03E-43 3.30 5.96E-20 
HCK 2.56 9.34E-10 2.54 2.63E-07 
HECW2 3.49 1.16E-18 5.14 1.16E-19 
HIST1H1D 2.35 1.09E-04 2.97 1.22E-06 
HIST1H2BL 2.10 4.76E-07 2.17 1.69E-07 
Hist3h2ba 3.60 2.05E-05 3.09 1.19E-04 
HMHA1 16.35 2.54E-74 7.16 6.22E-38 
IGDCC4 2.46 6.78E-27 2.03 4.08E-12 
IGHA1 15.06 1.68E-04 14.14 7.63E-04 
IL6 2.13 9.65E-17 2.23 2.96E-11 
INSL3 2.58 4.03E-89 2.42 8.09E-53 
IRF6 2.44 5.13E-13 2.67 8.00E-10 
ITGA6 2.82 3.65E-75 2.49 1.54E-29 
JAK3 2.48 8.60E-133 2.39 3.28E-74 
KCNC3 3.70 1.92E-180 3.01 8.55E-146 
KCNK1 11.15 1.04E-73 3.97 1.37E-23 
KCNQ5 2.15 1.33E-21 2.13 1.84E-14 
KCNS3 6.67 1.01E-14 5.49 7.08E-09 
KDM6A 2.14 5.57E-30 2.34 1.08E-30 
KIAA1467 4.34 1.57E-99 3.16 3.75E-44 
KIF1A 5.75 7.00E-12 5.57 7.13E-12 
Klra18 4.76 2.62E-36 4.46 1.55E-15 
Klra4 4.82 3.68E-35 3.99 7.92E-13 
KRT8 4.90 1.69E-27 3.31 6.55E-15 
KRT18 7.68 2.63E-19 3.99 1.80E-12 
KRT80 2.75 6.13E-08 2.87 3.26E-10 
LAMA2 11.49 5.24E-06 3.31 5.92E-05 
LAMC2 2.08 7.46E-19 2.58 3.04E-20 
LCE1B 18.23 1.92E-05 47.56 1.02E-12 
LCE1E 10.30 1.71E-07 4.93 1.11E-04 
Lce1f 8.88 8.75E-10 3.26 1.37E-04 
Lce1g 8.89 4.03E-32 6.63 5.00E-19 
Lce1h 9.29 2.34E-21 7.07 1.06E-13 
LIMCH1 7.74 7.57E-243 5.52 1.60E-93 
LIN28B 11.89 7.58E-09 4.63 8.88E-04 
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LMO7 4.05 4.54E-32 3.37 1.10E-18 
LOC100503496 2.59 3.43E-09 2.30 3.15E-04 
LOXL4 3.33 2.51E-09 3.67 1.01E-12 
LRCH2 4.36 1.29E-05 4.96 2.19E-09 
LRRK2 3.21 8.30E-08 4.42 8.30E-09 
LTBP1 3.73 2.22E-214 3.29 2.21E-106 
LURAP1L 3.29 9.50E-39 2.75 2.73E-20 
Ly6a 999.00 5.66E-04 4.21 5.38E-06 
MAB21L2 6.02 1.41E-125 4.29 2.75E-61 
MANSC1 6.82 5.26E-07 21.21 2.60E-10 
MAP2 3.22 2.81E-41 2.36 5.03E-16 
MAP7 5.38 2.45E-16 2.35 8.71E-06 
MAP3K13 2.81 6.37E-11 3.40 6.21E-13 
MAP7D2 3.74 1.19E-08 3.24 1.42E-07 
Masp1 8.44 8.05E-38 5.53 4.58E-22 
MATN4 3.13 4.70E-307 2.51 8.38E-96 
MDGA1 2.04 1.59E-12 2.07 1.57E-11 
MECOM 4.16 3.02E-05 6.43 7.16E-04 
MEIG1 4.37 3.75E-16 3.78 7.66E-07 
MEIS3 4.25 4.07E-23 2.43 6.36E-09 
MFAP3L 2.49 1.51E-13 2.42 8.82E-09 
MME 3.17 2.19E-09 3.86 3.63E-08 
MMP15 2.41 0.00E+00 2.21 4.19E-215 
Msx3 8.88 8.75E-10 5.86 3.42E-08 
MYH14 3.23 3.62E-05 4.44 1.68E-06 
NAT8L 2.46 3.63E-12 2.49 3.57E-10 
NDUFA4L2 2.99 8.56E-67 4.52 1.03E-63 
NECAB1 28.53 1.46E-08 6.86 3.66E-04 
NFATC1 3.45 3.21E-71 3.12 2.05E-48 
NFATC2 3.19 8.21E-34 3.80 4.16E-33 
NPAS1 2.84 4.34E-05 2.79 1.86E-04 
NPR2 9.75 4.88E-286 6.12 2.60E-181 
NPR3 4.79 6.90E-33 2.45 1.76E-10 
OAS3 4.90 1.07E-08 7.86 3.24E-12 
ODZ3 2.56 7.32E-161 2.30 7.23E-91 
OLFM2 2.16 3.90E-05 2.63 2.66E-08 
Olfr212/Olfr213 7.70 5.36E-11 16.71 1.67E-04 
OTUD1 2.61 1.67E-14 2.08 1.05E-06 
PAK6 2.64 4.35E-55 4.17 2.17E-88 
PARM1 3.72 7.58E-211 2.42 1.52E-79 
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PAX3 999.00 9.83E-05 15.43 3.58E-04 
PCOLCE2 4.92 8.92E-30 3.52 1.90E-11 
Pde4d 5.22 4.32E-14 3.86 6.91E-09 
Peg12 2.15 5.43E-05 2.57 4.89E-05 
PEX5L 4.51 7.36E-09 7.83 1.43E-14 
PIANP 5.31 1.38E-27 6.79 1.21E-21 
PKP1 2.44 3.08E-05 2.95 1.00E-04 
PLCG2 2.73 6.77E-11 3.86 9.40E-12 
PLCL2 4.45 2.44E-14 3.39 2.05E-10 
PLCXD2 2.88 2.04E-79 3.46 1.02E-83 
PLD5 3.29 1.86E-41 2.18 5.37E-12 
PM20D1 2.98 1.44E-06 4.88 1.74E-17 
POU3F3 6.54 6.02E-10 3.75 2.21E-05 
POU4F3 8.22 1.58E-13 3.86 2.36E-06 
PPL 12.29 5.69E-182 7.94 5.62E-112 
PPP1R16B 8.76 3.82E-63 9.64 4.86E-37 
PPP2R2C 3.93 4.57E-130 3.13 4.12E-62 
PRDM6 6.64 3.12E-97 3.80 3.65E-34 
PRDM16 2.77 6.18E-09 2.87 6.48E-08 
PRSS56 2.63 4.11E-13 2.67 1.71E-07 
PTPRB 5.76 9.99E-174 5.20 2.31E-132 
RAB37 4.36 8.83E-19 2.95 8.79E-07 
RAB39B 20.21 3.88E-11 7.71 9.33E-05 
RADIL 4.70 1.04E-10 3.74 5.15E-05 
RAP1GAP2 3.03 4.83E-33 3.76 1.60E-34 
RAP1GAP 2.06 3.35E-04 2.67 1.43E-05 
RASD1 3.34 1.89E-16 2.13 8.85E-06 
RASGEF1A 4.42 4.59E-13 4.00 2.75E-08 
RBM20 4.63 6.41E-33 6.32 3.74E-33 
RHBDL2 2.13 2.99E-04 3.07 2.70E-05 
RHOV 2.52 1.20E-07 2.30 2.52E-05 
RIMS2 59.96 5.84E-53 44.99 6.80E-34 
RMRP 2.55 7.73E-31 2.13 3.40E-08 
RNF152 3.72 8.56E-12 2.79 1.18E-07 
Rprl2 999.00 2.16E-16 999.00 1.25E-12 
Rprl3 999.00 3.24E-40 999.00 1.18E-17 
RUNX1T1 10.30 2.45E-22 6.03 3.93E-14 
SCT 2.08 8.16E-07 2.40 4.93E-04 
SDC3 3.22 5.62E-101 2.52 9.48E-53 
SEMA3G 4.88 5.46E-10 3.94 2.54E-07 
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SEMA7A 4.23 1.33E-10 2.57 6.55E-06 
SH2D4A 3.56 1.03E-43 3.75 7.34E-17 
SH3BGR 6.08 4.88E-04 6.11 1.64E-04 
SHC3 12.28 1.84E-06 20.57 1.67E-05 
SLC2A5 5.32 1.11E-06 2.85 7.25E-04 
SLC38A4 3.57 1.04E-05 3.57 4.91E-04 
SLC4A4 4.33 7.81E-128 4.22 3.50E-108 
SLC7A5 3.96 0.00E+00 2.09 1.13E-192 
Snhg9 3.14 6.89E-28 4.36 3.18E-88 
SNRPN 6.34 1.55E-09 3.54 6.55E-05 
SNTG1 4.96 1.29E-22 6.31 8.13E-11 
SNURF 6.24 2.48E-09 3.54 6.55E-05 
SORCS2 2.88 1.15E-25 2.88 4.16E-24 
SOX11 13.08 1.24E-18 3.11 8.76E-07 
SOX13 4.82 1.86E-58 3.19 1.42E-27 
SP6 3.34 1.59E-135 2.40 1.08E-48 
ST6GAL1 4.13 1.50E-44 3.30 5.63E-25 
ST8SIA2 7.61 5.98E-15 2.38 1.20E-06 
STOX2 2.19 2.51E-34 2.00 1.61E-15 
SYCE1 6.58 1.50E-15 13.71 4.53E-17 
SYT13 999.00 4.83E-09 13.50 2.37E-06 
TACSTD2 9.77 6.66E-19 3.18 7.17E-06 
TBX1 13.47 3.76E-07 5.46 5.99E-04 
TBX4 9.19 3.20E-10 5.66 7.26E-05 
TEX15 2.12 1.35E-18 2.52 3.74E-26 
TFRC 3.32 8.56E-29 3.28 2.98E-30 
THBD 3.02 2.50E-39 2.83 2.50E-21 
TLL1 17.43 1.76E-09 7.71 5.70E-06 
TLR5 7.47 1.42E-10 4.24 1.25E-05 
TMEFF2 2.92 6.96E-54 2.39 1.11E-26 
TMEM132C 12.15 4.49E-09 5.14 5.98E-05 
TNFAIP3 2.39 1.20E-65 2.24 1.90E-46 
TNFRSF19 13.08 6.39E-07 3.86 9.09E-04 
TNFRSF11B 3.36 5.69E-98 2.06 3.76E-28 
TRANK1 39.62 5.59E-12 11.57 1.54E-07 
TSIX 999.00 0.00E+00 342.57 1.86E-187 
TUBA8 3.27 2.02E-08 2.68 5.48E-05 
UNCX 2.95 2.02E-07 5.01 3.50E-07 
Usp44 6.69 2.11E-11 4.11 2.22E-05 
VAX2 8.19 9.86E-06 14.14 1.12E-06 
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VCAN 3.62 1.57E-150 2.42 2.78E-91 
VEGFC 2.42 2.50E-75 2.00 2.18E-28 
WASF3 7.81 3.28E-11 15.75 7.58E-14 
WNT3 2.60 4.27E-43 2.02 3.61E-13 
WNT7A 5.86 1.55E-19 3.98 1.09E-17 
WNT7B 2.74 4.45E-08 3.62 2.27E-06 
WSCD1 3.79 7.96E-09 6.43 2.58E-09 
XIST 999.00 0.00E+00 2090.96 0.00E+00 
Xlr3c 9.04 4.11E-31 6.30 6.33E-10 
ZDHHC2 5.91 3.82E-102 3.20 2.46E-44 
ZDHHC14 2.63 1.67E-06 2.62 6.15E-05 
1010001B22Rik -5.60 1.84E-05 -3.63 5.04E-09 
1010001N08Rik -2.19 2.60E-16 -3.40 2.98E-53 
2210408F21Rik -2.03 5.09E-04 -2.03 5.14E-09 
2410017I17Rik -9.92 2.70E-97 -6.52 1.00E-92 
2610507I01Rik -7.78 2.50E-08 -9.78 1.03E-14 
8030451A03Rik -4.07 1.42E-20 -7.17 7.45E-74 
9530026P05Rik -2.33 5.87E-04 -2.41 1.47E-11 
9530082P21Rik -27.23 3.37E-08 -21.77 3.58E-20 
A130040M12Rik -2.93 2.10E-04 -2.22 3.20E-05 
A630023A22Rik -5.45 6.25E-07 -5.43 1.27E-23 
ACVR1B -2.98 1.12E-17 -4.32 1.57E-63 
ADAM12 -2.59 2.00E-45 -3.64 5.58E-163 
ADAM33 -2.14 1.25E-04 -3.65 2.62E-13 
ADAMTS14 -3.33 4.24E-07 -2.85 4.25E-10 
ADAMTSL2 -10.50 0.00E+00 -5.83 0.00E+00 
AHR -2.02 3.00E-88 -2.24 2.37E-187 
ALCAM -2.93 4.99E-261 -2.79 0.00E+00 
AMDHD1 -7.78 4.62E-14 -11.86 7.63E-45 
ANGPTL7 -19.29 2.07E-72 -30.64 0.00E+00 
ANKRD34A -2.71 6.69E-06 -2.94 5.70E-13 
ANTXR1 -2.09 1.07E-37 -2.47 8.04E-97 
ANTXRL -8.04 1.24E-05 -6.20 1.78E-11 
APOE -3.66 8.68E-122 -6.95 0.00E+00 
ATOH8 -6.70 1.55E-38 -8.01 1.85E-104 
ATP1B1 -3.86 0.00E+00 -4.56 0.00E+00 
AUTS2 -4.22 1.31E-45 -4.54 2.79E-100 
AVPR1A -3.42 2.73E-42 -3.85 6.05E-110 
BC023719 -3.25 1.71E-06 -5.19 1.23E-17 
BCL3 -2.09 2.88E-08 -2.04 1.08E-10 
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BEGAIN -10.50 1.83E-05 -2.63 5.51E-05 
BHLHE41 -2.78 1.76E-19 -2.35 9.65E-30 
BMF -4.51 4.12E-04 -6.60 1.84E-13 
BNIP3 -2.07 1.44E-04 -2.12 2.24E-09 
C3 -2.65 2.60E-48 -3.28 6.97E-142 
C1qtnf6 -2.10 5.47E-20 -2.45 5.17E-45 
C1S -2.13 1.16E-115 -3.44 0.00E+00 
C2orf40 -21.78 3.89E-12 -25.63 8.73E-76 
CACNA1A -3.23 1.15E-13 -4.48 3.99E-37 
CADM1 -7.03 5.81E-150 -7.47 0.00E+00 
CCDC68 -3.41 2.00E-07 -5.63 2.75E-29 
CCDC141 -2.03 1.39E-07 -2.96 1.52E-27 
CD1D -3.77 1.07E-06 -3.59 4.83E-15 
CDYL2 -6.48 2.25E-04 -4.26 8.54E-05 
CEBPD -2.24 1.93E-32 -2.36 1.01E-76 
CFH -3.15 6.87E-60 -3.32 4.49E-165 
CFI -5.45 6.25E-07 -12.70 3.95E-37 
CISH -2.80 6.40E-22 -3.06 1.03E-47 
Clca4 -10.78 3.55E-64 -8.33 3.70E-197 
Clca1/Clca2 -8.43 0.00E+00 -9.07 0.00E+00 
CLCN5 -2.05 2.11E-14 -2.23 6.42E-29 
CLDN15 -7.43 7.24E-16 -13.13 6.83E-81 
CLU -3.74 1.29E-41 -4.26 3.52E-125 
CMKLR1 -3.11 4.13E-09 -4.86 9.74E-31 
CMYA5 -2.54 8.55E-04 -6.31 5.97E-17 
CNKSR3 -2.14 6.05E-16 -2.33 1.64E-42 
CNRIP1 -2.68 5.38E-07 -3.79 1.55E-13 
CPQ -2.15 1.02E-08 -3.24 2.05E-35 
CPXM1 -2.70 6.00E-62 -4.27 0.00E+00 
CRLF2 -2.01 2.67E-35 -2.14 1.05E-96 
CTSW -2.73 1.64E-34 -3.16 9.56E-108 
CXADR -2.19 1.39E-142 -2.24 9.35E-258 
Cyp2d22 -6.37 4.77E-18 -7.32 4.86E-34 
DAAM2 -3.12 5.53E-22 -5.94 4.24E-120 
DCN -2.27 3.28E-60 -4.06 0.00E+00 
DDC -2.38 1.02E-06 -2.39 2.66E-18 
DPEP1 -2.39 1.28E-05 -2.80 6.58E-12 
DPP4 -3.01 3.13E-44 -3.55 5.77E-101 
E130102H24Rik -2.30 7.94E-04 -3.76 3.34E-20 
EHD3 -5.39 4.36E-188 -9.14 0.00E+00 
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ELN -3.15 2.35E-49 -7.56 0.00E+00 
EMILIN1 -2.88 3.60E-43 -5.33 1.00E-150 
EN1 -2.61 1.82E-17 -2.16 1.75E-28 
ENTPD4 -2.06 4.54E-12 -2.14 2.08E-61 
EPS8 -2.45 1.75E-52 -2.26 3.56E-93 
EZR -2.10 6.37E-317 -2.02 0.00E+00 
F730043M19Rik -2.84 7.19E-08 -2.59 1.86E-17 
FADS6 -3.00 7.58E-05 -3.10 8.22E-07 
FAM110C -3.02 1.49E-57 -3.17 4.41E-134 
FAM163A -6.48 2.25E-04 -3.61 9.69E-06 
FAM163B -14.00 3.32E-04 -9.34 5.29E-17 
FAM176B -2.57 7.16E-100 -2.16 1.09E-129 
FAM180A -2.59 8.85E-52 -2.74 1.32E-194 
FGF2 -3.70 4.50E-22 -2.90 1.87E-38 
FGL2 -6.54 1.15E-06 -7.36 1.38E-14 
FIGF -2.29 8.85E-21 -2.50 7.65E-72 
FMOD -4.05 1.37E-283 -3.81 0.00E+00 
FOLR1 -2.14 6.43E-37 -2.66 3.79E-157 
GAS1 -2.57 5.06E-209 -2.47 0.00E+00 
GAS7 -2.45 1.68E-04 -4.76 3.11E-22 
GBP2 -42.01 9.01E-13 -118.62 2.28E-32 
GBX2 -2.33 5.87E-04 -3.28 4.25E-09 
GGCT -2.30 1.38E-12 -2.23 3.77E-30 
GGT5 -3.83 7.11E-31 -3.94 5.68E-64 
GLI1 -3.74 7.13E-08 -4.12 1.06E-13 
Gm2895 -5.20 4.23E-43 -4.16 1.17E-120 
Gm10389 -3.55 2.05E-16 -3.06 3.13E-31 
Gm10824 -2.81 4.24E-04 -3.81 1.44E-17 
Gm15506 -13.23 4.90E-07 -5.97 4.70E-10 
GMPR -2.13 5.49E-11 -2.97 9.92E-50 
GNAI1 -2.45 7.84E-12 -2.04 1.25E-11 
GPNMB -2.63 6.21E-27 -3.01 2.78E-61 
GPR88 -3.56 8.65E-04 -7.74 3.41E-19 
GPR153 -2.01 6.21E-08 -2.43 3.76E-17 
GPSM3 -2.02 2.78E-06 -2.09 4.07E-13 
Gsta4 -2.91 1.99E-15 -3.07 9.02E-32 
GUCY1A3 -15.45 7.90E-77 -20.06 5.52E-163 
H2-M2 -4.11 1.14E-04 -32.45 3.53E-54 
H2-Q10 -3.61 4.77E-160 -6.38 0.00E+00 
H3f3a/H3f3b -2.13 6.67E-223 -3.23 0.00E+00 
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H6PD -2.61 4.15E-69 -3.81 1.11E-262 
HAL -7.17 2.14E-36 -10.60 4.49E-159 
HDDC3 -8.03 7.63E-43 -6.68 1.29E-75 
HLA-B -10.83 0.00E+00 -23.04 0.00E+00 
HLA-DQB1 -3.38 1.72E-99 -3.19 3.13E-172 
HLX -3.01 3.92E-05 -4.35 1.71E-10 
HOXB2 -5.65 1.06E-17 -5.62 2.57E-31 
HOXB3 -5.11 1.46E-24 -7.00 4.29E-57 
HOXB4 -2.58 4.16E-12 -3.32 1.61E-25 
HOXD4 -2.11 3.07E-06 -2.07 5.52E-14 
HSD11B1 -14.39 1.02E-07 -12.20 6.58E-15 
ICAM5 -2.44 8.84E-05 -2.92 1.96E-11 
ID1 -4.04 2.31E-298 -5.44 0.00E+00 
ID3 -4.28 0.00E+00 -4.67 0.00E+00 
IGFBP4 -3.57 9.89E-86 -5.12 0.00E+00 
IGFBP6 -3.16 2.39E-21 -3.35 2.24E-62 
IGLON5 -3.82 5.66E-15 -7.86 6.24E-39 
IL13RA1 -2.06 1.75E-07 -2.39 7.35E-17 
IL1RL2 -2.72 7.93E-08 -4.79 1.28E-38 
IL4R -2.73 7.91E-69 -3.66 2.30E-209 
INPP5D -9.22 5.63E-14 -9.04 3.84E-37 
INPPL1 -2.25 2.09E-197 -2.44 0.00E+00 
ITGA7 -3.09 4.74E-74 -3.29 6.82E-129 
ITGBL1 -4.87 2.10E-19 -6.72 5.06E-48 
IVL -2.69 4.57E-26 -3.44 4.48E-84 
KCNT1 -2.38 1.96E-09 -2.65 2.22E-23 
KIAA1199 -2.59 2.18E-33 -3.93 3.29E-146 
KIAA1324L -6.80 3.72E-45 -9.25 6.07E-121 
KLHL30 -4.41 1.75E-57 -5.69 2.69E-182 
LCP1 -2.40 8.68E-15 -2.76 6.31E-42 
LPAR1 -2.46 5.52E-82 -3.31 0.00E+00 
LRRN4 -4.30 1.80E-214 -7.59 0.00E+00 
LRTM2 -13.61 2.90E-07 -10.10 1.72E-06 
LSP1 -2.08 2.46E-18 -3.28 8.55E-85 
MAF -2.05 5.85E-31 -2.20 2.37E-101 
MAN1C1 -2.12 7.78E-75 -2.28 1.93E-169 
MDM4 -2.14 5.21E-44 -2.03 4.85E-91 
MEGF6 -6.98 2.67E-166 -8.13 0.00E+00 
MFAP2 -2.35 6.83E-16 -3.95 1.09E-74 
MGP -80.95 0.00E+00 -114.50 0.00E+00 
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MGST1 -2.46 3.80E-90 -2.40 6.69E-152 
Mirg -2.02 4.21E-05 -2.92 4.34E-25 
MMP3 -5.60 5.26E-31 -14.46 1.67E-279 
MMP16 -2.38 1.20E-35 -2.40 9.76E-53 
MMP19 -2.14 5.31E-09 -3.29 2.57E-52 
MMRN2 -2.81 4.24E-04 -2.19 8.08E-06 
MOB4 -3.61 6.18E-34 -2.02 1.50E-43 
MPP1 -2.20 3.94E-43 -2.12 3.89E-71 
MSRB2 -2.13 4.66E-04 -2.48 2.35E-09 
MTSS1 -2.31 1.28E-22 -2.82 3.31E-81 
MTUS2 -3.05 1.97E-15 -4.99 1.22E-77 
MYLK3 -2.07 1.83E-07 -2.59 6.12E-19 
MYLK -2.44 3.11E-38 -2.45 3.33E-102 
NAPRT1 -2.88 1.23E-06 -2.96 2.26E-11 
NDRG1 -2.34 6.75E-82 -3.01 3.72E-266 
Neat1 -2.68 1.50E-40 -2.88 3.66E-90 
NEU3 -2.61 1.22E-28 -2.49 3.12E-44 
NID2 -3.04 0.00E+00 -2.94 0.00E+00 
NKD2 -2.79 4.65E-06 -3.81 5.61E-20 
NLRC3 -3.22 1.69E-41 -3.44 7.82E-97 
NPL -2.37 8.60E-05 -5.78 8.94E-30 
NPR1 -2.76 2.22E-35 -2.72 1.56E-70 
NR1H4 -2.84 1.73E-06 -4.37 6.11E-41 
NRGN -2.70 3.16E-04 -5.63 2.12E-26 
NUP210 -2.13 3.88E-10 -2.33 7.06E-19 
Nup62cl -6.13 4.69E-18 -5.05 8.15E-20 
NXPH1 -2.48 1.23E-16 -2.24 3.62E-47 
OLFML3 -2.01 3.53E-12 -4.51 4.94E-96 
OLR1 -5.22 3.79E-14 -5.99 5.85E-30 
OTUD7A -6.22 2.92E-06 -4.98 1.96E-12 
PCDH9 -3.09 3.25E-25 -2.52 2.54E-26 
PCDH10 -3.67 1.07E-43 -2.18 5.00E-24 
PCDH17 -14.68 4.09E-109 -14.50 4.93E-230 
PDE2A -7.49 5.24E-12 -8.23 2.05E-36 
PDE3A -14.00 3.32E-04 -18.93 4.23E-05 
PDGFRA -10.00 3.48E-72 -18.41 0.00E+00 
PDLIM4 -2.33 5.24E-07 -2.35 6.03E-18 
PDZD2 -5.10 9.12E-113 -14.51 6.70E-07 
PLEK -3.98 2.08E-05 -3.79 2.88E-07 
PLXNA4 -2.14 1.18E-36 -2.18 1.16E-67 
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PNLDC1 -6.51 3.37E-13 -9.61 1.31E-43 
PNMAL2 -15.56 2.08E-08 -14.51 1.13E-12 
PPM1N -2.50 3.43E-05 -3.15 4.23E-16 
PPP2R2B -3.93 4.84E-35 -4.30 2.56E-82 
PRPH -2.44 2.79E-09 -3.25 3.06E-19 
PRR15 -3.22 1.38E-16 -10.33 1.09E-135 
PRSS12 -6.83 2.74E-22 -5.08 2.60E-43 
PTN -4.57 1.08E-15 -2.68 5.10E-21 
PYCARD -4.67 3.95E-08 -10.58 1.83E-64 
RAB27B -2.04 1.22E-05 -4.44 2.53E-40 
RAB40B -2.27 8.42E-06 -2.01 6.17E-14 
RAB6B -2.19 5.66E-07 -4.24 1.66E-31 
RASL11A -3.48 2.90E-59 -3.72 2.91E-248 
RASL11B -2.40 5.90E-51 -2.65 2.37E-148 
RBM46 -7.26 5.35E-05 -3.53 2.61E-04 
RBM47 -2.70 1.20E-04 -2.37 6.16E-06 
Rcan2 -2.27 1.10E-20 -2.38 1.18E-41 
REC8 -5.06 4.99E-04 -7.89 3.95E-11 
RGS3 -3.30 7.66E-48 -4.08 1.75E-151 
RGS16 -2.51 1.67E-14 -3.41 3.99E-45 
RGS20 -5.45 2.90E-05 -22.72 3.68E-11 
RIMS1 -3.11 2.69E-04 -3.01 7.21E-07 
RORC -4.61 3.34E-09 -6.50 3.04E-31 
S100A4 -7.76 0.00E+00 -6.19 0.00E+00 
SAA2 -40.45 2.75E-12 -265.00 3.81E-73 
SCARB2 -2.59 0.00E+00 -2.62 0.00E+00 
SEMA5A -2.44 9.55E-06 -2.50 7.48E-09 
SEMA6D -3.06 1.42E-05 -10.10 5.15E-31 
SEPP1 -2.90 9.79E-12 -5.82 4.47E-69 
SERPINA3 -2.82 6.60E-18 -4.29 4.79E-92 
Serpina3k -19.45 7.87E-06 -6.31 3.87E-09 
Serpinb6b -24.12 1.79E-38 -38.04 3.49E-191 
SFRP1 -5.26 1.26E-119 -4.74 1.42E-216 
SFRP2 -2.77 4.27E-69 -3.28 5.04E-196 
SH2D5 -8.56 2.17E-09 -7.09 7.05E-15 
SLC39A4 -2.68 4.33E-13 -3.98 2.81E-40 
SLC43A3 -2.44 2.06E-221 -2.54 0.00E+00 
SLFN13 -2.62 5.51E-12 -4.99 6.32E-53 
SLIT3 -2.50 4.87E-88 -2.50 5.59E-113 
SMAD9 -5.71 3.62E-09 -3.55 1.80E-14 
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SMOC2 -4.87 2.07E-29 -5.86 4.82E-79 
SMPDL3A -3.33 8.36E-06 -4.30 2.12E-13 
SMTNL2 -3.11 4.19E-22 -3.18 2.70E-40 
SNCAIP -2.11 3.35E-09 -2.16 5.33E-25 
SNTG2 -3.76 4.38E-26 -2.24 9.90E-28 
SOD3 -6.50 1.65E-31 -5.71 1.60E-73 
SPP1 -6.81 7.78E-06 -5.75 4.92E-08 
SPRR2G -3.53 9.51E-07 -8.12 1.68E-106 
SPRY2 -2.04 1.21E-39 -2.34 8.12E-81 
ST3GAL1 -4.87 4.91E-42 -7.01 2.57E-170 
STAC -3.70 2.56E-09 -3.57 1.09E-17 
STAP2 -2.01 1.43E-05 -3.10 1.33E-20 
STBD1 -8.08 1.47E-178 -8.80 0.00E+00 
STEAP4 -9.18 2.99E-10 -13.88 3.13E-52 
SV2A -2.63 1.28E-08 -2.62 7.26E-13 
SVEP1 -4.57 8.96E-51 -4.68 9.85E-124 
SYNGR1 -3.36 1.17E-71 -2.26 5.87E-51 
SYNPO2 -2.43 1.80E-08 -5.42 1.75E-51 
TAF5 -2.44 2.63E-17 -13.00 0.00E+00 
TCF21 -4.28 2.11E-233 -5.23 0.00E+00 
TEK -5.08 3.84E-12 -7.53 3.41E-33 
TF -3.18 7.17E-71 -2.78 1.72E-135 
TGFBI -15.95 9.12E-24 -39.26 4.94E-170 
TGFBR3 -2.69 1.18E-31 -4.28 2.08E-149 
THRB -3.05 3.06E-08 -2.85 6.21E-20 
TLR4 -2.70 4.56E-05 -3.13 2.02E-13 
TMEM108 -2.21 1.43E-44 -2.19 2.98E-82 
TMEM215 -16.14 1.85E-16 -10.64 1.04E-40 
TMEM176B -2.02 5.57E-58 -2.12 2.19E-148 
TNC -4.29 0.00E+00 -6.69 0.00E+00 
TNIK -2.54 6.60E-17 -2.67 1.80E-35 
TNNT2 -5.00 0.00E+00 -5.24 0.00E+00 
TSPAN18 -4.18 1.90E-09 -3.00 3.64E-09 
UCP2 -3.84 0.00E+00 -5.40 0.00E+00 
VSTM2A -62.24 4.16E-19 -167.84 4.79E-46 
VTCN1 -7.78 2.03E-05 -4.12 3.65E-09 
WBSCR17 -2.76 1.46E-10 -2.00 3.49E-09 
XDH -2.83 7.08E-58 -3.43 1.83E-198 
ZFHX4 -11.28 6.56E-06 -19.35 1.56E-13 
ZNF575 -2.18 9.89E-06 -2.09 3.01E-10 
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ZNF608 -2.19 8.18E-12 -2.04 1.64E-19 
ZNF697 -2.04 4.53E-34 -2.14 4.32E-72 


























GENES >2-FOLD DYSREGULATED BETWEEN TGFBR3+/+ AND TGFBR3-/- 
























XIST 8672.44 0.00E+00 999.00 0.00E+00 
TSIX 1488.02 0.00E+00 999.00 3.64E-84 
9030619P08Rik 999.00 2.25E-17 999.00 2.34E-09 
CHST7 999.00 3.03E-04 999.00 8.94E-04 
Ly6a 999.00 6.56E-22 999.00 3.60E-05 
RIMS2 999.00 1.75E-41 999.00 4.42E-21 
Rprl2 999.00 3.62E-11 999.00 2.86E-37 
Rprl3 999.00 4.33E-18 188.45 4.85E-57 
CKM 999.00 7.73E-13 8.72 5.48E-06 
ALX4 122.35 1.13E-38 72.13 1.94E-21 
FGF10 32.24 8.58E-19 999.00 7.60E-07 
SYCE1 30.77 7.07E-18 40.57 6.59E-12 
CTNND2 24.91 3.12E-14 999.00 5.23E-06 
CSGALNACT1 24.32 7.02E-192 14.58 6.47E-59 
MFAP5 21.61 2.38E-23 4.96 3.45E-05 
RIPK4 17.22 1.61E-09 27.95 3.78E-08 
SYN2 16.85 1.48E-17 4.57 2.66E-09 
FZD10 16.49 4.47E-09 27.05 6.98E-08 
Usp44 16.12 7.43E-09 13.53 5.87E-04 
BCAT1 13.96 1.91E-126 9.34 2.89E-31 
PLD5 13.31 2.02E-19 28.85 2.05E-08 
CTHRC1 13.24 3.48E-124 24.13 2.09E-102 
COL9A2 12.46 8.70E-04 999.00 2.47E-04 
DSCAML1 12.46 1.66E-09 7.89 9.34E-07 
CRABP2 12.00 1.78E-93 9.39 1.18E-22 
PPP2R2C 11.58 7.73E-14 4.99 5.53E-10 
PVRL4 11.45 3.89E-21 8.84 2.06E-09 
MS4A10 10.91 3.97E-43 5.05 4.30E-08 
FAXC 10.91 3.21E-22 3.29 1.92E-05 
PCOLCE2 10.72 1.92E-19 9.92 5.90E-07 
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Xlr3c 10.47 4.52E-32 4.36 2.35E-04 
IL17RE 10.21 5.04E-31 16.83 9.50E-13 
LIMCH1 10.16 5.39E-117 15.07 2.33E-81 
TSHR 9.89 3.54E-05 9.02 1.73E-04 
CD80 9.77 2.72E-25 33.36 9.40E-10 
FAM134B 9.53 5.74E-05 8.57 3.02E-04 
DSP 9.46 2.53E-22 10.25 2.15E-23 
B4GALNT2 9.43 2.11E-73 9.92 1.67E-20 
Klra18 9.38 1.26E-29 999.00 2.75E-06 
NT5E 9.21 3.66E-14 6.01 6.92E-04 
Klra4 9.18 8.42E-29 999.00 2.75E-06 
GALNTL4 9.01 1.26E-31 10.37 1.58E-13 
LMO7 8.71 5.99E-172 8.85 4.15E-55 
IL6 8.48 1.00E-12 13.53 5.87E-04 
NKX2-8 8.37 8.45E-32 11.15 4.38E-26 
CYFIP2 8.36 1.46E-20 3.98 1.40E-06 
CUX2 8.33 4.70E-14 4.06 6.67E-05 
SEC14L5 8.30 6.32E-06 13.53 5.66E-07 
HS3ST6 8.14 3.54E-15 5.41 1.73E-10 
ALOX5 8.06 1.36E-22 4.96 1.53E-06 
WASF3 7.98 8.96E-15 4.06 6.67E-05 
PARM1 7.75 2.21E-51 5.26 6.45E-24 
NFATC1 7.64 5.62E-28 5.77 4.36E-14 
D730039F16Rik 7.64 8.29E-31 4.96 6.99E-08 
CKMT1A/CKMT1B 7.42 4.85E-12 15.63 1.01E-11 
RAI2 7.33 1.65E-10 4.85 2.48E-06 
TSPAN12 7.14 1.91E-11 5.86 1.09E-04 
RARRES2 7.10 7.85E-175 2.91 4.97E-16 
CNKSR1 6.89 3.12E-07 999.00 9.94E-06 
MAMDC2 6.89 2.42E-25 3.04 2.68E-05 
NPR2 6.84 1.23E-94 5.02 3.94E-54 
ANXA8L2  6.73 2.57E-264 9.73 2.85E-218 
EPB41L3 6.70 1.95E-17 2.71 4.25E-04 
CGREF1 6.69 5.50E-38 8.17 1.75E-27 
SPOCK2 6.69 1.46E-18 3.85 8.02E-06 
SERPINE2 6.60 1.51E-176 6.25 2.41E-121 
PIANP 6.59 7.79E-53 8.34 2.54E-19 
SH2D4A 6.55 2.27E-53 6.49 9.69E-17 
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HMHA1 6.46 2.97E-25 10.14 4.55E-25 
KLRG2 6.42 3.16E-28 3.25 5.09E-08 
POSTN 6.41 1.73E-05 16.23 9.95E-05 
ST14 6.41 9.42E-53 10.97 4.20E-54 
C19orf33 6.32 4.92E-194 8.15 1.61E-73 
MAB21L2 6.31 5.91E-15 5.14 2.64E-08 
BAI1 6.23 9.37E-18 10.14 3.84E-17 
KRT8 6.23 5.28E-28 4.13 2.69E-10 
P2RX3 6.07 6.62E-29 2.57 2.40E-09 
Plk5 6.04 4.24E-05 6.01 6.92E-04 
CST9L 6.02 1.07E-23 4.87 2.13E-04 
NIPAL4 5.97 1.86E-21 10.19 3.13E-21 
SNAI3 5.86 3.11E-16 5.94 5.22E-12 
SP9 5.79 1.63E-20 8.72 7.47E-35 
Tnfrsf26 5.74 1.39E-141 7.60 7.20E-38 
PPL 5.67 2.87E-31 5.10 2.06E-23 
PPP1R16B 5.66 5.47E-11 14.73 5.90E-11 
CTSC 5.62 9.75E-04 14.43 3.26E-04 
GJB3 5.62 2.32E-14 4.87 2.13E-04 
FLT1 5.55 3.77E-25 32.01 1.00E-17 
EXOC3L2 5.55 3.26E-07 3.01 3.55E-04 
ST6GAL1 5.50 4.32E-18 3.36 1.08E-04 
SVOP 5.47 3.52E-101 5.35 8.17E-44 
KCNC3 5.41 5.75E-25 13.93 1.70E-28 
AMN 5.32 3.02E-13 9.92 6.50E-09 
FGF5 5.29 8.33E-47 3.49 1.00E-06 
GRHL3 5.28 4.77E-24 5.07 9.35E-18 
SCN4B 5.22 2.04E-07 12.92 1.95E-09 
ACOT11 5.13 5.59E-20 5.30 6.79E-14 
ITGA6 5.05 2.07E-22 2.64 2.35E-14 
GNA15 5.01 2.96E-19 5.57 3.78E-10 
PTPRB 4.97 4.93E-14 12.77 1.73E-17 
PERP 4.95 8.39E-249 4.73 4.66E-121 
KIAA1467 4.93 7.46E-14 4.71 1.09E-06 
COL11A1 4.92 1.90E-50 3.53 5.78E-21 
WNT3 4.87 7.40E-11 8.42 2.14E-10 
NOG 4.86 8.86E-248 4.30 2.88E-139 
SRPX 4.81 0.00E+00 3.65 1.28E-61 
ANGPTL4 4.80 2.58E-13 61.31 3.71E-18 
MEIS3 4.80 3.14E-31 5.32 6.00E-17 
192 
 
Appendix H: Continued 























VNN1 4.79 1.02E-100 5.14 3.23E-56 
GAL3ST2 4.69 1.16E-07 7.94 3.16E-08 
HCK 4.68 5.61E-16 5.47 3.07E-12 
PRDM8 4.67 1.83E-11 4.16 1.56E-07 
EGFL8 4.64 6.04E-294 4.13 1.34E-21 
PEX5L 4.59 5.35E-13 3.94 1.61E-09 
FGFBP3 4.58 3.85E-51 5.91 5.43E-19 
SLC37A2 4.58 6.74E-21 5.19 3.80E-19 
Serpinb9b 4.51 5.11E-68 5.82 1.49E-18 
1700030C10Rik 4.42 7.60E-17 2.91 3.35E-04 
LRRC3 4.40 4.11E-08 3.81 6.94E-05 
TEX15 4.40 7.76E-10 3.23 1.05E-04 
MYH14 4.26 3.46E-07 2.95 9.20E-05 
DKKL1 4.25 1.31E-06 6.99 7.99E-06 
ANKS1B 4.24 1.36E-44 2.91 2.11E-16 
COL5A3 4.23 4.50E-15 3.76 5.32E-06 
MMP15 4.20 8.58E-73 6.83 3.91E-72 
Ces2f 4.18 7.98E-36 4.96 3.49E-13 
RLN1 4.15 2.90E-04 999.00 4.70E-04 
GPX3 4.13 5.09E-18 2.34 1.99E-05 
LEFTY2 4.09 8.85E-10 6.99 7.99E-06 
SHISA4 4.07 1.15E-305 2.42 1.09E-38 
PAK6 4.05 1.49E-11 3.95 3.09E-08 
SHANK2 4.05 1.24E-24 2.30 1.40E-07 
C9orf116 4.02 1.16E-158 3.27 9.07E-36 
WISP1 4.01 7.61E-193 6.96 3.03E-108 
PROS1 3.98 1.70E-49 3.44 1.25E-18 
FAM124A 3.91 3.95E-08 4.01 2.83E-05 
C1orf115 3.90 2.48E-46 2.57 8.40E-07 
STRA6 3.89 1.55E-08 3.10 1.80E-05 
Snhg9 3.87 4.67E-28 5.05 1.62E-11 
CEND1 3.86 3.64E-06 13.53 5.66E-07 
ENHO 3.85 9.28E-05 6.99 7.99E-06 
SH3YL1 3.85 4.71E-15 5.91 2.92E-09 
Fhod3 3.83 2.81E-38 4.01 4.39E-31 
RBM20 3.82 3.33E-19 5.86 4.95E-17 
SCN3B 3.81 1.05E-105 3.70 1.92E-47 
PID1 3.80 2.77E-17 3.25 5.08E-10 
TMSB10/TMSB4X 3.80 0.00E+00 2.57 0.00E+00 
SOX13 3.78 8.10E-07 4.73 4.02E-06 
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PDGFRL 3.78 2.04E-09 4.66 9.09E-05 
CPE 3.78 2.40E-192 3.42 4.36E-97 
NRN1 3.73 8.70E-19 4.67 8.04E-08 
PITPNM3 3.73 7.82E-06 4.12 1.58E-04 
A730035I17Rik 3.73 7.82E-06 3.38 9.48E-04 
PRDM6 3.70 1.07E-30 2.62 1.14E-08 
SLC7A3 3.68 2.45E-34 3.70 5.11E-12 
SERPINF1 3.66 2.18E-71 2.41 1.01E-17 
PLTP 3.62 0.00E+00 5.42 9.40E-322 
SLC17A9 3.61 7.95E-12 2.75 3.07E-05 
GPC4 3.60 4.66E-50 2.17 2.06E-28 
MREG 3.59 3.71E-31 3.06 1.58E-13 
MATN4 3.58 2.36E-22 12.62 1.43E-22 
ADRB3 3.57 1.31E-25 5.61 5.69E-20 
CORO2A 3.57 2.23E-18 5.02 8.73E-17 
CRIP1 3.53 0.00E+00 2.41 3.19E-118 
STOX2 3.51 1.25E-23 4.81 2.67E-16 
BFSP2 3.48 6.45E-14 3.43 3.56E-06 
REEP2 3.47 5.36E-56 4.20 2.40E-32 
CELF5 3.44 3.38E-69 2.32 1.82E-22 
TNFRSF18 3.37 1.57E-67 3.55 1.66E-39 
PDK4 3.37 2.41E-06 3.25 3.88E-04 
Bmyc 3.35 7.25E-65 3.93 2.71E-30 
REM1 3.35 1.15E-35 3.91 4.44E-05 
RPRM 3.35 1.09E-69 3.70 5.87E-35 
PSTPIP1 3.35 8.58E-74 3.15 1.78E-32 
ANGPTL2 3.32 1.32E-30 2.71 3.77E-20 
5830418P13Rik 3.30 6.62E-23 2.68 1.45E-08 
PITPNC1 3.30 1.96E-39 2.61 9.79E-13 
SLC29A4 3.29 7.09E-12 2.66 1.58E-04 
P2RX7 3.27 2.62E-39 5.62 1.87E-39 
ANKRD35 3.26 1.96E-10 4.06 8.95E-07 
LTBP1 3.26 7.07E-79 3.88 1.95E-30 
ABCG1 3.24 1.43E-11 4.61 3.50E-11 
C13orf33 3.24 2.23E-45 2.54 1.89E-07 
MMP10 3.21 1.38E-08 8.42 9.51E-06 
DCXR 3.21 6.36E-219 2.51 1.76E-72 
RASGRP3 3.20 2.88E-11 3.20 2.48E-04 
PLEK2 3.20 8.06E-27 3.10 7.17E-08 
CTSH 3.17 3.96E-28 3.83 7.50E-08 
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CCBE1 3.17 2.20E-62 2.20 1.84E-09 
PTPRVP 3.16 2.58E-71 2.75 1.79E-43 
RAP1GAP2 3.13 2.13E-04 3.25 3.88E-04 
SIGLEC10 3.12 1.01E-29 2.98 1.50E-07 
ARHGAP24 3.12 1.91E-12 2.31 2.22E-04 
Nppb 3.09 1.13E-16 7.21 4.69E-06 
ANKRD1 3.04 2.05E-174 12.87 1.44E-207 
RPL22L1 3.04 2.23E-149 4.10 1.38E-17 
PRRG4 3.04 2.37E-63 3.25 2.45E-21 
SERPINB9 3.03 4.21E-130 2.36 6.82E-13 
FSTL3 3.01 2.77E-06 2.64 9.72E-04 
UCHL1 2.99 1.29E-116 5.72 3.16E-47 
DES 2.99 5.24E-45 3.95 3.03E-36 
ATG9B 2.98 6.72E-42 5.15 7.89E-42 
C16orf89 2.98 9.53E-16 4.15 1.85E-08 
LTB4R 2.98 1.37E-59 3.12 6.90E-26 
PDIA5 2.94 5.16E-98 2.50 1.46E-27 
KCNJ4 2.93 3.01E-08 4.21 4.50E-13 
Apol10a 2.92 1.84E-23 5.71 2.23E-16 
SP6 2.91 7.61E-10 3.35 7.93E-08 
LMOD1 2.90 2.01E-12 4.09 2.92E-08 
PVRL1 2.90 9.58E-35 2.30 5.17E-12 
CD109 2.87 9.87E-167 2.64 5.72E-35 
VWA7 2.87 2.01E-16 2.60 1.05E-08 
HPRT1 2.84 3.42E-235 2.46 1.13E-44 
Ugt1a7c 2.82 7.42E-101 3.54 1.24E-41 
UGT1A6 2.81 1.33E-80 3.19 1.18E-30 
CDKL2 2.81 1.73E-18 2.75 3.07E-05 
FAM212B 2.81 1.39E-131 2.69 4.89E-51 
COL18A1 2.80 9.81E-125 5.14 1.08E-144 
HLA-DRB1 2.80 6.10E-222 3.32 1.95E-145 
CYBA 2.80 9.65E-160 2.89 5.46E-31 
1700003M07Rik 2.79 2.35E-14 4.43 3.30E-07 
DLX2 2.79 2.71E-19 2.84 1.11E-09 
PRKAA2 2.79 2.77E-16 2.67 1.17E-06 
FAM129C 2.78 1.54E-04 4.25 9.94E-05 
SLC2A9 2.78 3.81E-16 2.96 6.28E-08 
CA12 2.78 8.19E-15 2.71 5.25E-07 
UGT1A4 2.77 2.87E-64 3.71 2.31E-33 
UGT1A9 2.77 2.87E-64 3.70 3.55E-33 
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UGT1A1 2.77 1.64E-64 3.64 8.80E-33 
UGT1A3 2.77 1.11E-64 3.54 1.14E-31 
FAM26E 2.74 2.14E-04 4.33 9.00E-04 
SCUBE3 2.74 5.88E-13 3.00 3.28E-13 
MDM2 2.72 0.00E+00 2.39 0.00E+00 
SCXA/SCXB 2.71 1.95E-12 2.32 5.06E-07 
NDUFA13 2.70 0.00E+00 2.86 5.67E-136 
9530053A07Rik 2.69 3.85E-23 5.70 1.21E-19 
EVPL 2.69 5.22E-13 2.88 1.72E-11 
TM4SF1 2.67 9.81E-113 3.22 2.02E-27 
WNT11 2.65 6.30E-82 4.29 1.60E-66 
HEBP2 2.65 7.76E-66 2.62 1.31E-18 
ABCB1 2.63 7.70E-06 3.80 6.29E-07 
CCND1 2.63 0.00E+00 2.75 3.95E-124 
VAMP5 2.63 1.16E-80 2.47 3.18E-22 
DAPK2 2.62 6.77E-08 4.91 4.15E-07 
EIF2S3 2.61 1.25E-138 3.48 9.19E-47 
PRR7 2.61 1.76E-20 2.71 1.76E-09 
Ces2e 2.60 1.68E-211 3.19 2.56E-122 
NDUFC2 2.60 0.00E+00 2.04 1.57E-41 
FBXO25 2.60 1.13E-115 2.01 1.56E-17 
MESP2 2.58 3.11E-08 5.27 7.89E-11 
TMEM37 2.58 4.63E-28 3.78 5.06E-14 
NTN4 2.57 6.49E-12 3.31 2.82E-11 
ARHGEF4 2.57 2.02E-09 3.23 3.41E-12 
ITGB4 2.54 1.75E-126 5.04 1.61E-212 
Peg12 2.53 3.39E-08 3.41 3.97E-04 
ACPP 2.52 9.33E-07 3.85 8.02E-06 
CTH 2.52 4.25E-14 3.83 7.50E-08 
INHBA 2.52 1.23E-39 3.52 6.85E-25 
P4HA3 2.52 4.06E-07 2.95 1.89E-06 
SDC1 2.52 5.91E-230 2.62 2.22E-95 
TMEM125 2.50 1.26E-06 5.59 2.91E-05 
NDUFB6 2.50 3.60E-280 3.38 1.12E-81 
Miat 2.49 6.18E-08 8.12 1.65E-05 
GFRA2 2.49 2.90E-06 3.13 2.79E-05 
COX6B2 2.49 3.72E-237 2.17 1.66E-53 
2900026A02Rik 2.49 2.25E-81 2.08 1.77E-23 
GLCE 2.48 1.09E-15 2.59 5.63E-04 
HMCN2 2.47 2.09E-10 2.39 5.97E-06 
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VCAN 2.46 4.35E-07 2.86 3.53E-05 
SYTL1 2.46 8.36E-27 2.45 2.25E-15 
Ifi27l1 2.46 1.47E-303 2.10 1.57E-57 
DUSP15 2.45 7.57E-13 2.57 5.55E-08 
CYP1B1 2.44 5.39E-181 3.01 3.83E-58 
Pmaip1 2.44 9.21E-164 2.90 2.13E-49 
Snhg8 2.42 9.54E-236 2.22 2.84E-26 
Snora24 2.42 1.16E-235 2.22 1.24E-26 
SPR 2.41 1.56E-64 2.21 7.41E-19 
SAPCD1 2.40 6.15E-04 4.77 1.50E-05 
LAMC2 2.40 4.71E-11 3.61 1.19E-09 
CXXC4 2.39 1.15E-04 5.64 1.82E-04 
HYAL1 2.39 1.66E-86 3.28 1.42E-73 
DGKA 2.39 3.50E-57 2.65 2.59E-41 
AKR1B1 2.38 1.55E-74 2.61 5.55E-32 
Gm6644 2.38 1.55E-74 2.61 5.55E-32 
VAT1L 2.38 1.34E-13 2.29 1.98E-04 
B4GALNT1 2.37 1.27E-05 4.41 4.48E-06 
PLCXD2 2.36 7.76E-27 2.73 4.60E-18 
HTRA1 2.36 1.75E-141 2.38 5.00E-70 
GLDC 2.36 7.49E-18 2.21 7.48E-09 
B230344G16Rik 2.35 1.75E-11 5.75 2.57E-28 
PPP2R3C 2.35 2.37E-73 2.09 5.80E-08 
RPS2 2.34 0.00E+00 3.82 0.00E+00 
Rps28 2.34 3.76E-296 2.47 4.26E-71 
RPS29 2.34 1.49E-294 2.45 3.25E-68 
INHBB 2.33 1.24E-18 3.84 1.76E-31 
LTB4R2 2.32 4.51E-54 3.43 2.96E-52 
FKBP1B 2.32 1.48E-08 2.55 4.94E-05 
SCN1B 2.32 2.18E-44 2.42 3.53E-37 
MMP2 2.32 0.00E+00 2.15 1.06E-301 
FAM115C 2.31 8.86E-24 2.94 5.53E-12 
IMMP1L 2.31 5.82E-16 2.83 3.14E-04 
GDF15 2.30 7.57E-08 4.90 2.48E-10 
9230114K14Rik 2.29 7.82E-48 2.23 2.79E-06 
FBXW9 2.28 2.41E-182 2.76 2.60E-87 
POLR3K 2.28 2.26E-106 2.43 2.79E-27 
MGLL 2.28 6.25E-159 2.18 9.43E-45 
TTLL9 2.27 3.03E-05 4.24 3.07E-06 
FAM132B 2.26 1.80E-22 3.56 4.21E-33 
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ITGB1 2.25 0.00E+00 2.22 6.25E-231 
NDUFA1 2.25 1.00E-271 2.21 3.71E-44 
ATP5E 2.24 0.00E+00 3.18 1.10E-78 
LGALS1 2.24 0.00E+00 2.07 0.00E+00 
SDC3 2.23 4.84E-04 6.61 2.43E-04 
CDO1 2.23 2.01E-34 3.62 7.55E-29 
MTHFS 2.23 8.68E-27 2.39 2.25E-06 
CDC42BPG 2.23 6.33E-173 2.30 1.66E-106 
METRNL 2.23 3.83E-162 2.08 1.08E-38 
TSPAN8 2.22 6.97E-05 10.37 3.19E-05 
CILP2 2.22 3.06E-05 3.68 8.25E-06 
LINC00493 2.22 6.66E-23 3.28 7.81E-08 
NOTCH3 2.22 1.24E-43 2.45 4.68E-49 
PLEKHN1 2.22 4.50E-21 2.41 3.93E-12 
1110038B12Rik 2.22 1.29E-152 2.40 1.99E-26 
PMEPA1 2.19 3.22E-117 2.16 1.56E-70 
PET100 2.18 2.68E-81 2.05 1.27E-13 
Gm10393 2.17 3.34E-139 3.86 1.18E-80 
TRIB3 2.17 1.88E-94 3.30 1.15E-31 
ARF6 2.16 6.29E-47 3.70 9.77E-42 
C15orf59 2.16 1.39E-12 3.63 1.89E-13 
4932441J04Rik 2.16 2.59E-14 2.28 9.36E-04 
MRPS14 2.16 1.04E-112 2.12 6.86E-22 
DHRS9 2.15 3.74E-16 2.45 5.21E-06 
GLIPR2 2.15 7.15E-81 2.19 3.36E-20 
ORAOV1 2.15 1.15E-81 2.19 1.42E-23 
EFNA3 2.14 3.01E-05 4.66 6.06E-12 
TRIM7 2.14 8.20E-16 2.67 8.67E-16 
EFS 2.14 8.52E-19 2.45 9.17E-14 
DRD4 2.13 1.00E-07 2.71 6.97E-05 
PIGF 2.13 3.87E-50 2.47 3.02E-19 
COX17 2.13 1.95E-145 2.46 2.40E-42 
CHD5 2.12 2.57E-06 3.61 1.19E-09 
PLCD4 2.12 2.72E-04 2.42 5.96E-04 
AIF1L 2.11 5.39E-42 4.35 4.00E-62 
ATP5I 2.11 9.75E-121 2.15 7.79E-24 
ISG15 2.10 0.00E+00 3.62 0.00E+00 
NAT6 2.10 9.75E-58 2.80 6.45E-50 
FAM176C 2.10 1.29E-05 2.52 6.95E-06 
PTGR1 2.10 2.13E-48 2.24 6.94E-12 
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DYNLT3 2.10 9.77E-117 2.21 3.44E-23 
TMEFF2 2.10 5.68E-20 2.19 1.47E-09 
CDH26 2.09 1.69E-05 4.77 1.50E-05 
SLC25A40 2.09 1.03E-21 2.08 3.21E-07 
COX6A2 2.08 3.25E-06 35.16 2.73E-10 
LEFTY1 2.08 6.78E-11 3.74 1.75E-09 
SERPINI1 2.08 2.65E-04 3.70 4.57E-05 
PI4K2B 2.08 2.04E-26 2.95 3.71E-20 
HSDL2 2.08 2.29E-28 2.40 9.25E-12 
WNT9A 2.07 6.01E-61 2.60 9.10E-57 
CDKN2A 2.06 0.00E+00 2.69 0.00E+00 
TPD52 2.06 2.88E-45 2.40 2.04E-20 
SIVA1 2.05 9.31E-118 2.18 3.33E-42 
ACER3 2.03 9.71E-38 2.72 1.01E-14 
GLRX5 2.02 2.19E-23 2.73 2.14E-34 
KANK3 2.01 2.03E-23 2.77 2.27E-27 
ITGB5 2.00 4.20E-50 2.60 5.18E-65 
RPS18 2.00 1.63E-93 2.31 2.84E-58 
BTBD6 -2.01 4.66E-07 -2.18 1.62E-15 
ATXN7L1 -2.01 3.05E-08 -2.33 1.51E-22 
SARDH -2.02 5.09E-22 -2.32 1.61E-54 
FMNL1 -2.03 5.94E-04 -2.18 1.64E-12 
SSFA2 -2.03 4.64E-32 -2.22 3.98E-62 
Clca1/Clca2 -2.03 9.02E-07 -2.60 0.00E+00 
INPPL1 -2.04 9.46E-181 -2.62 0.00E+00 
HSPA1A/HSPA1B -2.04 3.18E-28 -5.16 0.00E+00 
STXBP6 -2.05 6.08E-05 -2.18 1.21E-21 
SEMA3E -2.05 1.81E-04 -2.31 4.71E-17 
MDK -2.05 4.40E-06 -2.53 9.30E-20 
OSGIN1 -2.06 4.49E-12 -3.09 1.71E-94 
NOD1 -2.08 9.01E-40 -2.01 8.49E-76 
SPEF1 -2.09 3.04E-04 -2.61 4.74E-20 
RNF39 -2.10 1.17E-04 -2.18 5.99E-18 
IL1R1 -2.10 7.01E-27 -2.39 2.41E-108 
SAA2 -2.10 4.45E-07 -2.90 7.66E-66 
LAYN -2.11 1.22E-05 -2.58 3.67E-25 
ALDH1A2 -2.11 1.54E-05 -2.62 4.37E-20 
CLU -2.11 1.02E-16 -2.96 1.12E-128 
INPP5A -2.13 1.02E-21 -2.51 3.07E-54 
FLI1 -2.15 4.81E-15 -2.19 7.67E-53 
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ENTPD4 -2.15 7.90E-24 -2.25 1.42E-68 
S1PR3 -2.15 1.35E-11 -2.74 4.97E-69 
ATP1B1 -2.16 6.81E-279 -2.10 0.00E+00 
SLC48A1 -2.18 2.65E-94 -2.40 0.00E+00 
Ifi204 -2.18 2.77E-14 -2.69 8.05E-82 
NRP2 -2.18 2.17E-37 -3.00 3.50E-210 
CNKSR3 -2.19 1.64E-23 -2.39 6.65E-65 
TRIB1 -2.20 2.31E-17 -2.41 2.22E-57 
ABCC10 -2.20 6.30E-15 -2.80 6.75E-46 
FDXR -2.22 3.14E-14 -2.10 9.28E-36 
CHD6 -2.22 7.53E-05 -2.28 4.99E-08 
NPR1 -2.22 1.24E-10 -2.75 8.62E-29 
EPAS1 -2.22 3.17E-09 -2.95 1.31E-30 
ZFP36L2 -2.23 7.76E-51 -2.81 1.89E-262 
GCLC -2.23 1.10E-10 -3.17 1.72E-44 
MKI67 -2.24 2.74E-143 -2.54 0.00E+00 
HDDC3 -2.24 1.92E-06 -2.79 9.75E-32 
ST3GAL1 -2.25 3.25E-121 -2.33 0.00E+00 
DENND4B -2.26 1.03E-07 -2.02 2.97E-10 
A730090H04Rik -2.26 7.39E-04 -2.11 1.12E-09 
9930014A18Rik -2.27 3.99E-41 -2.06 2.25E-115 
NXPH1 -2.27 8.83E-06 -2.34 5.11E-13 
H6PD -2.27 6.01E-73 -2.67 4.60E-253 
PTGS1 -2.28 7.25E-67 -2.01 4.57E-141 
PRKCB -2.29 9.48E-05 -3.46 2.07E-16 
ANXA11 -2.29 1.18E-06 -3.78 1.24E-22 
CENPF -2.32 8.11E-25 -2.09 4.82E-44 
RAPGEFL1 -2.34 1.70E-04 -2.02 2.64E-06 
GCLM -2.34 4.46E-28 -2.54 1.31E-70 
TMEM173 -2.34 1.00E-28 -3.63 1.53E-229 
FAM84A -2.35 7.43E-70 -2.60 0.00E+00 
STK11IP -2.36 4.24E-08 -2.21 1.74E-22 
TUBA4A -2.36 9.51E-18 -4.31 2.63E-174 
CPQ -2.37 1.93E-11 -2.09 7.06E-22 
Gbp6 -2.39 9.16E-04 -2.21 1.58E-09 
SLFN13 -2.39 3.21E-06 -3.42 5.12E-62 
TULP4 -2.41 1.74E-06 -2.08 2.35E-07 
SERPING1 -2.42 7.22E-227 -3.34 0.00E+00 
RGS16 -2.42 5.20E-10 -4.35 5.85E-79 
BBS1 -2.43 1.66E-05 -2.32 4.78E-11 
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AMOT -2.44 4.87E-15 -2.35 2.89E-30 
Hist1h2af -2.46 8.09E-58 -5.06 0.00E+00 
GPR146 -2.48 7.22E-11 -3.19 1.25E-43 
HOXD4 -2.49 8.52E-16 -2.01 6.18E-33 
Mocs1 -2.49 4.50E-26 -2.27 4.35E-74 
HIST1H2AD -2.49 9.45E-61 -2.63 1.02E-97 
NETO2 -2.49 4.81E-15 -2.99 4.77E-66 
ABHD15 -2.50 4.16E-04 -9.10 1.22E-05 
NRIP1 -2.53 5.32E-30 -2.10 4.52E-27 
SYNE2 -2.54 6.49E-300 -2.06 5.83E-236 
RCOR2 -2.54 1.99E-07 -2.71 1.55E-14 
PTPRZ1 -2.54 1.61E-22 -3.06 1.25E-81 
MATN2 -2.55 2.29E-12 -2.53 1.60E-34 
SLC16A5 -2.55 8.13E-06 -2.66 1.17E-15 
MT1H -2.56 2.90E-08 -12.82 0.00E+00 
IDUA -2.58 1.68E-07 -3.00 1.41E-21 
NLGN2 -2.59 6.80E-79 -2.03 1.09E-116 
C030034L19Rik -2.59 5.44E-06 -2.12 1.13E-06 
MAOA -2.62 9.83E-82 -2.31 1.95E-251 
FOXP2 -2.63 1.53E-06 -2.10 4.29E-08 
IGSF3 -2.64 4.15E-30 -3.19 1.52E-147 
ELMO1 -2.67 5.09E-05 -2.93 2.16E-13 
STEAP4 -2.67 1.33E-09 -3.47 1.58E-55 
EMILIN1 -2.67 1.27E-29 -3.57 6.90E-115 
H2-T3-like -2.68 3.71E-04 -8.50 1.38E-18 
SLC43A3 -2.71 3.12E-112 -2.12 1.66E-177 
USP25 -2.71 4.72E-06 -3.26 1.02E-07 
CNIH2 -2.73 5.90E-06 -2.33 4.37E-08 
NR4A1 -2.74 2.28E-33 -2.03 8.95E-36 
ZNF503 -2.74 5.24E-33 -3.55 2.23E-120 
RANBP17 -2.77 2.92E-07 -2.08 2.43E-10 
BDH1 -2.77 1.26E-04 -2.29 8.93E-09 
SRRM4 -2.77 8.50E-13 -2.32 8.04E-25 
HIST1H2AB -2.77 2.22E-62 -3.91 1.03E-214 
SPSB1 -2.82 4.68E-54 -2.49 2.47E-101 
CCNO -2.82 9.31E-04 -4.53 9.49E-21 
SHANK3 -2.83 2.26E-08 -2.38 7.99E-10 
CCDC8 -2.89 4.84E-06 -2.73 2.56E-08 
ADAM33 -2.90 5.26E-17 -3.73 8.32E-53 
PDGFRA -2.91 7.86E-82 -2.94 0.00E+00 
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EIF4G3 -2.93 3.65E-185 -2.37 8.56E-262 
XDH -2.93 1.96E-262 -3.17 0.00E+00 
MERTK -2.93 4.65E-47 -3.99 2.61E-173 
HIST2H2AC -2.97 3.13E-25 -2.01 4.32E-11 
EHD3 -2.97 0.00E+00 -3.09 0.00E+00 
BCL3 -2.98 5.90E-38 -2.25 1.58E-50 
FAM13C -2.99 1.51E-53 -2.06 9.08E-45 
C3 -3.00 2.00E-153 -2.76 1.80E-233 
HIVEP3 -3.02 5.89E-54 -2.57 1.04E-88 
GBP5 -3.03 1.01E-04 -4.17 9.38E-17 
ARHGAP32 -3.04 5.53E-90 -2.53 9.95E-128 
PKDCC -3.04 5.43E-23 -3.13 5.24E-63 
EGR2 -3.05 4.73E-04 -2.65 5.21E-09 
SH3PXD2B -3.07 5.75E-41 -2.22 8.81E-59 
SEMA6D -3.07 3.13E-51 -2.41 2.60E-66 
FXYD1 -3.07 2.42E-04 -2.45 6.98E-14 
GSTT1 -3.07 1.85E-11 -2.81 1.44E-25 
LIN7A -3.14 8.76E-06 -2.60 1.95E-11 
GSTM5 -3.18 4.70E-44 -4.04 3.15E-208 
B3GALT1 -3.19 2.07E-05 -2.03 5.03E-07 
ACTN3 -3.19 6.50E-14 -3.77 6.35E-37 
H2-T3 -3.19 2.07E-05 -9.03 3.78E-20 
MYLK -3.23 2.25E-155 -2.71 1.23E-313 
APOE -3.26 1.35E-154 -7.83 0.00E+00 
RORC -3.27 7.53E-18 -2.52 7.73E-31 
ANTXR1 -3.30 4.49E-95 -2.12 2.44E-89 
FAM110C -3.31 7.91E-138 -2.77 5.16E-233 
NDRG1 -3.33 1.61E-134 -2.37 1.08E-205 
ZFP36 -3.33 1.20E-120 -2.83 1.58E-229 
ARHGEF3 -3.38 5.11E-08 -2.70 2.45E-14 
SUSD2 -3.39 3.67E-12 -3.62 6.44E-34 
HCN4 -3.40 3.38E-10 -3.14 1.23E-26 
SLC2A13 -3.43 1.17E-07 -3.16 1.86E-11 
STBD1 -3.43 4.97E-24 -5.11 8.38E-146 
MPP6 -3.44 2.07E-13 -2.24 1.79E-11 
CABLES1 -3.44 2.25E-07 -2.98 5.68E-09 
BICC1 -3.45 0.00E+00 -2.68 0.00E+00 
SCD -3.51 1.28E-81 -2.13 6.54E-85 
E130310I04Rik -3.51 5.08E-17 -3.95 8.37E-40 
AVPR1A -3.52 2.46E-35 -2.96 2.04E-104 
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SEPP1 -3.64 2.43E-43 -2.85 1.03E-84 
FOSB -3.64 1.69E-08 -5.19 5.09E-41 
PYCARD -3.66 1.02E-04 -3.48 3.41E-13 
H2-Q10 -3.66 8.02E-112 -7.13 6.33E-320 
CHRDL1 -3.67 8.46E-06 -2.55 6.83E-11 
ZKSCAN2 -3.74 3.91E-04 -2.43 4.70E-04 
HLF -3.74 4.37E-07 -2.49 4.52E-07 
F730043M19Rik -3.74 3.91E-04 -4.10 5.73E-19 
CISH -3.75 2.48E-19 -3.45 2.72E-40 
DAAM2 -3.79 2.10E-24 -3.45 2.16E-63 
HIST1H2BB -3.83 6.21E-31 -2.99 1.32E-06 
KALRN -3.88 2.82E-90 -4.30 5.71E-124 
PRPH -3.92 2.65E-93 -5.77 2.09E-200 
SFRP1 -3.93 8.76E-68 -2.34 6.95E-50 
AUTS2 -3.93 1.80E-62 -3.12 1.19E-103 
CACNA1A -3.93 7.51E-11 -3.48 8.15E-24 
NRXN2 -3.94 7.18E-05 -5.14 3.27E-26 
PLEKHA6 -3.95 2.40E-102 -4.58 1.36E-09 
TGM1 -3.99 1.84E-07 -3.05 4.00E-12 
PPARGC1B -4.01 4.60E-12 -2.23 2.95E-08 
KIAA1324L -4.05 6.50E-29 -3.78 5.96E-53 
GGT5 -4.05 9.62E-10 -4.82 3.39E-25 
TGFBI -4.05 2.09E-26 -8.26 3.05E-256 
RTN1 -4.11 7.43E-83 -2.69 2.46E-101 
LGALS2 -4.11 9.78E-12 -2.85 2.26E-32 
C1orf226 -4.13 5.15E-33 -3.30 4.54E-50 
SEZ6L -4.15 3.16E-13 -6.42 1.21E-35 
FADS6 -4.16 1.75E-15 -2.83 9.72E-38 
MGP -4.17 0.00E+00 -3.59 0.00E+00 
BMP4 -4.19 1.41E-210 -2.05 1.54E-159 
PEG10 -4.19 6.07E-26 -2.20 5.40E-14 
ACVR1B -4.23 8.78E-41 -4.28 5.08E-109 
PGAM2 -4.25 2.07E-12 -2.38 2.72E-14 
CAPN6 -4.25 1.21E-09 -3.60 9.50E-14 
RASSF4 -4.29 2.30E-08 -3.78 5.09E-23 
ALPL -4.31 1.49E-05 -2.91 1.10E-05 
PCDHAC2 -4.35 7.36E-14 -2.63 1.29E-17 
CDH23 -4.44 3.07E-04 -2.55 1.92E-04 
IL1RL2 -4.53 1.52E-07 -6.47 2.39E-34 
Rpph1 -4.63 0.00E+00 -4.29 1.40E-134 
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CNRIP1 -4.64 5.70E-16 -3.06 1.08E-30 
ELN -4.64 8.26E-277 -5.44 0.00E+00 
RASL11A -4.67 4.28E-242 -3.17 0.00E+00 
GUCY1A3 -4.68 3.58E-101 -3.78 2.02E-265 
TNC -4.68 0.00E+00 -4.23 0.00E+00 
TGM2 -4.69 0.00E+00 -2.55 0.00E+00 
PDZD2 -4.71 5.15E-08 -2.42 2.73E-106 
IL16 -4.74 1.65E-07 -17.50 7.75E-40 
TMEM196 -4.77 5.28E-07 -3.25 1.64E-13 
PDE3A -4.99 5.84E-05 -5.87 8.33E-09 
GSTA3 -5.02 2.70E-40 -3.22 2.21E-83 
PLEK -5.08 5.67E-09 -3.32 3.56E-17 
HLA-B -5.16 2.31E-27 -15.05 0.00E+00 
TEK -5.25 3.49E-24 -5.41 6.34E-51 
9430069I07Rik -5.27 6.40E-04 -4.29 2.76E-04 
LRP3 -5.27 6.40E-04 -8.19 1.22E-12 
CADM1 -5.29 6.76E-77 -3.58 1.15E-196 
HIST1H1A -5.32 1.47E-18 -5.83 1.80E-09 
NOS1AP -5.49 2.81E-30 -3.96 9.59E-34 
TRPS1 -5.55 1.05E-05 -2.37 4.19E-05 
GALNT14 -5.55 3.58E-04 -2.91 3.84E-04 
TMTC1 -5.65 1.05E-09 -3.03 1.31E-13 
MGAT3 -5.73 7.81E-48 -3.16 2.20E-59 
H19 -5.80 6.44E-114 -2.34 6.61E-153 
HIST2H3C -5.88 7.99E-50 -2.61 2.80E-119 
ZNF521 -5.89 4.98E-87 -3.00 3.16E-64 
RHOBTB1 -6.17 2.05E-29 -2.90 1.46E-30 
FAM189A2 -6.18 1.79E-07 -6.14 8.17E-16 
BMF -6.19 2.85E-24 -4.64 9.18E-57 
Cyp2d22 -6.33 6.42E-17 -5.67 6.96E-33 
TPBGL -6.43 9.75E-11 -5.29 1.44E-30 
UCP2 -6.44 3.70E-241 -9.12 0.00E+00 
LINGO1 -6.51 8.46E-53 -12.31 9.98E-308 
ITGB8 -6.52 5.39E-09 -3.43 1.19E-13 
USH1G -6.84 1.67E-07 -6.82 1.16E-14 
HAS1 -6.91 5.07E-15 -2.32 7.97E-06 
HOXB4 -7.02 4.85E-11 -4.39 1.04E-19 
IGFBP5 -7.17 8.84E-47 -2.42 1.28E-43 
CMYA5 -7.21 2.64E-10 -3.26 1.02E-07 
DOCK10 -7.21 1.45E-12 -8.87 2.85E-18 
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PDE2A -7.21 9.76E-06 -12.28 1.65E-23 
HOXB3 -7.27 1.44E-11 -6.68 4.18E-36 
CLDN15 -7.31 1.28E-68 -3.91 1.84E-142 
CFI -7.54 2.73E-07 -3.64 7.07E-08 
PIEZO2 -7.76 2.83E-06 -3.33 1.95E-05 
HOXB2 -7.76 6.37E-19 -7.53 2.56E-56 
A930033H14Rik -8.32 6.14E-04 -3.04 5.91E-06 
SLC39A4 -8.40 3.45E-11 -5.85 4.50E-22 
Pdlim3 -8.65 1.20E-08 -8.19 2.27E-31 
AR -8.87 3.23E-04 -28.66 1.64E-07 
FGL2 -9.00 2.35E-15 -11.08 9.65E-84 
CDH13 -9.02 8.70E-25 -8.40 7.48E-43 
TGFBR3 -9.27 2.19E-114 -6.44 8.81E-258 
SOSTDC1 -9.43 1.69E-04 -6.14 5.21E-19 
2410017I17Rik -9.45 5.24E-43 -7.73 9.94E-77 
IGLON5 -10.60 5.59E-19 -2.87 7.63E-18 
SLC16A2 -10.87 1.91E-11 -5.89 7.33E-18 
SYNPO2 -10.91 8.45E-26 -8.47 5.57E-72 
SLC40A1 -11.65 1.22E-05 -2.03 3.73E-08 
AQP1 -11.65 1.22E-05 -9.73 3.27E-14 
ALDOC -11.73 3.29E-160 -8.03 0.00E+00 
8030451A03Rik -12.20 6.29E-06 -5.69 1.52E-05 
Serpinb6b -12.31 2.44E-25 -5.80 1.65E-86 
ACSS3 -12.57 1.20E-08 -5.96 6.79E-16 
PRR15 -13.31 1.64E-46 -6.44 1.46E-182 
BC023719 -13.31 3.15E-09 -9.04 1.62E-24 
9530082P21Rik -13.31 1.64E-06 -18.56 3.50E-20 
NR4A3 -14.42 4.85E-04 -13.06 3.48E-18 
NPAS4 -15.53 2.45E-04 -2.92 1.61E-05 
FAM19A2 -16.08 5.50E-08 -2.31 1.15E-05 
2610507I01Rik -16.08 5.50E-08 -8.44 9.01E-16 
PCDH17 -16.35 3.48E-191 -8.56 8.82E-241 
TSHZ3 -17.75 6.15E-05 -31.39 3.17E-08 
HLX -19.96 7.72E-37 -11.56 1.79E-70 
Dcaf12l1 -22.18 3.77E-06 -4.10 1.91E-06 
FMO2 -23.29 1.86E-06 -6.11 1.81E-16 
GBP2 -28.17 8.79E-35 -22.03 2.31E-66 
VSTM2A -31.05 1.30E-08 -45.32 5.80E-55 
TMEM215 -32.16 7.89E-17 -21.08 5.39E-41 
SORBS2 -39.56 6.58E-31 -30.57 5.13E-104 
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PNLDC1 -48.80 1.29E-13 -8.12 7.73E-25 
STC1 -64.70 2.53E-52 -18.02 0.00E+00 



























Ackerman, K. G., B. J. Herron, et al. (2005). "Fog2 is required for normal 
diaphragm and lung development in mice and humans." PLoS Genet 1(1): 
58-65. 
 
Aikawa, E., P. Whittaker, et al. (2006). "Human semilunar cardiac valve 
remodeling by activated cells from fetus to adult: implications for postnatal 
adaptation, pathology, and tissue engineering." Circulation 113(10): 1344-
52. 
 
Akiyama, H., M. C. Chaboissier, et al. (2004). "Essential role of Sox9 in the 
pathway that controls formation of cardiac valves and septa." Proc Natl 
Acad Sci U S A 101(17): 6502-7. 
Alfieri, C. M., J. Cheek, et al. (2010). "Wnt signaling in heart valve development 
and osteogenic gene induction." Dev Biol 338(2): 127-35. 
Andres, J. L., D. DeFalcis, et al. (1992). "Binding of two growth factor families to 
separate domains of the proteoglycan betaglycan." J Biol Chem 267(9): 
5927-30. 
Angel, P. M., D. Nusinow, et al. "Networked-based Characterization of 
Extracellular Matrix Proteins from Adult Mouse Pulmonary and Aortic 
Valves." J Proteome Res. 
Araki, T., M. G. Mohi, et al. (2004). "Mouse model of Noonan syndrome reveals 
cell type- and gene dosage-dependent effects of Ptpn11 mutation." Nat 
Med 10(8): 849-57. 
Attar, M. A., J. C. Salem, et al. (2012). "CNK3 and IPCEF1 produce a single 
protein that is required for HGF dependent Arf6 activation and migration." 
Exp Cell Res 318(3): 228-37. 
Audic, S. and J. M. Claverie (1997). "The significance of digital gene expression 
profiles." Genome Res 7(10): 986-95. 
Austin, A. F., L. A. Compton, et al. (2008). "Primary and immortalized mouse 
epicardial cells undergo differentiation in response to TGFbeta." 
Developmental dynamics : an official publication of the American 
Association of Anatomists 237(2): 366-76. 
Azhar, M., R. B. Runyan, et al. (2009). "Ligand-specific function of transforming 
growth factor beta in epithelial-mesenchymal transition in heart 
development." Dev Dyn 238(2): 431-42. 
Baldwin, H. S. and M. Solursh (1989). "Degradation of hyaluronic acid does not 
prevent looping of the mammalian heart in situ." Dev Biol 136(2): 555-9. 
207 
 
Barnett, J. V. and J. S. Desgrosellier (2003). "Early events in valvulogenesis: a 
signaling perspective." Birth Defects Res C Embryo Today 69(1): 58-72. 
Bartram, U., D. G. Molin, et al. (2001). "Double-outlet right ventricle and 
overriding tricuspid valve reflect disturbances of looping, 
myocardialization, endocardial cushion differentiation, and apoptosis in 
TGF-beta(2)-knockout mice." Circulation 103(22): 2745-52. 
Beg, A. A., W. C. Sha, et al. (1995). "Embryonic lethality and liver degeneration 
in mice lacking the RelA component of NF-kappa B." Nature 376(6536): 
167-70. 
Beppu, H., R. Malhotra, et al. (2009). "BMP type II receptor regulates positioning 
of outflow tract and remodeling of atrioventricular cushion during 
cardiogenesis." Dev Biol 331(2): 167-75. 
Bernanke, D. H. and R. R. Markwald (1982). "Migratory behavior of cardiac 
cushion tissue cells in a collagen-lattice culture system." Dev Biol 91(2): 
235-45. 
Blobe, G. C., X. Liu, et al. (2001). "A novel mechanism for regulating 
transforming growth factor beta (TGF-beta) signaling. Functional 
modulation of type III TGF-beta receptor expression through interaction 
with the PDZ domain protein, GIPC." J Biol Chem 276(43): 39608-17. 
Blobe, G. C., W. P. Schiemann, et al. (2001). "Functional roles for the 
cytoplasmic domain of the type III transforming growth factor beta receptor 
in regulating transforming growth factor beta signaling." J Biol Chem 
276(27): 24627-37. 
Bochmann, L., P. Sarathchandra, et al. (2010). "Revealing new mouse epicardial 
cell markers through transcriptomics." PLoS One 5(6): e11429. 
Brown, C. B., A. S. Boyer, et al. (1996). "Antibodies to the Type II TGFbeta 
receptor block cell activation and migration during atrioventricular cushion 
transformation in the heart." Dev Biol 174(2): 248-57. 
Brown, C. B., A. S. Boyer, et al. (1999). "Requirement of type III TGF-beta 
receptor for endocardial cell transformation in the heart." Science 
283(5410): 2080-2. 
Brutsaert, D. L., G. W. De Keulenaer, et al. (1996). "The cardiac endothelium: 
functional morphology, development, and physiology." Prog Cardiovasc 
Dis 39(3): 239-62. 
Buermans, H. P., B. van Wijk, et al. (2010). "Comprehensive gene-expression 
survey identifies wif1 as a modulator of cardiomyocyte differentiation." 
PLoS One 5(12): e15504. 
208 
 
Burke, J. R., M. A. Pattoli, et al. (2003). "BMS-345541 is a highly selective 
inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme 
and blocks NF-kappa B-dependent transcription in mice." J Biol Chem 
278(3): 1450-6. 
Butcher, J. T. and R. R. Markwald (2007). "Valvulogenesis: the moving target." 
Philos Trans R Soc Lond B Biol Sci 362(1484): 1489-503. 
Butcher, J. T., R. A. Norris, et al. (2007). "Periostin promotes atrioventricular 
mesenchyme matrix invasion and remodeling mediated by integrin 
signaling through Rho/PI 3-kinase." Dev Biol 302(1): 256-66. 
Cai, C. L., J. C. Martin, et al. (2008). "A myocardial lineage derives from Tbx18 
epicardial cells." Nature 454(7200): 104-8. 
Camenisch, T. D., D. G. Molin, et al. (2002). "Temporal and distinct TGFbeta 
ligand requirements during mouse and avian endocardial cushion 
morphogenesis." Dev Biol 248(1): 170-81. 
Camenisch, T. D., J. A. Schroeder, et al. (2002). "Heart-valve mesenchyme 
formation is dependent on hyaluronan-augmented activation of ErbB2-
ErbB3 receptors." Nat Med 8(8): 850-5. 
Camenisch, T. D., A. P. Spicer, et al. (2000). "Disruption of hyaluronan synthase-
2 abrogates normal cardiac morphogenesis and hyaluronan-mediated 
transformation of epithelium to mesenchyme." J Clin Invest 106(3): 349-
60. 
Capdevila, J., T. Tsukui, et al. (1999). "Control of vertebrate limb outgrowth by 
the proximal factor Meis2 and distal antagonism of BMPs by Gremlin." Mol 
Cell 4(5): 839-49. 
Chakraborty, S., J. Cheek, et al. (2008). "Shared gene expression profiles in 
developing heart valves and osteoblast progenitor cells." Physiol 
Genomics 35(1): 75-85. 
Chan-Thomas, P. S., R. P. Thompson, et al. (1993). "Expression of homeobox 
genes Msx-1 (Hox-7) and Msx-2 (Hox-8) during cardiac development in 
the chick." Dev Dyn 197(3): 203-16. 
Cheifetz, S., T. Bellon, et al. (1992). "Endoglin is a component of the 
transforming growth factor-beta receptor system in human endothelial 
cells." J Biol Chem 267(27): 19027-30. 
Chen, B., R. T. Bronson, et al. (2000). "Mice mutant for Egfr and Shp2 have 
defective cardiac semilunar valvulogenesis." Nat Genet 24(3): 296-9. 
Chen, Y. H., M. Ishii, et al. (2008). "Msx1 and Msx2 are required for endothelial-
mesenchymal transformation of the atrioventricular cushions and 
patterning of the atrioventricular myocardium." BMC Dev Biol 8: 75. 
209 
 
Chen, Z. F. and R. R. Behringer (1995). "twist is required in head mesenchyme 
for cranial neural tube morphogenesis." Genes Dev 9(6): 686-99. 
Christiaen, L., A. Stolfi, et al. (2010). "BMP signaling coordinates gene 
expression and cell migration during precardiac mesoderm development." 
Developmental biology 340(2): 179-87. 
Christodoulou, D. C., J. M. Gorham, et al. (2011). "Construction of normalized 
RNA-seq libraries for next-generation sequencing using the crab duplex-
specific nuclease." Curr Protoc Mol Biol Chapter 4: Unit4 12. 
Christodoulou, D. C., J. M. Gorham, et al. (2011). "Quantification of gene 
transcripts with deep sequencing analysis of gene expression (DSAGE) 
using 1 to 2 microg total RNA." Current protocols in molecular biology / 
edited by Frederick M. Ausubel ... [et al.] Chapter 25: Unit25B 9. 
Christoffels, V. M., T. Grieskamp, et al. (2009). "Tbx18 and the fate of epicardial 
progenitors." Nature 458(7240): E8-9; discussion E9-10. 
Cole, W. C. and D. G. Welsh (2011). "Role of myosin light chain kinase and 
myosin light chain phosphatase in the resistance arterial myogenic 
response to intravascular pressure." Arch Biochem Biophys 510(2): 160-
73. 
Combs, M. D. and K. E. Yutzey (2009). "Heart valve development: regulatory 
networks in development and disease." Circ Res 105(5): 408-21. 
Compton, L. A., D. A. Potash, et al. (2007). "Coronary vessel development is 
dependent on the type III transforming growth factor beta receptor." Circ 
Res 101(8): 784-91. 
Compton, L. A., D. A. Potash, et al. (2006). "Transforming growth factor-beta 
induces loss of epithelial character and smooth muscle cell differentiation 
in epicardial cells." Dev Dyn 235(1): 82-93. 
Connolly, H. M., J. L. Crary, et al. (1997). "Valvular heart disease associated with 
fenfluramine-phentermine." N Engl J Med 337(9): 581-8. 
Conway, S. J., D. J. Henderson, et al. (1997). "Pax3 is required for cardiac neural 
crest migration in the mouse: evidence from the splotch (Sp2H) mutant." 
Development 124(2): 505-14. 
Craig, E. A., A. F. Austin, et al. (2010). "TGFbeta2-mediated production of 
hyaluronan is important for the induction of epicardial cell differentiation 
and invasion." Exp Cell Res 316(20): 3397-405. 
Craig, E. A., P. Parker, et al. (2010). "Involvement of the MEKK1 signaling 
pathway in the regulation of epicardial cell behavior by hyaluronan." Cell 
Signal 22(6): 968-76. 
210 
 
Craig, E. A., P. Parker, et al. (2009). "Size-dependent regulation of Snail2 by 
hyaluronan: its role in cellular invasion." Glycobiology 19(8): 890-8. 
Criswell, T. L. and C. L. Arteaga (2007). "Modulation of NFkappaB activity and E-
cadherin by the type III transforming growth factor beta receptor regulates 
cell growth and motility." J Biol Chem 282(44): 32491-500. 
Criswell, T. L., N. Dumont, et al. (2008). "Knockdown of the transforming growth 
factor-beta type III receptor impairs motility and invasion of metastatic 
cancer cells." Cancer research 68(18): 7304-12. 
Cross, N. A., S. Chandrasekharan, et al. (2005). "The expression and regulation 
of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate 
cells: relevance to the accumulation of versican." Prostate 63(3): 269-75. 
de la Pompa, J. L., L. A. Timmerman, et al. (1998). "Role of the NF-ATc 
transcription factor in morphogenesis of cardiac valves and septum." 
Nature 392(6672): 182-6. 
del Monte, G., J. C. Casanova, et al. (2007). "Differential Notch signaling in the 
epicardium is required for cardiac inflow development and coronary vessel 
morphogenesis." Circulation research 108(7): 824-36. 
del Monte, G., J. Grego-Bessa, et al. (2007). "Monitoring Notch1 activity in 
development: evidence for a feedback regulatory loop." Dev Dyn 236(9): 
2594-614. 
DeLaughter, D. M., L. Saint-Jean, et al. (2011). "What chick and mouse models 
have taught us about the role of the endocardium in congenital heart 
disease." Birth Defects Res A Clin Mol Teratol 91(6): 511-25. 
Dennis, G., Jr., B. T. Sherman, et al. (2003). "DAVID: Database for Annotation, 
Visualization, and Integrated Discovery." Genome Biol 4(5): P3. 
DeRuiter, M. C., R. E. Poelmann, et al. (1992). "The development of the 
myocardium and endocardium in mouse embryos. Fusion of two heart 
tubes?" Anat Embryol (Berl) 185(5): 461-73. 
Derynck, R. and Y. E. Zhang (2003). "Smad-dependent and Smad-independent 
pathways in TGF-beta family signalling." Nature 425(6958): 577-84. 
Desgrosellier, J. S., N. A. Mundell, et al. (2005). "Activin receptor-like kinase 2 
and Smad6 regulate epithelial-mesenchymal transformation during cardiac 
valve formation." Dev Biol 280(1): 201-10. 
Dettman, R. W., W. Denetclaw, Jr., et al. (1998). "Common epicardial origin of 
coronary vascular smooth muscle, perivascular fibroblasts, and 
intermyocardial fibroblasts in the avian heart." Dev Biol 193(2): 169-81. 
211 
 
Dewulf, N., K. Verschueren, et al. (1995). "Distinct spatial and temporal 
expression patterns of two type I receptors for bone morphogenetic 
proteins during mouse embryogenesis." Endocrinology 136(6): 2652-63. 
Dickson, M. C., H. G. Slager, et al. (1993). "RNA and protein localisations of TGF 
beta 2 in the early mouse embryo suggest an involvement in cardiac 
development." Development 117(2): 625-39. 
Doetschman T, B. J., Runyan R, Camenisch TD, Heimark RL, Granzier HL, 
Conway SJ, Azhar A (2012). "Transforming growth factor beta signaling in 
adult cardiovascular diseases and repair." Cell and tissue research 347(2): 
539-548. 
Dupuis, L. E., D. R. McCulloch, et al. (2011). "Altered versican cleavage in 
ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease." 
Developmental biology 357(1): 152-64. 
Enard, W. (2011). "FOXP2 and the role of cortico-basal ganglia circuits in speech 
and language evolution." Curr Opin Neurobiol 21(3): 415-24. 
Enciso, J. M., D. Gratzinger, et al. (2003). "Elevated glucose inhibits VEGF-A-
mediated endocardial cushion formation: modulation by PECAM-1 and 
MMP-2." J Cell Biol 160(4): 605-15. 
Erickson, S. L., K. S. O'Shea, et al. (1997). "ErbB3 is required for normal 
cerebellar and cardiac development: a comparison with ErbB2-and 
heregulin-deficient mice." Development 124(24): 4999-5011. 
Ernkvist, M., N. Luna Persson, et al. (2009). "The Amot/Patj/Syx signaling 
complex spatially controls RhoA GTPase activity in migrating endothelial 
cells." Blood 113(1): 244-53. 
Fraidenraich, D., E. Stillwell, et al. (2004). "Rescue of cardiac defects in id 
knockout embryos by injection of embryonic stem cells." Science 
306(5694): 247-52. 
French, C. A., M. Groszer, et al. (2007). "Generation of mice with a conditional 
Foxp2 null allele." Genesis 45(7): 440-6. 
Frieden, L., Townsend, TA, Vaught, D, DeLaughter, D., Hwang, Y, Barnett, JV, 
Chen, J. (2010). "Regulation of heart valve morphogenesis by Eph 
receptor ligand, ephrin-A1. ." Developmental Dynamics in press. 
Galvin, K. M., M. J. Donovan, et al. (2000). "A role for smad6 in development and 
homeostasis of the cardiovascular system." Nat Genet 24(2): 171-4. 
Garg, V., A. N. Muth, et al. (2005). "Mutations in NOTCH1 cause aortic valve 
disease." Nature 437(7056): 270-4. 
212 
 
Gassmann, M., F. Casagranda, et al. (1995). "Aberrant neural and cardiac 
development in mice lacking the ErbB4 neuregulin receptor." Nature 
378(6555): 390-4. 
Gelb, B. D. and M. Tartaglia (2006). "Noonan syndrome and related disorders: 
Dysregulated RAS-mitogen activated protein kinase signal transduction." 
Hum Mol Genet 15 Spec No 2: R220-6. 
Gitler, A. D., Y. Zhu, et al. (2003). "Nf1 has an essential role in endothelial cells." 
Nat Genet 33(1): 75-9. 
Gittenberger-de Groot, A. C., M. P. Vrancken Peeters, et al. (1998). "Epicardium-
derived cells contribute a novel population to the myocardial wall and the 
atrioventricular cushions." Circ Res 82(10): 1043-52. 
Gittenberger-de Groot, A. C., E. M. Winter, et al. (2010). "Epicardium-derived 
cells (EPDCs) in development, cardiac disease and repair of ischemia." 
Journal of cellular and molecular medicine 14(5): 1056-60. 
Go, A. S., D. Mozaffarian, et al. (2013). "Heart disease and stroke statistics--
2013 update: a report from the American Heart Association." Circulation 
127(1): e6-e245. 
Gonzalez-Iriarte, M., R. Carmona, et al. (2003). "Development of the coronary 
arteries in a murine model of transposition of great arteries." J Mol Cell 
Cardiol 35(7): 795-802. 
Gordon, J. W., J. A. Shaw, et al. (2011). "Multiple facets of NF-kappaB in the 
heart: to be or not to NF-kappaB." Circ Res 108(9): 1122-32. 
Goumans, M. J., G. Valdimarsdottir, et al. (2003). "Activin receptor-like kinase 
(ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling." 
Mol Cell 12(4): 817-28. 
Goumans, M. J., G. Valdimarsdottir, et al. (2002). "Balancing the activation state 
of the endothelium via two distinct TGF-beta type I receptors." Embo J 
21(7): 1743-53. 
Greulich, F., C. Rudat, et al. "Mechanisms of T-box gene function in the 
developing heart." Cardiovasc Res 91(2): 212-22. 
Grieskamp, T., C. Rudat, et al. (2011). "Notch signaling regulates smooth muscle 
differentiation of epicardium-derived cells." Circulation research 108(7): 
813-23. 
Hamburger, V. and H. L. Hamilton (1951). "A series of normal stages in 
development of the chick embryo." Journal of Morphology 88(1): 49-92. 
213 
 
Han, L. and A. I. Gotlieb (2011). "Fibroblast growth factor-2 promotes in vitro 
mitral valve interstitial cell repair through transforming growth factor-
beta/Smad signaling." Am J Pathol 178(1): 119-27. 
Hartnett, L., C. Glynn, et al. (2010). "Insulin-like growth factor-2 regulates early 
neural and cardiovascular system development in zebrafish embryos." Int 
J Dev Biol 54(4): 573-83. 
Hauser, M. (2005). "Congenital anomalies of the coronary arteries." Heart 91(9): 
1240-5. 
Hill, C. R., N. S. Sanchez, et al. (2012). "BMP2 signals loss of epithelial character 
in epicardial cells but requires the Type III TGFbeta receptor to promote 
invasion." Cellular signalling 24(5): 1012-22. 
Hinton, R. B., Jr., J. Lincoln, et al. (2006). "Extracellular matrix remodeling and 
organization in developing and diseased aortic valves." Circ Res 98(11): 
1431-8. 
Hoffman, J. I. (1968). "Natural history of congenital heart disease. Problems in its 
assessment with special reference to ventricular septal defects." 
Circulation 37(1): 97-125. 
Hurle, J. M. and E. Colvee (1983). "Changes in the endothelial morphology of the 
developing semilunar heart valves. A TEM and SEM study in the chick." 
Anat Embryol (Berl) 167(1): 67-83. 
Hurle, J. M., E. Colvee, et al. (1980). "Development of mouse semilunar valves." 
Anat Embryol (Berl) 160(1): 83-91. 
Hurlstone, A. F., A. P. Haramis, et al. (2003). "The Wnt/beta-catenin pathway 
regulates cardiac valve formation." Nature 425(6958): 633-7. 
Inai, K., R. A. Norris, et al. (2008). "BMP-2 induces cell migration and periostin 
expression during atrioventricular valvulogenesis." Dev Biol 315(2): 383-
96. 
Ishii, Y., R. J. Garriock, et al. (2010). "BMP signals promote proepicardial 
protrusion necessary for recruitment of coronary vessel and epicardial 
progenitors to the heart." Dev Cell 19(2): 307-16. 
Iwamoto, R., S. Yamazaki, et al. (2003). "Heparin-binding EGF-like growth factor 
and ErbB signaling is essential for heart function." Proc Natl Acad Sci U S 
A 100(6): 3221-6. 
Jackson, L. F., T. H. Qiu, et al. (2003). "Defective valvulogenesis in HB-EGF and 




Jain, R., K. A. Engleka, et al. "Cardiac neural crest orchestrates remodeling and 
functional maturation of mouse semilunar valves." J Clin Invest 121(1): 
422-30. 
Jen, Y., K. Manova, et al. (1996). "Expression patterns of Id1, Id2, and Id3 are 
highly related but distinct from that of Id4 during mouse embryogenesis." 
Dev Dyn 207(3): 235-52. 
Jiao, K., M. Langworthy, et al. (2006). "Tgfbeta signaling is required for 
atrioventricular cushion mesenchyme remodeling during in vivo cardiac 
development." Development 133(22): 4585-93. 
Kaartinen, V., J. W. Voncken, et al. (1995). "Abnormal lung development and 
cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-
mesenchymal interaction." Nat Genet 11(4): 415-21. 
Kalluri, R. (2009). "EMT: when epithelial cells decide to become mesenchymal-
like cells." The Journal of clinical investigation 119(6): 1417-9. 
Kalluri, R. and R. A. Weinberg (2009). "The basics of epithelial-mesenchymal 
transition." The Journal of clinical investigation 119(6): 1420-8. 
Kalman, F., S. Viragh, et al. (1995). "Cell surface glycoconjugates and the 
extracellular matrix of the developing mouse embryo epicardium." Anat 
Embryol (Berl) 191(5): 451-64. 
Kamm, K. E. and J. T. Stull (2001). "Dedicated myosin light chain kinases with 
diverse cellular functions." J Biol Chem 276(7): 4527-30. 
Katz, T. C., M. K. Singh, et al. (2012). "Distinct compartments of the proepicardial 
organ give rise to coronary vascular endothelial cells." Dev Cell 22(3): 
639-50. 
Kawagoe, T., S. Sato, et al. (2008). "Sequential control of Toll-like receptor-
dependent responses by IRAK1 and IRAK2." Nat Immunol 9(6): 684-91. 
Kern, C. B., W. O. Twal, et al. (2006). "Proteolytic cleavage of versican during 
cardiac cushion morphogenesis." Developmental dynamics : an official 
publication of the American Association of Anatomists 235(8): 2238-47. 
Kern, C. B., W. O. Twal, et al. (2006). "Proteolytic cleavage of versican during 
cardiac cushion morphogenesis." Dev Dyn 235(8): 2238-47. 
Keyes, W. M., C. Logan, et al. (2003). "Expression and function of bone 
morphogenetic proteins in the development of the embryonic endocardial 
cushions." Anat Embryol (Berl) 207(2): 135-47. 
Khairy, P., J. A. Hosn, et al. (2008). "Multicenter research in adult congenital 
heart disease." International journal of cardiology 129(2): 155-9. 
215 
 
Kikuchi, K., V. Gupta, et al. (2011). "tcf21+ epicardial cells adopt non-myocardial 
fates during zebrafish heart development and regeneration." Development 
138(14): 2895-902. 
Kirkbride, K. C., T. A. Townsend, et al. (2008). "Bone morphogenetic proteins 
signal through the transforming growth factor-beta type III receptor." J Biol 
Chem 283(12): 7628-37. 
Kitamura, K., H. Miura, et al. (1999). "Mouse Pitx2 deficiency leads to anomalies 
of the ventral body wall, heart, extra- and periocular mesoderm and right 
pulmonary isomerism." Development 126(24): 5749-58. 
Komiyama, M., K. Ito, et al. (1987). "Origin and development of the epicardium in 
the mouse embryo." Anat Embryol (Berl) 176(2): 183-9. 
Kramer, R., N. Bucay, et al. (1996). "Neuregulins with an Ig-like domain are 
essential for mouse myocardial and neuronal development." Proc Natl 
Acad Sci U S A 93(10): 4833-8. 
Kraus, F., B. Haenig, et al. (2001). "Cloning and expression analysis of the 
mouse T-box gene Tbx20." Mechanisms of Development 100(1): 87-91. 
Kretzschmar, M. and J. Massague (1998). "SMADs: mediators and regulators of 
TGF-beta signaling." Curr Opin Genet Dev 8(1): 103-11. 
Krishnamurthy, V. K., A. M. Opoka, et al. (2012). "Maladaptive matrix remodeling 
and regional biomechanical dysfunction in a mouse model of aortic valve 
disease." Matrix Biol 31(3): 197-205. 
Krug, E. L., C. H. Mjaatvedt, et al. (1987). "Extracellular matrix from embryonic 
myocardium elicits an early morphogenetic event in cardiac endothelial 
differentiation." Dev Biol 120(2): 348-55. 
Kruithof, B. P., B. van Wijk, et al. (2006). "BMP and FGF regulate the 
differentiation of multipotential pericardial mesoderm into the myocardial 
or epicardial lineage." Developmental biology 295(2): 507-22. 
Kruzynska-Frejtag, A., M. Machnicki, et al. (2001). "Periostin (an osteoblast-
specific factor) is expressed within the embryonic mouse heart during 
valve formation." Mech Dev 103(1-2): 183-8. 
Kwee, L., H. S. Baldwin, et al. (1995). "Defective development of the embryonic 
and extraembryonic circulatory systems in vascular cell adhesion 
molecule (VCAM-1) deficient mice." Development 121(2): 489-503. 
Lai, Y. T., K. B. Beason, et al. (2000). "Activin receptor-like kinase 2 can mediate 
atrioventricular cushion transformation." Dev Biol 222(1): 1-11. 
216 
 
Lakkis, M. M. and J. A. Epstein (1998). "Neurofibromin modulation of ras activity 
is required for normal endocardial-mesenchymal transformation in the 
developing heart." Development 125(22): 4359-67. 
Lampugnani, M. G., M. Resnati, et al. (1992). "A Novel Endothelial-Specific 
Membrane-Protein Is a Marker of Cell Cell Contacts." Journal of Cell 
Biology 118(6): 1511-1522. 
Lavine, K. J. and D. M. Ornitz (2009). "Shared circuitry: developmental signaling 
cascades regulate both embryonic and adult coronary vasculature." 
Circulation research 104(2): 159-69. 
Lebrin, F., M. J. Goumans, et al. (2004). "Endoglin promotes endothelial cell 
proliferation and TGF-beta/ALK1 signal transduction." Embo J 23(20): 
4018-28. 
Lee, J. G. and E. P. Kay (2012). "NF-kappaB is the transcription factor for FGF-2 
that causes endothelial mesenchymal transformation in cornea." Invest 
Ophthalmol Vis Sci 53(3): 1530-8. 
Lee, M. P. and K. E. Yutzey (2011). "Twist1 directly regulates genes that promote 
cell proliferation and migration in developing heart valves." PLoS One 
6(12): e29758. 
Lee, N. Y., B. Ray, et al. (2008). "Endoglin promotes transforming growth factor 
beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration 
through its association with GIPC." J Biol Chem 283(47): 32527-33. 
Lencinas, A., A. L. Tavares, et al. (2012). "Collagen gel analysis of epithelial-
mesenchymal transition in the embryo heart: an in vitro model system for 
the analysis of tissue interaction, signal transduction, and environmental 
effects." Birth Defects Res C Embryo Today 93(4): 298-311. 
Lepilina, A., A. N. Coon, et al. (2006). "A dynamic epicardial injury response 
supports progenitor cell activity during zebrafish heart regeneration." Cell 
127(3): 607-19. 
Lewis, E. F., L. A. Moye, et al. (2003). "Predictors of late development of heart 
failure in stable survivors of myocardial infarction: the CARE study." 
Journal of the American College of Cardiology 42(8): 1446-53. 
Li, S., J. Weidenfeld, et al. (2004). "Transcriptional and DNA binding activity of 
the Foxp1/2/4 family is modulated by heterotypic and homotypic protein 
interactions." Mol Cell Biol 24(2): 809-22. 
Li, S., D. Zhou, et al. (2004). "Advanced cardiac morphogenesis does not require 
heart tube fusion." Science 305(5690): 1619-22. 
Li, S. W., D. J. Prockop, et al. (1995). "Transgenic mice with targeted inactivation 
of the Col2 alpha 1 gene for collagen II develop a skeleton with 
217 
 
membranous and periosteal bone but no endochondral bone." Genes Dev 
9(22): 2821-30. 
Lie-Venema, H., I. Eralp, et al. (2008). "Periostin expression by epicardium-
derived cells is involved in the development of the atrioventricular valves 
and fibrous heart skeleton." Differentiation 76(7): 809-19. 
Liebner, S., A. Cattelino, et al. (2004). "Beta-catenin is required for endothelial-
mesenchymal transformation during heart cushion development in the 
mouse." J Cell Biol 166(3): 359-67. 
Lim, J. and J. P. Thiery (2012). "Epithelial-mesenchymal transitions: insights from 
development." Development 139(19): 3471-86. 
Lim, S., E. Bae, et al. (2012). "TRAF6 mediates IL-1beta/LPS-induced 
suppression of TGF-beta signaling through its interaction with the type III 
TGF-beta receptor." PLoS One 7(3): e32705. 
Limana, F., M. C. Capogrossi, et al. (2011). "The epicardium in cardiac repair: 
from the stem cell view." Pharmacology & therapeutics 129(1): 82-96. 
Limana, F., A. Zacheo, et al. (2007). "Identification of myocardial and vascular 
precursor cells in human and mouse epicardium." Circulation research 
101(12): 1255-65. 
Lin, A. E., P. H. Birch, et al. (2000). "Cardiovascular malformations and other 
cardiovascular abnormalities in neurofibromatosis 1." Am J Med Genet 
95(2): 108-17. 
Lin, Y. Z., S. Y. Yao, et al. (1995). "Inhibition of nuclear translocation of 
transcription factor NF-kappa B by a synthetic peptide containing a cell 
membrane-permeable motif and nuclear localization sequence." J Biol 
Chem 270(24): 14255-8. 
Lincoln, J., R. Kist, et al. (2007). "Sox9 is required for precursor cell expansion 
and extracellular matrix organization during mouse heart valve 
development." Dev Biol 305(1): 120-32. 
Lloyd-Jones, D., R. J. Adams, et al. (2010). "Executive summary: heart disease 
and stroke statistics--2010 update: a report from the American Heart 
Association." Circulation 121(7): 948-54. 
Lockhart, M., E. Wirrig, et al. (2011). "Extracellular matrix and heart 
development." Birth Defects Res A Clin Mol Teratol 91(6): 535-50. 
Loffredo, C. A. (2000). "Epidemiology of cardiovascular malformations: 
prevalence and risk factors." Am J Med Genet 97(4): 319-25. 
218 
 
Loomes, K. M., D. B. Taichman, et al. (2002). "Characterization of Notch receptor 
expression in the developing mammalian heart and liver." Am J Med 
Genet 112(2): 181-9. 
Lopez-Casillas, F., S. Cheifetz, et al. (1991). "Structure and expression of the 
membrane proteoglycan betaglycan, a component of the TGF-beta 
receptor system." Cell 67(4): 785-95. 
Lopez-Casillas, F., J. L. Wrana, et al. (1993). "Betaglycan presents ligand to the 
TGF beta signaling receptor." Cell 73(7): 1435-44. 
Lozano, R., M. Naghavi, et al. (2012). "Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 2010." Lancet 380(9859): 
2095-128. 
Luna-Zurita, L., B. Prados, et al. (2010). "Integration of a Notch-dependent 
mesenchymal gene program and Bmp2-driven cell invasiveness regulates 
murine cardiac valve formation." The Journal of clinical investigation 
120(10): 3493-507. 
Lyons, K. M., R. W. Pelton, et al. (1990). "Organogenesis and pattern formation 
in the mouse: RNA distribution patterns suggest a role for bone 
morphogenetic protein-2A (BMP-2A)." Development 109(4): 833-44. 
Ma, L., M. F. Lu, et al. (2005). "Bmp2 is essential for cardiac cushion epithelial-
mesenchymal transition and myocardial patterning." Development 
132(24): 5601-11. 
MacGrogan, D., M. Nus, et al. "Notch signaling in cardiac development and 
disease." Curr Top Dev Biol 92: 333-65. 
Major, R. J. and K. D. Poss (2007). "Zebrafish Heart Regeneration as a Model for 
Cardiac Tissue Repair." Drug discovery today. Disease models 4(4): 219-
225. 
Manasek, F. J. (1969). "Embryonic development of the heart. II. Formation of the 
epicardium." J Embryol Exp Morphol 22(3): 333-48. 
Manasek, F. J. (1970). "Sulfated extracellular matrix production in the embryonic 
heart and adjacent tissues." J Exp Zool 174(4): 415-39. 
Manasek, F. J., M. Reid, et al. (1973). "Glycosaminoglycan synthesis by the early 
embryonic chick heart." Dev Biol 35(2): 332-48. 
Manner, J. (1992). "The development of pericardial villi in the chick embryo." 
Anat Embryol (Berl) 186(4): 379-85. 
Manner, J. (1993). "Experimental study on the formation of the epicardium in 
chick embryos." Anat Embryol (Berl) 187(3): 281-9. 
219 
 
Manner, J. (1999). "Does the subepicardial mesenchyme contribute 
myocardioblasts to the myocardium of the chick embryo heart? A quail-
chick chimera study tracing the fate of the epicardial primordium." Anat 
Rec 255(2): 212-26. 
Maron, B. J. and G. M. Hutchins (1974). "The development of the semilunar 
valves in the human heart." Am J Pathol 74(2): 331-44. 
Masuda, M., T. Maruyama, et al. (2010). "CADM1 interacts with Tiam1 and 
promotes invasive phenotype of human T-cell leukemia virus type I-
transformed cells and adult T-cell leukemia cells." J Biol Chem 285(20): 
15511-22. 
Matsumoto, K., M. Shionyu, et al. (2003). "Distinct interaction of versican/PG-M 
with hyaluronan and link protein." J Biol Chem 278(42): 41205-12. 
McBride, K. L., M. F. Riley, et al. (2008). "NOTCH1 mutations in individuals with 
left ventricular outflow tract malformations reduce ligand-induced 
signaling." Hum Mol Genet 17(18): 2886-93. 
McKellar, S. H., D. J. Tester, et al. (2007). "Novel NOTCH1 mutations in patients 
with bicuspid aortic valve disease and thoracic aortic aneurysms." J 
Thorac Cardiovasc Surg 134(2): 290-6. 
Medvedev, A. E., A. Lentschat, et al. (2002). "Dysregulation of LPS-induced Toll-
like receptor 4-MyD88 complex formation and IL-1 receptor-associated 
kinase 1 activation in endotoxin-tolerant cells." J Immunol 169(9): 5209-
16. 
Mellgren, A. M., C. L. Smith, et al. (2008). "Platelet-derived growth factor receptor 
beta signaling is required for efficient epicardial cell migration and 
development of two distinct coronary vascular smooth muscle cell 
populations." Circ Res 103(12): 1393-401. 
Mendelsohn, C., D. Lohnes, et al. (1994). "Function of the retinoic acid receptors 
(RARs) during development (II). Multiple abnormalities at various stages 
of organogenesis in RAR double mutants." Development 120(10): 2749-
71. 
Mercado-Pimentel, M. E., A. D. Hubbard, et al. (2007). "Endoglin and Alk5 
regulate epithelial-mesenchymal transformation during cardiac valve 
formation." Dev Biol 304(1): 420-32. 
Merki, E., M. Zamora, et al. (2005). "Epicardial retinoid X receptor alpha is 
required for myocardial growth and coronary artery formation." Proc Natl 
Acad Sci U S A 102(51): 18455-60. 
Meyer, D. and C. Birchmeier (1995). "Multiple essential functions of neuregulin in 
development." Nature 378(6555): 386-90. 
220 
 
Mikawa, T. and R. G. Gourdie (1996). "Pericardial mesoderm generates a 
population of coronary smooth muscle cells migrating into the heart along 
with ingrowth of the epicardial organ." Dev Biol 174(2): 221-32. 
Min, C., S. F. Eddy, et al. (2008). "NF-kappaB and epithelial to mesenchymal 
transition of cancer." J Cell Biochem 104(3): 733-44. 
Mjaatvedt, C. H., R. C. Lepera, et al. (1987). "Myocardial specificity for initiating 
endothelial-mesenchymal cell transition in embryonic chick heart 
correlates with a particulate distribution of fibronectin." Dev Biol 119(1): 
59-67. 
Mjaatvedt, C. H., H. Yamamura, et al. (1998). "The Cspg2 gene, disrupted in the 
hdf mutant, is required for right cardiac chamber and endocardial cushion 
formation." Dev Biol 202(1): 56-66. 
Mohamed, S. A., Z. Aherrahrou, et al. (2006). "Novel missense mutations 
(p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic 
valve." Biochem Biophys Res Commun 345(4): 1460-5. 
Molin, D. G., U. Bartram, et al. (2003). "Expression patterns of Tgfbeta1-3 
associate with myocardialisation of the outflow tract and the development 
of the epicardium and the fibrous heart skeleton." Dev Dyn 227(3): 431-44. 
Monzani, E., R. Bazzotti, et al. (2009). "AQP1 is not only a water channel: it 
contributes to cell migration through Lin7/beta-catenin." PLoS One 4(7): 
e6167. 
Moore, A. W., L. McInnes, et al. (1999). "YAC complementation shows a 
requirement for Wt1 in the development of epicardium, adrenal gland and 
throughout nephrogenesis." Development 126(9): 1845-57. 
Moore, A. W., A. Schedl, et al. (1998). "YAC transgenic analysis reveals Wilms' 
tumour 1 gene activity in the proliferating coelomic epithelium, developing 
diaphragm and limb." Mech Dev 79(1-2): 169-84. 
Morabito, C. J., R. W. Dettman, et al. (2001). "Positive and negative regulation of 
epicardial-mesenchymal transformation during avian heart development." 
Developmental biology 234(1): 204-215. 
Morgelin, M., M. Paulsson, et al. (1995). "Evidence of a defined spatial 
arrangement of hyaluronate in the central filament of cartilage 
proteoglycan aggregates." Biochem J 307 ( Pt 2): 595-601. 
Mylonakis, E. and S. B. Calderwood (2001). "Infective endocarditis in adults." N 
Engl J Med 345(18): 1318-30. 
Nakajima, Y., V. Mironov, et al. (1997). "Expression of smooth muscle alpha-
actin in mesenchymal cells during formation of avian endocardial cushion 
221 
 
tissue: a role for transforming growth factor beta3." Dev Dyn 209(3): 296-
309. 
Newman, P. J., M. C. Berndt, et al. (1990). "Pecam-1 (Cd31) Cloning and 
Relation to Adhesion Molecules of the Immunoglobulin Gene 
Superfamily." Science 247(4947): 1219-1222. 
Ng, C. M., A. Cheng, et al. (2004). "TGF-beta-dependent pathogenesis of mitral 
valve prolapse in a mouse model of Marfan syndrome." J Clin Invest 
114(11): 1586-92. 
Niessen, K., Y. Fu, et al. (2008). "Slug is a direct Notch target required for 
initiation of cardiac cushion cellularization." J Cell Biol 182(2): 315-25. 
Niu, S., J. J. Bahl, et al. (1998). "Structure, regulation and function of avian 
glypican." J Mol Cell Cardiol 30(3): 537-50. 
Niwa, H., J. Miyazaki, et al. (2000). "Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells." Nat Genet 
24(4): 372-6. 
Norris, R. A., R. A. Moreno-Rodriguez, et al. (2008). "Periostin regulates 
atrioventricular valve maturation." Dev Biol 316(2): 200-13. 
Olivey, H. E., L. A. Compton, et al. (2004). "Coronary vessel development: the 
epicardium delivers." Trends in cardiovascular medicine 14(6): 247-51. 
Olivey, H. E., N. A. Mundell, et al. (2006). "Transforming growth factor-beta 
stimulates epithelial-mesenchymal transformation in the proepicardium." 
Dev Dyn 235(1): 50-9. 
Olivey, H. E. and E. C. Svensson (2010). "Epicardial-myocardial signaling 
directing coronary vasculogenesis." Circulation research 106(5): 818-32. 
Ozdamar, B., R. Bose, et al. (2005). "Regulation of the polarity protein Par6 by 
TGFbeta receptors controls epithelial cell plasticity." Science 307(5715): 
1603-9. 
Paige, S. L., S. Thomas, et al. (2012). "A temporal chromatin signature in human 
embryonic stem cells identifies regulators of cardiac development." Cell 
151(1): 221-32. 
Parikh, N. I., P. Gona, et al. (2009). "Long-term trends in myocardial infarction 
incidence and case fatality in the National Heart, Lung, and Blood 
Institute's Framingham Heart study." Circulation 119(9): 1203-10. 
Partanen, J., E. Armstrong, et al. (1992). "A Novel Endothelial-Cell Surface-
Receptor Tyrosine Kinase with Extracellular Epidermal Growth-Factor 
Homology Domains." Molecular and Cellular Biology 12(4): 1698-1707. 
222 
 
Paruchuri, S., J. H. Yang, et al. (2006). "Human pulmonary valve progenitor cells 
exhibit endothelial/mesenchymal plasticity in response to vascular 
endothelial growth factor-A and transforming growth factor-beta2." Circ 
Res 99(8): 861-9. 
Pentassuglia, L. and D. B. Sawyer (2009). "The role of Neuregulin-1beta/ErbB 
signaling in the heart." Exp Cell Res 315(4): 627-37. 
Perego, C., C. Vanoni, et al. (2002). "Invasive behaviour of glioblastoma cell lines 
is associated with altered organisation of the cadherin-catenin adhesion 
system." J Cell Sci 115(Pt 16): 3331-40. 
Perkins, S. J., A. S. Nealis, et al. (1989). "Immunoglobulin fold and tandem 
repeat structures in proteoglycan N-terminal domains and link protein." J 
Mol Biol 206(4): 737-53. 
Person, A. D., R. J. Garriock, et al. (2005). "Frzb modulates Wnt-9a-mediated 
beta-catenin signaling during avian atrioventricular cardiac cushion 
development." Dev Biol 278(1): 35-48. 
Person, A. D., S. E. Klewer, et al. (2005). "Cell biology of cardiac cushion 
development." Int Rev Cytol 243: 287-335. 
Poelmann, R. E., A. C. Gittenberger-de Groot, et al. (1993). "Development of the 
cardiac coronary vascular endothelium, studied with antiendothelial 
antibodies, in chicken-quail chimeras." Circ Res 73(3): 559-68. 
Potts, J. D., J. M. Dagle, et al. (1991). "Epithelial-mesenchymal transformation of 
embryonic cardiac endothelial cells is inhibited by a modified antisense 
oligodeoxynucleotide to transforming growth factor beta 3." Proc Natl Acad 
Sci U S A 88(4): 1516-20. 
Potts, J. D. and R. B. Runyan (1989). "Epithelial-mesenchymal cell 
transformation in the embryonic heart can be mediated, in part, by 
transforming growth factor beta." Dev Biol 134(2): 392-401. 
Rabkin-Aikawa, E., M. Farber, et al. (2004). "Dynamic and reversible changes of 
interstitial cell phenotype during remodeling of cardiac valves." J Heart 
Valve Dis 13(5): 841-7. 
Rabkin, E., M. Aikawa, et al. (2001). "Activated interstitial myofibroblasts express 
catabolic enzymes and mediate matrix remodeling in myxomatous heart 
valves." Circulation 104(21): 2525-32. 
Red-Horse, K., H. Ueno, et al. (2010). "Coronary arteries form by developmental 
reprogramming of venous cells." Nature 464(7288): 549-53. 
Reese, D. E., T. Mikawa, et al. (2002). "Development of the coronary vessel 
system." Circ Res 91(9): 761-8. 
223 
 
Rensen, S. S. M., P. A. F. M. Doevendans, et al. (2007). "Regulation and 
characteristics of vascular smooth muscle cell phenotypic diversity." 
Netherlands Heart Journal 15(3): 100-108. 
Ricciardelli, C., A. J. Sakko, et al. (2009). "The biological role and regulation of 
versican levels in cancer." Cancer Metastasis Rev 28(1-2): 233-45. 
Riethmacher, D., E. Sonnenberg-Riethmacher, et al. (1997). "Severe 
neuropathies in mice with targeted mutations in the ErbB3 receptor." 
Nature 389(6652): 725-30. 
Rivera-Feliciano, J., K. H. Lee, et al. (2006). "Development of heart valves 
requires Gata4 expression in endothelial-derived cells." Development 
133(18): 3607-18. 
Roberts, A. E., T. Araki, et al. (2007). "Germline gain-of-function mutations in 
SOS1 cause Noonan syndrome." Nat Genet 39(1): 70-4. 
Roberts, K. E., J. J. McElroy, et al. (2004). "BMPR2 mutations in pulmonary 
arterial hypertension with congenital heart disease." Eur Respir J 24(3): 
371-4. 
Robiolio, P. A., V. H. Rigolin, et al. (1995). "Carcinoid heart disease. Correlation 
of high serotonin levels with valvular abnormalities detected by cardiac 
catheterization and echocardiography." Circulation 92(4): 790-5. 
Rodgers, L. S., S. Lalani, et al. (2008). "Differential growth and multicellular villi 
direct proepicardial translocation to the developing mouse heart." Dev Dyn 
237(1): 145-52. 
Roger, V. L., A. S. Go, et al. (2012). "Heart disease and stroke statistics--2012 
update: a report from the American Heart Association." Circulation 125(1): 
e2-e220. 
Rosati, B., F. Grau, et al. (2006). "Regional variation in mRNA transcript 
abundance within the ventricular wall." J Mol Cell Cardiol 40(2): 295-302. 
Rousso, D. L., C. A. Pearson, et al. (2012). "Foxp-mediated suppression of N-
cadherin regulates neuroepithelial character and progenitor maintenance 
in the CNS." Neuron 74(2): 314-30. 
Ruffell, B. and P. Johnson (2005). "Chondroitin sulfate addition to CD44H 
negatively regulates hyaluronan binding." Biochem Biophys Res Commun 
334(2): 306-12. 
Ruffell, B., G. F. Poon, et al. (2011). "Differential use of chondroitin sulfate to 
regulate hyaluronan binding by receptor CD44 in Inflammatory and 
Interleukin 4-activated Macrophages." J Biol Chem 286(22): 19179-90. 
224 
 
Saggin, L., S. Ausoni, et al. (1988). "Troponin-T Switching in the Developing Rat-
Heart." Journal of Biological Chemistry 263(34): 18488-18492. 
Saggin, L., L. Gorza, et al. (1989). "Troponin-I Switching in the Developing 
Heart." Journal of Biological Chemistry 264(27): 16299-16302. 
Sanchez, N. S. and J. V. Barnett (2012). "TGFbeta and BMP-2 regulate 
epicardial cell invasion via TGFbetaR3 activation of the 
Par6/Smurf1/RhoA pathway." Cellular signalling 24(2): 539-48. 
Sanchez, N. S., C. R. Hill, et al. (2011). "The cytoplasmic domain of TGFbetaR3 
through its interaction with the scaffolding protein, GIPC, directs epicardial 
cell behavior." Dev Biol 358(2): 331-43. 
Sanford, L. P., I. Ormsby, et al. (1997). "TGFbeta2 knockout mice have multiple 
developmental defects that are non-overlapping with other TGFbeta 
knockout phenotypes." Development 124(13): 2659-70. 
Sato, T., M. Gotoh, et al. (2003). "Differential roles of two N-
acetylgalactosaminyltransferases, CSGalNAcT-1, and a novel enzyme, 
CSGalNAcT-2. Initiation and elongation in synthesis of chondroitin 
sulfate." J Biol Chem 278(5): 3063-71. 
Schlueter, J., J. Manner, et al. (2006). "BMP is an important regulator of 
proepicardial identity in the chick embryo." Developmental biology 295(2): 
546-58. 
Schroeder, J. A., L. F. Jackson, et al. (2003). "Form and function of developing 
heart valves: coordination by extracellular matrix and growth factor 
signaling." J Mol Med 81(7): 392-403. 
Schubert, F. R., R. C. Mootoosamy, et al. (2002). "Wnt6 marks sites of epithelial 
transformations in the chick embryo." Mech Dev 114(1-2): 143-8. 
Sedmera, D., T. Pexieder, et al. (2000). "Developmental patterning of the 
myocardium." Anat Rec 258(4): 319-37. 
Sengbusch, J. K., W. He, et al. (2002). "Dual functions of [alpha]4[beta]1 integrin 
in epicardial development: initial migration and long-term attachment." J 
Cell Biol 157(5): 873-82. 
Serluca, F. C. (2008). "Development of the proepicardial organ in the zebrafish." 
Dev Biol 315(1): 18-27. 
Sha, W. C., H. C. Liou, et al. (1995). "Targeted disruption of the p50 subunit of 




Shapiro, I. M., A. W. Cheng, et al. (2011). "An EMT-driven alternative splicing 
program occurs in human breast cancer and modulates cellular 
phenotype." PLoS Genet 7(8): e1002218. 
Shelton, E. L. and K. E. Yutzey (2008). "Twist1 function in endocardial cushion 
cell proliferation, migration, and differentiation during heart valve 
development." Dev Biol 317(1): 282-95. 
Shen, R., Y. B. Ouyang, et al. (2002). "Grap negatively regulates T-cell receptor-
elicited lymphocyte proliferation and interleukin-2 induction." Mol Cell Biol 
22(10): 3230-6. 
Shi, Y. and J. Massague (2003). "Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus." Cell 113(6): 685-700. 
Shirai, M., K. Imanaka-Yoshida, et al. (2009). "T-box 2, a mediator of Bmp-Smad 
signaling, induced hyaluronan synthase 2 and Tgfbeta2 expression and 
endocardial cushion formation." Proc Natl Acad Sci U S A 106(44): 18604-
9. 
Shull, M. M., I. Ormsby, et al. (1992). "Targeted disruption of the mouse 
transforming growth factor-beta 1 gene results in multifocal inflammatory 
disease." Nature 359(6397): 693-9. 
Sibilia, M., B. Wagner, et al. (2003). "Mice humanised for the EGF receptor 
display hypomorphic phenotypes in skin, bone and heart." Development 
130(19): 4515-25. 
Singh, R., W. M. Hoogaars, et al. (2012). "Tbx2 and Tbx3 induce atrioventricular 
myocardial development and endocardial cushion formation." Cell Mol Life 
Sci 69(8): 1377-89. 
Smith, C. L., S. T. Baek, et al. (2011). "Epicardial-derived cell epithelial-to-
mesenchymal transition and fate specification require PDGF receptor 
signaling." Circ Res 108(12): e15-26. 
Smith, K. A., I. C. Joziasse, et al. (2009). "Dominant-negative ALK2 allele 
associates with congenital heart defects." Circulation 119(24): 3062-9. 
Smith, T. K. and D. M. Bader (2007). "Signals from both sides: Control of cardiac 
development by the endocardium and epicardium." Semin Cell Dev Biol 
18(1): 84-9. 
Song, L., R. Fassler, et al. (2007). "Essential functions of Alk3 during AV cushion 
morphogenesis in mouse embryonic hearts." Dev Biol 301(1): 276-86. 
Sridurongrit, S., J. Larsson, et al. (2008). "Signaling via the Tgf-beta type I 
receptor Alk5 in heart development." Dev Biol 322(1): 208-18. 
226 
 
Stankunas, K., C. T. Hang, et al. (2008). "Endocardial Brg1 represses ADAMTS1 
to maintain the microenvironment for myocardial morphogenesis." Dev 
Cell 14(2): 298-311. 
Stennard, F. A., M. W. Costa, et al. (2005). "Murine T-box transcription factor 
Tbx20 acts as a repressor during heart development, and is essential for 
adult heart integrity, function and adaptation." Development 132(10): 
2451-62. 
Stephen, L. J., A. L. Fawkes, et al. (2007). "A critical role for the EphA3 receptor 
tyrosine kinase in heart development." Dev Biol 302(1): 66-79. 
Strutz, F., H. Okada, et al. (1995). "Identification and characterization of a 
fibroblast marker: FSP1." J Cell Biol 130(2): 393-405. 
Sugi, Y., H. Yamamura, et al. (2004). "Bone morphogenetic protein-2 can 
mediate myocardial regulation of atrioventricular cushion mesenchymal 
cell formation in mice." Dev Biol 269(2): 505-18. 
Swift, M. R. and B. M. Weinstein (2009). "Arterial-venous specification during 
development." Circulation research 104(5): 576-88. 
Tadano, M., H. Edamatsu, et al. (2005). "Congenital semilunar valvulogenesis 
defect in mice deficient in phospholipase C epsilon." Mol Cell Biol 25(6): 
2191-9. 
Tartaglia, M., K. Kalidas, et al. (2002). "PTPN11 mutations in Noonan syndrome: 
molecular spectrum, genotype-phenotype correlation, and phenotypic 
heterogeneity." Am J Hum Genet 70(6): 1555-63. 
Tartaglia, M., E. L. Mehler, et al. (2001). "Mutations in PTPN11, encoding the 
protein tyrosine phosphatase SHP-2, cause Noonan syndrome." Nat 
Genet 29(4): 465-8. 
Tartaglia, M., L. A. Pennacchio, et al. (2006). "Gain-of-function SOS1 mutations 
cause a distinctive form of Noonan syndrome." Nat Genet. 
Tauseef, M., N. Knezevic, et al. (2012). "TLR4 activation of TRPC6-dependent 
calcium signaling mediates endotoxin-induced lung vascular permeability 
and inflammation." J Exp Med 209(11): 1953-68. 
Tevosian, S. G., A. E. Deconinck, et al. (2000). "FOG-2, a cofactor for GATA 
transcription factors, is essential for heart morphogenesis and 
development of coronary vessels from epicardium." Cell 101(7): 729-39. 
Tidball, J. G. (1992). "Distribution of collagens and fibronectin in the 




Tidball, J. G. (1992). "Identification and distribution of a novel, collagen-binding 
protein in the developing subepicardium and endomysium." J Biol Chem 
267(29): 21211-9. 
Timmerman, L. A., J. Grego-Bessa, et al. (2004). "Notch promotes epithelial-
mesenchymal transition during cardiac development and oncogenic 
transformation." Genes Dev 18(1): 99-115. 
Tjew, S. L., K. L. Brown, et al. (2005). "Expression of N-acetylglucosamine 6-O-
sulfotransferases (GlcNAc6STs)-1 and -4 in human monocytes: 
GlcNAc6ST-1 is implicated in the generation of the 6-sulfo N-
acetyllactosamine/Lewis x epitope on CD44 and is induced by TNF-
alpha." Glycobiology 15(7): 7C-13C. 
Tomanek, R. J., A. Sandra, et al. (2001). "Vascular endothelial growth factor and 
basic fibroblast growth factor differentially modulate early postnatal 
coronary angiogenesis." Circ Res 88(11): 1135-41. 
Townsend, T. A., J. Y. Robinson, et al. (2011). "BMP-2 and TGFbeta2 shared 
pathways regulate endocardial cell transformation." Cells Tissues Organs 
194(1): 1-12. 
Townsend, T. A., J. Y. Robinson, et al. (2011). "Endocardial cell epithelial-
mesenchymal transformation requires Type III TGFbeta receptor 
interaction with GIPC." Cellular signalling 24(1): 247-56. 
Townsend, T. A., J. L. Wrana, et al. (2008). "Transforming growth factor-beta-
stimulated endocardial cell transformation is dependent on Par6c 
regulation of RhoA." J Biol Chem 283(20): 13834-41. 
Tran, D. D., C. A. Corsa, et al. (2011). "Temporal and spatial cooperation of 
Snail1 and Twist1 during epithelial-mesenchymal transition predicts for 
human breast cancer recurrence." Mol Cancer Res 9(12): 1644-57. 
Trapnell, C., L. Pachter, et al. (2009). "TopHat: discovering splice junctions with 
RNA-Seq." Bioinformatics 25(9): 1105-11. 
Troyanovsky, B., T. Levchenko, et al. (2001). "Angiomotin: an angiostatin binding 
protein that regulates endothelial cell migration and tube formation." J Cell 
Biol 152(6): 1247-54. 
Vallabhapurapu, S. and M. Karin (2009). "Regulation and function of NF-kappaB 
transcription factors in the immune system." Annu Rev Immunol 27: 693-
733. 
van Wijk, B., Q. D. Gunst, et al. (2012). "Cardiac regeneration from activated 
epicardium." PLoS One 7(9): e44692. 
228 
 
Verstrepen, L., T. Bekaert, et al. (2008). "TLR-4, IL-1R and TNF-R signaling to 
NF-kappaB: variations on a common theme." Cell Mol Life Sci 65(19): 
2964-78. 
Vetter, G., A. Le Bechec, et al. (2009). "Time-resolved analysis of transcriptional 
events during SNAI1-triggered epithelial to mesenchymal transition." 
Biochem Biophys Res Commun 385(4): 485-91. 
Vieira, J. M. and P. R. Riley (2011). "Epicardium-derived cells: a new source of 
regenerative capacity." Heart 97(1): 15-9. 
Viragh, S. and C. E. Challice (1981). "The origin of the epicardium and the 
embryonic myocardial circulation in the mouse." Anat Rec 201(1): 157-68. 
von Gise, A. and W. T. Pu (2012). "Endocardial and epicardial epithelial to 
mesenchymal transitions in heart development and disease." Circ Res 
110(12): 1628-45. 
Vrljicak, P., A. C. Chang, et al. (2010). "Genomic analysis distinguishes phases 
of early development of the mouse atrio-ventricular canal." Physiol 
Genomics 40(3): 150-7. 
Vrljicak, P., R. Cullum, et al. (2012). "Twist1 transcriptional targets in the 
developing atrio-ventricular canal of the mouse." PLoS One 7(7): e40815. 
Wang, B., J. Weidenfeld, et al. (2004). "Foxp1 regulates cardiac outflow tract, 
endocardial cushion morphogenesis and myocyte proliferation and 
maturation." Development 131(18): 4477-87. 
Wang, J., S. Sridurongrit, et al. (2005). "Atrioventricular cushion transformation is 
mediated by ALK2 in the developing mouse heart." Dev Biol 286(1): 299-
310. 
Wang, L., E. R. Hauser, et al. (2007). "Peakwide mapping on chromosome 3q13 
identifies the kalirin gene as a novel candidate gene for coronary artery 
disease." Am J Hum Genet 80(4): 650-63. 
Wang, Q., R. S. Reiter, et al. (2001). "Comparative studies on the expression 
patterns of three troponin T genes during mouse development." 
Anatomical Record 263(1): 72-84. 
Wang, X. F., H. Y. Lin, et al. (1991). "Expression cloning and characterization of 
the TGF-beta type III receptor." Cell 67(4): 797-805. 
Wei, Q., N. R. Manley, et al. (2011). "Whole mount in situ hybridization of E8.5 to 
E11.5 mouse embryos." J Vis Exp(56). 
Wessels, A. and J. M. Perez-Pomares (2004). "The epicardium and epicardially 
derived cells (EPDCs) as cardiac stem cells." Anat Rec A Discov Mol Cell 
Evol Biol 276(1): 43-57. 
229 
 
Wiater, E., C. A. Harrison, et al. (2006). "Identification of distinct inhibin and 
transforming growth factor beta-binding sites on betaglycan: functional 
separation of betaglycan co-receptor actions." J Biol Chem 281(25): 
17011-22. 
Wilm, B., A. Ipenberg, et al. (2005). "The serosal mesothelium is a major source 
of smooth muscle cells of the gut vasculature." Development 132(23): 
5317-28. 
Wilting, J., K. Buttler, et al. (2007). "The proepicardium delivers hemangioblasts 
but not lymphangioblasts to the developing heart." Developmental biology 
305(2): 451-9. 
Wirrig, E. E., B. S. Snarr, et al. (2007). "Cartilage link protein 1 (Crtl1), an 
extracellular matrix component playing an important role in heart 
development." Dev Biol 310(2): 291-303. 
Wu, B., Z. Zhang, et al. (2012). "Endocardial cells form the coronary arteries by 
angiogenesis through myocardial-endocardial VEGF signaling." Cell 
151(5): 1083-96. 
Yang, J. T., H. Rayburn, et al. (1995). "Cell adhesion events mediated by alpha 4 
integrins are essential in placental and cardiac development." 
Development 121(2): 549-60. 
You, H. J., T. How, et al. (2009). "The type III transforming growth factor-beta 
receptor negatively regulates nuclear factor kappa B signaling through its 
interaction with beta-arrestin2." Carcinogenesis 30(8): 1281-7. 
Yu, H., P. M. Smallwood, et al. (2010). "Frizzled 1 and frizzled 2 genes function 
in palate, ventricular septum and neural tube closure: general implications 
for tissue fusion processes." Development 137(21): 3707-17. 
Yu, S., D. Crawford, et al. (2011). "The chemokine receptor CXCR7 functions to 
regulate cardiac valve remodeling." Dev Dyn 240(2): 384-93. 
Yutzey, K. E., M. Colbert, et al. (2005). "Ras-related signaling pathways in valve 
development: ebb and flow." Physiology (Bethesda) 20: 390-7. 
Zanin, M. K., J. Bundy, et al. (1999). "Distinct spatial and temporal distributions of 
aggrecan and versican in the embryonic chick heart." Anat Rec 256(4): 
366-80. 
Zeisberg, M. and E. G. Neilson (2009). "Biomarkers for epithelial-mesenchymal 
transitions." The Journal of clinical investigation 119(6): 1429-37. 
Zhao, Q., A. J. Beck, et al. (2011). "Developmental ablation of Id1 and Id3 genes 




Zheng, Y., S. Vertuani, et al. (2009). "Angiomotin-like protein 1 controls 
endothelial polarity and junction stability during sprouting angiogenesis." 
Circulation research 105(3): 260-70. 
Zhou, B., L. B. Honor, et al. (2011). "Adult mouse epicardium modulates 
myocardial injury by secreting paracrine factors." The Journal of clinical 
investigation 121(5): 1894-904. 
Zhou, B., Q. Ma, et al. (2009). "Fog2 is critical for cardiac function and 
maintenance of coronary vasculature in the adult mouse heart." J Clin 
Invest 119(6): 1462-76. 
Zhou, B., Q. Ma, et al. (2008). "Epicardial progenitors contribute to the 
cardiomyocyte lineage in the developing heart." Nature 454(7200): 109-
13. 
 
 
 
 
 
 
 
 
